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Abstract 
 
Background 
Airways diseases are increasingly recognised to be poorly defined phenomena with 
overlapping pathophysiology and symptoms. They are a significant and growing cause of 
morbidity, with increasing numbers of people affected globally and no improvement in key 
outcomes in the UK for the last decade despite ever increasing expenditure. The 
classification of airway diseases has changed little in the last 50 years, and may no longer be 
fit for purpose due to the growing appreciation of the complexity and heterogeneity of 
airways disease and the advent of molecular-based diagnostic techniques to target specific 
treatment.  
 
Aim 
To investigate whether strategies based on the measurement of selected phenotypic and 
biological characteristics of airways disease can help to improve the understanding of their 
pathogenesis and targeting of treatment. 
 
Methods 
Three characteristics of airways disease, namely (1) exhaled nitric oxide, (2) chronic 
productive cough of unknown cause and (3) the airway microbiota were 
described/measured in selected cohorts of patients in three clinical studies. Measurement 
of each of these characteristics was used to answer focused clinical questions regarding the 
pathogenesis and treatment of aspects of airways disease.  
 
Results 
(1) The baseline measurement of FENO in steroid naïve subjects with symptoms suggestive of 
asthma had a low diagnostic value for asthma but was an excellent predictor of inhaled 
steroid treatment response. (2) A cohort of subjects with chronic productive cough of 
unknown cause was described. These subjects tended to have radiological evidence of 
airway dilatation and chronic inflammatory changes but not significant bronchiectasis. Their 
cough responded well to treatment with azithromycin, with ongoing neutrophilic airway 
inflammation a particularly strong predictor of treatment response. (3) There were no 
significant differences in the abundance or community structure of the bacterial 
communities in the airways between subjects with mild (BTS 2) or severe (BTS 4) asthma or 
between severe (BTS 4) asthma patients taking inhaled fluticasone or budesonide. However 
a number of differences in relative abundance of certain species (including enrichment of 
Haemophilus parainfluenzae in the fluticasone group) were noted on comparison of the 
groups.  
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Conclusions 
This thesis provides support for a new approach to the classification and treatment of 
airways disease. The recognition of pathologically important processes (treatable traits) 
which can be used to predict response to targeted treatment has the potential to 
revolutionise the management of airways disease and result in improved patient outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
Thesis: Aim and Outline 
 
Airways diseases are increasingly recognised to be poorly defined phenomena with 
overlapping pathophysiology and symptoms. They are a significant and growing cause of 
morbidity, with increasing numbers of people affected globally and no improvement in key 
outcomes in the UK for the last decade despite ever increasing expenditure. The 
classification of airway diseases has changed little in the last 50 years, and may no longer be 
fit for purpose due to the growing appreciation of the complexity and heterogeneity of 
airways disease and the advent of molecular-based diagnostic techniques to target specific 
treatment. Recognition of specific phenotypic and biological markers underlying patterns of 
disease which will respond to targeted treatments has the potential to revolutionise the 
management of airways disease and result in improved patient outcomes.  
The overall aim of this thesis is to investigate whether selected phenotypic and biological 
characteristics of airways disease can be used to improve targeting of treatment. An outline 
of the structure of the thesis with individual study aims is as follows: 
Firstly, the current definitions of airways disease and the existing healthcare burden of 
these conditions will be determined. Existing literature regarding the causes and specificity 
of symptoms of airways disease will be reviewed. The pathophysiological processes 
underlying airways disease and main phenotypic groups in which these characteristics 
predominate will then be considered along with review of the main treatments targeting 
these processes. 
Chapter 2 titled ‘The utility of exhaled nitric oxide in patients with suspected asthma’ 
explores the importance of making a diagnosis of asthma in order to institute timely and 
effective treatment to control symptoms, the features and diagnostic accuracy of tests used 
to ‘diagnose’ asthma and the most recent guidelines for asthma diagnosis. The aim of the 
study is to investigate the utility of measuring exhaled nitric oxide for diagnosing asthma or 
predicting response to inhaled steroid treatment.  
Chapter 3 ‘Chronic Productive Cough and the use of Macrolides in Airways Disease’ reviews 
the current literature regarding the symptom of chronic productive cough and its causes as 
well as the mechanisms of action and use to date of macrolides in respiratory disease. The 
aim of the study is to describe in detail the underlying pathophysiology of a cohort of 
patients with the symptom of chronic productive cough who have had the usual underlying 
causes for this symptom excluded whilst simultaneously assessing the effectiveness of an 
open label trial of low dose azithromycin in treating this symptom.   
Chapter 4 ‘The microbiota in asthma’ examines the small but rapidly growing body of 
evidence in the emergent field of respiratory bacterial microbiota analysis. These techniques 
use DNA based sequencing to examine the bacterial communities of the airways in 
unprecedented detail. A systematic study of the airways microbiota of subjects with 
different severities of asthma using different doses and types of inhaled steroids is 
described. The aim of this study is to examine the effect of inhaled steroid dose and type on 
15 
 
the bacterial content of the airways, providing information that may be relevant to the 
targeting of inhaled steroid treatment.  
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Chapter 1: Background 
1.1 Introduction 
“Airways diseases” can be broadly defined as diseases affecting the transmitting structures 
(airways) that allow the passage of gases into and out of the lungs. They affect the airways 
by causing inflammation of the airway walls, which can result in tissue damage, narrowing 
or obstruction of the airways. Many different ‘types’ of airway disease including asthma, 
chronic obstructive pulmonary disease (COPD),’bronchitis’ and bronchiectasis have been 
described which affect over 400 million people worldwide (1). 
Despite the increasingly high global burden of airways disease and many advances in the 
understanding of the causes, progression and management of these conditions they remain 
poorly defined with few changes in their classification in the last 50 years. A change in the 
approach to classifying airways diseases may be required owing to an increasing recognition 
of their underlying complexity and heterogeneity and the promise of forthcoming novel 
biological agents that may be targeted to specific patients using certain biomarkers.  
Airways diseases lead to the development of various symptoms including cough, wheeze 
and shortness of breath.  The accuracy of diagnosing airways diseases based upon eliciting 
these symptoms in a clinical history is uncertain. However, previous work has indicated that 
a significant proportion of primary care physicians often make diagnoses of airways diseases 
on features from clinical history alone so it is important to establish the discriminatory value 
of these symptoms.  
The diagnosis and management of airways disease may be improved using objective tests 
capable of measuring and quantifying the pathophysiological processes that underlie them. 
For example, establishing the underlying pattern of airway inflammation in subjects with 
airways disease has been determined to be of great value in guiding treatment. Exhaled 
nitric oxide (FENO) is an easily measured biomarker of ongoing Th2 inflammation in the 
airways, but its role in the diagnosis and management of airways disease remains unclear.  
The current classification of airways diseases means that some subjects presenting with 
symptoms of airways disease are not easily categorised with one of the existing disease 
labels. One such cohort of subjects present with the symptom of chronic productive cough 
(“chronic bronchitis”) which is not explained by any of the recognised causes for this 
symptom even after thorough investigation. Initial indications suggest that treatment with 
long term low dose macrolides may improve the symptom burden in this group of patients. 
However, the underlying pathophysiology of this cohort of patients and their response to 
macrolide treatment are still to be determined.  
Finally, a hitherto under-explored component of the pathophysiology of airways disease is 
the contribution of bacteria extant within the airways to features of disease. New DNA-
based detection techniques have revealed that communities of bacteria (microbiota) in the 
airways of subjects with airways disease are different to those from healthy subjects and 
include potentially pathogenic species. Whether or not the composition of the microbiota 
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differs between subjects with different severities of airways disease using different doses 
and types of inhaled steroids is yet to be established. 
It is clear from the preceding background that there are a number of important factors in 
the treatment and management of airways disease that require further consideration and 
investigation. Accordingly it would be appropriate to review in greater detail: the 
epidemiology, symptoms, and pathophysiology of airways disease, the use of investigations 
in the diagnosis of airways disease, causes of chronic productive cough and the use of 
macrolides in airways disease and the existing knowledge regarding the composition of the 
microbiota in airways disease.  
1.2 Airways Disease: Definitions and Epidemiology 
The terminology used to describe airways disease has an interesting history and has long 
been a subject of great debate. Arguably the modern roots of current definitions of airways 
disease arise from a meeting of the CIBA Guest Symposium in 1959 (2), when at that time 
the terms “asthma”, “emphysema” and “chronic bronchitis” were often used 
interchangeably. The recommendations of the symposium were that these conditions 
should collectively be known as “chronic non-specific lung disease” (CNSLD). However, this 
phrase was considered too “cumbersome” for clinical practice and it was suggested 
therefore that patients should be classified with the following diagnostic labels: (1) “Chronic 
bronchitis” which “refers to the condition of subjects with chronic or recurrent excessive 
mucous secretion in the bronchial tree” and/or (2) “Generalised obstructive lung disease” 
which “refers to the condition of subjects with widespread narrowing of the bronchial 
airways, at least on expiration, causing an increase above the normal in resistance to air 
flow”. The latter category could be further subdivided into groups comprising (i) 
“intermittent or reversible” i.e. asthma or (ii) “irreversible or persistent” which would later 
come to be known as chronic obstructive pulmonary disease (COPD).  
The idea that these described diagnostic labels were distinct conditions and arose from 
different underlying pathophysiological processes would become known as the “British 
hypothesis” (3). This was in contrast to the so called “Dutch hypothesis”, first put forward by 
Orie and de Vries in 1961 (4). This alternative hypothesis stated that “asthma, chronic 
bronchitis and emphysema should be considered as different expressions of the same 
disease entity, in which both endogenous (host) and exogenous (environmental) factors play 
a role in the pathogenesis”. The Dutch hypothesis therefore opposed the use of distinct 
diagnostic labels, and recommended instead the original collective term of CNSLD. Debate 
still continues as to the pros and cons of these different hypotheses of airways disease (5, 6) 
with both protagonists seemingly accumulating growing bodies of evidence to endorse their 
respective positions (7, 8) and some studies also providing support for both hypotheses (9). 
Current international guidelines regard asthma and COPD as distinct and epidemiological 
studies also define them differently, although in recent years the ‘crossover’ diagnostic label 
of Asthma-COPD Overlap Syndrome has also been formally recognised (10).  
The current definitions of asthma, COPD and bronchiectasis with estimates of their 
prevalence, morbidity and mortality are discussed in more detail below. 
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1.2.1 Asthma 
1.2.1.1 Definition 
Asthma is defined by the Global Initiative for Asthma (GINA) principally as “a heterogeneous 
disease, usually characterized by chronic airway inflammation” which “is defined by the 
history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and 
cough that vary over time and in intensity, together with variable expiratory airflow 
limitation” (11). 
This definition, which is notable in its lack of specificity, describes asthma as a 
heterogeneous disease, i.e. a disease that is diverse in its characteristics and identifies the 
key features of the condition as being airway inflammation, variable respiratory symptoms 
and intermittent airflow obstruction. It does not attempt to objectively define asthma based 
on physiological or biological parameters. 
1.2.1.2 Epidemiology 
Asthma is one of the most common chronic diseases in the Western world, with around 10% 
of the UK population affected (12) and with an estimated 300 million cases worldwide. 
However, national prevalence figures are difficult to compare owing to the lack of a 
universal standardised definition (13). After increasing for many decades the prevalence of 
asthma in Western industrialised countries now seems to be falling (14). Nevertheless, the 
increasing incidence in developing countries such as China and India means that global 
prevalence of the condition is rising (15). 
1.2.1.3 Morbidity/Mortality 
Asthma is a significant cause of morbidity globally, accounting for an estimated 22.2 million 
disability adjusted life years (DALYs - i.e. the sum of years lost due to premature mortality 
and years of life lived with disability, adjusted for the severity of disability). This figure 
represented ~1% of the global disease burden in 2013 (16). The condition is estimated to 
cause 489,000 deaths worldwide per year (0.9% of all causes globally) (17) and was 
responsible for 1216 deaths in the UK in 2014 (18). 
Both the morbidity and mortality from asthma improved markedly from the 1950s to the 
2000s (19, 20). However, over the last decade the rates of asthma exacerbations (21), 
hospitalisation from asthma (22), asthma control measures (23) and mortality from asthma 
in the UK (24, 25) have not significantly changed.  
The social and economic costs of asthma are substantial in developed and developing 
countries (26, 27) and the overall cost of asthma to the UK economy is estimated to be 
around £1 billion per year (18, 28). This increasing cost burden is mostly due to the 
increasing direct costs of asthma from treatment and hospitalisation due to asthma 
exacerbations (26, 29) but also significant indirect costs due to absenteeism from work and 
loss of productivity (30).  
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1.2.2 Chronic Obstructive Pulmonary Disease (COPD) 
1.2.2.1 Definition 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines COPD as follows 
(31): 
 "COPD, a common preventable and treatable disease, is characterized by airflow limitation 
that is usually progressive and associated with an enhanced chronic inflammatory response 
in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities 
contribute to the overall severity in individual patients” 
Again it is evident that this definition is more a general description of features usually 
associated with COPD than an attempt to define the condition based on objective 
physiological or biological parameters.  
1.2.2.2 Epidemiology 
The prevalence of COPD is difficult to estimate accurately due to the lack of a standardised 
definition. Different studies have used varying case definition criteria, including 
symptomatology as assessed by questionnaire, doctor diagnosis or lung function criteria 
(32). Indeed, differences in the lung function testing criteria for assessing limitation between 
the two main published guidelines in this area led to a significant difference in the number 
of subjects classified as having airflow obstruction, and hence COPD (33).  
A meta-analysis of population based COPD prevalence data published between 1990 and 
2004 generated a pooled prevalence of 7.6%, but this was largely based on data from 
Europe and North America with limited reports from elsewhere (34). A more recent meta-
analysis suggested a global increase in the prevalence of COPD, with prevalence increasing 
in all regions, but particularly in the Eastern Mediterranean and African regions (albeit 
based on limited data) (35). 
1.2.2.3 Morbidity/Mortality 
Morbidity and mortality from COPD is substantial and increasing globally. In 2013 an 
estimated 72 million DALYs (2.9% of global disease burden) were lost to COPD (16) 
representing an increase of 8.2% since 2005. COPD caused an estimated 2,931,000 deaths 
worldwide in 2013 (5.3% of all causes globally) (17); an increase of 21% since 1990. In the 
UK, COPD caused 29,776 deaths in 2012 (36). 
Premature mortality from COPD seems to be improving in developed countries although 
figures from the World Health Organisation (WHO) showed that early mortality from COPD 
was twice as high in the UK than the rest of Europe in 2012 (37). 
The number of hospitalisations and emergency admissions of patients with COPD increased 
in the USA between 2001-2012 (38) and the rate of emergency admissions for the condition 
in the UK did not change significantly between 2003 and 2013 (39). The overall cost of COPD 
to the UK economy is estimated at £1.2 billion (40) and both direct and indirect costs of 
COPD are expected to continue increasing globally over coming years (41). 
 
29 
 
1.2.3 Bronchiectasis 
1.2.3.1 Definition 
Bronchiectasis is generally defined as the “irreversible abnormal dilatation of the bronchi”. 
This structural pathological change is usually accompanied by clinical symptoms, the most 
common of which is a chronic productive cough (42). The condition is diagnosed by a high 
resolution computed tomography (HRCT) scan demonstrating a bronchus with an internal 
diameter wider than its adjacent pulmonary artery which fails to taper. Bronchi which can 
be visualised 1-2 cm from the pleural surface is an additional radiological feature (43). 
1.2.3.2 Epidemiology 
Limited current data regarding international prevalence rates for bronchiectasis are 
available, although studies from the UK and USA suggest the prevalence of the condition is 
increasing (44-46). The total prevalence in the UK was estimated at 301/100,000 men and 
351/100,000 women in 2004, rising to 486/100,000 in men and 566/100,000 in women in 
2013 (46). It is unclear if this reflects a true increase in the number of cases or increased 
recognition of the condition due to more widespread HRCT scanning (45, 47). Bronchiectasis 
is more prevalent in women and the prevalence generally rises with age, being highest in 
those aged ≥70 years (46).  
1.2.3.3 Morbidity/Mortality 
A valid estimate of the morbidity from bronchiectasis is difficult owing to a lack of data in 
comparison to other chronic respiratory diseases. Subjects with bronchiectasis have a 
significantly increased risk of mortality in comparison with the general population. In the UK 
the age adjusted mortality rate is 1438/100,000 for women with bronchiectasis as 
compared to 636/100,000 in the general population, whilst for men these mortality rates 
are 1915/100,000 vs. 895/100,000 respectively (46). Mortality due to bronchiectasis 
apparently increased in the UK from 797 recorded deaths in 2001 to 908 in 2007, although 
this increase was driven by increasing mortality rates in the two oldest age groups which 
were simultaneously falling in the three youngest age groups (48). 
The limited data available regarding the cost of inpatient episodes of bronchiectasis suggest 
the direct costs of managing the condition are considerable (49, 50). These direct costs are 
likely to continue to rise, with increased numbers of hospitalisations and emergency 
admissions secondary to the condition reported in both the USA (51) and Germany (52); as 
well as increasing numbers of ICU admissions secondary to bronchiectasis in the UK (53). 
The indirect costs of bronchiectasis are unclear but these are also likely to be significant.   
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1.2.4 Airways Disease: The scale of the problem 
Ambiguity in the definitions of distinct ‘conditions’ of airways disease above may reflect the 
growing recognition of the complexity and heterogeneity of airways disease. A lack of 
specificity has almost become necessary when “defining” asthma and COPD so that these 
disease labels might encompass the increasingly diverse spectrum of airway pathology and 
resultant patterns of disease recognised in a growing number of people worldwide. 
The massive, and increasing, healthcare and socioeconomic burden secondary to airways 
disease is readily apparent. The growing numbers of people affected are likely to lead to 
increasing direct and indirect healthcare costs in the coming decades and treatment costs 
are also likely to increase due to growing availability of a number of novel therapies. 
Unfortunately, the improvements seen from the 1950s to the 2000s in key outcomes such 
as exacerbations of airways disease, hospitalisations for airways disease and asthma control 
measures seem to have stalled over the last decade despite an increased expenditure (23). 
A new approach to the characterisation and management of airways disease may be 
required to reflect their complex and heterogeneous nature and to improve treatment 
outcomes. The purpose of this thesis was 1) to examine the phenotypic and 
pathophysiological characteristics of certain airways diseases and 2) to investigate novel 
strategies based on the identification of these characteristics that might improve the 
treatment of disease.  
The first step in this process is to consider the importance and discriminatory value of the 
most obvious and direct phenotypic characteristics expressed by individuals with airways 
disease:  their symptoms.  
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1.3 Symptoms of Airways Disease  
Airways disease usually leads to the development of various symptoms in an affected 
subject. These symptoms include cough, wheeze, shortness of breath (or dyspnoea) and a 
sensation of ‘tightness’ of the chest.  
The accuracy of diagnosing airways disease based upon eliciting these symptoms in a clinical 
history is unclear. However, previous work has indicated that a significant proportion of 
primary care physicians often make diagnoses of airways disease based on history alone (54-
56). It is important therefore, to establish the discriminatory value of these symptoms. 
Accordingly, the prevalence of certain respiratory symptoms and their predictive value for 
the diagnosis of airways disease will be discussed along with a brief overview of other 
pulmonary and extrapulmonary conditions that can also cause these symptoms. 
1.3.1 Cough 
Causes of the symptom of cough are often classified by duration, for example the categories 
used by the American College of Chest Physicians (ACCP), are “acute” (<3 weeks), “sub-
acute” (3-8 weeks), or “chronic” cough (>8 weeks) (57). As the majority of cases of acute 
and sub-acute cough are secondary to infection these will not be discussed further in this 
section, and only cough more likely to be secondary to airways disease, i.e. “chronic” cough 
with a duration of >8 weeks, will be considered. 
The causes of a predominantly productive cough are discussed later (Section 1.6.2) and so 
this section describes cough in general terms.  
1.3.1.1 Prevalence 
A recently completed meta-analysis found that the regional prevalence of chronic cough 
varied between ~2% in Africa to ~18% in Oceania, with a prevalence in Europe of around 
13% (58). However, this analysis was subject to several limitations including significant 
heterogeneity in the definition of chronic cough and a relative lack of data from non-
European countries. 
Other factors or conditions that have recognised associations with chronic cough include 
respiratory wheezing (59), symptoms of gastro-oesophageal reflux disease (60), smoking 
(61) and exposure to airborne environmental pollutants (62, 63). 
1.3.1.2 Specificity as a symptom of airways disease 
a) Asthma 
Several investigators have attempted to determine the sensitivity and specificity of 
symptoms of airways disease for the diagnosis of asthma. These studies have differed 
slightly in their use of a ‘gold standard’ signifier of asthma diagnosis. In some studies this 
‘standard’ has been a physician diagnosis of asthma based on symptoms alone, whilst others 
have used a physician diagnosis of asthma based on symptoms plus an objective test. A 
comparison of the values of sensitivity and specificity of each of these symptoms for asthma 
diagnosis is shown in Table 1.1.  
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Sistek et al. in the SAPALDIA study (64) attempted to predict the diagnostic value of 11 
different respiratory symptoms to diagnose asthma in 9651 subjects who completed a 
symptom questionnaire. ‘Doctor diagnosed asthma’ (DDA) was defined as a positive answer 
to each of the questions: “Have you ever had asthma?” “Was this asthma confirmed by a 
doctor?” and “Have you had an attack of asthma in the last 12 months?”. Two-hundred and 
twenty-five subjects (2.3%) had DDA. The symptom of chronic cough was defined as a 
positive answer to the question: “Do you usually cough during the day or at night, on most 
days for as much as 3 months each year over at least 2 years?” and the symptom of 
nocturnal cough defined as a positive answer to the question: “Have you been woken up by 
an attack of coughing at any time in the last 12 months?”. Chronic cough had a sensitivity of 
21.5% with a specificity of 95.2% for DDA, whilst nocturnal cough had a sensitivity of 49.3% 
and a specificity of 72.3%. 
A similar study by Sistek et al. (65) used the same symptom questionnaire in 784 patients 
who also underwent objective testing for asthma in the form of the methacholine bronchial 
challenge test. This test assesses the response of the airways to a nebulised agent that is 
known to cause airway constriction (methacholine) and a positive result is often interpreted 
as objective evidence of a diagnosis of asthma (discussed in greater detail in Section 
2.2.2.4). The same definitions of DDA, chronic cough and nocturnal cough were used and 
one-hundred and four subjects (8.3%) had DDA. In this population the sensitivity and 
specificity for the symptom of chronic cough were found to be 43.1% and 83.9% 
respectively for DDA whilst the symptom of nocturnal cough had a sensitivity of 60% and a 
specificity of 66.1%. Bronchial challenge testing by comparison had a sensitivity of 84.6% 
and specificity of 80.5% for DDA.  
Choi et al. (66) assessed the use of a questionnaire containing five questions regarding the 
symptoms of asthma to discriminate between 210 subjects with asthma, as diagnosed by a 
positive methacholine challenge or bronchodilator reversibility testing, and 92 without 
asthma. These authors found that paroxysmal coughing was less common in asthmatics 
than in non-asthmatics and had only a 16% and 42% sensitivity and specificity respectively 
for diagnosing asthma. 
Schleich et al. (67) used a similar symptom questionnaire to interrogate the symptoms 
experienced by 174 corticosteroid naïve subjects with respiratory symptoms who were 
diagnosed as having asthma (n=82) or not having asthma (n=92). Subjects were assigned to 
the two groups on the basis of methacholine challenge testing. The symptoms of diurnal 
cough (sensitivity 66% and specificity 26%) and nocturnal cough (sensitivity 37% and 
specificity 65%) were again found to be lacking in both sensitivity and specificity for the 
diagnosis of asthma. 
Schneider et al. (68) attempted to determine the diagnostic accuracy of certain respiratory 
symptoms listed on a structured questionnaire for asthma and COPD in subjects from GP 
(n=219), inpatient (n=300) and outpatient (n=259) settings. Asthma was diagnosed by a 
respiratory physician on the basis of results of whole body plethysmography as well as 
bronchodilator reversibility testing (in those with airways obstruction) or methacholine 
challenge (in those without obstruction). The sensitivity and specificity for the symptom of 
33 
 
cough for asthma diagnosis varied from 43-53% and 32-64% respectively in the different 
healthcare settings. 
Finally Lim et al. (69) investigated whether five questions on symptoms of asthma as 
recommended by the GINA guidelines could accurately diagnose asthma, as defined by a 
positive methacholine challenge test, in a group of 680 subjects. Methacholine challenge 
testing was positive in 164 patients and negative in 516 and the symptom of nocturnal 
cough had a sensitivity of 62% and a specificity of 44% for the identification of methacholine 
test positive patients. 
b) COPD 
A number of studies have observed significant associations between symptoms of cough 
and productive cough and a diagnosis of COPD or “airflow limitation”. An increased 
likelihood of COPD diagnosis in subjects with the symptom of dry cough or “cough” 
(unspecified if productive or not) has been observed  in studies by Lamprecht (70), Freeman 
(71), Hanania (72), Van Schayck (73), Albers (74), Minas (75) and Ohar (76) (See Table 1.2). 
Increased odds of COPD in subjects specifically with a cough productive of sputum were 
noted in studies by Lamprecht (70), Medbo (77) and Ohar (76). 
Few studies have attempted to assess the predictive value of symptoms for diagnosing 
COPD. Ohar et al. (76) investigated the accuracy of respiratory symptoms to diagnose 
airflow obstruction in 3955 subjects undergoing work-related medical evaluations. COPD 
was diagnosed in subjects with airflow obstruction ≥40 years who had a smoking pack year 
history of ≥20 years. Subjects with cough had increased likelihood of airflow obstruction, 
and this was further increased in smoking subjects with a cough (n=2917). The sensitivity 
and specificity of cough for COPD (airflow obstruction and specified smoking history) in the 
whole population were 69% and 48% respectively and were very similar in the smoking 
subjects alone at 71% and 44% (Table 1.2).   
Murgia et al. (78) investigated the sensitivity and specificity of chronic bronchitis symptoms 
(cough with sputum production for ≥3 months within 1 year for 2 consecutive years) for the 
diagnosis of COPD (actually airways obstruction as defined by pulmonary function 
measures) in a sample of 3892 subjects from the general Swedish population. For the whole 
population chronic bronchitis symptoms were found to have a sensitivity of ~5% and a 
specificity of ~98% for airways obstruction. These values were similar when groups were 
sub-classified by gender and smoking status. 
The definitions of ‘COPD’ in both of these studies (76, 78) are questionable and both studies 
could more accurately be described as assessing the value of symptoms to predict airways 
obstruction (both of which may include a significant percentage of subjects with asthma) 
but their findings are summarised here for completeness.  
c) Bronchiectasis 
Published data for the predictive value of symptoms for diagnosing radiologically significant 
bronchiectasis is scarce. 
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It is clear that the symptom of productive cough is present in a high proportion of subjects 
with bronchiectasis. For example, King et al. (42) found that 99/103 (96%) subjects in a 
cross-sectional study of patients with new diagnoses of bronchiectasis had the symptom of 
productive cough 
A few authors have previously investigated the degree of correlation between the symptom 
of sputum production/productive cough and the diagnosis and extent of bronchiectasis as 
demonstrated on HRCT scan. Smith et al. (79) studied 40 subjects with chronic sputum 
production and found the continual production of purulent sputum (as described on clinical 
history taking) had a significant predictive value for the presence of bronchiectasis. This 
value is not listed in the paper, but by calculation using a 2x2 table the odds of a subject 
having bronchiectasis with the symptom of continuous purulent sputum were around 7 
times those of subjects who never produced purulent sputum or only did so during 
exacerbations  (odds ratio (OR) 6.9; 95% confidence interval (CI) 1.3-37.2). The calculated 
sensitivity and specificity of this symptom for bronchiectasis were 55.6% and 84.6% 
respectively. Lynch et al. (80) assessed the relationship between the clinical and HRCT 
findings of 261 subjects with radiologically diagnosed bronchiectasis. They found a weak but 
significant positive correlation between daily sputum volume and scores of bronchiectasis 
severity on CT (r=0.2; p<0.01) but no correlation between dyspnoea and bronchiectasis 
score.   
Finally, Kamath et al. (81) investigated the association between clinical features and a 
radiological diagnosis of bronchiectasis in 46 subjects with clinical features suggestive of 
bronchiectasis (results only available as conference abstract). Cough, cough productive of 
sputum, and haemoptysis were not found to be significant predictors of bronchiectasis (See 
Table 1.3).  
1.3.1.3 Other conditions that cause cough 
As well as asthma there are a number of other conditions that can cause chronic cough. 
a) Cough variant asthma/atopic cough/eosinophilic bronchitis 
These three related conditions have all been described as causes of chronic cough. 
Cough variant asthma (CVA) presents as a dry cough without other symptoms of asthma 
such as dyspnoea or wheeze (82, 83). Diagnosis is based on the clinical history plus 
demonstration of airways hyperreactivity (84) and eosinophilic inflammation in sputum or 
broncho-alveolar lavage (BAL) (85).  The pathophysiological mechanism for cough in CVA is 
not fully understood (86). 
Eosinophilic bronchitis (EB) describes a group of patients with cough secondary to 
eosinophilic airway inflammation but with no bronchial reactivity (87). Diagnosis of the 
condition is made in patients with an appropriate clinical history, negative bronchial 
challenge and significant sputum eosinophilia (88). EB shares many similar pathological 
features to asthma but unlike in asthma the airway submucosa does not demonstrate mast 
cells within airway smooth muscle (89), which may explain why subjects with EB do not have 
hyperreactive airways like many of those with asthma. 
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Atopic cough (or eosinophilic tracheobronchitis) was described by Fujimura et al. (90) as an 
isolated chronic cough in atopic individuals with cough hypersensitivity and normal 
bronchial responsiveness who demonstrate eosinophilic inflammation in sputum (91). These 
authors have suggested that atopic cough is a distinct entity to CVA and EB with a differing 
clinical course (92) although this view is controversial (93). Many of the features of atopic 
cough and EB overlap, although a few differentiating features have been described including 
a) a lack of eosinophils in BAL fluid of subjects with atopic cough (94), b) a lower risk of 
progression to asthma in atopic cough (95) than in EB patients and c) a significant treatment 
response to H1 receptor antagonists in atopic cough patients (94) that is not usually seen in 
those presenting with EB.  
The reported percentage of cases of cough seen in the specialist respiratory clinic owing to 
asthma or one of these three conditions (which are difficult to separate owing to the 
definitions used) have varied between 10-35% in the UK and USA and ~50% in Japan (96). EB 
alone has previously been estimated to account for around 15% of cases of cough referred 
to secondary care in the UK (97).  
b) Gastro oesophageal reflux disease (GORD) 
GORD is defined as “symptoms or complications resulting from the reflux of gastric contents 
into the oesophagus or beyond, into the oral cavity (including larynx) or lung” (98). The 
condition has a prevalence of 10-30% in both Europe and the USA which is thought to be 
increasing (99). 
Typical symptoms of GORD include heartburn, chest pain and regurgitation but the 
condition may also cause chronic cough. Several mechanisms for GORD-associated cough 
have been proposed but the two most commonly accepted of these are the “reflux” and 
“reflex” theories (100). The reflux theory posits that reflux (which may be acidic or non-
acidic in pH) that rises above the oesophagus is aspirated into the larynx and pulmonary 
tree and stimulates cough as a protective mechanism (101). The reflex theory states that 
due to the shared embryological origin of the oesophagus and trachea reflux into the 
oesophagus can trigger an oesophageobronchial reflex which manifests as cough (102). 
There is some evidence that cough itself can trigger reflux, which may in turn lead to more 
cough and the establishment of a so-called “cough-reflux-cough” cycle (102). 
Estimates of the contribution of GORD to the overall burden of chronic cough vary greatly. 
Figures from various studies included in a review of the literature of causes of chronic cough 
range between 5-40% of cases of cough secondary to GORD in the specialist respiratory 
clinic in the UK and USA (96). GORD associated cough would appear to account for far fewer 
cases of chronic cough in Japan (96). 
c) Post-nasal drip syndrome (PNDS) 
PNDS refers to the drainage of nasal secretions into the pharynx. It is a clinical diagnosis 
based on patient reported symptoms of a ‘drip’ sensation at the back of the throat, 
accompanied by the need for frequent throat clearing and nasal stuffiness or nasal 
discharge. Other clinical features that support the diagnosis include the presence of 
nasopharyngeal or oropharyngeal secretions and/or mucosal ‘cobblestoning’ on 
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examination, radiological findings and an improvement in cough symptoms with 
appropriate treatment (103). 
The pathophysiological mechanism of cough associated with PNDS was classically thought to 
be due to stimulation of cough receptors in the larynx from the ‘drip’ down of secretions 
from the nose and sinuses (104), although there appears to be little direct evidence to 
support this. Alternative mechanisms such as increased sensitivity of cough receptors in the 
upper airway (105) or increased central sensitisation to nasal sensory afferent input (106) 
may be involved. Owing to the unclear mechanism of cough the 2006 ACCP guidelines 
recommended the term ‘Upper Airway Cough Syndrome’ be used in preference to PNDS 
(103). 
The percentage of cases of cough seen in the specialist respiratory clinic caused by PNDS is 
difficult to determine owing to the lack of pathognomonic features of the condition and 
different diagnostic criteria and estimates have ranged from 6% to 87% in the UK and USA 
(96). 
1.3.2 Wheeze  
A wheeze is a continuous musical sound produced on expiration that is often thought to be 
a “classic” sign or symptom of asthma although it can result from a spectrum of respiratory 
disorders that cause airflow obstruction (107, 108). Wheezing results from the passage of air 
through narrowed or obstructed airways from the larynx down to the small bronchi and is 
thought to be due to oscillations of opposing walls of the narrowed airway (109). Airway 
narrowing may occur due to bronchoconstriction which can be a feature of asthma but can 
also be caused by airway wall oedema as well as extrinsic or intrinsic compression of the 
airways (110). 
The causes of wheeze in children and adults differ greatly. Wheeze is extremely common in 
children and by the age of six up to 50% will have had at least one episode of wheeze (111). 
Small children commonly develop wheeze acutely secondary to upper and lower airway 
infections and sometimes may develop more serious conditions such as 
laryngotracheobronchitis (croup) or bronchiolitis. Recurrent childhood wheeze is often 
secondary to asthma, allergy and GORD (112). 
In adults, asthma and COPD are two of the most common causes of recurrent wheeze 
although there are various other extra- (e.g. vocal cord dysfunction) and intra-thoracic (e.g. 
bronchiectasis, cardiac failure) causes of chronic wheeze (113).  
1.3.2.1 Prevalence 
The prevalence of wheeze in adults has previously been assessed in three large scale 
population studies that were used to estimate the prevalence of asthma. 
The first of these, the National Health And Nutrition Examination Survey (NHANES) included 
nearly 19,000 US adults aged ≥20 surveyed between 1988-1994 (114). The mean prevalence 
of wheeze (defined as any episode of wheeze in the last 12 months), including all age and 
ethnic groups was 16.4% and this figure was significantly higher (17.7%) in non-Hispanic 
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whites than in any other ethnic group. In addition to ethnicity, poverty, smoking status, hay 
fever and obesity were all found to be significantly associated with wheezing. 
The European Community Respiratory Health Survey (ECRHS) I included nearly 140,000 
adults aged 20-44 surveyed between 1990 and 1993 from 22 different countries including a 
few non-European countries such as India, USA and New Zealand (115). The median 
prevalence of wheeze (any episode of wheeze in the last 12 months) was 20.7% and this 
figure varied greatly between the countries surveyed from 4.1% in India to 32% in Ireland 
(115). Factors found to be significantly associated with wheeze considering the data as a 
whole included the use of gas cookers and occupational exposure. Independent analysis of 
regional data demonstrated significant associations between wheeze and age, allergic 
sensitisation, smoking status, living in damp dwellings and number of siblings (116). 
Finally the RHINE study included nearly 15,000 adults aged 30-54 from Northern Europe 
surveyed between 1999-2001 who had previously taken part in the first ECRHS survey (117). 
The prevalence of wheeze (any episode of wheeze in the last 12 months) was 17.3% and 
wheeze was found to be strongly associated with increased risk of new onset asthma.  
1.3.2.2 Specificity as a symptom of airways disease 
a) Asthma 
The SAPALDIA study reported wheeze (i.e. a “wheezing or whistling in your chest at any time 
in the last 12 months”) to be the most sensitive symptom for diagnosing asthma with a 
sensitivity of 75% and specificity of 87% (Table 1.1) (64). When subjects were asked 
additionally if they had experienced shortness of breath in combination with wheeze in the 
last 12 months the sensitivity was reduced to 65% but with an increase in specificity to 95%. 
Subjects were also asked if they had experienced wheeze without having a cold at the time 
and this question was also less sensitive (60%) but more specific (94%) than asking about 
wheeze alone. The authors calculated a measure of diagnostic efficacy which combines the 
values of sensitivity and specificity (a ‘Youden index’) for each individual symptom and for 
combinations of all the different symptoms. Wheeze had the highest Youden index (with 0 
being the minimum value and 1 the maximum) of 0.62 of the individual symptoms. The 
combination of symptoms with the highest Youden index was wheezing in addition to two 
or more nocturnal symptoms (from cough, chest tightness and dyspnoea) with an index of 
0.66. 
The study by Sistek et al. (65) of adult New Zealanders also found wheeze to be the most 
sensitive symptom for asthma diagnosis with a sensitivity of 93.9%, although the specificity 
of wheeze was lower than that determined in the SAPALDIA study at 76.4%. The symptom 
and combination of symptoms with the highest Youden indices were wheeze alone (0.7) and 
wheeze plus dyspnoea (0.72). 
Tomita et al. (118) attempted to derive a ‘scoring algorithm’ to use for predicting asthma in 
adult patients by collecting clinical data from 566 adult patients with non-specific 
respiratory symptoms. Asthma was diagnosed by respiratory physicians on the basis of 
symptoms and signs with either bronchodilator reversibility and/or bronchial 
hyperresponsiveness. The only symptom enquired about was wheeze which was found to 
38 
 
have a sensitivity of 30% and a specificity of 87% for asthma diagnosis and this was not used 
in the final algorithm where instead a “wheeze sound” on examination was used owing to 
its higher sensitivity (90%) and specificity (95%). 
Sensitivities and specificities for wheeze as a diagnostic symptom of asthma in the studies 
by Choi et al. (66), Schleich et al. (67), Schneider et al. (68), and Lim et al. (69) are 
summarised in Table 1.1. 
b) COPD 
Wheeze has been demonstrated to have a significant association with a diagnosis of COPD. 
Odds ratios from studies by Medbo et al. (77), Lamprecht et al. (70), Hanania et al. (72), Van 
Schayck et al. (73), Kotz et al. (119), Minas et al. (75) and Vandervoorde et al. (120) are 
listed in Table 1.2. Ohar et al. (76) also found a significant association between wheeze and 
COPD diagnosis and calculated wheeze to have a sensitivity of 68% and specificity of 55% for 
diagnosing COPD (airflow obstruction).  
c) Bronchiectasis 
It is unclear how useful the symptom of wheeze is for identifying underlying bronchiectasis 
although it is likely to have a low predictive value. Previous studies have reported low 
incidence of reported wheeze as a symptom in populations of bronchiectatic patients. Li et 
al. (121)  found that 14/136 subjects had wheeze on presentation, in comparison to 47/136 
with cough. Also, King et al. (42) noted wheeze on examination in only 22 out of 103 (21%) 
subjects with newly diagnosed bronchiectasis. Kamath et al. (81) did not find wheeze to be a 
significant predictor of radiological bronchiectasis (Table 1.3).      
1.3.2.3 Other conditions that cause wheeze 
The symptom of wheeze, owing to its underlying pathophysiology, might be expected to 
have a degree of specificity for airways disease. 
However, as mentioned above, some conditions that are not primarily diseases of the lower 
airways may present as wheeze and be mistaken for cases of airways disease, perhaps most 
notably vocal cord dysfunction and ‘cardiac asthma’ (secondary to congestive heart failure) 
and these will be discussed briefly here. 
a) Vocal Cord dysfunction (VCD) 
VCD or “paradoxical vocal fold motion” is a syndrome characterised by abnormal vocal cord 
adduction leading to partial airway obstruction at the level of the larynx (122). The vocal 
cords may adduct in a paroxysmal fashion during the inspiratory or expiratory phases of the 
respiratory cycle resulting in symptoms such as inspiratory stridor (often mischaracterised 
as wheezing), cough and a feeling of tightness in the chest or throat (123). 
The three main criteria used to establish a diagnosis of VCD are (1) clinical symptoms e.g. 
dyspnoea, noisy breathing or stridor (2) visualisation of vocal cord adduction on 
laryngoscopy and (3) consistent pulmonary function tests. Pulmonary function testing 
usually reveals normal spirometry with no significant reversibility, normal airway reactivity 
as assessed by bronchial challenge testing and an abnormal flow volume loop, normally with 
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a flattened inspiratory limb which can be reproduced with a challenge test such as 
histamine (124, 125).  
The proportion of cases of wheeze (or more correctly, stridor) secondary to VCD is unclear. 
The condition is frequently misdiagnosed as asthma (126) and the two conditions commonly 
co-exist with up to 50% of VCD patients also having a diagnosis of asthma based on 
objective measures (123, 127). This may make it difficult to determine which of these two 
conditions is the primary cause of a subject’s symptoms. Wheeze is a common symptom 
reported by VCD patients, with a prevalence of 36% (124) and 51% (128) being reported in 
two previous reviews of the literature. 
b) Cardiac asthma 
The term “cardiac asthma” has been used to describe airflow obstruction and resultant 
wheezing secondary to congestive heart failure (129). The observation that airflow 
obstruction occurs during times of cardiogenic pulmonary oedema was first made over a 
century ago (130) and various mechanisms including reflex bronchoconstriction due to 
increased pulmonary vascular pressure (131), airway obstruction due to intraluminal 
oedema (131) or bronchial mucosal hypertrophy (132) and increased airway 
hyperresponsiveness (AHR) (133, 134) have been postulated.  
Cardiac asthma is prevalent in elderly patients (>65 years old) with congestive heart failure 
and may be present in up to a third of these cases (135). However, other signs and 
symptoms of congestive heart failure would usually be present in these patients, making 
primary airways disease less likely as the cause of wheeze. 
1.3.3 Dyspnoea 
Dyspnoea has been defined as “a subjective experience of breathing discomfort that 
consists of qualitatively distinct sensations that vary in intensity” (136). 
Three of the most well described of these sensations include “air hunger”, increased work or 
effort of breathing and chest tightness. Accumulating evidence suggests that distinct 
pathophysiological mechanisms may underlie these sensations, which may be experienced 
separately or in combination by a subject whose perception of these sensations is 
influenced by myriad non-sensory factors including emotional state (137) and attention 
(138). 
“Air hunger” or “unsatisfied inspiration” is the perception of not being able to “take in” 
enough air. This seems to arise when increased ventilatory demand (e.g. due to exercise or 
when a subject is hypercapnic or hypoxic) cannot be met by a subject’s ventilatory capacity 
(139). This creates an imbalance between the respiratory motor drive of the brainstem 
(which is relayed to the cerebral cortex via a so-called ‘corollary discharge’) and the afferent 
feedback from mechanoreceptors in the lungs, airways and chest wall leading to the 
development of the unpleasant air hunger sensation (140). 
An unpleasant sensation of increased “work” or “effort” of breathing is often reported by 
patients with obstructive lung diseases or respiratory muscle weakness (141). This sensation 
has been reproduced in research volunteers by increasing external resistance to breathing 
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(142), weakening respiratory muscles through fatigue (143) or neuromuscular blockade 
(144). This unpleasant sensation is probably due in some way to the decreased ability of 
respiratory muscles to meet ventilatory demand when required (owing to deranged 
ventilatory mechanics). This phenomenon leads, in turn, to an increased central respiratory 
motor drive and heightened perception by the subject of increased respiratory effort (142, 
145).  
The cause of the sensation of ‘chest tightness’ in subjects with asthma has not been fully 
explained although this is likely to be related to bronchoconstriction (146). The chest 
tightness sensation may not result from the increased work of breathing during 
bronchoconstriction but instead be due to the stimulation of airway receptors such as 
rapidly adapting receptors (RARs) or C-fibre receptors (147). 
1.3.3.1 Prevalence 
Prevalence rates of dyspnoea symptoms are difficult to estimate owing to the subjective 
description of this sensation (148, 149) as well as linguistic differences that may lead to 
either conflation or separation of dyspnoea or ‘shortness of breath’ with a chest tightness 
sensation (150). Also, some subjects may be more likely to perceive they are dyspnoeic in 
the absence of an organic cause (151) and activity induced dyspnoea may sometimes be 
mistakenly perceived as pathological when in fact it is appropriate for an individual at a 
certain level of fitness (152). 
Figures from the ECHRS I survey suggested a median prevalence of nocturnal dyspnoea (any 
episode of being woken by shortness of breath in the last 12 months) of 7.3% with a range 
of 1.5% in Iceland to 11.4% in Australia. The same survey also found a median prevalence of 
nocturnal chest tightness (any episode of being woken by chest tightness in the last 12 
months) of 13.5% with a range of 6.2% in Italy to 20.5% in Australia (115). 
The RHINE study found a prevalence of nocturnal dyspnoea (any episode of being woken by 
shortness of breath in the last 12 months) of 3.5% with no association between this 
symptom and increased risk of new onset asthma. The prevalence of nocturnal chest 
tightness (any episode of being woken by chest tightness in the last 12 months) was 7.3% 
and there was no association with this symptom and increased risk of new onset asthma 
(117). 
1.3.3.2 Specificity as a symptom of airways disease 
a) Asthma 
Despite the subjectivity in the definitions of dyspnoea and chest tightness, sensitivity and 
specificity values for their potential for asthma diagnosis have been determined. However 
the values obtained for both sensitivity and specificity of dyspnoea and chest tightness as 
symptoms of airway disease vary markedly from study to study (Table 1.1). Generally the 
specificity values of dyspnoea at rest from these studies are high for asthma, whereas values 
for sensitivity and specificity of dyspnoea on exertion are moderately good. 
b) COPD 
Dyspnoea has been demonstrated to have a significant association with a diagnosis of 
COPD. Odds ratios from a number of studies are listed in Table 1.2. Ohar et al. also found a 
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significant association between dyspnoea and COPD diagnosis and calculated dyspnoea to 
have a sensitivity of 75% but a specificity of only 37% for diagnosing COPD.  
c) Bronchiectasis 
The predictive value of dyspnoea for bronchiectasis is again unclear, although this is likely to 
be low. King et al. (42) found 62/103 (60%) subjects to be dyspnoeic at the time of diagnosis 
of bronchiectasis. Lynch et al. (80) found no correlation between dyspnoea score and extent 
of bronchiectasis on HRCT, although the study by Smith et al. (79) found a weak positive 
correlation between these two variables.  
Kamath et al. (81) did not find “breathlessness” to be a useful predictor of radiological 
bronchiectasis (Table 1.3).  
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 Sistek et 
al. 
(2001) 
Sistek et 
al. 
(2006) 
Choi et 
al. 
Schleich 
et al. 
Schneider 
et al. 
Lim et al. Tomita 
et al. 
Cough: 
Diurnal        
Sensitivity 21.5 43.1 16 66 43-53   
Specificity 95.2 83.9 42 26 32-64   
Nocturnal        
Sensitivity 49.3 93.9    62  
Specificity 72.3 76.4    45  
Wheeze: 
Diurnal        
Sensitivity 75 65 9 57 52-76 51 30 
Specificity 87 95 79 62 34-66 66 87 
Nocturnal        
Sensitivity    56    
Specificity    79    
Chest tightness: 
Diurnal        
Sensitivity    73 31-44   
Specificity    60 54-83   
Nocturnal        
Sensitivity 49 20      
Specificity 86 75      
Dyspnoea: 
At rest        
Sensitivity 47.1 43.1 11 73 9-40   
Specificity 94.9 92.9 71 55 78-88   
On 
exercise 
    On 
walking 
  
Sensitivity 69.3 75.4   5-36 70  
Specificity 75.7 76.5   32-93 49  
     With 
minimal 
exercise 
  
Sensitivity     3-32   
Specificity     43-94   
Nocturnal        
Sensitivity 46.2 41.5      
Specificity 96 95.8      
Table 1.1: The sensitivities (%) and specificities (%) of different 
symptoms of airways disease for the diagnosis of asthma, as 
reported in different studies
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 Lamprecht 
et al.  
Medbo 
et al. (a) 
Freeman 
et al.  
Hanania 
et al. (b) 
Van Schayck 
et al.  (c) 
Kotz et 
al.  
Albers et 
al. 
Minas 
et al. 
Vandevoorde 
et al. 
Ohar et 
al.  (d) 
Murgia 
et al.  
Cough: 
Odds Ratio 
(95% CI) 
2.3* 
(1.7-3.1) 
1.1† (0.8-
1.5) 
2.4 
(1.2-4.7) 
2 
(1.3-3.0) 
1.2  2.3 
(1.1-4.6) 
2.5 
(1.7-3.6) 
NS 2.0*  
(1.7-2.3) 
 
Sensitivity          69  
Specificity          48  
Cough with sputum: 
Odds Ratio 
(95% CI) 
2.6* 
(1.9-3.4) 
1.6† (1.1-
2.4) 
  1.3 1.5 
(0.7-2.2) 
2.2 
(0.8-5.9) 
NS NS 1.7 
(1.4-2.1) 
 
Sensitivity          56 0.05 
Specificity          60 0.98 
Wheeze: 
Odds Ratio 
(95% CI) 
3.4* 
(2.6-4.5) 
1.5† (1.2-
1.8) 
2.2 
(0.9-5.5) 
1.8 
(1.1-2.8) 
1.6 
(p<0.001) 
1.7 
(1.1-2.7) 
 1.5 
(1-2.3) 
4.7 
(2.1-10.4) 
1.9 
(1.6-2.3) 
 
Sensitivity          68  
Specificity          55  
Dyspnoea: 
Odds Ratio 
(95% CI) 
2.4* 
(1.9-3.2) 
1.8† (1.2-
2.6) 
3 
(1.5-5.9) 
0.9 
(0.5-1.4) 
1.3 
(p<0.001) 
 0.9 
(0.4-1.9) 
2.4 
(1.6-3.5) 
NS 1.2 
(1-1.5) 
 
Sensitivity          75  
Specificity          37  
Table 1.2: The odds ratios, sensitivities (%) and specificities (%) of different symptoms of airways disease 
for the diagnosis of COPD (statistically significant odds ratios highlighted in bold)  
 
All OR calculated using multivariate logistic regression except *univariate analysis and †binary logistic regression 
COPD case definition unless otherwise noted defined as post-bronchodilator FEV1/FVC ratio <0.70 
(a) COPD case definition: pre BD FEV1/FVC ratio <0.7 if ≤69 years; pre BD FEV1/FVC ratio <0.65 if ≥70 years 
(b) COPD case definition: pre BD FEV1/FVC ratio <0.7 
(c) COPD case definition: pre BD FEV1/FVC ratio < lower limit of normal as per ATS-ERS guidelines 
(d) COPD case definition: pre BD FEV1/FVC ratio <0.7 and aged ≥40 years and ≥20 pack year smoking history
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 Kamath et al. Smith et al. 
Cough: 
Odds Ratio (95% CI) 1.7 (0.3-11)  
Sensitivity 91.3  
Specificity 13.6  
Cough with sputum: 
Odds Ratio (95% CI) 0.32 (0-3.3) 6.9 (1.3-37.2) 
Sensitivity 87 55.6 
Specificity 4.6 84.6 
Haemoptysis: 
Odds Ratio (95% CI) 1.2 (0.3-4.3)  
Sensitivity 30.4  
Specificity 72.7  
Wheeze: 
Odds Ratio (95% CI) 2.3 (0.7-7.5)  
Sensitivity 65.2  
Specificity 54.5  
Dyspnoea: 
Odds Ratio (95% CI) 1.31 (0.4-4.5)  
Sensitivity 69.6  
Specificity 36.4  
Table 1.3: The odds ratios, sensitivities (%) and specificities (%) of 
different symptoms of airways disease for the diagnosis of 
bronchiectasis 
 
1.3.4 Summary 
In summary the predictive value of cough, wheeze and dyspnoea have been evaluated in 
large population studies. 
Evidence suggests that none of these symptoms are particularly sensitive or specific for 
diagnosing airways disease when used alone. Wheeze is likely to be the most useful 
symptom in identifying disease with a significant component of airway obstruction such as 
classical descriptions of asthma or COPD, whilst productive cough is likely to be most useful 
for diagnosing bronchiectasis. The presence of certain combinations of symptoms that vary 
in time and intensity may be more specific for an underlying diagnosis of asthma. 
Such a lack of discriminatory value for symptoms in diagnosing airways disease is likely due 
to the fact that multiple types of airways disease and many other conditions not related to 
the airways cause the same symptoms. Accordingly, although eliciting an accurate 
description of symptoms will always be an important starting point in the description of 
airways disease, superior ways of characterising patients disease are required. This process 
should begin with an understanding of the underlying pathophysiology of airways disease.  
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1.4 Pathophysiology of Airways Disease 
1.4.1 Introduction 
There is some controversy in the field of airways disease regarding the extent to which 
airways disorders can be classified as distinct conditions or whether these should be 
considered as a spectrum of disease with different pathological components. Key concepts 
that require definition at this point are the phenotype and endotype of an individual. The 
phenotype of an individual refers to the observable disease characteristics of that individual 
resulting from the interaction of its genetic material with the environment. The term 
endotype describes a subtype of a disease defined by a distinct pathological mechanism 
(153).  
Clearly there are many patients who display the ‘classical’ asthma phenotype with features 
of allergic asthma starting in childhood, just as there are many of those with the ‘classical’ 
COPD phenotypes of smoking-induced neutrophilic chronic bronchitis or emphysema. 
However, there are also a significant number of individuals who exhibit features classically 
attributed to both of these conditions (154) or who may additionally display features of 
disease more commonly associated with chronic infective states such as bronchiectasis 
(155). 
The recognition of different phenotypes of airways disease and the different pathological 
components that contribute to this disease is a research area of growing interest. This has 
led to the development of biological therapies targeting specific endotypes. There is much 
further work to be done to elucidate the distinctive patterns of disease underlying particular 
phenotypes. Such an understanding should ultimately lead to more targeted therapies 
required for successful treatment of a spectrum of disease and this will enable clinicians to 
progress from the current ‘one size fits all’ approach to the management of airways disease. 
1.4.2 Previous definitions and divisions of airways disease components 
The characterisation of airways disease as a combination of clearly defined pathological 
components is not a new concept, having first been proposed in the 1960s as part of the 
“Dutch Hypothesis” (4) outlined in Section 1.2. This hypothesis emphasised the description 
of different pathological components in each individual patient on an overall spectrum of 
“chronic non-specific lung disease”.  
The separation of different pathological mechanisms into “components” of lung disease is 
known as a nominalist approach to the definition of disease (156), and this approach has 
been advocated by various authors (5, 157, 158) in contrast to the essentialist approach that 
considers asthma, COPD and bronchiectasis as being distinct disease entities with little or no 
overlap. 
A system devised to characterise airways disease based on the assessment of five relatively 
independent pathophysiological abnormalities, “the A to E of airways disease” has 
previously been described (159). The aim of this approach is to provide a framework by 
which to assess the relative contribution of each of these disease components to an 
individual patient’s disease and use this to guide phenotype-directed treatment. Even more 
recently a new paradigm based on the identification of phenotypic or endotypic 
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characteristics (‘treatable traits’) to guide individualised treatment in airways disease 
irrespective of a disease label has been proposed (160). It is therefore important to discuss 
some of the most well characterised pathological components of airways disease and 
explore the relationships between these different factors. In addition, the relative 
contributions of these factors to common phenotypes of airways disease and targeted 
treatments for each of these components is also assessed. 
1.4.3 Airway Hyperresponsiveness (AHR) 
1.4.3.1 Definition 
AHR refers to the exaggerated narrowing of airways through airway smooth muscle 
mediated bronchoconstriction following exposure to a direct or indirect stimulus (161). 
This is detected clinically using bronchial challenge testing, which exposes subjects to a 
stepwise increase in the dose of a recognised bronchoconstriction stimulus such as 
methacholine whilst measuring their lung function, as in the so-called methacholine 
challenge test (MCT). The measure used to quantify AHR is the provocative concentration or 
dose of the agent that induces a 20% fall in FEV1 (PC20 or PD20). This test will be discussed 
further in the ‘Diagnosis of Asthma’ section (Section 1.5.3.4). 
1.4.3.2 Affected Phenotypes 
AHR is a particularly characteristic feature of the classical asthma syndrome, and is thought 
to be responsible for the symptoms of short term, sudden onset shortness of breath, 
wheeze and chest tightness, sometimes in response to a recognised allergen. It has been 
suggested that the presence of AHR in asthmatic patients may be an independent risk factor 
for a reduced FEV1 later in life (162, 163) and fixed airflow obstruction (164). 
AHR is also commonly noted in patients with a diagnosis of COPD (165) with up to 50% of 
COPD patients having some degree of AHR (166).  Its presence in patients diagnosed with 
this condition is associated with an increased risk of mortality (167).  
Healthy individuals with no recognised respiratory disease can also demonstrate AHR on 
bronchial challenge testing as well as smokers and those with conditions including allergic 
rhinitis and respiratory infections (168). Data from a cohort study suggest that in 
asymptomatic individuals, AHR is a risk factor for the later development of airways disease 
(169). 
1.4.3.3 Pathological Mechanism 
It has been observed that some patients with asthma lack a protective bronchodilator effect 
that occurs on deep inspiration which is present in healthy individuals (170). The loss of this 
protective mechanism appears to be critical in the development of AHR (171) and may be 
due to increased inflammation and mast cell infiltration of airway smooth muscle as noted 
in a group of asthma patients (172). Mast cell infiltration of the smooth muscle bundle 
seems to be one of the key pathological changes in AHR (173), and previous work has 
demonstrated a linear relationship between these two variables (174). 
A series of in vitro studies have implicated abnormalities in airway smooth muscle structure 
and function in the development of AHR. These include increased airway smooth muscle 
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mass (175), which was thought to lead to AHR by generating excessive force when 
contracting (175, 176). However, more recent work suggests that increased dynamic muscle 
stiffness (due to the failure of the airway smooth muscle to relax and lengthen during deep 
inspiration) may be a more important mechanism (177). Other factors that have been 
proposed to contribute to AHR in asthma include increased vagal tone (178) and increases in 
free intracellular calcium (179) or activation of the Rho kinase pathway (180) leading to 
increased smooth muscle contractility. 
1.4.3.4 Treatment  
a) β-agonists  
Short and long acting β2-agonists are the most effective established treatments for AHR, 
although β2-adrenergic receptors may become downregulated with over frequent exposure 
to inhaled β2-agonist (181) and lead to patient tolerance to β2-agonist therapy (182, 183). 
New ultra-long-acting forms of β2-agonists (indacaterol) have recently been developed. 
b) Long acting anti muscarinic receptor antagonists (LAMAs) 
LAMAs have been demonstrated to have a significant and sustained bronchodilator effect in 
patients with COPD (184) and a modest sustained improvement in bronchodilation using 
LAMAs has also been observed in subjects with asthma poorly controlled by standard 
treatment (185). The bronchodilation effect of LAMAs occurs via competition with 
acetylcholine at muscarinic receptors on airway smooth muscle (186). This established 
bronchodilator effect of LAMAs might be expected to mitigate against AHR although the 
direct evidence that LAMAs reduce AHR (“bronchoprotective” effect) is mixed as some 
studies have demonstrated a bronchoprotective effect of LAMAs (187, 188) whilst others 
have not (189). It has been suggested that LAMAs may exert a bronchoprotective effect via 
indirect mechanisms (i.e. by effects on the levels of inflammatory mediators) rather than by 
a direct effect on airway smooth muscle (190). Therefore any future studies aiming to 
further elucidate the effect of LAMAs on AHR may need to utilise different types of 
(‘indirect’) bronchial challenge testing that do not assess bronchoconstriction to direct 
challenge agents such as methacholine or histamine.  
c) Inhaled steroids 
It is well established that inhaled steroids improve AHR (191, 192), possibly as early as 3 
hours after the first dose (193, 194). This effect is dose dependent (195) and AHR may 
continue to improve for weeks to months after starting treatment (191, 196, 197) . The 
improvement is usually at least one doubling dose shift in PC20/PD20 with a low-medium 
dose inhaled corticosteroid (ICS) (<1000 µg BDP equivalent/day) and two doubling dose 
shifts with high dose ICS (≥1000 µg BDP equivalent/day) (192). The mechanisms by which 
ICS improve AHR are not fully delineated but these may include a decrease in airway 
vascular permeability (198) or inhibition of the overexpression and activation of CPI-17 
(199), an inhibitor protein which inhibits phosphorylation of myosin phosphatase and 
ultimately leads to smooth muscle contraction. 
d) Anti TNFα agents 
TNFα is a mast cell produced mediator that has been strongly linked to the development of 
AHR making it a promising therapeutic target in refractory asthma (200, 201). Use of the 
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TNFα blocker etanercept was initially evaluated in a small randomised controlled trial (RCT) 
conducted by Berry et al. (202) which compared this treatment against placebo in a double-
blind, crossover pilot study of 10 patients with refractory asthma. Etanercept treatment 
significantly improved bronchial reactivity, as assessed by MCT, and quality of life scores in 
refractory asthma patients. 
Unfortunately, a multicentre RCT (203) assessing the effect of TNFα blockade using 
golimumab in 309 patients with severe persistent asthma had to be discontinued 24 weeks 
into treatment due to the significantly increased risk of serious infection and cases of 
malignancy seen in the group treated with golimumab. No significant differences were seen 
in the endpoints of pre-bronchodilator FEV1 and number of severe exacerbations between 
the active and placebo groups at the point the trial was stopped. However, post-hoc analysis 
of the data demonstrated a significantly reduced number of severe exacerbations in a sub-
group of patients with significant reversibility (>12% at baseline).  
e) Anti TSLP antibodies 
TSLP is a cytokine derived from epithelial cells which is an important mediator in allergic 
inflammatory responses and acts directly on mast cells and eosinophils (204). The 
expression of TLSP has been demonstrated to be increased in subjects with asthma (205) 
and a genetic variant of the TSLP gene is associated with increased risk of asthma and AHR 
(206).  
An RCT of 31 subjects with mild allergic asthma demonstrated reduced AHR to specific 
allergens and to methacholine as well as reductions in indices of airway inflammation 
following anti TSLP treatment (207). Further evaluation of this intervention in subjects with 
severe poorly controlled asthma is ongoing (208).  
f) Bronchial thermoplasty 
Bronchial thermoplasty is a technique that delivers radiofrequency (RF) energy to airway 
tissue causing heating of the airway tissue. RF energy is delivered via a catheter during 
bronchoscopy to proximal conducting airways with the intention of heating tissue and 
reducing airway smooth muscle mass (209, 210). To date, three RCTs of bronchial 
thermoplasty have been conducted. 
The multicentre AIR1 trial (211) compared bronchial thermoplasty (n=56) against usual care 
(n=56) in asthmatic patients requiring inhaled corticosteroids and long acting β-agonists 
(LABAs) to control asthma. The intervention group experienced significantly fewer asthma 
exacerbations 3 and 12 months post treatment, as well as improved morning peak flows, 
asthma quality of life and asthma control 12 months after treatment. There was no 
significant difference in lung function or, interestingly, in airway responsiveness following 
treatment however, and adverse events requiring hospitalisation (including asthma 
exacerbations and partial left lower lobe collapse in one patient) were more common in the 
intervention group. 
The RISA study (212) evaluated the use of bronchial thermoplasty in severe asthmatics with 
persistent symptoms despite high dose ICS (>750 µg of fluticasone a day plus LABA ± any 
other medicines including oral steroids). Fifteen subjects underwent bronchial thermoplasty 
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in comparison to 17 who had usual care. All subjects were maintained on their usual steroid 
dose for 16 weeks after the procedure and then investigators attempted to wean inhaled 
(or oral) steroids. Following thermoplasty, patients had a transient worsening of asthma 
symptoms and 4 of the 15 patients were hospitalised with 2 having partial collapse of the 
lobe that had been treated. However, 22 weeks after treatment patients from the 
intervention group had significantly reduced use of rescue medication and improved pre-
bronchodilator FEV1 and asthma control questionnaire scores. After 52 weeks, patients from 
the thermoplasty group had significantly reduced their steroid doses in comparison to the 
control group and maintained the improvements in reduced rescue medication use and 
asthma control scores. 
Finally, the AIR2 study (213) compared thermoplasty (n=190) to a sham treatment (n=101) 
in asthmatic patients with symptoms refractory to high dose ICS/LABAs. Patients were 
randomly allocated to the thermoplasty or sham groups and the primary outcome was the 
difference in Asthma Quality of Life Questionnaire (AQLQ) scores from baseline at 6, 9, and 
12 months. The intervention group demonstrated a significantly higher improvement in 
AQLQ scores as well as showing a significant reduction in severe exacerbation rate (32%), 
the number of days lost from work/school/daily activities (66%) and the number of A&E 
visits (84%).  
Follow up studies for the AIR, AIR 2 and RISA trials have suggested that the procedure has a 
good long term safety profile, with no added clinical complications and no significant 
deterioration in the measured benefits in the thermoplasty groups compared to the control 
groups up to 5 years after the procedure (214-216). 
1.4.3.5 Summary 
AHR is a prominent pathological feature of airways disease most commonly found in 
patients with classical asthma syndrome, although it may be present independently or in 
conjunction with other conditions. The pathophysiological processes underlying AHR that 
have been identified to date include abnormalities of airway smooth muscle structure and 
function and smooth muscle infiltration by mast cells. AHR is usually effectively treated with 
β-agonist therapy and ICS, but other options are now available for patients with symptoms 
refractory to β-agonist treatment including anti-muscarinic agents, and in more severe 
cases, bronchial thermoplasty. 
1.4.4 Fixed Airway Obstruction (FAO) 
1.4.4.1 Definition 
Airway obstruction (or “limitation”) is defined in the 2005 European Respiratory Society 
(ERS) guidelines as “a disproportionate reduction of maximal airflow from the lung in 
relation to the maximal volume that can be displaced from the lung” (217). In terms of 
spirometry the ERS guidelines define this as an FEV1/VC ratio “below the 5th percentile of 
the predicted value” (217) whereas GOLD guidelines define this as an FEV1/FVC ratio <70% 
(218). Hence, fixed airway obstruction (FAO) may be defined at its simplest as airway 
obstruction that does not significantly improve in response to bronchodilators – i.e. the FEV1 
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fails to improve by ≥200 mL and ≥12% from baseline (assuming that the baseline FEV1 is 
sufficiently low to allow improvement by these parameters, i.e. <~80%). 
FAO has also previously been defined by a post bronchodilator FEV1/FVC ratio <70% on ≥2 
occasions (31, 219, 220) although this value has not been universally agreed (221). 
1.4.4.2 Affected Phenotypes 
The demonstration of FAO is necessary for the diagnosis of COPD and the fixed nature of 
this obstruction (i.e. non-significant reversibility of the airways to bronchodilators) 
traditionally has been the distinguishing diagnostic feature between COPD and asthma, with 
the airways in the latter condition classically demonstrating bronchodilator reversibility. 
However, as mentioned above, a significant proportion of COPD patients demonstrate AHR 
and some clinical trials have reported up to 50% of subjects with diagnosed COPD had 
significant reversibility as per American Thoracic Society (ATS) guidelines (222, 223).  
FAO also affects a significant proportion of asthmatic patients and seems to be particularly 
prevalent in subjects with severe or difficult to treat asthma. Long term follow up studies of 
asthmatic subjects with reversible airflow limitation suggest that around 16-26% of patients 
eventually develop FAO (220, 224). Studies specifically assessing the characteristics of 
severe or difficult to treat asthmatics by contrast report prevalence rates of FAO of 50-60% 
(219, 221). 
The ‘Asthma-COPD overlap syndrome’ (ACOS) is a term used to describe subjects with 
overlapping diagnoses of asthma and COPD i.e. symptoms relating to increased airflow 
variability and airflow obstruction that is incompletely reversible (10). ACOS is recognised 
not as a single condition but rather a combination of two or more obstructive airways 
syndromes such as “asthma”, “emphysema” or “chronic bronchitis” (225, 226). Analyses of 
the prevalence of separate and combined obstructive airways syndromes in large scale 
population studies estimate 13-19% of subjects with obstructive lung disease in the UK and 
USA have more than one type of obstructive lung disease (154, 227). Marsh et al. (228) 
categorised around 10% of 469 patients in a study to classify the relative proportions of 
phenotypes of COPD with ACOS. Patients labelled as having ACOS may experience an 
increased frequency of more severe exacerbations of airways disease than those who have 
been diagnosed with either of these conditions in isolation (227, 229). 
The presence of FAO in any of the phenotypes described above is a predictor of increased 
morbidity, including increased decline in FEV1 and increased frequency of exacerbations 
(229), as well as mortality (230, 231). 
1.4.4.3 Pathological mechanism 
Fixed airflow obstruction is thought to result from the pathophysiological process known as 
airway remodelling. Airway remodelling refers to structural changes observed in the large 
and small airways of subjects with airway disease including asthma and COPD (232, 233). 
Biopsies from patients diagnosed with COPD have revealed many structural changes in the 
remodelled large and small airways such as increased epithelial thickness and epithelial 
metaplasia. In addition, changes in the extracellular matrix (ECM) of the airway wall 
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including fibrosis and goblet cell hyperplasia, and increased thickness of airway smooth 
muscle (234) are also apparent. Changes of remodelling observed in the small airways and 
lung parenchyma of subjects with COPD include emphysema with loss of alveolar 
attachments and collagen deposition (235) and peribronchial fibrosis (236). 
Similar pathological features have been noted in the remodelled airways of asthmatics 
including airway wall thickening, epithelial cell proliferation with increased epithelial cell 
shedding, subepithelial fibrosis, goblet cell hyperplasia, increased airway smooth muscle 
mass and bronchial neovascularisation (237, 238).  
Despite there being considerable overlap in many of these pathophysiological processes 
between subjects diagnosed with asthma and COPD, there are also some notable 
differences.  
Firstly, although airway remodelling occurs in both conditions throughout the bronchial 
tree, there is a higher burden of structural changes associated with COPD in the small 
airways (236) and lung parenchyma than in asthma. In certain phenotypes of COPD, 
including alpha 1-antitrypsin deficiency, destruction of the alveolar walls (i.e. 
emphysematous change) may develop which is not typically a feature of asthma (239). 
Secondly, airway wall thickening may be less pronounced in COPD (239-241) possibly due to 
a lesser degree of airway smooth muscle thickening (242), although some studies have 
shown no difference (243). Thickening of the basement membrane has been well described 
in asthma and comparative studies assessing basement membrane thickness in bronchial 
biopsies from asthma and COPD patients have concluded this feature is more prominent in 
bronchial cells from asthmatic subjects (244, 245). Finally, bronchial 
neovascularisation/angiogenesis may be a prominent feature of the asthmatic airway (246), 
particularly in those with severe steroid-dependent asthma (247), whereas this is not a 
significant finding in COPD (248).  
1.4.4.4 Treatment 
As the pathogenesis of airway remodelling is not well understood this has understandably 
hindered the development of therapeutic agents specifically targeted against this process. 
Despite this, a number of (mostly in vitro) studies have sought to assess the effects of 
conventional asthma therapies on remodelling. The most promising results so far using ICS 
and bronchial thermoplasty will now be discussed. 
a) Inhaled corticosteroids (ICS) 
ICS are the most well studied asthma treatment with regards to their effects on airway 
remodelling. Asthmatic patients with FAO have been demonstrated to show no 
improvement to LABA monotherapy in terms of lung function and asthma control but may 
still respond to ICS treatment in terms of these measures (249).  
In vitro studies have suggested ICS may reduce airway smooth muscle hyperplasia (250) and 
improve vascular remodelling (251). A number of clinical investigations have also shown 
improvements in various parameters related to remodelling with ICS treatment including a 
reduction in basement membrane thickness (252, 253), epithelial remodelling (254) and 
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vascular remodelling (255) although these improvements have not been observed in all 
studies (256, 257). 
b) Bronchial thermoplasty 
Bronchial thermoplasty (Section 1.4.3.4) has been proposed as a therapy to target airway 
remodelling owing to its purported mechanism of action in reducing airway smooth muscle 
(ASM) mass. The evidence of its effect on ASM comes from canine proof of concept studies 
(209) and a safety study in nine human lung cancer patients (without asthma). Data derived 
from the human safety study where RF energy was applied to lung segments/lobes which 
were later resected, indicated that on average a 50% reduction in ASM mass occurred (258).  
There are suggestions from a limited case series of 3 patients that bronchial thermoplasty 
reduces ASM mass in the asthmatic airways (259), and this may be the mechanism leading 
to an observed clinical benefit. However, this approach requires further evaluation in future 
clinical trials. 
1.4.4.5 Summary 
FAO secondary to airway remodelling is undoubtedly an important pathological mechanism 
in subjects with COPD, severe or difficult to treat asthma and ACOS which leads to increased 
morbidity and mortality in these groups. Certain pathological features of remodelling have 
been observed in the airways but the pathogenesis and natural history of this process are 
not fully understood. This may have led to an under-appreciation of airway remodelling as a 
significant factor in the phenotyping of airways disease and much further work needs to be 
done to characterise this phenomenon and develop effective treatment to prevent FAO. 
1.4.5 Airway Inflammation 
Airway inflammation (bronchitis) is a cardinal feature of airway disease. The importance of 
recognising the heterogeneity of types of airway inflammation and their underlying 
pathophysiological mechanisms has only been established relatively recently, in parallel 
with the introduction and standardisation of investigations that are able to measure and 
classify types of airways inflammation. 
Through the use of one of these techniques, the microscopy and differential cell count of 
induced sputum, four main subtypes of airway inflammation have been recognised and 
these are (1) eosinophilic, (2) neutrophilic, (3) mixed granulocytic and (4) paucigranulocytic 
(260). 
Both eosinophilic and neutrophilic airway inflammation will be discussed in further detail 
below. The mixed granulocytic and paucigranulocytic inflammatory subtypes are of 
uncertain significance, although it has been suggested that subjects with a mixed 
granulocytic pattern may represent a ‘transitional’ phenotype between neutrophilic and 
eosinophilic subtypes or vice versa (261). Patients displaying paucigranulocytic inflammation 
seem to have relatively normal lung function (262) and display similar gene expression at 
the RNA level to healthy controls (261), which may suggest this is consistent with a mild 
inflammatory airways disease phenotype. 
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1.4.6 Eosinophilic Inflammation  
1.4.6.1 Definition 
The eosinophilic inflammatory subtype is the most clearly defined with a standard definition 
of >3% eosinophils/total sputum cell count (263).  
1.4.6.2 Affected Phenotypes 
Ongoing eosinophilic inflammation is a notable feature of airway disease. Eosinophilic 
asthma is the best studied asthma ‘phenotype’ and it is estimated that between 40-50% of 
people with an asthma diagnosis have underlying eosinophilic airways inflammation (264, 
265).  
The stability and/or reproducibility of eosinophilic inflammation over time seems to vary 
with different severities of airways disease. Sputum eosinophilia seems to be persistent in 
certain sub-phenotypes of asthma with reproducible sputum eosinophil counts obtained 
over a 5 year period in a cohort of adult patients with severe asthma despite ICS treatment 
(266). McGrath et al. (267) studied a group of 157 patients with mild to moderate asthma 
and found 35 (22%) to have a persistent eosinophilia whilst not using ICS treatment, whilst 
49 (31%) had an intermittent eosinophilia and 73 (47%) were persistently non-eosinophilic. 
In a comparable group of 167 patients with mild asthma on ICS treatment 12 (7%) were 
persistently eosinophilic, 34 (20%) had an intermittent eosinophilia and 121 (72%) were 
non-eosinophilic. This study demonstrates one of the difficulties of determining the 
underlying type of inflammation, namely that steroid treatment tends to suppress 
eosinophilic inflammation and may prolong neutrophil survival (268). Sputum inflammatory 
phenotypes do not seem to be stable in children with asthma. Fleming et al. (269) found 
that of 59 children (42 with severe asthma and 17 with mild to moderate asthma) who had 
sputum samples processed for differential cell counts every 3 months for a year, 63% 
displayed 2 or more inflammatory subtypes during this period. 
Some investigations have suggested that the degree of eosinophilic inflammation may 
directly correlate with the severity of disease in patients with an asthma diagnosis (221, 
270-273) although others have found no evidence for this (274-276). Other investigators 
have suggested that it is not asthma severity but asthma control that correlates with the 
degree of eosinophilic inflammation, with worse control being associated with higher levels 
of inflammation (277-280). A number of more recent studies in which investigators have 
attempted to identify sub-groups of asthmatic patients with similar phenotypic 
characteristics using statistical methods such as cluster analysis have characterised several 
clusters (groups with shared phenotypic characteristics) of patients exhibiting eosinophilic 
inflammation with varying severities of disease, and this may explain some of the 
discrepancies found in previous investigations (281, 282).  
Eosinophilic inflammation has also been demonstrated in 20-40% of patients with a 
diagnosis of COPD (283). The relationship between lung function and the degree of 
eosinophilic inflammation in COPD is unclear. Lams et al. (284) demonstrated a significant 
negative correlation between FEV1 and the ratio of activated eosinophils to total eosinophils 
in endobronchial biopsy samples taken from COPD patients and Balzano et al. (285) similarly 
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found a negative correlation between FEV1 and sputum eosinophil count/eosinophilic 
cationic protein (ECP) levels. In contrast, Hogg et al. (236) found no significant correlation 
between COPD severity as graded by GOLD score, and level of small airway eosinophilic 
inflammation.  
The diagnostic term ‘eosinophilic bronchitis’ is generally used to describe a disease state in 
which eosinophilic inflammation of the airways is the sole pathological feature, without AHR 
and variable airflow obstruction that might be seen in a classical asthma phenotype (88). EB 
typically presents as a chronic cough, and although the incidence and prevalence of the 
condition are unclear, it is thought to be responsible for between 10-30% of cases of chronic 
cough referred to the specialist respiratory clinic (286). 
1.4.6.3 Pathological mechanism 
Eosinophilic inflammation has been well studied in asthma, and classically associated with 
allergic sensitisation and a Th2 cell-dependent, IgE mediated inflammatory response. 
The current understanding regarding the immunopathology of eosinophilic inflammation is 
summarised diagrammatically in Fig 1.1.  
 
Figure 1.1: Immunopathology of eosinophilic inflammation in 
asthma (adapted from Barnes P. (287))  
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Th2 mediated asthma with eosinophilic inflammation can also be triggered by other non-
allergenic stimuli such as viral infection and air pollution (288). This may be due to cytokines 
released from the bronchial epithelium in response to these insults, such as TSLP release in 
response to viral infections (289) or release of cytokines including IL-8 and GM-CSF in 
response to airway pollutants (290). 
a) Eosinophils 
Eosinophils are a key effector cell in the inflammatory response noted in eosinophilic 
asthma and release a variety of substances including: 
 Pre-stored cytotoxic proteins including eosinophil cationic protein, eosinophil 
peroxidase and major basic protein, all of which may play a role in the epithelial 
damage observed in the airways of asthmatics (291). 
 Th1 and Th2 cytokines and chemokines which contribute to the maintenance of 
ongoing inflammation (292).  
 Fibrogenic cytokines including TGF-β which may contribute to sub-epithelial 
fibrosis/airway remodelling (293). 
Eosinophils can also directly regulate the inflammatory response by influencing Th1 and Th2 
cytokine generation from T cells (294) and the pulmonary dendritic cell response to allergen 
exposure, promoting a Th2 dominated immune response and suppressing Th1/Th17 
responses (295). 
1.4.6.4 Treatment 
a) Corticosteroids 
There is substantial evidence that sputum eosinophilia is a strong predictor of response to 
steroid therapy (268, 296, 297). Various studies have attempted to titrate corticosteroid 
treatment depending on the degree of eosinophilic inflammation present, as assessed by 
induced sputum differential cell count or exhaled nitric oxide assessment. A meta-analysis 
studying the titration of treatment based on sputum eosinophil count based on three 
studies conducted in patients with asthma concluded that this strategy would be an 
effective way of minimising asthma exacerbations without a net increase in the dose of ICS 
(298). A similar study involving patients with COPD (299) found that a sputum based 
strategy significantly reduced the number of severe exacerbations in the sputum group 
compared to the control group. A meta-analysis of 6 RCTs including adults, adolescents and 
children investigating the titration of steroid treatment based on exhaled nitric oxide 
monitoring (298), which has a positive correlation with sputum eosinophilia (300), failed to 
show any significant improvement in the exacerbation rate using this approach.  
A sub-phenotype of patients with severe refractory asthma has been identified with a 
characteristically persistent eosinophilia despite standard high dose inhaled steroid 
treatment (281). This group of patients typically have few daily symptoms, develop features 
of airways disease later in life (281), and may also have problems with rhinosinusitis (301) or 
aspirin sensitivity (302). The persistent eosinophilia is associated with persistent airflow 
limitation (221), an increased rate of asthma exacerbations (303) and a dependence on oral 
corticosteroid therapy (304). It has been hypothesised that this group of patients may have 
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a greater degree of small airway inflammation (305), which would explain their relative 
insensitivity to treatment with standard ICS therapy and need for long courses of systemic 
steroid treatment to improve their asthma control. Small particle inhaled steroids may be of 
some benefit in treating patients in this sub-phenotypic group due to their theorised greater 
penetration into the small airways. Small particle ICS have been shown to reduce the 
number of eosinophils in small airway biopsies (306) and suppress sputum eosinophil counts 
in subjects with refractory asthma (307) as well as reducing the number of asthma 
exacerbations in patients with severe persistent asthma (308). However, many of these 
patients still require long term systemic steroid treatment and are at risk of the significant 
side effects of this treatment (309).  
Attempts have been made to develop more targeted therapies for refractory asthma, which 
is frequently associated with ongoing eosinophilic inflammation. 
b) Anti IgE 
The first biological therapy licensed for asthma treatment in the UK is the recombinant 
humanised monoclonal anti-IgE antibody omalizumab. Omalizumab attenuates the early 
and late phase allergic responses to allergen by inhibiting the binding of IgE to the high-
affinity IgE receptor (FcεRI) on the surface of mast cells and basophils, resulting in down-
regulation of IgE receptors and inhibition of inflammatory mediator release (310). 
Although serum IgE levels do not correlate with levels of tissue eosinophils treatment with 
omalizumab has been shown to reduce airway and blood eosinophil counts (311). This may 
be because the down-regulation of the FcεRI receptor on basophils and mast cells limits 
allergic IgE-mediated responses and prevents Th2 cytokine release and eosinophilic airway 
infiltration (312).  
Meta-analyses of multiple clinical trials have confirmed the therapeutic efficacy of 
omalizumab as an additional treatment to corticosteroids and LABA therapy in patients with 
severe persistent allergic asthma (313). Data from these trials revealed that baseline total 
IgE was the only baseline predictor of treatment efficacy, but that there were treatment 
benefits regardless of IgE levels (314). 
c) Anti IL-5 
Owing to the importance of the cytokine IL-5 in increasing eosinophil production, 
recruitment and survival in eosinophilic asthma this is a rational target for therapy in this 
condition. Animal studies showed significantly reduced levels of airway eosinophils and AHR 
in response to allergen following anti-IL-5 treatment (315). 
Initial clinical trials in humans of anti-IL-5 treatment failed to replicate these findings and 
despite reducing serum eosinophil counts showed no significant effect on AHR or clinical 
benefit (316-318). However, these studies did not specify an asthmatic patient cohort with 
eosinophilic asthma, and the fact that they were undertaken with an unselected asthma 
cohort may have contributed to their failure to demonstrate any obvious clinical 
improvement. Later trials that selected patient cohorts with refractory eosinophilic asthma 
showed improvements in clinical measures with anti-IL-5 treatment (mepolizumab). These 
included a significant reduction in asthma exacerbations, improved symptom scores and 
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quality of life and improved FEV1 (319, 320). Mepolizumab has now been approved by NICE 
as a treatment for subjects with severe refractory eosinophilic asthma in the UK (321). 
Further anti-IL5 therapies including reslizumab (322) and benralizumab (323) have also been 
demonstrated to significantly reduce asthma exacerbation frequency in subjects with severe 
uncontrolled eosinophilic asthma and are likely to be approved in the near future.  
d) Anti IL-13 
Another important cytokine in Th2 mediated asthma with a key role in eosinophil 
recruitment into airways is IL-13 (324). Corren et al. (325) conducted a clinical trial of the 
anti-IL-13 treatment lebrikizumab in 219 adult asthma patients with uncontrolled asthma 
refractory to corticosteroids and LABA therapy. There was a significant improvement in FEV1 
from baseline in the treatment arm compared to placebo, which was more significant in 
subjects with high levels of ongoing Th2 inflammation at baseline (as defined by high serum 
periostin levels). Phase 3 studies however did not consistently show a significant reduction 
in asthma exacerbations in Th2 biomarker-high patients with lebrikizumab (326). 
e) Anti IL-4 
IL-4 is an important mediator of allergic asthma, and is responsible for many of the key 
pathophysiological features of this condition. These include the differentiation of CD4+ T 
cells into effector Th2 cells, isotype class switching of B cells to produce IgE in the allergen 
sensitisation stage (327), and promoting goblet cell hyperplasia and mucus production in 
the early allergic response (328). 
IL-4 and IL-13 signal through different receptors, but both receptors share the α subunit of 
the IL-4 receptor (IL-4Rα) (327). Several anti-IL-4 agents have been investigated in clinical 
trials thus far. The IL-4 monoclonal antibody pascolizumab was well tolerated in Phase I 
trials, but failed to show any significant clinical benefit in a Phase II study and further 
development was discontinued (329). The recombinant human IL-4Rα antagonist 
altrakincept (330) and the IL-4/IL-13 cytokine heterodimeric receptor antagonist pitinkinra 
(331) showed some modest benefit in clinical measures in Phase I/II clinical trials but both 
agents have also been discontinued. 
Wenzel et al. (332) conducted a double blind placebo-controlled trial of dupilumab, a 
humanized monoclonal antibody to the IL-4Rα subunit in 104 patients with moderate to 
severe persistent asthma and eosinophilia. Subjects in the treatment group showed a 
significant improvement in lung function and a reduced number of exacerbations in 
comparison to the placebo group after withdrawal of ICS and LABA therapy. Dupilumab also 
decreased levels of Th2 associated biomarkers from baseline including FENO and IgE levels. A 
further large scale RCT (n=769) in patients with uncontrolled persistent asthma also showed 
significant improvements in lung function and severe exacerbation rate with Dupilumab 
irrespective of baseline eosinophil count (333). Phase 3 trials are ongoing. 
1.4.6.5 Summary 
Eosinophilic inflammation is a well-defined, relatively well-characterised process which is a 
pathological feature of several different airway diseases. It is usually associated with allergic 
asthma but there appear to be different phenotypes of asthma of which eosinophilic 
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inflammation is a feature. Eosinophilic inflammation normally responds well to steroids and 
monitoring sputum eosinophil counts in patients with eosinophilic asthma and COPD has 
proven to be a successful strategy in titrating steroid doses. However there is a sub-group of 
patients with severe asthma who may exhibit persistent eosinophilic inflammation 
refractory to high dose corticosteroid treatment.  Newly developed biological agents 
targeting the chemical mediators of Th2 inflammation are being developed and these may 
prove effective in subjects with corticosteroid resistant asthma and/or corticosteroid 
resistant eosinophilic inflammation as part of other airway conditions. 
1.4.7 Neutrophilic Inflammation  
1.4.7.1 Definition 
Diagnostic criteria for neutrophilic inflammation in sputum is less well defined due to a 
greater variability and an observed increase in differential neutrophil count seen with age 
(334), although this has previously been defined as either >61% neutrophils/total sputum 
cell count based on the 95th percentile value in a healthy population (260) or >77.7% based 
on +2 standard deviations from a healthy population mean (335). 
1.4.7.2 Affected Phenotypes 
Neutrophilic airways inflammation is well recognised in patients diagnosed with COPD. 
Elevated neutrophil counts have been detected in sputum and BAL samples from subjects 
with stable COPD (336) and these have been found to directly correlate with the degree of 
airflow obstruction (337) and air trapping (338). 
Neutrophilic inflammation is also one of the main pathological features of bronchiectasis, in 
which it is thought to be an ongoing response to bacterial colonisation of the airways. 
Sputum neutrophilia in bronchiectasis may be particularly prominent, with a percentage of 
neutrophils of the overall cell count in BAL or sputum of up to 90% (339, 340). Patients with 
the highest bacterial load in the airways tend to have higher proportions of neutrophils in 
sputum cell counts (340). 
A significant sub-group of 20-30% of patients with diagnosed asthma also have underlying 
neutrophilic inflammation (260, 296). This is more frequent in older patients (281), obese 
women (341), smokers (342) and in more severe disease (343, 344), and has also been 
reported as a significant autopsy finding in cases of fatal asthma (345). The degree of 
neutrophilia inversely correlates with lung function (346, 347) and has also been 
demonstrated to relate to the degree of gas trapping (346, 348). The significance of an 
increased sputum neutrophil count in patients with asthma has however been questioned, 
owing to the potential confounding effect of steroid treatment in reducing sputum 
eosinophils and possibly increasing sputum neutrophils (268). However, a neutrophilic 
inflammatory pattern has been observed in steroid naïve asthmatic individuals (267, 296) as 
well as asthmatic individuals who have had steroids withdrawn (268), suggesting this is a 
distinct phenotype.  
The stability of the neutrophilic asthma phenotype seems unclear. Studies including those 
by Green et al. (303) and Simpson et al. (260) suggest that ‘non-eosinophilic asthma’ is a 
stable subtype over a period of 1-5 years. This term however includes any patient not 
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meeting the criteria for eosinophilic asthma (>3% eosinophils in total sputum count) and as 
such incorporates those with mixed granulocytic and paucigranulocytic inflammatory 
subtypes as described above as well as individuals displaying a neutrophilic phenotype. Al-
Samri et al. (349) found a large amount of variability in sputum inflammatory cell types from 
61 patients with moderate and severe asthma on corticosteroid therapy over the course of 
1 year, with stable phenotypes found in only a third of subjects. A more recent investigation 
using cluster analysis profiling techniques to try and delineate different phenotypic asthma 
groups found that sputum inflammatory cell counts are a less stable feature to try and sub-
classify disease than physiological variables including lung function, reversibility and age of 
onset of disease (350). 
1.4.7.3 Pathological Mechanism 
Current evidence seems to suggest that neutrophilic inflammation may initially occur due to 
alterations in the innate immune response. The innate immune response is a rapid reaction 
by elements of the immune system to certain highly conserved structures common to whole 
classes of micro-organisms known as pathogen associated molecular patterns (PAMPs). 
PAMPs are quickly recognised by pattern recognition receptors such as toll-like receptors 
(TLRs) which are expressed by a variety of cells. These include dendritic cells and 
macrophages, and once recognition has occurred these cells are activated immediately to 
respond to the detection of a pathogen, mostly through the release of cytokines (351). 
In patients with neutrophilic asthma and bronchiectasis increased expression of TLR2, the 
pro-inflammatory cytokines IL-8 and IL-1β and increased levels of endotoxins have been 
noted in comparison to patients with eosinophilic inflammation or healthy controls (339). In 
further support of the role of TLR2 in the development of neutrophilic inflammation 
Buckland et al. (352) observed in a murine model of allergic bronchopulmonary aspergillosis 
(ABPA) that TLR2 deficiency resulted in decreased levels of airway inflammation, AHR and 
mucous metaplasia. Increased expression of TLR2 may be secondary to the prolonged 
presence of bacterial products, pro-inflammatory cytokines or the use of corticosteroids 
(353). This suggests that corticosteroid use, which is effective at reducing ongoing 
eosinophilic inflammation, could potentially worsen neutrophilic inflammation (354). 
Work by Simpson et al. (355) proposed that activation of TLR2 by any of these factors could 
lead to activation of what the authors describe as the ‘Neutrophil Activation Cycle’. This 
model comprises of positive feedback interactions between three inflammatory mediators, 
the levels of which are known to be increased in patients with ongoing neutrophilic 
inflammation, namely IL-8 (CXCL8) (339, 356), and the released neutrophil proteases 
neutrophil elastase (NE) and matrix metalloproteinase (MMP) -9 (340, 357, 358). These 
studies suggest that amplification of the original inflammatory response through this cycle 
may contribute to persistence of bacteria in the airways through the mechanisms of mucus 
hypersecretion and impaired bacterial phagocytosis. The continuing colonisation of bacteria 
in the airways only serves to further increase expression of TLR2, resulting in further 
activation of the Neutrophil Activation Cycle.  
Evidence is increasing that Th17 cells, a subset of T helper cells that produce the cytokine IL-
17, are also involved in the development of neutrophilic inflammation in asthma (359, 360) 
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which is resistant to corticosteroid treatment (361). Increased IL-17 levels in sputum from 
asthmatic patients significantly correlate with sputum neutrophil counts (362) and increased 
IL-17 expression has been noted in BAL and bronchial biopsies from patients with asthma 
(363, 364) and COPD (365, 366).  
1.4.7.4 Treatment 
a) Macrolides 
One of the most well studied treatments for neutrophilic inflammation are macrolide 
antibiotics, which have been shown to significantly improve outcomes in conditions with a 
component of neutrophilic inflammation including diffuse panbronchiolitis (DPB), COPD, 
cystic fibrosis (CF) and bronchiectasis (367). Further detail on the trials investigating the use 
of macrolides to date in airways disease and their postulated mechanisms of action can be 
found elsewhere (Section 3.2.2). 
b) Monoclonal antibodies 
Clinical trials of anti CXCL8 and anti CXCR2 (a CXCL8 receptor) therapy have been carried out 
in patients with COPD. Anti-CXCL8 treatment was demonstrated to be safe and also 
improved dyspnoea scores in a group of COPD patients over a 3 month period (368). 
However this made no significant difference to lung function, health scores or 6 minute 
walking distance. Two separate CXCR2 antagonists have been demonstrated in proof of 
principle clinical trials to reduce levels of blood (369) and sputum (370) neutrophils in COPD 
patients, but neither of these resulted in improvement of any clinical measures. 
c) Other medications 
Other potential agents under investigation  for the treatment of neutrophilic inflammation 
include anti-TNFα therapy (371, 372), statins (373), theophylline (374) and anti-IL-17 
monoclonal antibodies (375), but evidence for the significant efficacy of any of these 
interventions is currently lacking.  
1.4.7.5 Summary 
Neutrophilic inflammation is an important pathophysiological process in a number of airway 
diseases. It is less well defined and characterised than eosinophilic inflammation, but 
elements of its pathobiology are becoming better understood, including the importance of 
alterations in innate immune mechanisms, the proposed ‘neutrophil activation cycle’ and 
the role of Th17 cells in its development. Macrolide antibiotics are proving to be an effective 
treatment in many conditions with underlying neutrophilic inflammation, and other 
treatment options are currently being investigated. 
1.4.8 Summary  
Instead of using diagnostic labels airways diseases may instead be described as a 
combination of relatively independent pathophysiological components. Relative levels of 
‘contribution’ of these components in combination with extra-pulmonary pathologies 
reviewed elsewhere (157) may contribute to the broad spectrum of resultant clinical 
phenotypes of airways disease. Information derived from quantitative measurement of 
these pathological components can be used to target treatment specifically against these 
pathological processes and has been demonstrated to improve patient outcomes.  
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Further clarification of the relationships between these components is required and a 
number of investigators are now attempting to define common phenotypes or ‘clusters’ of 
disease based on the relative contributions of these pathophysiological processes (362). 
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1.5 The utility of exhaled nitric oxide in patients with suspected 
asthma  
1.5.1 Introduction 
As discussed in the previous chapter, asthma is one of the most common chronic diseases in 
the UK. It was shown there that untreated asthma is associated with a high morbidity and 
mortality. There is an appreciation that the majority of asthma exacerbations and deaths 
due to asthma can be avoided with timely recognition. It is therefore essential that the 
condition is recognised early in order to institute treatment promptly (25).  
However, making a diagnosis of “asthma” may be difficult. This arises partly from the 
imprecise meaning of the term asthma itself and also the non-specific nature of respiratory 
symptoms as previously discussed. 
The importance in recognising and treating asthma combined with the difficulties in making 
a diagnosis appear to have led to an “over-diagnosis” of asthma and the evidence for this 
will be discussed below. 
Next, the investigations used in patients with suspected asthma which measure different 
components of the condition such as airflow obstruction, airway inflammation and AHR will 
be reviewed. Particular emphasis is placed on bronchial challenge testing (a measure of 
AHR) and exhaled nitric oxide measurement (a measure of airway inflammation). 
Guidelines for the diagnosis of asthma have been issued by various organisations to attempt 
to guide physicians in this subject and the most recent of these are critically appraised.  
Finally, a proposed alternative use of exhaled nitric oxide measurement allowing the 
prediction of a response to a specific treatment (inhaled steroids), rather than attempting to 
diagnose asthma, will be discussed before outlining the specific aims and objectives of this 
study. 
1.5.2 Over-diagnosis of asthma  
With the realisation that asthma morbidity and mortality rates were unacceptably high 
between the 1980s and early 2000s (376, 377) there were well founded concerns regarding 
the under-diagnosis of asthma (378-380). An increasing awareness of the condition may 
have led to much higher rates of diagnosis (14, 381). However, with the current emphasis 
now being on not ‘missing’ a diagnosis of asthma and with many diagnoses of asthma being 
made on clinical assessment alone, which as demonstrated in the previous chapter is 
unreliable, more recent data suggests that asthma is now over-diagnosed in the community. 
LindenSmith et al. (382) studied a group of 90 adult asthmatics with physician diagnosed 
asthma to determine the proportion of these subjects who met the Canadian Thoracic 
Society (CTS) guidelines for asthma. After subject details were taken and clinical history and 
a symptom questionnaire were carried out, each of these subjects underwent spirometry 
with reversibility. Those who did not demonstrate reversibility were asked to keep a 14 day 
peak flow diary with all subjects undergoing MCT. Asthma was diagnosed in any subject with 
a suggestive clinical history and either significant reversibility, peak flow variability of ≥20% 
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over a 7 day period or AHR with a PC20 of ≤8 mg/mL of methacholine. Of the 90 patients 
who completed the study only 53 patients (59%) met the CTS guidelines for a diagnosis with 
asthma. In the group of subjects who were found not to have objective evidence of asthma 
23 (62%) were taking medications for asthma. Approximately half of the entire study group 
had never had any formal pulmonary function testing.  
McGrath et al. (383) demonstrated in a study of 304 subjects recruited from the community 
with physician diagnosed asthma that 83 of these (27%) had a negative MCT, and hence a 
low likelihood of asthma. The subjects with negative MCTs typically had normal lung 
function, an adult onset of symptoms and no history of exacerbation requiring oral steroids, 
which in combination with their negative MCTs makes it likely that the majority of these 
individuals did not have asthma.  
Aaron et al. (384) conducted a study of 496 individuals (242 obese and 254 non-obese) with 
physician diagnosed asthma to determine how many had objective evidence of asthma. 
After clinical histories and symptom/quality of life questionnaires were carried out, 
spirometry and reversibility tests were performed. Patients with no significant reversibility 
underwent MCT. Any subject with a negative MCT who was taking inhaled steroids had the 
dose of these halved and any anti-leukotriene therapy was stopped. A repeat MCT was 
carried out on the latter subjects 2-3 weeks later. Any of those subjects who had a second 
negative MCT had all ICS and LABA stopped before undergoing a third MCT 2-3 weeks later. 
If this third and last MCT was negative all asthma medications were stopped and the subject 
was followed up 6 months later. Overall asthma was excluded in 77/242 (32%) of obese 
patients and 73/254 (29%) of non-obese patients with no significant difference in over-
diagnosis of asthma between the two groups. Of these 150 patients, 98 (65%) did not 
require the use of asthma medications or require medical care due to asthma symptoms 
over a 6 month period. Despite this study finding no difference in the rate of over-diagnosis 
of asthma between obese and non-obese individuals, epidemiological data suggests that 
obese subjects are around twice as likely to be diagnosed with asthma as non-obese 
individuals (385).  
Van Huisstede et al. (386) attempted to investigate the potential for over- or under-
diagnosis of asthma in a study of 86 morbidly obese patients awaiting bariatric surgery. 
These workers found that of the 32 patients with a physician diagnosis of asthma, 13 (41%) 
had no objective evidence of asthma, whereas in the 54 subjects who had not previously 
been investigated for asthma 17 (31%) were newly diagnosed with asthma. 
Over-diagnosis of asthma leads to unnecessary over-treatment of subjects with ICS. In 
addition to the findings of Aaron et al. discussed above, other studies have also highlighted 
the inappropriate over prescription of ICS. 
Lucas et al. (387) assessed the diagnoses and reasons for using ICS of 2271 patients referred 
to a primary care diagnostic centre over the course of 6 months for pulmonary function 
tests. Of these 1171 used ICS and 354 (30%) had no clear indication for using steroids based 
on their medical history and spirometry results. One-hundred and forty-nine of these 
patients were asked to stop ICS treatment for 3 months and then re-attend for repeat 
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spirometry. Of the 71 that did so, only 5 developed asthma-like symptoms and were 
restarted on ICS, whilst the other 66 had no issues after stopping steroids. After one year 
the remaining 205 (of 354) patients who had an unclear reason for ICS use and the 78 
patients who did not return for repeat spirometry (total of 283) were asked to return for 
spirometry. 49 of these had stopped ICS with no problems, 89 were still taking ICS for no 
clear reason, 79 failed to re-attend and 66 had indications to continue with ICS therapy. In 
all at least 11% of those originally using steroids did not require them and at least 15% of 
those still taking ICS at the end of the study had unclear reasons for doing so. The authors 
estimate that up to 26% of all patients in the study probably did not require ICS treatment. 
1.5.2.1 Summary 
Having previously been under-diagnosed there are compelling data suggesting that asthma 
is now over-diagnosed. This not only leads to unnecessary confusion and anxiety on behalf 
of patients labelled with an incorrect diagnosis but also to overuse of expensive inhaled 
medication with cost implications for the NHS and potentially unnecessary exposure to ICS 
side effects.  
The accuracy of asthma diagnosis may be improved by the use of objective tests that are 
capable of measuring and quantifying the degree of the ongoing pathological processes and 
these will now be reviewed. 
1.5.3 Comparison of investigations for the diagnosis of asthma: 
1.5.3.1 Sensitivity and Specificity 
Before discussion of the various investigations used to support a diagnosis of asthma it is 
important to clarify the terms used to compare the diagnostic usefulness of these 
investigations. These terms include the sensitivity (the percentage of subjects who “have” 
asthma and test “positive”); specificity (the percentage of subjects who “do not have” 
asthma and test “negative”); positive predictive value (percentage of subjects who test 
“positive” and “have” asthma) and negative predictive values (percentage of subjects who 
test “negative” and “do not have” asthma) of these tests. 
In order to determine the usefulness of investigations for diagnosing asthma and “optimal” 
cut-points with maximum sensitivity and specificity for this purpose many studies have used 
Receiver Operator Characteristics (ROC) analysis. This statistical technique uses values 
calculated for the sensitivity and specificity of a test at regular unit intervals to produce a 
ROC curve, the area under which is essentially a measure of the diagnostic utility of that 
test. An area under the curve (AUC) of 1 would be consistent with a perfect test that was 
capable of distinguishing between a subject with the incident condition and one without the 
condition correctly every time. An area under the curve of 0.5 would be consistent with a 
test that is no better at correctly identifying if a subject has the incident condition or not 
than randomly guessing.  
It is worth noting that assessment of the sensitivity and specificity of any of these 
investigations in diagnosing asthma is problematic owing to the lack of an independent 
confirmatory (or ‘gold standard’) test against which a comparison can be made. In subjects 
who have mild symptoms suggestive of asthma investigations are often compared against 
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“physician diagnosis” of asthma, which is based on clinical history, examination and 
pulmonary function testing. However, as it is the difficulty in making a clinical diagnosis of 
asthma that has led to the need for further investigation, it is clear that this is not a reliable 
gold standard test against which all other investigations should be judged.  
1.5.3.2 Tests for variable airflow obstruction 
a) Spirometry 
i) Description of test 
It is generally accepted that spirometry should be the initial investigation in any subject 
above 5 years of age with a suspected diagnosis of asthma.  
The test measures the volume of air that can be exhaled by the subject, allowing the 
measurement of certain parameters including the forced expiratory volume in the 1st 
second (FEV1), the maximum volume of air expelled from the lungs following maximum 
inhalation (vital capacity or VC) and another similar measure, the forced vital capacity (FVC), 
which is the same as the VC but the subject is asked to exhale as forcefully and rapidly as 
possible. 
ii) Significant (”positive”) result 
Airflow obstruction is determined by the presence of a reduced FEV1:VC ratio or a reduced 
FEV1:FVC ratio. The European Respiratory Society (ERS)/ATS spirometry guidelines 
recommend that a subject’s calculated FEV1:VC ratio should be compared to a predicted 
value based on their age, height, gender and race. Values that are below the 5th centile of 
the frequency distribution for the relevant reference population are considered below the 
“normal range” (217). In contrast to this the GOLD guidelines for spirometry consider 
airflow obstruction to be present if the FEV1/FVC ratio is <70% (218). 
A combination of symptoms suspicious of asthma together with a reduced FEV1:VC or 
FEV1:FVC ratio is consistent with a high probability of a diagnosis of asthma. A proviso to this 
is that as asthma is an intermittent condition with variable airflow obstruction, spirometry 
may be normal in asthmatic individuals in between symptomatic episodes. 
iii) Sensitivity/specificity for asthma diagnosis 
Spirometers are superior to peak flow meters for the assessment of airflow obstruction, 
which should not be used for diagnosing asthma as they are less accurate and more effort 
dependent (388-390). 
Spirometry has a good specificity for asthma (90%) but a low sensitivity (29%) making it 
possible to ‘rule in’ asthma but virtually impossible to ‘rule out’ the diagnosis when 
spirometry is normal (391). 
b) Peak flow variability 
i) Description of test 
The peak expiratory flow rate (PEFR) is the maximal exhalation rate of a subject after a full 
inspiration (392). It is most commonly measured using a peak flow meter, which is a small 
portable flow-gauge device. Peak flow measurements are of use in assessing suspected 
variable airflow obstruction, although peak flow is predominantly determined by the calibre 
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of large airways, as opposed to FEV1 which is determined by the calibre of both large and 
medium sized airways (393). 
Owing to the relative ease of use, portability and inexpensiveness of peak flow meters they 
can be used by patients to obtain self-assessed peak flow measurements in the community. 
Recording peak flow measurements at least twice daily over a specified period of time 
allows the calculation of peak flow variability, which can be used to estimate the degree of 
AHR experienced by a patient on a daily basis under normal work/life conditions. 
ii) Significant (”positive”) result 
There are different strategies for interpreting peak flow values but one of the most common 
of these is to calculate a peak flow variability index. These indices are normally calculated by 
determining the difference between the highest and lowest PEFR readings in a day, then 
dividing this difference by the mean of all the PEFR readings taken in that day (392, 394).  
Significant values for peak flow variability are disputed due to large overlaps in values 
between asthmatic and non-asthmatic subjects (393, 395) but population studies of non-
asthmatic adults suggest that the upper limit of normal PEFR variability (assessed using 4 or 
more peak flow readings per day) is <20% (396, 397). 
iii) Sensitivity/specificity for asthma diagnosis 
Peak flow variability has been shown to have a low diagnostic value for asthma in a primary 
care setting (398-400). A clinical study of 3074 patients using a calculated PEFR variability 
value of ≥20% on ≥2 days in a 3 week period to diagnose asthma found this cut-point to 
have a sensitivity of just 36% with a specificity of 90% and a positive predictive value of 
16.4% (395). Again, this means PEFR variability is useful for diagnosing asthma when 
positive but it is not useful to ‘rule out’ asthma. 
c) Bronchodilator response testing (“Reversibility”) 
i) Description of test 
Patients found to have airway obstruction on spirometry should undergo bronchodilator 
response testing to determine the degree of reversibility of their bronchoconstriction to an 
inhaled β2-agonist. Following baseline readings, 400 µg of salbutamol is administered from 
a pressurised inhaler device via a spacer and after waiting 15 min spirometry is repeated.  
ii) Significant (”positive”) result 
There is no clear consensus on what a significant response to a bronchodilator constitutes 
but this is most often taken as “an increase of 12% and 200 mL in FEV1 or FVC over the 
baseline value as recommended by the ATS (217).  
Results from the Burden of Obstructive Lung Disease (BOLD) study (401) seem to broadly 
support the clinical significance of these criteria with the estimated 95th centile values (with 
95% CI) for change in FEV1 post bronchodilator in a population of 3922 healthy never 
smokers found to be 284 mL (263-305 mL) and 12% (11.2-12.8%) above baseline with a 
corresponding average increase in FVC of 322 mL (271-373 mL) and 10.5% (8.9-12%). 
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iii) Sensitivity/specificity for asthma diagnosis 
Unfortunately the traditional paradigm of separating asthma (classically thought of as a 
disease with ‘reversible’ airway obstruction) and diseases thought to display fixed airway 
obstruction (especially COPD) has been demonstrated to be unreliable with many asthmatic 
subjects displaying a degree of fixed airway obstruction and a large proportion of COPD 
patients demonstrating significant reversibility (402). 
Indeed as a diagnostic test for asthma, bronchodilator response testing suffers from similar 
problems to spirometry in that it has a low sensitivity and hence a low negative predictive 
value, leading to a high false negative rate (400, 403, 404).  
A comparative study by Hunter et al. (403) of different diagnostic tests in a population of 
adults with mild asthma (in comparison to a gold standard of clinical diagnosis based on 
history and presence of airflow obstruction) found reversibility testing (using a much lower 
cut-off of >3% increase in FEV1) to have a sensitivity of 49% with a specificity of 70% for 
asthma diagnosis. Goldstein et al. (400) compared the diagnostic utility of peak flow 
variability, MCT and reversibility in 57 patients with suspected asthma. Only 3 of these 
subjects exhibited post-BD FEV1 responses ≥12%, meaning reversibility had almost 100% 
specificity but only 6% sensitivity for asthma diagnosis.  
 
1.5.3.3 Tests for airways inflammation 
a) Sputum differential cell count 
i) Description of test 
Airway inflammation is a characteristic pathological feature of asthma and can be assessed 
directly through the microscopic examination of induced sputum. 
Sputum induction is a well described technique (405) consisting of the inhalation of 
hypertonic saline of increasing concentrations by the subject in order to encourage the 
expectoration of sputum. The mechanisms for this effect are not entirely clear but are 
thought to be either due to the osmotic effects of hypertonic saline in the airways (406, 
407) or an enhancement of mucociliary clearance (408, 409). Unfortunately, hypertonic 
saline is also known to cause bronchoconstriction in asthmatic subjects (410), and this 
sometimes occurs despite pre-treatment with a β2-agonist (411). This is possibly due to 
mast cell activation (412) or neurogenic reflexes (413).  
Therefore despite the relatively non-invasive nature of this technique in comparison to 
bronchoscopic methods to obtain samples that give a direct measure of airway 
inflammation, it is not suitable for use outside a closely monitored setting (411). Reports of 
the success rate of sputum induction in producing an adequate sputum sample for analysis 
range between ~70-100% in both adults (264, 414) and children (415, 416). Also, special 
expertise is required to process sputum samples in order to perform a cell count and 
processing must take place within hours of obtaining the sample in order to obtain a reliable 
result, further limiting the applicability of this technique outside a specialist centre (417).  
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Microscopy of induced sputum from asthmatics has allowed the identification and study of 
different inflammatory subtypes, based on the inflammatory cells identified in the sputum. 
The four main inflammatory subtypes identified are the eosinophilic, neutrophilic, 
granulocytic and paucigranulocytic types (260), of which, with regards to the diagnosis of 
asthma only the eosinophilic type will be discussed further in this section. 
ii) Significant (”positive”) result 
Different definitions have been used for sputum eosinophilia from 1% to 3% 
eosinophils/total sputum cell count. Studies investigating the mean % eosinophil count in 
the induced sputum of healthy non-smokers found this to be around 0.4% (335, 418) and it 
has been recommended a value of ≥3% be used to identify patients with eosinophilic 
inflammation with optimum reproducibility (263). 
iii) Sensitivity/specificity for asthma diagnosis 
Studies that have used sputum eosinophil count for asthma diagnosis include Hunter et al. 
(403) (as described above) who calculated a sensitivity and specificity using a cut-off value of 
>1% of 72% and 80% respectively when compared to physician diagnosis of asthma. 
Di Lorenzo et al. (419) compared the validity of sputum eosinophil count with MCT, PEF 
variability, FEV1/FVC ratio, serum eosinophil and ECP levels in diagnosing asthma in a 
population of 60 mild asthmatics, 30 patients with GORD and asthma-like symptoms and 25 
healthy volunteers. These workers concluded that a sputum eosinophil count of >1% had a 
sensitivity of 90% and a specificity of 92%  for the diagnosis of asthma, which was superior 
to all the other tests assessed except the MCT which was roughly equivalent with a 
sensitivity of 90% and specificity of 89%. 
In summary, the sputum differential cell count is useful for identifying eosinophilic (and 
neutrophilic) inflammation, although not necessarily asthma per se. However, this test is 
difficult to administer outside a specialist centre due to the safety aspects of sputum 
induction and the expertise required to process sputum samples and produce a valid cell 
count. 
 
1.5.3.4 Tests for airway hyper-responsiveness  
a) Principles of AHR testing 
AHR is one of the pathological hallmarks of the classic asthma syndrome (Section 1.4.3). 
Despite being a vague term, it can be defined as an “exaggerated narrowing of airways 
through airway smooth muscle mediated bronchoconstriction following exposure to a direct 
or indirect stimulus” (161). 
The response of the airway to bronchoconstrictor stimuli is measured clinically by bronchial 
challenge testing, which exposes subjects to a stepwise increase in the dose of the selected 
stimulus whilst measuring their lung function. This allows a dose-response curve to be 
produced from which the different components of AHR can be elucidated. 
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i) Types of bronchoconstrictor stimuli 
The stimuli that cause a bronchoconstriction response can be divided into 2 groups; direct 
and indirect. 
Direct bronchoconstrictor stimuli are those which act directly on receptors present in airway 
smooth muscle causing contraction. These include methacholine which acts on muscarinic 
(M3) receptors and histamine which acts on H1 receptors as well as leukotrienes C4 and D4 
(420) and prostaglandins D2 and F2α (421). 
Indirect stimuli cause bronchoconstriction via the release of constrictor mediators (such as 
histamine and prostaglandins) from inflammatory cells (such as mast cells). These mediators 
then act on receptors in airway smooth muscle. Such stimuli include allergens, exercise 
(422), osmotic agents such as mannitol or hypertonic saline (423) or adenosine 
monophosphate (AMP) (424).  
ii) Dose response curve 
There are 2 relatively independent components of AHR; airway sensitivity and airway 
reactivity. Airway sensitivity refers to the minimum level/dose of a stimulus that causes 
bronchoconstriction, i.e. the greater the airway sensitivity to a substance, the greater the 
left-shift of the dose response curve from ‘normal’. Airway reactivity refers to the 
incremental relationship between the level/dose of stimulus and the degree of bronchial 
constriction i.e. the higher the airway reactivity to a substance, the steeper the gradient of 
the dose response curve (see Fig. 2.1). 
 
 
 
70 
 
 
Figure 1.2: A dose-response curve from bronchial challenge testing 
demonstrating the components of AHR of airways ‘hypersensitivity’ 
and ‘hyperreactivity’  (adapted from Lotvall et al. (425))  
 
As shown in Fig. 2.1, the same degree of hyper-responsiveness may result from either an 
increase in airways hypersensitivity or hyperreactivity, although these two different 
mechanisms may reflect different pathological components that lead to increased 
bronchoconstriction (426, 427). In general however, AHR testing does not tend to consider 
these components differently and is used to determine whether a subject has increased 
AHR in relation to a “normal” cut-off point to certain types of bronchoconstrictor stimuli, as 
discussed below. 
b) Fixed and variable direct AHR 
It is thought there may be two components of the “hyper-response” to direct stimuli: fixed 
and variable.  
The “fixed” component is traditionally considered to reflect chronic persistent structural 
changes in the airway i.e. airway remodelling, and it has been suggested that this may be 
the predominant mechanism for AHR in conditions of fixed airway obstruction (428). A 
number of investigators have demonstrated that the lower the baseline FEV1, the greater 
the magnitude of AHR (429-431), and it was thought that increased airway wall thickness, at 
a given degree of airway smooth muscle contraction, resulted in greater airway narrowing 
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(425). However, the situation may be more complicated than this, and a more recent study 
(427) using HRCT to assess airway thickness in asthmatics found that airway wall thickness 
was inversely correlated with airway reactivity (whereas airway sensitivity correlated with 
eosinophilic airway inflammation). 
The “variable” component of direct AHR is thought to reflect the degree of airway 
inflammation and can therefore change rapidly in response to pro-inflammatory stimuli 
such as allergen inhalation or direct challenge or anti-inflammatory stimuli such as ICS.  
This proposed combination of these two components of the airway response to direct 
stimuli may explain certain clinical observations. These include (1) the short term 
improvement, though incomplete inhibition of AHR, of certain asthmatic patients with ICS to 
direct bronchoconstrictors, presumably due to reversal of variable AHR with some 
persistent degree of fixed AHR (432); (2) the continuing persistence of AHR in some groups 
of asthmatic patients despite long periods of high dose ICS (252, 432) due to fixed AHR and 
(3) the positive AHR response of individuals with airway remodelling but without a clinical 
diagnosis of asthma due to fixed AHR (168).  However, this relationship is yet to be fully 
validated and may prove more complex than outlined here. 
 
c) Direct bronchial provocation tests 
i) Description of test 
The methacholine bronchial provocation test (MCT) is the most widely used bronchial 
challenge test, and there are standardised protocols for its administration through tidal 
breathing using a nebuliser (433) or deep inhalations using a dosimeter (434). 
These techniques differ slightly in their methodology but both basically involve the 
inhalation of saline as a baseline control, followed by doubling concentrations of 
methacholine (from 0.03 mg/mL to 16 mg/mL) with measurement of the FEV1 after each 
inhalation until either the highest dose has been inhaled or the FEV1 has fallen by 20% (PC20) 
(434). The tidal breathing method may be preferable as some evidence suggests the 
dosimeter/deep inhalation method induces bronchodilatation leading to a lower diagnostic 
sensitivity for asthma (435-438).  
Asthmatic subjects are often both more sensitive and more reactive to methacholine than 
those without asthma, and hence have a lower PC20. However, individuals with other airway 
diseases in which permanent airflow obstruction is a feature, such as COPD, may also exhibit 
an increased response to direct stimuli.  
ii) Significant (”positive”) result 
Defining absolute values of PC20 to conclusively rule out or rule in asthma is not possible due 
to the overlap in values observed when comparing results from healthy volunteers and 
subjects diagnosed with asthma.  
Two differing statistical approaches may be used when interpreting the results of a MCT 
with regards to determining the likelihood of a subject having asthma or not. 
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The first of these is through the process of decision analysis, in which a pre-test probability 
of a subject having asthma is calculated, as well as a post-test probability that takes into 
account the pre-test probability and results of the MCT (439). The difference between the 
pre and post-test probabilities reflects the usefulness of the MCT results in helping to 
determine if a subject has asthma or not. The pre-test probability in this situation is 
influenced by the clinical history of the subject. This means that if the subject was chosen at 
random from the general population, the pre-test probability of that subject having asthma 
would be very low (i.e. around 5-10% which is the prevalence of asthma in the general 
population (12)), whereas if the subject had symptoms suggestive of asthma the pre-test 
probability would be much higher (although difficult to provide an exact value) (440). 
Approximate values of post-test probabilities can be estimated from pre-test probability 
values and different values of PC20. For example, a series of curves demonstrating post-test 
probability values for given pre-test probability values at different values of PC20 can be 
used, as shown in Fig. 2.2, adapted from the ATS guidelines for Methacholine and Exercise 
Challenge testing (434).  
The alternative approach for using MCT results to assess a subjects likelihood of having 
asthma can be described as a “categorical” method, which assumes that (1) asthma is 
present or absent (2) that the MCT result is either positive or negative for AHR and (3) that 
there is a gold standard test for asthma (434). This allows definitions for the sensitivity and 
the specificity of the test to be used, and this approach is much more commonly used than 
decision analysis in assessing the utility of MCT in diagnosing asthma. Different PC20 cut-
points have been used by different authors to signify “positive” and “negative” MCTs and 
these are discussed further in the next section.  
 
73 
 
 
Figure 1.3: Curves illustrating pre-test and post-test probability of 
asthma after a methacholine challenge test with four PC 2O values. 
(adapted from ATS guidelines on methacholine challenge testing 
(434))  
  
iii) Sensitivity and specificity of direct AHR testing/MCT 
Table 1.4 summarises the results of a literature review concerning the determination of the 
diagnostic utility for asthma of direct bronchial challenge testing. Some of these studies are 
discussed in further detail here. 
In one of the first studies to assess the utility of direct bronchial challenge testing for asthma 
diagnosis in a non-selected population Cockcroft et al. defined a PC20 cut-point for the 
histamine challenge of <8 mg/mL (433) (Table 1.4). In a study of 500 randomly selected 
college students to identify those with current symptomatic asthma this cut-point had a 
high sensitivity (100%), specificity (93%) and NPV (100%), although the PPV was poor (29%), 
which may have been due to the low prevalence of asthma in the population (441). By 
lowering the cut-point to <1 mg/mL, the specificity and positive predictive value of the test 
were increased to ~100% (441).  
This often quoted study is frequently used to support the assertion that direct bronchial 
challenge testing is the most accurate diagnostic test for asthma. However, the main 
weakness of this investigation is that a diagnosis of asthma (“current symptomatic asthma”) 
was defined by questionnaire rather than by physician diagnosis or any objective testing. As 
questions on symptoms alone are poor diagnostic indicators of asthma and are unlikely to 
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discriminate well between asthma and conditions leading to similar symptoms (e.g. PNDS or 
respiratory infection both of which may also cause a degree of AHR (168)) the certainty of 
the “diagnoses” of asthma in this study could be questioned.   
Hunter et al. (403) found similarly high levels of both sensitivity (91%) and specificity (90%) 
using MCT with a PC20 cut-point of <8 mg/mL for asthma diagnosis. However, this study 
assessed the diagnostic utility of the same objective tests it used to define asthma (PEF 
variability, reversibility and positive MCT). Virtually all of the subjects classified as having 
asthma exhibited a positive MCT, suggesting that this was the most important criterion in 
classification. Therefore, even though MCT clearly outperformed PEF variability, reversibility 
and other investigations not used to define asthma (including blood and sputum eosinophil 
counts), these results should be assessed with some caution as the sensitivity and specificity 
values are largely based on the ability of a positive MCT to identify subjects with a positive 
MCT. 
More recent studies examining the use of the MCT in certain patient groups have not found 
a similarly high level of diagnostic sensitivity including studies by Hedman et al. (442), 
Anderson et al. (443), Sverrild et al. (444), Sumino et al. (445) and Backer et al. (446) as 
shown in Table 1.4.  
Sumino et al. (445) assessed the influence of factors such as the use of ICS, race and atopic 
status on the sensitivity of methacholine to identify asthma and found that in asthmatics 
taking regular ICS the sensitivity of the test was 77%. These workers also determined that 
the sensitivity using a cut-off (PC20) of 8 mg/mL was significantly lower in Caucasian (69%) in 
comparison to African American subjects (95%) and in non-atopic (52%) in comparison to 
atopic subjects (82%).   
Backer et al. (446) assessed the sensitivity and specificity of the MCT, along with the 
mannitol challenge test, PEFR variability and reversibility, to diagnose asthma in 190 
individuals with ‘suspected asthma’ in comparison to asthma diagnosis made by a panel of 
three independent respiratory physicians (based on symptoms, presence of atopy and 
baseline spirometry). None of the tests provided good combinations of sensitivity and 
specificity for asthma diagnosis, although MCT had the highest sensitivity of 69% (with 
specificity of 57%). Interestingly, the clinical diagnoses of asthma made by respiratory 
physicians generated a low level of agreement, with agreement between all three observers 
occurring in only 42% of cases and poor agreement between different pairs of observers as 
assessed by the kappa statistic (a measure of inter-observer agreement). 
The MCT does not appear to be a particularly sensitive test for asthma in paediatric 
populations with the ‘best’ combinations of sensitivity and specificity for the test in a study 
by Liem et al. (447) for cohorts of atopic boys (67% sensitivity 75% specificity using a PC20 of 
≤2 mg/mL) and girls (71% sensitivity 69% specificity using a PC20 of ≤4 mg/mL) being 
relatively low. These values were even lower for non-atopic individuals. 
In conclusion the MCT, although not as sensitive in diagnosing asthma as originally 
described, is still probably the most sensitive test for asthma diagnosis. Owing to this higher 
sensitivity and hence NPV it is best employed as a test to “rule out” rather than “rule in” 
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asthma, and its sensitivity will be  highest when the pre-test probability of asthma is 
between 30-70% (441, 448).  
iv) Indirect challenge tests 
Indirect challenge testing using stimuli including exercise and inhaled mannitol challenge is 
thought to be less sensitive but more specific for diagnosing asthma (428, 444, 446), 
although some studies have demonstrated comparable values for both measures (443, 444, 
449).  
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Study author Population Type of 
bronchial 
challenge 
testing 
Criteria for asthma 
diagnosis 
Method of analysis Optimal cut-
point for 
diagnosis 
Sensitivity, 
specificity, NPV 
and PPV 
Cockcroft et 
al.  
(441) 
500 randomly 
selected young 
(20-29) students 
Histamine 
challenge test 
 “current symptomatic 
asthma” as defined by 
ATS “Adult 
Questionnaire on 
Respiratory Disease” 
Calculated 
sensitivities/specificities 
for certain cut-points 
Using ≤8 mg/mL 
 
 
 
 
Using ≤1 mg/mL 
Sensitivity 
100%, 
Specificity 93%  
NPV 100% 
PPV 29% 
 
Sensitivity 41% 
Specificity 100% 
NPV 98% 
PPV 86% 
Nieminen et 
al. 
(448) 
791 consecutive 
adult patients 
referred to 
pulmonary clinic 
with symptoms 
of dyspnoea, 
wheezing, 
prolonged cough 
or history of 
asthma 
MCT 
(dosimeter) 
Physician diagnosis with 
objective test. 
 
Objective tests were:  
1) Documented 
variation in FEV1/PEFR 
of ≥15% post BD OR 
2) Repeatedly ≥20% 
spontaneous daily 
variation in PEFR over 2 
week period 
3) IN ADDITION TO (1) 
or (2) ≥15% decrease in 
FEV1 after specific 
Calculated sensitivity etc. 
for MCT cut-point of 
2600 µg.   
 
Test was considered to 
be positive (for bronchial 
hyperreactivity) if PD20 
FEV1 ≤2600 µg  
≤2600 µg Sensitivity 89%, 
Specificity 76%  
NPV 91% 
PPV 71% 
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allergen provocation or 
exercise test 
Hedman et al. 
(442) 
230 consecutive 
adult patients 
referred to 
pulmonary clinic 
with symptoms 
of dyspnoea, 
wheezing or 
cough of 
unknown cause. 
Patients with 
previous asthma 
diagnosis or ICS 
use in last 4 
weeks excluded 
MCT 
(dosimeter) 
As per Nieminen et al. 
(85) 
ROC analysis 
 
Methacholine 
positivity/bronchial 
hyperresponsiveness 
defined as PD20 FEV1 
≤6900 µg 
≤6900 µg Sensitivity 77%, 
Specificity 82%  
NPV 91% 
PPV 60% 
 
Popovic-Grle 
et al.(450) 
 
195 patients 
referred by GP 
with dyspnoea 
MCT 
(details 
unclear) 
Diagnosis based on 
questionnaire 
Calculated 
sensitivity/specificity/PPV 
and NPV 
≤8 mg/mL Sensitivity 97%, 
Specificity 85%  
NPV 92% 
PPV 94% 
Hunter et al. 
(403) 
69 patients 
diagnosed with 
asthma, 20 
subjects referred 
to outpatient 
clinic and found 
to have 
‘pseudoasthma’ 
MCT  
(tidal 
breathing) 
Physician diagnosis with 
symptoms consistent 
with asthma and FEV1 > 
65% predicted with ≥1 
of: 
(1) PC20 FEV1 < 8 mg/mL 
(2) >15% increase in 
post BD FEV1 
Calculated 
sensitivity/specificity/PPV 
and NPV 
≤8 mg/mL Sensitivity 91%, 
Specificity 90%  
NPV 75% 
PPV 97% 
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and 21 healthy 
controls  
(3) > 20% maximum 
within-day variability of 
PEF when measured 
twice daily for > 14 days 
Koskela et al. 
(451) 
37 consecutive 
patients with a 
new diagnosis of 
asthma from 
outpatient clinic  
Mannitol 
challenge 
 
Histamine 
challenge test 
(dosimeter) 
Physician diagnosis 
based on clinical 
assessment plus ≥1 of: 
1) Documented 
variation in FEV1/PEFR 
of ≥15% post BD  
2) Repeatedly ≥20% 
daily variation in PEFR 
over a 2 week period 
3) ≥15% decrease in 
FEV1 after specific 
allergen provocation or 
exercise test 
Calculated sensitivity of 
both challenge tests 
Histamine PD15 
≤0.4 mg 
 
≤1 mg 
 
Mannitol ≤635 
mg 
 
 
 
Sensitivity 49% 
 
Sensitivity 81% 
 
Sensitivity 51% 
Anderson et 
al. 
(443) 
509 subjects (6-
50) with signs 
and symptoms 
of asthma 
according to NIH 
questionnaire 
but without 
previous 
diagnosis of 
asthma 
Mannitol 
challenge 
(commercially 
available test 
kit – Aridol, 
Pharmaxis 
Ltd, Australia) 
 
MCT 
(dosimeter) 
Physician diagnosis 
based on clinical 
assessment, FEV1 
reversibility and 
exercise challenge 
results 
Calculated sensitivity and 
specificity of both 
challenge tests 
MCT  
PC20 ≤16 mg/mL 
 
 
 
 
Mannitol  
PD15 ≤635 mg 
Methacholine 
Sensitivity 51%, 
Specificity 75%  
NPV 46% 
PPV 78% 
 
Mannitol 
Sensitivity 55%, 
Specificity 73%  
NPV 48% 
PPV 79% 
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Sverrild et al. 
(444) 
238 randomly 
selected young 
adults 
Mannitol  
(commercially 
available test 
kit – Aridol, 
Pharmaxis 
Ltd, Australia) 
 
MCT 
Diagnosis based on 
asthma symptoms 
within the last 12 
months in combination 
with either a FENO level 
>30 ppb, a history of 
allergic 
rhinoconjunctivitis, 
dermatitis, a +ve skin 
prick test, a familial 
predisposition to atopic 
disease, nonallergic 
rhinoconjunctivitis, or 
an FEV1/FVC ratio < 75% 
ROC analysis MCT  
PD20 ≤8 µmol 
 
Mannitol  
PD15 ≤635 mg 
Methacholine  
ROC AUC 0.849 
Sensitivity 69%, 
Specificity 80%  
NPV 90% 
PPV 49% 
 
Mannitol 
ROC AUC 0.891 
Sensitivity 59%, 
Specificity 98%  
NPV 91% 
PPV 90% 
Sumino et al. 
(445) 
126 “asthmatic” 
patients 
receiving 
controller 
medications 
MCT 
(dosimeter 
method) 
Physician diagnosed 
stable asthma; current 
treatment for asthma in 
the preceding 12 
months with regular use 
of controller 
medications (ICS, 
leukotriene receptor 
modifiers, or both); no 
asthma exacerbation in 
the prior 4 weeks; and 
pre-bronchodilator 
FEV1 ≥70%  
Calculated sensitivity and 
specificity of MCT 
MCT  
PC20 ≤8 mg/mL 
Sensitivity 77% 
Specificity 96% 
PPV 96% 
NPV 75% 
Kim et al. 50 “asthmatic” MCT “Asthmatic” subjects ROC analysis MCT  Methacholine  
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(449) patients  (Dosimeter 
method) 
 
Mannitol  
(commercially 
available test 
kit – Aridol, 
BL&H Co Ltd, 
Seoul, 
S.Korea) 
 
had received previous 
physician diagnosis of 
asthma, had recurrent 
symptoms of asthma 
(wheezing and 
dyspnoea) and were 
using medication for 
asthma ≥6 months 
before enrolment 
PC20 ≤16 mg/mL 
 
 
 
 
 
Mannitol  
PD15 ≤635 mg 
ROC AUC 0.89 
Sensitivity 44%, 
Specificity 
98.1%  
NPV 65.4% 
PPV 95.7% 
 
Mannitol 
ROC AUC 0.77 
Sensitivity 48%, 
Specificity 
92.6%  
NPV 65.8% 
PPV 85.7% 
Backer et al. 
(446) 
190 patients 
with “suspected 
asthma” 
MCT 
(Dosimeter 
method) 
 
Mannitol  
(commercially 
available test 
kit – Aridol™) 
Physician diagnosis 
based on symptoms, 
presence of atopy and 
baseline spirometry 
Calculated 
sensitivity/specificity/PPV 
and NPV 
Methacholine  
PD20 ≤7.8 µmol 
 
Mannitol  
PD15 ≤635 mg 
Methacholine  
Sensitivity 69%, 
Specificity 57%  
NPV 48% 
PPV 74% 
 
Mannitol 
Sensitivity 38%, 
Specificity 82%  
NPV 42% 
PPV 79% 
Table 1.4: The utility of bronchial challenge testing for the diagnosis of asthma
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v) Airway hyperresponsiveness and airway inflammation  
The relationship between AHR and airway inflammation is a complicated one. Crimi et al. 
(452) found no correlation between AHR to methacholine and airway inflammation (as 
quantified by numbers of inflammatory cells in sputum, BAL or bronchial biopsy) in a cohort 
of 71 mild to moderate atopic asthmatic patients. Rosi et al. (275), using the method of 
factor analysis to determine the relatedness of AHR to histamine, reversible airway 
obstruction and eosinophilic airway inflammation in a cohort of 99 patients with chronic 
stable asthma also concluded there was no correlation between AHR and airway 
inflammation and that these should be considered  as separate dimensions of disease. 
Other investigators have found only a weak correlation between the two parameters (300, 
453, 454). 
Evidence suggests that the correlation is stronger between airway sensitivity to indirect 
agents and the proportion of eosinophils in induced sputum than for sensitivity to direct 
agents (455, 456). Both Scollo et al. (457) and Porsbjerg et al. (458) also identified significant 
relationships between airway sensitivity to indirect agents (exercise and mannitol) and FENO 
values, although a certain proportion of asthmatic subjects responsive to indirect agents 
have normal FENO values (456, 459) and these individuals may have non-eosinophilic asthma 
(458).  
1.5.3.5 Summary: Asthma over-diagnosis and comparison of investigations for the diagnosis 
of asthma 
Recent data suggest asthma, a diagnosis of which is often based on clinical assessment in a 
primary care setting, is now over-diagnosed. A number of objective measures of well 
described pathological features of asthma with cut-points based on the optimal separation 
of ‘asthmatic’ and ‘non-asthmatic’ populations have been proposed to try and objectively 
define the condition. Unfortunately although these investigations may be useful in 
‘confirming’ a label of asthma in subjects with commensurate symptoms if they are positive 
(high specificity), a negative test result is often not helpful (low sensitivity). AHR testing in 
the form of the MCT was thought to be the closest to a ‘gold standard’ test for asthma, but 
more recent studies in unselected populations have revealed this test may have a more 
modest sensitivity value than initially believed. One caveat to this is the sputum eosinophil 
count, which appears to be sensitive at identifying ongoing eosinophilic inflammation, 
rather than asthma per se, and this test has demonstrated utility at guiding management 
decisions in eosinophilic (Th2 high) asthma. Another investigation used to assess airway 
inflammation, exhaled nitric oxide testing, has also been proposed as a diagnostic test for 
asthma, and the utility of this test will now be examined. 
 
1.5.4 Exhaled Nitric Oxide (FENO) in asthma diagnosis 
1.5.4.1 Introduction  
Nitric Oxide (NO) is a gaseous signalling molecule with multiple critical roles in human 
physiology. As well as regulating airway function, NO is a mediator of vasodilation, a 
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neurotransmitter and an important molecule in the immune response, where it is generated 
by phagocytes to kill invading bacteria. 
NO is synthesised by three different isoforms of the NO synthase (NOS) enzyme: the 
neuronal (nNOS/NOS1), inducible (iNOS/NOS2) and endothelial (eNOS/NOS3) isoforms, each 
of which have different physiological functions. 
A brief review of NO production by these NOS isoforms and the physiology and 
pathophysiology of NO in the context of airways disease will now be discussed. 
1.5.4.2 NO in airways disease 
a) Production of NO 
All three NOS isoforms are found in the airways and produce differing amounts of NO. The 
neuronal and endothelial isoforms are usually collectively referred to as the ‘constitutive’ 
NOS isoenzymes, in comparison to the inducible (NOS2) isoenzyme. The significance of this 
is that whereas the constitutive isoenzymes are dependent on the influx of calcium ions and 
produce small amounts of NO, the inducible NOS2 type is “induced” by infectious or 
inflammatory stimuli to produce much larger amounts of NO, independent of calcium influx. 
Neuronal NOS enzymes are found mostly in cholinergic nerves in the airways, where they 
serve to inhibit bronchoconstriction by the production of NO, which inhibits cholinergic 
bronchoconstriction of the airways by acting as a functional antagonist to acetylcholine in 
airway smooth muscle (460). Low concentrations of NOS 1 are also found in airway 
epithelial cells. 
Endothelial NOS enzymes are predominantly found in the endothelial cells of the 
bronchopulmonary circulation and have a role in regulating vascular blood flow (461). 
However, eNOS is also expressed in airway epithelial cells, where it may contribute to the 
regulation of ciliary beating (462).  
Inducible NOS enzymes are mostly found in airway epithelial cells, although they are also 
expressed in alveolar macrophages and nasal endothelial and epithelial cells. Several studies 
have reported increased NOS2 expression in the airway epithelial cells of asthma patients, 
which is reduced by ICS (463-465). Lane et al. (465) also found higher levels of iNOS mRNA in 
the airway epithelial cells of asthmatic children as well as a significant correlation between 
iNOS expression and FENO levels, suggesting that increased expression of the iNOS isotype is 
responsible for the higher FENO levels observed in asthmatic patients. This finding was 
supported by the results of a placebo-controlled double blind RCT by Hansel et al. (466) in 
which the investigators determined that the oral administration of an iNOS selective NOS 
inhibitor to groups of healthy subjects and mild asthmatics reduced exhaled nitric oxide 
levels by >90% from baseline. 
iNOS enzymes are known to be induced by a variety of pro-inflammatory cytokines including 
IL-4 (464, 467, 468) and IL-13 (469, 470), via activation of signal transducer and activator of 
transcription (STAT)-6. Both IL-4 and IL-13 have prominent roles in the Th2 mediated 
inflammation known to occur in allergic airway inflammation. Hence, FENO can be 
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considered a proxy marker for Th2 mediated inflammation, an important finding that will be 
further explored later. 
Other potential sources of excess NO in asthma have been suggested, including the release 
of NO from S-nitrosothiols (471, 472) and the protonation of nitrites in airway lining fluid 
forming nitric acid which releases NO with acidification (473, 474).  
b) Exhaled nitric oxide and eosinophilic inflammation 
Traditionally FENO has been viewed as a marker of eosinophilic airway inflammation. Some 
of the earlier studies investigating the relationship between these two variables found no 
correlation (475, 476) or only a weak correlation (477) between them. However, the 
majority show a good correlation between FENO levels and sputum eosinophils (300, 478-
481), blood eosinophils (482, 483), serum ECP (482, 483), eosinophils in BAL fluid (484) and 
eosinophil count in endobronchial biopsy specimens (89, 278, 485). 
Nevertheless, more recent evidence from clinical trials of monoclonal antibodies in asthma 
have suggested that FENO might be more accurately be described as a marker of Th2 
mediated airway inflammation, of which eosinophilic inflammation is a prominent feature. 
Halder et al. (319) showed that treatment with mepolizumab, an anti-IL-5 monoclonal 
antibody, significantly decreased both sputum and blood eosinophil counts but had no 
effect on FENO levels.  
Conversely, Corren et al. (325) found that treatment with the anti-IL-13 monoclonal 
antibody lebrikizumab significantly increased peripheral blood eosinophils and significantly 
reduced FENO levels, especially in subjects with high levels of ongoing Th2 inflammation at 
baseline (as defined by high serum periostin levels). 
The reason for this disconnect between FENO levels and eosinophilic inflammation may be 
because IL-4 and IL-13 regulate iNOS induction and hence NO production via STAT-6 
dependent mechanisms. In contrast, IL-5 activates eosinophils through mechanisms that do 
not involve STAT-6 (and hence do not induce iNOS) and this activation occurs mostly in the 
systemic circulation (486). 
As FENO levels seem to reflect the degree of ongoing Th2 inflammation, it is not surprising 
that they are a sensitive marker of corticosteroid-responsiveness (487). The synthesis of IL-4 
and IL-13 is inhibited by corticosteroids, and this effect is likely due to steroid inhibition of 
transcription factor GATA-3 (488).  
c) Detection of NO 
Exhaled NO can be detected by several different techniques which can generally be 
categorised as spectroscopic (including chemiluminescence and laser spectroscopy) (489) or 
electrochemical detection (490).  
Spectroscopic detection methods involve the measurement of products of a reaction 
involving NO. These include a chemiluminescence technique which relies on the reaction 
between NO and ozone which produces NO2 in an excited state. A photon is emitted as the 
NO2 molecule returns to its ground state, which is detected by a photon multiplier tube and 
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converted into an electrical current. The output voltage of the detector is therefore 
proportional to the NO concentration (491). Despite the extremely high sensitivity of this 
technique (down to a concentration of 1 ppb) ensuring it is the “gold standard” for NO 
detection, the method requires sophisticated expensive equipment which is too large to be 
portable and therefore only of use in a research setting (492).  
By contrast, electrochemical detection methods directly detect NO, and although the 
sensitivity of these devices is not yet as high as chemiluminescence devices, they show a 
good level of agreement for all ranges of values (493-495). Their use is rapidly increasing in 
clinical studies as they are portable, relatively inexpensive and easy to use and maintain 
(492). 
d) Measurement of NO 
Detailed discussion of the models of NO excretion from the lungs and measurement of NO 
levels from different lung compartments is beyond the scope of this thesis. Briefly FENO 
concentration is inversely proportional to the exhalation flow of air from the lungs (496), 
although this is a complex relationship with NO elimination rates varying throughout 
different phases of exhalation, as certain structures in the lung such as the alveoli are not 
rigid and change volume during exhalation (497).  
Certain models have been formulated to account for the relative contribution of NO from 
the airway and alveolar compartments in exhalation (498-500), and interest in the area of 
NO exchange dynamics remains. This is due to the potential usefulness of being able to 
discriminate between ongoing eosinophilic inflammation in the large airways or small 
airways/alveoli (501).  
Largely however, most ongoing clinical studies measuring FENO levels tend to do so 
according to the ATS/ERS guidelines (502), which recommend a standardised exhaled flow 
rate of 50mL/s and specify the other technical considerations critical in obtaining 
standardised and reproducible FENO measurements.  
1.5.4.3 Reference values for exhaled nitric oxide 
Several investigations have attempted to determine reference values of FENO for 
populations of “healthy” adults. Some of the earlier studies in this field measured the NO 
values of “healthy” populations, without considering potential confounders and it has since 
become clear that there are a number of independent factors (discussed further below) that 
significantly affect NO values which need to be taken into account when trying to estimate 
population reference values. 
Some of the most reliable estimates of “normal” ranges of NO in various selected 
populations therefore come from studies that have measured and adjusted for confounders 
including age, sex, height, atopic status, smoking status and inhaled steroid usage. The 
results of the largest of these studies in adult populations with clearly specified subgroups 
are summarised in Table 1.5 below, whilst the findings from studies of subjects with asthma 
are summarised in Table 1.6: 
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Authors No of 
subjects 
Group studied Mean ± SD 
(ppb)  
FENO device and flow 
rate  
Factors not 
considered 
Olivieri et 
al. (503)  
204  
 
Healthy non-smoking 
male adults (n=102) 
Healthy non-smoking 
female adults (n=102) 
(5th – 95th 
centiles) 
4.5 – 20.6 
 
3.6 – 18.2 
Online 
chemiluminescence 
analyser  
(CLD88, Ecomedics, 
Switzerland) 
250 mL/s 
Atopy 
Olin et al. 
(504)  
1131  
 
By atopic status 
Healthy non-smoking 
non-atopic individuals 
(n=845) 
Non-smoking atopic 
individuals (n=286) 
By gender 
Non-smoking males 
(n=558) 
Non-smoking females 
(n=573) 
Mean and (5th-
95th centiles) 
 
16 (5.9 – 58.8) 
 
 
18.8 (5.9-47.1) 
 
 
18.5 (16.7-57.1) 
 
14.9 (5.4-41.5) 
NiOX online 
chemiluminescence 
analyser 
(Aerocrine, Solna, 
Sweden) 
50 mL/s 
 
Travers 
et al. 
(505)  
528 ‘Healthy’ controls 
(n=193) 
17.9 (7.8 – 41.1) NiOX online 
chemiluminescence 
analyser 
(Aerocrine, Solna, 
Sweden) 
50 mL/s 
Atopy, 
smoking 
Sundy et 
al. (506)  
994 ‘Healthy’ non-smokers 
(n=895) 
 
‘Healthy’ smokers 
(n=99) 
20.5 ± 213 
 
 
13.9 ± 18 
Sievers 280i Nitric 
Oxide Analyzer  
(NOA; GE Analytical 
Instruments, 
Boulder, CO, USA) 
50 mL/s 
Atopy 
Levesque 
et al. 
(507)  
895 ‘Healthy’ non-smoking 
males (n=271) 
 
‘Healthy’ non-smoking 
females (n=587) 
27 ± 26 
 
 
18 ± 18 
 
Sievers 280i Nitric 
Oxide Analyzer  
(NOA; GE Analytical 
Instruments, 
Boulder, CO, USA) 
50 mL/s 
Atopy 
Table 1.5: FENO reference values from the largest studies 
carried out in ‘healthy’ subjects  
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Authors No of 
subjects 
Group studied Mean ± SD 
(ppb) 
FENO device and flow 
rate 
Factors not 
considered 
Olin et al. 
(508) 
1090  
 
Asthmatics (never 
smoked) (n=1038) 
Non-asthmatics (never 
smoked) (n=52) 
Median 
(IQR) 
19.9 (14.6-
31.4) 
17 (12.7-
23.5) 
NiOX online 
chemiluminescence 
analyser 
(Aerocrine, Solna, 
Sweden) 
50 mL/s 
 
Shaw et al. 
(509)  
118 2 groups of non-
smoking asthmatics 
Group 1 (n=58) 
 
Group 2 (n=60) 
Mean  
(68% CI) 
29.2 (14 -
61) 
31.2 (13.3-
73.1) 
NiOX online 
chemiluminescence 
analyser 
(Aerocrine, Solna, 
Sweden) 
50 mL/s 
 
Travers et al. 
(505)  
137 Asthmatics 25 ± 15.2 NiOX online 
chemiluminescence 
analyser 
(Aerocrine, Solna, 
Sweden) 
50 mL/s 
Atopy, 
smoking 
Michils et al. 
(510)  
341 Non-smoking 
asthmatics  
Total (n=341) 
ICS naïve (142) 
ICS dose >500 µg BDP 
equivalent 
 
 
32.9 
49.8 
20.5 
LR 2000 online 
chemiluminescence 
analyser  
(Logan Research Ltd, 
Rochester, UK) 
50 mL/s 
Atopy 
Table 1.6: FENO reference values from the largest studies 
carried out in cohorts of asthma patients 
 
Due to these multiple confounding factors in interpreting NO levels and the significant 
overlap between values for “healthy” subjects and asthmatic subjects, standard reference 
ranges for NO cannot be applied to patients in a clinical setting. Instead, the use of “cut-
points” has been proposed to try and delineate subjects with an abnormally high NO, in 
whom ongoing Th2 airways inflammation is likely, and those with a low NO, in whom active 
Th2 inflammation is unlikely.  
Multiple investigations have attempted to use various FENO cut-points for the diagnosis of 
asthma, as discussed further in the following section. 
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1.5.4.4 Previous studies using FENO for diagnosis of asthma 
Table 1.7 summarises the results of a literature review relating to the diagnostic utility for 
asthma of measuring FENO levels. Some of these studies will be discussed in further detail 
below. 
Dupont et al. (511) assessed the measurement of FENO as a diagnostic tool in asthma in 240 
consecutive non-smoking patients referred to an outpatient clinic with symptoms of 
obstructive airways disease. The cut-off point of FENO >13 ppb was associated with the 
highest combination of specificity (80%) and sensitivity (85%) i.e. the best test accuracy. 
There was a significant overlap in this study in the FENO levels recorded from those patients 
diagnosed as asthmatic and those not thought to have asthma. This was reflected by the 
marked variation in sensitivity and specificity (steep gradient on ROC curve) over the narrow 
range of FENO values from values of 92.5% and 50% respectively using a cut-off of >10 ppb to 
values of 73.8% and 85% when using a cut-off of >15 ppb. Despite the good reproducibility 
of the FENO technique, values measured in healthy individuals may vary by up to 10% (or ~4 
ppb) (512, 513) and the within-subject variation of FENO values in asthmatics may be up to 
20% (512-514). This variation makes it difficult to recommend the use of a single cut-off 
point in trying to rule asthma in or out as a diagnosis. 
Smith et al. (515) compared the diagnostic utility of a range of investigations including 
clinical asthma assessment, FENO measurement, spirometry, reversibility, hypertonic saline 
challenge, induced sputum, peak flow measurements in a group of 47 subjects referred by 
their GPs with symptoms suggestive of asthma for a minimum of 6 weeks. The effect of a 
trial of oral prednisolone on these measurements was also assessed. Subjects were seen on 
three separate occasions at 2 week intervals and underwent a fixed sequence of these 
investigations, and at the final visit were diagnosed with asthma if they had a relevant 
history (as defined by ATS criteria) and a positive test for AHR and/or reversibility to a 
bronchodilator. Seventeen of the 47 patients (36%) were diagnosed with asthma at the end 
of the study (i.e. positive AHR/reversibility) with the other 30 classified as non-asthmatic. 
These 30 patients were given diagnoses including chronic rhinosinusitis (13 patients; 28%), 
extended post-viral respiratory syndrome (8 patients; 17%), GORD (6 patients; 13%), EB (2 
patients; 4%) and COPD (1 patient; 2%). The mean FEV1 and FEV1/FVC ratio were 
significantly lower in the asthmatic group than the non-asthmatic group and FENO and 
sputum eosinophils were significantly higher in the asthmatic group. Sensitivities for FENO > 
20 ppb and sputum eosinophil count > 3% were 88% and 86% respectively with 
corresponding specificities of 79% and 88%. Using ROC curve analysis these two tests were 
significantly more accurate in diagnosing asthma than any of the tests based on lung 
function, including any change in these parameters following a course of an oral steroid. As 
this study used reversibility and airways hyper-responsiveness (to hypertonic saline) as 
diagnostic “gold-standard” tests, these could not be compared to FENO in terms of diagnostic 
utility.  
Berkman et al. (516) compared FENO against methacholine and adenosine 5’-
monophosphate bronchial provocation tests for asthma diagnosis in a group of 85 patients 
with non-specific respiratory symptoms of over 3 months duration. The optimal FENO cut-off 
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point for diagnosis (based on clinical features, spirometry/reversibility or response to 
treatment) was >7 ppb which gave a sensitivity of 82.5% and a specificity of 88.9%. This 
compared favourably to the optimal cut-off values for MCT of ≤3 mg/mL, with a sensitivity 
of 87.5% and specificity of 86.7% for diagnosing asthma and a cut-off value for the 
adenosine 5’-monophosphate bronchial provocation test of ≤150 mg/mL with a sensitivity 
of 89.5% and a specificity of 95.6%. The cut-off point of >7 ppb for diagnosing asthma was 
found to be optimal also when using either of the bronchial challenge tests as the gold 
standard diagnostic test. The value of >7 ppb is low in comparison to other studies, but this 
provides an example of the difficulties in comparability of absolute FENO values determined 
in different studies owing to the different techniques and FENO analysers used, as well as 
possible differences in ambient NO levels (502). In this latter study, an expiratory flow rate 
of 250 mL/s was used, which is much higher than the ATS recommended expiratory flow 
rate of 50 mL/s, and due to the recognised inverse relationship between FENO values and 
exhaled flow rate, lower FENO values would be expected (502). 
Arora et al. (517) measured FENO levels in a population of 172 basic military trainees with 
symptoms suggestive of asthma. These trainees each had FENO levels measured before 
undergoing a clinical history and examination, spirometry and a histamine 
bronchoprovocation test. A diagnosis of asthma was made on the basis of these other 
investigations and FENO levels in all patients were reviewed. The 80% of trainees who were 
diagnosed as having asthma had significantly higher FENO levels than the non-asthmatic 
trainees, with mean values of 30 ppb for diagnosed asthmatics compared to 19 ppb for non-
asthmatics (p<0.001). However, a FENO cut-off with high values for both sensitivity and 
specificity could not be obtained. At the highest value for sensitivity (86%) at a cut-off of 
10.5 ppb the specificity was only 21%, whereas using a higher cut-off point of 46 ppb to give 
100% specificity reduced the sensitivity to 17%. 
Schneider et al. (518) attempted to determine the diagnostic accuracy of FENO as part of the 
routine diagnostic assessment of 393 patients attending respiratory private practice with 
symptoms suggestive of obstructive airway disease. For the whole population the optimal 
single cut-off point for asthma diagnosis was 25 ppb with a sensitivity/specificity of 49% and 
75% respectively. Using a “high” and “low” cut-off point to try and “rule in” and “rule out” 
asthma diagnosis, a “high” cut-off of >71 ppb had a PPV of 80% and the “low” cut-off of <9 
ppb had a NPV of 82%. Subgroup analysis was performed to determine the effect of various 
factors on the diagnostic accuracy of FENO and FENO levels were found to be lower in current 
smokers and also in instances when diagnoses were made solely using whole body 
plethysmography with no clinical assessment of patients. By omitting patients with sputum 
neutrophilia from analysis (although only a third of patients managed to produce sputum), 
the diagnostic accuracy of FENO was much improved with a PPV of 82% at a high cut-off of 31 
ppb and NPV of 81% at 12 ppb. These results demonstrate that the predictive value of FENO 
is low in a general population with a low pre-test probability of asthma. The diagnostic value 
may be improved if the value is interpreted with prior knowledge of a subject’s 
inflammatory subtype. However obtaining a sputum sample to determine inflammatory 
subtype would likely require sputum induction, which as mentioned above, is not a readily 
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available technique and needs careful patient monitoring. This limits the implementation of 
such an approach in many community or clinic settings. 
Cordeiro et al. (519) assessed the utility of FENO to diagnose asthma in a population of 114 
atopic individuals presenting to allergy clinic. Subjects with histories suggestive of asthma 
underwent histamine challenge. 42 subjects were diagnosed with asthma and 72 were 
diagnosed as non-asthmatic and the asthmatic patients were found to have a higher 
average FENO level (44 ppb vs 17 ppb; p <0.001). ROC analysis determined the optimal FENO 
cut-point to distinguish between asthma and “non-asthma” was 27 ppb with a sensitivity of 
78%, specificity of 92%, PPV of 86% and NPV 87%.  
1.5.4.5 Summary 
In summary, it would appear that FENO has greater sensitivity and specificity for the 
diagnosis of asthma than investigations such as spirometry, reversibility and peak flow 
monitoring, although it seems to be less sensitive than AHR testing.  
However, assessing the literature as a whole it is clear that FENO cannot be used to diagnose 
asthma in subjects with symptoms suggestive of asthma based on a single cut-point. When 
comparing different studies using FENO detection devices with a flow rate of 50 mL/s the cut-
points with optimal sensitivity and specificity for asthma diagnosis vary between 20 ppb 
(515) to 64 ppb (520). When this is limited further to studies using the same FENO detection 
device (NiOX MINO), the optimal cut-point still varies between 25 and 46 ppb, even though 
the two studies advocating these values were performed by the same authors (518, 521).  
A meta-analysis of the literature has been performed (522), which included 19 of the studies 
reviewed here and 6 studies assessing the diagnostic utility of FENO in children. The pooled 
results and summary ROC curve (AUC 0.84) produced suggested FENO is insufficiently 
sensitive (sensitivity 78%) and specific (specificity 74%) as a single investigation, but may be 
used in combination with other tests, to diagnose asthma. However, it seems that the 
pooled figures for sensitivity and specificity have been derived by combining studies with a 
significant range in values of FENO cut-points so the practical utility of this advice seems 
limited.  
The difficulties in using FENO for asthma diagnosis include: (1) the heterogeneous nature of 
the asthma syndrome with Th2-high (raised FENO) and Th2-low (low FENO) phenotypes (2) 
the variability of measured FENO levels between FENO detection devices, (3) the significant 
number of confounding factors that affect measured FENO such as smoking and ICS use and 
(4) the overlap in values between asthmatics and non-asthmatics with conditions such as EB 
and atopy. 
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Study author Population FENO device and 
flow rate 
Criteria for asthma 
diagnosis 
Method of 
analysis 
Optimal 
FENO cut-
point for 
diagnosis 
Sensitivity, 
specificity, positive 
and negative 
predictive values 
Chatkin et al. 
(523) 
38 consecutive 
patients referred to 
outpatient clinic with 
cough for ≥ 3 weeks, a 
normal chest 
radiograph and FEV1 > 
80% of predicted 
Online 
chemiluminescence 
analyser  
 
45 mL/s 
Physician diagnosis based 
on significant reversibility 
(≥12% of FEV1) or positive 
MCT (PC20 ≤8 mg/mL) 
Calculated 
sensitivity, 
specificity, PPV 
and NPV at 
10th, 25th, 
50th, 75th, 
and 90th 
percentiles of 
the NO 
distribution 
>30 ppb Sensitivity 75% 
Specificity 87% 
PPV 60% 
NPV 93% 
Dupont et al. 
(511) 
240 consecutive non-
smoking patients 
referred to outpatient 
clinic with symptoms 
of obstructive airways 
disease 
Online 
chemiluminescence 
analyser  
 
200 mL/s 
Physician diagnosis based 
on significant reversibility 
(≥12% of FEV1) and/or 
positive histamine 
challenge (PC20 ≤8 mg/mL)  
ROC analysis >13 ppb Sensitivity 85% 
Specificity 80% 
PPV 89.5% 
NPV 89.5% 
Smith et al. 
(515) 
47 subjects referred 
by GPs to outpatient 
clinic with symptoms 
suggestive of asthma 
Device not listed 
 
50 mL/s 
Significant reversibility 
(≥12% of FEV1) and/or 
provocative dose of 
hypertonic saline resulting 
in a 15% fall in FEV1 (PD15) 
of <20 mL 
ROC analysis  
(AUC 0.864) 
>20 ppb Sensitivity 88% 
Specificity 79% 
PPV 70% 
NPV 92% 
Berkman et 
al.  (516) 
85 subjects with non-
specific respiratory 
Chemiluminescence 
analyser (LR 2000, 
Physician diagnosis based 
on significant reversibility 
ROC analysis 
(AUC 0.896) 
>7 ppb Sensitivity 82.5% 
Specificity 88.9% 
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symptoms >3 months 
duration 
Logan Research, 
Rochester, UK) 
 
250 mL/s 
(≥12% of FEV1) or 
documented variability of 
FEV1 ≥12% at any time 
over follow up period 
 
OR 
Diagnosis based on +ve 
MCT (defined as PC20 ≤3 
mg/mL) 
 
PPV 89.1% 
NPV 85.4% 
 
 
 
Sensitivity 66.7% 
Specificity 72.9% 
PPV 68.3% 
NPV 71.4% 
Arora et al. 
(517) 
 
172 military trainees 
with symptoms 
suggestive of asthma 
Niox-Flex 
 
50 mL/s 
Physician diagnosis based 
on history, examination, 
spirometry and positive 
histamine challenge 
Calculated 
sensitivity/ 
specificity for 
different cut-
points 
Unable to 
determine 
optimal 
cut-point 
 
 
Cut-point 10.5 ppb 
Sensitivity 86%  
Specificity 21% 
 
Cut-point 46 ppb 
Sensitivity 17% 
Specificity 100% 
Heffler et al. 
(524) 
48 consecutive 
patients referred to 
allergy outpatients 
clinic with symptoms 
of rhinitis and lower 
airway symptoms 
NiOX online 
chemiluminescence 
analyser 
(Aerocrine, Solna, 
Sweden) 
 
50 mL/s 
Significant reversibility 
(≥12% of FEV1) and/or 
positive MCT (PD20 ≤800 
µg) 
ROC analysis 
(AUC 0.78) 
>36 ppb Sensitivity 77.8% 
Specificity 60% 
PPV 54% 
NPV 81.8% 
Fortuna et 
al. 
(525) 
50 patients 
respiratory 
outpatients clinic with 
symptoms suggestive 
Chemiluminescence 
analyser 
 
50 mL/s 
Positive MCT  
(PD20 ≤16 mg/mL) 
ROC analysis 
(AUC 0.8) 
>23 ppb Values for 23 ppb 
cut-point not 
stated. 
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of asthma (dry cough, 
wheeze, dyspnoea) 
For ≥20 ppb 
 
Sensitivity 77% 
Specificity 64% 
PPV 62% 
NPV 78% 
Sato et al. 
(526) 
71 consecutive 
patients attending 
respiratory clinic with 
prolonged cough or 
wheeze ≥3 weeks 
Chemiluminescence 
analyser  
 
50 mL/s 
Diagnosed as ‘bronchial 
asthma’ if (1) symptoms of 
cough and wheeze ≥3 
weeks 
(2) sputum eosinophilia 
(3) positive 
MCT/reversibility 
 
Diagnosed as ‘cough 
variant asthma’ if  
(1) cough without wheeze 
≥3 weeks 
(2) sputum eosinophilia 
(3) positive 
MCT/reversibility 
ROC analysis >38.8 ppb 
(to 
distinguish 
bronchial 
asthma or 
cough 
variant 
asthma 
from non-
asthmatics
) 
Sensitivity 79.2% 
Specificity 91.3% 
Bommarito 
et al. (527) 
109 symptomatic 
individuals from 
ECHRS cohort who 
consented to take 
part in study and have 
FENO levels measured 
Offline 
chemiluminescence 
analyser  
 
350 mL/s 
 Subjects with ‘current 
asthma’ were defined as 
those reporting asthma in 
life and ≥1 asthma-like 
symptom in the last 12 
months: wheezing or 
whistling, tightness in 
ROC analysis 
(AUC 0.79) 
>18.7 ppb Sensitivity 69.2% 
Specificity 71% 
PPV 24% 
NPV 95% 
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chest, asthma attacks or 
treatment for medically 
diagnosed asthma 
Kowal et al. 
(528) 
540 young adults with 
chronic cough (≥8 
weeks) referred to 
outpatient clinic 
No details of device  
 
50 mL/s 
All patients had normal 
baseline spirometry. 
Asthma diagnosis based 
on positive histamine 
challenge (PC20 ≤8 
mg/mL)/significant PEF 
variability/significant 
reversibility 
ROC analysis 
(AUC 0.92) 
>40 ppb Sensitivity 88.3% 
Specificity 82.6% 
PPV 72.6% 
NPV 93.1% 
Schneider et 
al. 
(521) 
160 patients 
presenting to GPs 
with symptoms 
suggestive of asthma 
(dyspnoea, cough or 
phlegm) ≥2 months 
duration 
NiOX MINO 
(Aerocrine, Solna, 
Sweden) 
 
50 mL/s 
Physician decision based 
on medical history, 
examination, spirometry, 
whole body 
plethysmography and 
MCT (PC20 ≤16 mg/mL) 
results 
ROC analysis 
(AUC 0.65) 
>46 ppb Sensitivity 32% 
Specificity 93% 
PPV 80% 
NPV 61% 
Pedrosa et 
al. 
(529) 
114 consecutive adult 
subjects with 
symptoms suggestive 
of asthma 
NiOX MINO 
(Aerocrine, Solna, 
Sweden) 
 
50 mL/s 
Positive MCT (PC20 ≤8 
mg/mL) 
ROC analysis 
(AUC 0.76) 
>40 ppb Sensitivity 74.3% 
Specificity 72.5% 
PPV 54.2% 
NPV 86.6% 
Cordeiro et 
al. 
(519) 
 
 
114 atopic individuals 
presenting to allergy 
clinic (symptoms not 
specified) 
Niox-Flex 
 
50 mL/s 
Referred by physician for 
histamine challenge if 
clinical assessment 
consistent with asthma. 
Positive histamine 
ROC analysis >27 ppb Sensitivity 78% 
Specificity 92% 
PPV 86% 
NPV 87% 
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challenge (PC20) cut-off 
not stated 
Fukuhara et 
al. 
(530) 
61 subjects presenting 
to outpatient clinic 
with ≥1 of recurrent 
cough, wheeze or 
dyspnoea 
NA623N, Chest MI, 
Tokyo, Japan 
Online 
chemiluminescence 
 
50 mL/s 
Asthma diagnosis based 
on  
(1) ≥1 of above symptoms 
(2) ≥2 of induced sputum 
eosinophilia, AHR and 
reversible airway 
obstruction 
(3) other diseases ruled 
out using CT and ‘other 
tests’ 
 
Compared diagnosis by 
these criteria against 
diagnosis using “FENO 
based criteria” based on 
(1) symptoms as above 
(2) FENO level ≥40 ppb 
(derived from prior 
studies) 
(3) other diseases ruled 
out 
Comparison of 
“conventional 
criteria” and 
“FENO based 
criteria” 
Pre-
specified 
cut-point 
of 40 ppb 
based on 
previous 
studies 
Sensitivity 78.6% 
Specificity 89.5% 
Concordance rate 
of 0.62 between 
two sets of criteria 
 
9/42 (21%) of 
patients 
‘misdiagnosed’ as 
not having asthma 
according to FENO 
based criteria 
Matsunaga 
et al. (531) 
142 subjects with 
respiratory symptoms 
referred to outpatient 
clinic and 224 subjects 
with no current 
NiOX MINO 
(Aerocrine, Solna, 
Sweden) 
 
50 mL/s 
Based on presence of 
“significant airway 
reversibility and or airway 
hyperresponsiveness” (not 
further specified) during 
ROC analysis 
 
For non-
smokers 
without 
 
 
>22 ppb 
 
 
 
 
Sensitivity 92% 
Specificity 90% 
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respiratory symptoms the follow up period. rhinitis 
(n=126) AUC 
0.92 
 
For non-
smokers with 
rhinitis 
(n=136) AUC 
0.88 
 
For smokers 
without 
rhinitis (n=49) 
AUC 0.94 
 
For smokers 
with rhinitis 
(n=55) AUC 
0.87 
 
 
 
 
>28 ppb 
 
 
 
 
 
>18 ppb 
 
 
 
 
>22 ppb 
 
 
 
 
Sensitivity 90% 
Specificity 77% 
 
 
 
 
Sensitivity 100% 
Specificity 87% 
 
 
 
Sensitivity 80% 
Specificity 86% 
Schleich et 
al. 
(67) 
174 patients referred 
to a pulmonary 
function laboratory 
with suspected 
asthma but normal 
spirometry and 
reversibility 
NiOX 
chemiluminescence 
analyser (Aerocrine, 
Solna, Sweden) 
 
50 mL/s 
Positive MCT  
(PC20 ≤16 mg/mL) 
ROC analysis 
(AUC 0.62) 
>34 ppb Sensitivity 35.4% 
Specificity 95.4% 
PPV 88% 
NPV 62% 
Malinovschi 
et al. (532) 
282 subjects from a 
group of 686 subjects 
NiOX MINO 
(Aerocrine, Solna, 
Physician diagnosis based 
on symptoms plus  ≥1 of 
ROC analysis 
 
For non-
smokers 
Sensitivity 77.8% 
Specificity 63.5% 
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who reported ≥2 
ongoing respiratory 
symptoms on an 
asthma questionnaire 
sent to a random 
population sample of 
10,400 subjects 
Sweden) 
 
50 mL/s 
the following: 
1) Positive MCT  
(PC20 ≤8 mg/mL).  
2) ≥250 mL increase in 
post BD FEV1 
3) Daily use of oral steroid, 
ICS, or inhaled β2-agonist 
4) Asthma symptoms 
during pollen season, 
eventually supported by 
allergic rhinitis, although 
no objective signs of 
asthma outside season  
For all subjects 
AUC 0.72 
 
Excluding 
current ICS 
users AUC 0.73 
 
Subjects 
divided into 
non, ex-
smoking and 
current 
smoking 
groups  
(n=108) 
>15 ppb 
 
For ex- 
smokers    
(n=62)        
>22 ppb 
 
For 
current 
smokers 
(n=112)       
>17 ppb 
PPV 60% 
NPV 80% 
 
Sensitivity 63.2% 
Specificity 86.1% 
PPV 67% 
NPV 84% 
 
Sensitivity 56.3% 
Specificity 82.5% 
PPV 57% 
NPV 82% 
Voutilainen 
et al.  
(533) 
 
Sedentary patients 
referred to outpatient 
clinic with symptoms 
suggestive of asthma 
NiOX 
chemiluminescence 
analyser (Aerocrine, 
Solna, Sweden) 
 
Flow rate not stated 
Positive histamine 
challenge (cut-off not 
stated) 
ROC analysis 
(AUC 0.83) 
Pre-
specified 
cut-point 
of >30 ppb 
as “high 
FENO” 
Not stated 
Katsoulis et 
al. 
(534) 
 
112 subjects with 
asthma-like 
symptoms and 
negative reversibility 
NiOX MINO 
(Aerocrine, Solna, 
Sweden) 
 
50 mL/s 
Positive MCT (PD20 <800 
μg) 
ROC analysis 
(AUC 0.69) 
>32 ppb Sensitivity 47% 
Specificity 85% 
Schneider et 
al. 
(518) 
393 patients 
presenting to GPs 
with 
NiOX MINO 
(Aerocrine, Solna, 
Sweden) 
Physician decision based 
on medical history, 
physical examination, 
ROC analysis 
(AUC 0.66) 
>25 ppb Sensitivity 49% 
Specificity 75% 
PPV 56% 
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symptoms suggestive 
of asthma (dyspnoea, 
cough or phlegm) ≥2 
months duration 
 
50 mL/s 
spirometry, whole body 
plethysmography and 
bronchial provocation 
(PC20 ≤16 mg/mL) results 
NPV 69% 
Wang et al. 
(520) 
923 consecutive 
patients referred to 
outpatient clinic with 
symptoms suggestive 
of asthma (recurrent 
wheezing, dyspnoea, 
chest tightness and/or 
cough, duration over 
6 months),  
Nano Coulomb nitric 
oxide analyser 
 
50 mL/s 
+ve MCT (cut-point not 
listed) 
 
 
OR 
 
+ve reversibility 
(considered +ve if post BD 
FEV1 15% and 200 mL 
higher than pre BD FEV1) 
ROC analysis  
(AUC 0.76) 
 
 
 
 
AUC 0.78 
>64 ppb 
 
 
 
 
 
>41 ppb 
For MCT +ve 
Sensitivity 52% 
Specificity 94.4% 
PPV 80.2% 
NPV 72.8% 
 
For reversibility +ve 
Sensitivity 72.4% 
Specificity 74.9% 
PPV 61.8% 
NPV 82.9% 
Table 1.7: The utility of FENO testing for the diagnosis of asthma
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1.5.5 Guidelines for the Diagnosis of Asthma 
1.5.5.1 British Thoracic Society (BTS) guidelines (2016) 
The BTS/Scottish Intercollegiate Guidelines Network (SIGN) guidelines recommend that a 
person presenting with suspected asthma should be clinically assessed and the probability 
of asthma determined (535).  
The clinical assessment should include careful enquiry regarding the following symptoms 
(Fig. 1.4): 
 
Figure 1.4: Clinical features to be enquired about during clinical 
assessment for asthma. From BTS guidelines (535). 
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This assessment should be used to classify whether the patient has a high, intermediate or 
low probability of asthma. Patients with a high probability should be offered a trial of 
treatment, and those with a low probability investigated for other conditions, with those in 
the intermediate group being assigned to a treatment trial or further investigation 
depending on their FEV1/FVC ratio, reversibility and possibly further investigations as shown 
in Fig. 1.5. 
 
Figure 1.5: Algorithm for further investigation or treatment of 
asthma following initial clinical assessment and spirometry. From 
BTS guidelines (535). 
 
For patients with intermediate probability of asthma the guidelines recommend further 
investigation of patients following spirometry, which may include tests to assess airflow 
variability or tests for eosinophilic inflammation/atopy prior to strategies of either watchful 
waiting or a treatment trial. 
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The formal inclusion of investigations such as challenge tests and FENO for consideration in 
the diagnostic algorithm are a new feature of the 2016 guidelines and were previously not 
included in the last 2014 update. Probably owing to the lack of clear evidence about the 
exact role of the tests in ‘diagnosing’ asthma they are included as ‘options’ that may be 
considered to provide extra evidence to support a diagnosis of asthma.     
1.5.5.2 National Heart, Lung, and Blood Institute (NHLBI) guidelines (2007) 
This guidance states that (536):  
In order to establish a diagnosis of asthma the clinician should determine that: 
— Episodic symptoms of airflow obstruction or airway hyperresponsiveness are present. 
— Airflow obstruction is at least partially reversible. 
— Alternative diagnoses are excluded 
The diagnosis should be made from a medical history, physical examination and spirometry 
with reversibility. If no clear diagnosis can be made, further investigations should be used to 
exclude asthma or consider other alternative diagnoses. 
Some of the “key indicators” from the medical history suggestive of a diagnosis of asthma 
include: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Key indicators from medical history suggestive of a 
diagnosis of asthma. From NHLBI guidelines (536). 
 Wheezing – high pitched whistling sounds when breathing out – especially in 
children. (Lack of wheezing and a normal chest examination do not exclude 
asthma) 
 History of any of the following : 
o Cough, worse particularly at night 
o Recurrent wheeze 
o Recurrent difficulty in breathing 
o Recurrent chest tightness 
 Symptoms occur or worsen in the presence of: 
o Exercise  
o Viral infection 
o Animals with fur or hair 
o House-dust mites (in mattresses, pillows, upholstered furniture, carpets) 
o Mold 
o Smoke (tobacco, wood) 
o Pollen 
o Changes in weather 
o Strong emotional expression (laughing or crying hard) 
o Airborne chemicals or dusts 
o Menstrual cycles 
 Symptoms occur or worsen at night, awakening the patient 
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Features that should be assessed for on physical examination include: 
 Hyperexpansion of the thorax; use of accessory muscles or chest deformity 
 Sounds of wheezing on chest auscultation/prolonged phase of forced expiration 
 Increased nasal secretion, mucosal swelling, and/or nasal polyps 
 Signs of allergic skin condition such as atopic dermatitis/eczema 
The guidelines then recommend that all patients over the age of 5 in whom asthma is being 
considered as a diagnosis should undergo spirometry with reversibility testing. As well as 
measuring FEV1 and FVC these guidelines also recommend measurement of the volume of 
air exhaled after the first 6 seconds of expiration (FEV6). This parameter should be measured 
instead of FVC in patients who might find sustaining maximal expiratory effort until 
complete expiration too arduous, such as patients with severe airflow obstruction.  
Based on the results of spirometry it can be determined if the patient has airways 
obstruction and whether or not this is reversible. Significant reversibility is defined as per 
ATS/ERS guidelines (537) as an increase in FEV1 of >200 mL and ≥12% from the baseline 
measure after inhalation of a short acting beta agonist (SABA).  
These guidelines are not explicit regarding the use of further investigations for the diagnosis 
of asthma and merely state that “additional studies are not routinely necessary but may be 
useful when considering alternative diagnoses” which should be considered “as 
appropriate”.  
1.5.5.3 Canadian Thoracic Society guidelines (2012) 
These guidelines state that “asthma is diagnosed by the combination of a comparable 
clinical history and objective measures of lung function” (538).  
Features of the clinical history should include “paroxysmal or persistent symptoms such as 
dyspnoea, chest tightness, wheezing, sputum production and cough, associated with 
variable airflow limitation and airway hyper-responsiveness to endogenous or exogenous 
stimuli”. 
The recommended measures of lung function are those in Fig. 1.7: 
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Figure 1.7: Recommended measures of lung function when 
considering diagnosis of asthma. From Canadian Thoracic Society 
Guidelines (538) 
 
These guidelines explicitly recommend bronchial challenge testing (with both methacholine 
and exercise) as an alternative objective diagnostic criterion for asthma. There is no further 
guidance on how to proceed if a patient has a clinical history consistent with asthma but 
normal pulmonary function tests and no mention of using measures of airway inflammation 
for asthma diagnosis. 
1.5.5.4 Comparison of guidelines 
a) Similarities 
All of these guidelines include recommendations for the clinical assessment of patients with 
suspected asthma and highlight certain features that make asthma more likely. These 
include symptoms of wheeze, dyspnoea, chest tightness and cough (especially nocturnal 
cough) that worsen in relation to recognised stimuli such as exercise and allergen exposure. 
All guidelines agree on performing spirometry, but after this they vary in the approach to 
further confirmation of a diagnosis of asthma. 
b) Differences 
There are a number of important differences between these sets of guidelines which are 
most apparent following the clinical assessment of patients and spirometry. 
The BTS/SIGN guidelines recommend classifying patients into groups with different 
probabilities of asthma prior to performing further investigations or instigating a treatment 
trial. The use of spirometry/reversibility and further investigations is reserved for those with 
an intermediate probability of asthma. In contrast, the NHLBI guidelines recommend all 
patients should undergo reversibility testing in addition to basic spirometry and then are not 
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explicit regarding the use of further investigations. CTS guidelines state that patients should 
preferably have spirometry and reversibility testing following clinical assessment, but that 
the results of other investigations including variability in serial peak flow measurements or 
positive methacholine/exercise challenge testing may be used instead to make a diagnosis 
of asthma.  
The BTS guidelines are the only one of the three sets of guidelines that endorse a trial of 
treatment in suspected asthma patients before performing further investigations such as 
reversibility testing. This may be a concession to pragmatism with evidence suggesting that 
many patients are started on ICS treatment for presumed asthma without even having 
spirometry performed (382).  
As the BTS guidelines are more extensive and more frequently updated than the other two 
guidelines they contain much more information about the further investigations that may 
be used in asthma. They also provide some comparison of their relative 
sensitivities/specificities. Investigations including challenge tests with methacholine, 
exercise and mannitol and FENO measurement are generally recommended in patients 
where the diagnosis is unclear but there is no guidance on the systematic use of these tests. 
The CTS guidelines also recommend bronchial challenge testing but only as an alternative to 
spirometry with reversibility for asthma diagnosis rather than in addition to this. 
1.5.5.5 Proposed NICE guidelines for asthma diagnosis  
This proposed set of guidelines, originally due for full release in 2015, are an attempt by the 
National Institute for Health and Care Excellence (NICE) to improve the efficiency and 
accuracy of diagnosing asthma (539).  The use of a series of objective tests in the format of a 
diagnostic algorithm is recommended based on review of the literature and an economic 
analysis assessing the likely cost implications of using these tests to diagnose asthma. 
In its current format, the algorithm recommends the use of spirometry followed by 
combinations of peak flow variability testing, FENO measurement and bronchial challenge 
testing to diagnose asthma. FENO measurement is suggested to “rule out” asthma (FENO <25 
ppb) or “rule in” asthma (FENO >40 ppb) with values between these two cut-points being 
labelled as intermediate, and the patient requiring further investigation. However, this 
approach is still likely to suffer from the problems of multiple confounding factors affecting 
FENO levels, including high FENO levels in subjects with other airway diseases and low FENO 
levels in subjects with neutrophilic asthma.  
Release of these guidelines is currently on hold while the “impact and feasibility” of 
measuring “quality-assured spirometry” and FENO in primary care to diagnose asthma in 
primary care is assessed, with an estimated release date of 2017. 
1.5.5.6 Summary  
All of the published guidelines appear to lack detail that may help guide the diagnostic 
process for asthma. Although the clinical assessment and use of spirometry in diagnosing 
asthma is well defined in this guidance, the role of further investigations that are well 
characterised such as reversibility testing and bronchial challenge testing is unclear. Tests of 
airways inflammation do not yet have an explicit role in the diagnosis of asthma in any 
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published guidance to date. The proposed NICE guidelines are an attempt to utilise further 
objective measures including FENO to diagnose asthma, although the feasibility of using 
objective tests for asthma diagnosis in the algorithm described requires validation and 
potential problems with this approach have been described above. Owing to its ease of 
measurement and the fact that results are available almost instantaneously FENO is clearly 
an attractive test to help guide asthma management but there is, as yet, no clear evidence it 
has a role in the diagnosis of asthma. However, an alternative use has been suggested for 
the technique in the assessment of subjects with suspected airways disease. 
1.5.6 The use of FENO to predict steroid response 
As FENO is a biomarker of ongoing Th2 inflammation and Th2 inflammation is usually 
responsive to corticosteroids a small number of studies have investigated the potential of 
FENO to predict subjects’ treatment response to corticosteroids irrespective of their 
underlying diagnosis. 
1.5.6.1 Previous studies assessing FENO to predict steroid response 
Smith et al. (540) aimed to evaluate the role of FENO measurements in predicting treatment 
response to ICS in a cohort of 52 patients with undiagnosed respiratory symptoms. Subjects 
were assessed in a respiratory clinic on 5 separate occasions over a 10 week period. A series 
of sequential diagnostic tests (including spirometry, reversibility, methacholine and 
adenosine monophosphate challenges, symptom diary/peak flow measurements and 
multiple FENO measurements) were carried out whilst subjects were being treated with a 4 
week course of inhaled placebo therapy, followed by a 4 week course of inhaled fluticasone.  
A response to steroid treatment was defined by: 
 an improvement in FEV1 of >12% or 
 an improvement in mean morning peak flow (over 7 day period) by >15% or 
 a reduction in composite symptom score by 1 point or 
 an improvement in PC20 AMP by ≥2 doubling dose shift 
The steroid response also took into account any response to the placebo treatment as any 
“placebo response” for any of these endpoints was subtracted from the steroid treatment 
response. Patients were also diagnosed with asthma if they had a corresponding symptom 
history (which all patients did) and either significant reversibility to short acting β-agonist, 
significant FEV1 or peak flow response to inhaled steroids (using same criteria as above) or a 
positive MCT.  
FENO was compared to the other baseline measurements (FEV1, FEV1 bronchodilator 
response, peak flow variation and methacholine PC20) in its ability to predict a response to 
steroids, based on the 4 defined measures of steroid response. This parameter was 
demonstrated to be significantly more accurate than all of the other baseline measurements 
for at least one of the steroid response measures and inferior in none, as measured by 
greater ROC AUC for comparative ROC curves. The optimum FENO cut-point for predictive 
purposes for all 4 steroid response measures was found to be >47 ppb, although there were 
patients with FENO levels lower than this who responded to treatment. For FENO >47 ppb 
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using ≥2 doubling dose increase in AMP PC20 as a response measure the sensitivity was 82%, 
specificity 91%, PPV 82% and NPV 91%. 
The results of this study were clearly dependent on the measure used to determine a 
“steroid response”. This was illustrated by the range of values for the specificity of FENO 
levels >47 ppb to predict steroid response from 71-91% for different response measures, 
suggesting that up to 30% of subjects in this group did not demonstrate a response to 
steroids. The authors suggested this may be because many of this group had near to normal 
lung function and hence had limited room for improvement in this metric, making the cut-
points used to define steroid response inappropriate for this population. It is possible that 
these patients as well as patients with lower FENO levels may also have demonstrated a 
response to steroid treatment if different measures of response such as change in FENO, long 
term symptom measures or quality of life data had been collected. 
Little et al. (541) assessed FENO levels as a marker of oral steroid response in 37 patients 
with chronic stable asthma. All had a diagnosis of asthma according to ATS criteria for ≥5 
years and all but one of the subjects were using regular ICS. A FENO level of >10 ppb at 
baseline was found to have a high specificity (90%) and positive predictive value (83%) for 
an improvement in FEV1 of >15% but a low sensitivity (59%). Interestingly, all of these values 
had better predictive accuracy than sputum eosinophilia of ≥4% (although 7 patients did not 
produce sputum), but it could be argued that both tests may have performed better if an 
outcome measure more reflective of the activity of Th2 inflammation had been chosen i.e. a 
measure related to number of exacerbations rather than lung function. 
Prieto et al. (542) also assessed the utility of FENO measurement to predict response to ICS in 
43 non-smoking subjects with chronic cough and FEV1 >80%. The cohort in this study had 
chronic cough of at least 8 weeks duration with no evidence of any lung disease on clinical 
or radiological assessment and had not previously received any treatment for pulmonary 
conditions including inhaled or oral corticosteroids. At the three baseline visits 
investigations including a high-resolution CT scan, spirometry with reversibility, FENO and 
bronchial challenge testing with methacholine and AMP were carried out. Subjects were 
then given 4 weeks treatment with inhaled fluticasone. The primary outcome of ICS 
response was defined by a >50% reduction in the mean daily cough symptom scores during 
the treatment period when compared with the baseline period. Interestingly, only 4/43 (9%) 
of these patients had a positive MCT so the frequency of “asthma” in this cohort was likely 
to be low. Nineteen patients (44%) responded well to ICS therapy but FENO was poor at 
predicting ICS response, with low sensitivity (53%), specificity (63%) and positive and 
negative predictive values (53% and 63% respectively) at the ‘optimal’ cut-off point of 20 
ppb. It is likely that due to the low incidence of asthma (or, at least, AHR) in this group that a 
significant proportion of the cohort were less likely to respond to ICS and this may partially 
explain the poor performance of FENO in predicting ICS response in this study. Also, it is 
questionable whether the chosen response variable (mean cough score rated on an 
unvalidated 5 point scale) had the necessary sensitivity to accurately discern a significant 
response. 
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1.5.6.2 ATS guidelines for the interpretation of FENO levels 
The ATS guidelines for the interpretation of FENO levels (543) published in 2011 concluded 
that FENO levels of <25 ppb (20 ppb in children) should be considered low and a strong 
indicator that responsiveness to steroids is unlikely. In addition, FENO levels >50 ppb (35 ppb 
in children) should be considered high and a strong indicator that steroid response is likely. 
The high cut-point of >50 ppb suggesting a likely response to steroids is advocated based on 
the results of only one study (540). In contrast, the lower cut-point of <25 ppb was 
suggested based on data from a variety of studies (458, 509, 511, 515, 517) and has been 
used because a high frequency of normal people are thought to have FENO levels up to 
around 22 ppb. The presence of ongoing Th2 inflammation at such levels is unlikely.  
According to the guidelines FENO levels between 25 and 50 ppb should be interpreted 
cautiously and their significance is unclear. Measured FENO levels in this range should be 
interpreted in the context of the individual patient’s clinical symptoms, concurrent 
medications, smoking status etc. and relative changes in FENO levels in this range, e.g. a 
reduction after the use of ICS, may be more important than absolute values.  
1.5.6.3 Summary 
Using FENO levels to predict steroid response would appear to be a logical approach given 
that FENO is a biomarker of Th2 inflammation and there is good evidence that this type of 
inflammation is responsive to steroid treatment. This approach avoids the complexities 
inherent in attempting to use the technique to classify heterogeneous airways diseases 
according to diagnostic labels. 
The study by Smith et al. provides good evidence that this strategy may be useful, but the 
optimal cut-point derived by these authors to predict ICS response (>47 ppb) may risk 
missing subjects with measured FENO levels in the ‘indeterminate’ range of 25-50 ppb 
identified in the ATS FENO guidelines who would benefit from steroid treatment. It would be 
useful for clinical practice if a ‘minimum’ FENO cut-point below which steroid response is 
unlikely could be determined in order to guide the decision of whether or not to initiate 
steroid treatment in subjects with symptoms suggestive of airways disease. 
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1.6 Chronic Productive Cough and the use of Macrolides in Airways 
Disease 
1.6.1 Introduction 
A chronic ‘productive’ or ‘wet’ cough is a common presenting complaint for patients 
attending the adult respiratory clinic. Most reviews and guidelines suggest that the causes 
of a productive cough are the same as those of a non-productive cough and as such the 
same diagnostic pathway should be followed (559).  
A cohort of adult patients presenting to respiratory clinic have been observed with chronic 
productive cough which improves with antibiotic treatment but usually relapses (560). Many 
patients in this cohort have suspected poorly controlled asthma but investigations including 
spirometry, bronchial challenges, chest X-ray, screen for immunodeficiency and HRCT scan 
are normal. Sputum culture is often positive for potentially pathogenic bacteria such as 
Haemophilus influenzae, but may be repeatedly negative. Initial observations suggest 
significant symptomatic improvement with a prolonged course of low dose azithromycin. 
A literature review regarding the causes of chronic productive cough was undertaken to 
ascertain if this cohort had been described previously or if this presentation could be 
adequately explained by one of the recognised causes of chronic productive cough. 
Following this the mechanisms of action and previous uses of macrolides in respiratory 
disease were also reviewed. 
1.6.2 Causes of Chronic Productive Cough 
For the purposes of this review the definition of a “chronic productive cough” was 
considered to be a cough regularly leading to the expectoration of sputum with the same 
duration as the standard definition of chronic cough i.e. more than 8 weeks (57). 
Conditions causing productive cough have been listed in an approximate order of 
prevalence from most to least frequent. 
 
1.6.2.1 Bronchiectasis 
Bronchiectasis is defined in Section 1.2.3.1. 
 
a) Epidemiology 
The epidemiology of bronchiectasis is reviewed in Section 1.2.3.2. 
 
b) Clinical Presentation 
The condition usually presents as a chronic productive cough (561), with daily sputum 
production (42). Other factors that suggest the diagnosis include haemoptysis, systemic 
features of weight loss and fatigue and multiple positive sputum cultures (42, 562). 
 
c) Pathology 
Bronchiectasis may be secondary to a multitude of other conditions (as listed in Table 1.8), 
with the most common predisposing factor thought to be post-respiratory infection (563, 
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564). However, a significant proportion of cases have no obvious discernable cause, 
although the number of these idiopathic cases reported differs markedly between studies 
(563-565). 
 
 
Table 1.8: Causes of bronchiectasis in approximate order of 
frequency from most to least common. Based on data from Pasteur 
et al. (563) and Shoemark et al. (564) 
 
It has been suggested that bronchiectasis is largely a result of dysregulation of the immune 
system, as it is often seen in patients with either immunodeficiencies or ‘hyperimmune’ 
(autoimmune) conditions such as Rheumatoid Arthritis or Inflammatory Bowel Disease (565, 
566). Although the initial step in the pathogenesis of the condition is not yet clear, it is 
broadly accepted that it progresses in a largely similar way, based on the ‘’vicious circle’ 
hypothesis proposed by Cole (567). This describes a cycle of airway inflammation, leading to 
structural airway damage and resultant mucous stasis, with the pooled mucus becoming 
colonised with bacteria, which initiate further inflammation (Fig 1.8).  
 
The most common sputum isolates, using standard microbiological approaches, from 
patients with bronchiectasis are the gram negative bacteria H. influenzae and Pseudomonas 
aeruginosa (568, 569). Colonisation of the sputum by first H. influenzae, and later P. 
aeruginosa, coincide with worsening of the clinical features of bronchiectasis including lung 
function and frequency of exacerbation (568, 569). 
 
d) Treatment 
Guidance on the treatment of bronchiectasis can be found in the BTS guidelines on 
bronchiectasis (570).  
Broad principles in the management of the condition include treatment of the underlying 
cause, monitoring of disease activity using lung function and regular sputum cultures, 
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airway clearance techniques and antibiotic treatment. These principles are further outlined 
in Table 1.9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: The ‘vicious circle’ hypothesis of bronchiectasis (after 
Cole (567))  
 
 
 
 
 
 
 
 
Environmental insult    + Background genetic 
susceptibility/defect in 
host defence 
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Principle of management  Specific management points 
Treatment of underlying cause e.g. allergic bronchopulmonary aspergillosis 
(ABPA) treatment, immunoglobulin 
replacement, treatment of rheumatoid 
arthritis or inflammatory bowel disease 
Monitoring of disease activity  Lung function measured annually (571, 
572) 
 Regular sputum cultures to determine 
colonising organisms and antibiotic 
resistance (568) 
Airway clearance techniques  Active cycle of breathing techniques 
(573) 
 Postural drainage (574) 
 Positive expiratory pressure devices e.g. 
Flutter (575), Acapella (576, 577) devices 
 High frequency chest wall oscillation 
devices (578) 
 Nebulised saline (579, 580) 
Antibiotic treatment Treatment of exacerbations 
 Definition of ‘exacerbation’ not 
universally agreed 
 No randomised controlled trials of 
antibiotic treatment for bronchiectasis 
exacerbations 
 Consensus opinion currently antibiotic 
treatment for 14 days (570) 
 Antibiotic choice based on likely 
causative organisms and sensitivities 
 Sputum culture should be sent prior to 
treatment 
P. aeruginosa eradication 
 If cultured for first time an attempt 
should be made to eradicate P. 
aeruginosa (581) 
Regular prophylactic antibiotic therapy 
 Patients having ≥3 exacerbations per 
year requiring antibiotic therapy or those 
with <3 exacerbations but with 
significant morbidity should be 
considered for long term antibiotics (570) 
such as macrolides (582) 
Table 1.9: Principles of management of bronchiectasis  
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1.6.2.2 Chronic bronchitis 
Chronic bronchitis is defined as “the presence of a chronic productive cough for more than 3 
months in 2 successive years” (583). It is almost invariably described as a feature of COPD 
secondary to smoking (583). 
 
a) Epidemiology 
The prevalence of chronic bronchitis in the general population is unclear, with many 
estimates ranging from 3-7% of adults experiencing symptoms (61, 584-588), although 
higher rates of up to 22% have been reported (589, 590). This uncertainty is probably due to 
different definitions of the condition, variable reporting of symptoms and the inclusion of 
subjects in these estimates with other conditions such as bronchiectasis.  
 
It is clear that individuals who are current or ex-smokers are more likely to have chronic 
bronchitis (61, 584, 587, 588, 590) and patients with COPD have a higher prevalence of 
chronic bronchitis, with up to 74% affected (591, 592). However, there seems to be a 
significant proportion of the general population experiencing these symptoms that do not 
have a formal respiratory diagnosis (587-590) and this group may be at greater risk of 
morbidity and mortality than healthy subjects. Guerra et al. (586) demonstrated that 
subjects under the age of 50 with symptoms of chronic bronchitis were significantly more 
likely to develop airflow limitation with increased risk of mortality than subjects without 
chronic bronchitis.  
 
b) Clinical Presentation 
Patients with chronic bronchitis present with a productive cough, although this symptom is 
often more unpredictable than the classic epidemiological definition of chronic bronchitis 
with much variation in the pattern of sputum production (593). Due to the large crossover 
of chronic bronchitis with COPD, many patients present with other features of COPD 
including dyspnoea and wheeze (594). 
 
Weatherall et al. (595) used cluster analysis to classify 175 patients with airways disease into 
5 separate phenotypes. They identified a ‘chronic bronchitis in non-smokers’ phenotype 
(n=38) with similarities to patients described in Section 3.1. This group tended to have 
relatively preserved lung function compared to the other phenotypic groups described in 
the study. However, these patients did not have HRCT scans to rule out bronchiectasis, so it 
is unclear if this may have been the cause for their symptoms. 
 
c) Pathology 
Productive cough in chronic bronchitis is secondary to excessive mucus secretions in the 
airways. Mucus is present in excessive amounts owing to over-production and 
hypersecretion from mucus-producing goblet cells and decreased airway clearance 
mechanisms. 
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Mucus overproduction is caused by exposure to inflammatory stimuli such as cigarette 
smoke (596, 597) and also viral (598) or bacterial (599) infection which lead to increased 
transcription of mucin genes due to activation of the epidermal growth factor receptor by 
inflammatory cells (597, 599). Unlike in asthma, in which mucous metaplasia is known to be 
a result of Th2 inflammation, the corresponding inflammatory response in COPD causing 
mucus over-production is not entirely clear, although it is thought to be Th17 mediated 
(366, 600). 
 
Continual exposure to inflammatory stimuli leads to increased numbers of goblet cells and 
mucin storage in the airways (598, 599, 601). As the severity of disease, i.e. extent of airway 
obstruction, worsens in COPD, the degree of mucous metaplasia and occlusion of the small 
airways by mucus tends to increase (236, 602). Mucus hypersecretion is caused by increased 
goblet cell degranulation due to neutrophil elastase (603). 
 
In conjunction with the increased amounts of mucus secreted into the airways, clearance of 
this mucus is impaired in patients with established COPD, owing to reduced ciliary function, 
occlusion of distal airways and respiratory muscle weakness leading to ineffective cough 
(236, 604). 
 
d) Treatment 
Treatment of chronic bronchitis is largely based on treatment of the underlying COPD, as 
per NICE COPD guidelines (605). 
 
Certain treatment considerations that may particularly apply to patients with chronic 
bronchitis include the use of mucolytic therapy and judicious use of antibiotic therapy based 
on sputum colour and culture results. Another promising emerging treatment that has 
demonstrated efficacy in this patient group is the phosphodiesterase inhibitor roflumilast. 
 
Mucolytic agents are widely prescribed to patients with chronic bronchitis in an attempt to 
improve their symptoms related to sputum production. The evidence for their use is mixed 
although a 2012 Cochrane review concluded that they may produce a small reduction in the 
exacerbation rate of patients with chronic bronchitis and COPD albeit with no difference in 
quality of life (606).There are some suggestions that chest physiotherapy (607) and 
inhalation of nebulised saline (608) may be beneficial in patients with patients with COPD 
but no RCT data assessing the impact of these interventions. 
 
It is generally accepted that for subjects with chronic bronchitis a change in the amount or 
nature of sputum produced, beyond day-to-day variation, may signify an exacerbation (605, 
609) and the production of green (purulent) sputum has been found to be highly sensitive 
(94.4%) and specific (77%) for the yield of a high bacterial sputum load (610). Guidelines 
therefore recommend antibiotic treatment following change in sputum quantity or quality 
(605, 609).  Sending sputum for culture undoubtedly has a role in the management of 
chronic bronchitis, especially when there is a lack of response to an initial antibiotic 
treatment (609). However, potentially pathogenic bacteria that often permanently colonise 
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the respiratory tract of symptomatically stable patients with COPD are frequently not 
isolated on standard sputum cultures (611). These colonising bacteria, most frequently H. 
influenzae, are associated with increased levels of airway inflammation, higher symptom 
burden and increased risk of exacerbation (612). The lack of sensitivity of standard sputum 
cultures to detect these bacteria has led to increasing interest in DNA-based bacterial 
detection techniques (613, 614). 
 
The long term use of low dose azithromycin has demonstrated efficacy in the treatment of 
patients with COPD with improved quality of life measures and decreased frequency of 
exacerbations (615). Long term macrolides should be used with some caution however 
owing to the recognised potential side effects including QT interval prolongation, 
disturbance of liver function, hearing loss and development of bacterial macrolide 
resistance (616). 
 
Finally, roflumilast which is a phosphodiesterase 4 inhibitor has been employed. This drug 
has anti-inflammatory effects in the airways by preventing the breakdown of intracellular 
cyclic AMP, a substance that when degraded leads to the release of inflammatory mediators 
(617). Two clinical trials assessing the effects of roflumilast (in addition to either salmeterol 
or tiotropium) vs placebo in patients with moderate to severe COPD and symptoms of 
chronic bronchitis both found that roflumilast significantly improved pre-bronchodilator 
FEV1 and exacerbation rate (618).  
 
1.6.2.3 Asthma with productive cough 
a) Epidemiology 
Limited data are available regarding the prevalence of chronic productive cough (or “chronic 
mucus hypersecretion”) in asthmatic patients, but there are reports of a significant 
subgroup of asthmatics in which these symptoms may be prominent. Two large scale 
European epidemiological studies reported the prevalence of chronic productive cough (≥ 3 
months sputum production for 2 successive years) symptoms in populations of asthmatic 
non-smokers of 39% (619) and 42% (620). These proportions were significantly higher for 
smokers with asthma, a finding replicated in a recent cross-sectional study by Thomson et 
al. (621). 
 
b) Clinical Presentation 
The symptom of chronic productive cough seems to be associated with an accelerated 
decline in FEV1 in asthmatic patients regardless of smoking status (619, 622). Thomson et al. 
found that asthmatic smokers with chronic productive cough had worse asthma control 
than those without a cough and asthmatic non-smokers with a productive cough had more 
exacerbations than those without cough (621).  
 
114 
 
c) Pathology 
The cause of chronic productive cough in asthmatic patients is not entirely clear. Possible 
pathologies underlying this symptom include mucus hypersecretion or chronic bacterial 
infection/colonisation. 
 
Mucus hypersecretion has long been recognised as a feature of asthma with mucus plugging 
of the airways acknowledged as a contributing factor in cases of fatal asthma (623). 
Pathophysiological features of mucus hypersecretion in asthma include goblet cell 
hyperplasia (624) and submucosal gland hypertrophy (625), both of which lead to increased 
sputum production. These changes are thought to be driven by Th2 lymphocyte release of 
cytokines IL-9 (626) and IL-13 (627) as well as mast cell infiltration of submucosal glands, 
with subsequent mast cell degranulation leading to increased amounts of luminal mucus 
(628).  
 
Certain groups of asthmatic patients have been identified with stable clinical features of 
disease that have sputum cultures positive for potentially pathogenic organisms. Studies by 
Wood et al. (629) and Green et al. (630) both identified sub-groups of ‘stable’ asthmatic 
patients with significant loads of potentially pathogenic bacteria (including H. influenzae) in 
sputum culture with high sputum neutrophil counts. All of the patients within these groups 
were taking high dose ICS, which have been linked with increased risk of respiratory 
infection. For example, inhaled fluticasone propionate has recently been shown to increase 
the risk of lower respiratory tract infections in patients with COPD (631, 632) and also 
asthma (633). It is possible that ICS lead to chronic bronchitis in some patients by reducing 
host defence mechanisms, contributing to chronic infection. A more recent investigation by 
Zhang et al. (634) found that 29/56 (52%) of a cohort of patients with severe but stable 
asthma (and bronchiectasis excluded by HRCT) produced positive sputum cultures, with H. 
influenzae most commonly cultured. Of the 29 patients with positive sputum cultures 23 
produced repeat sputum cultures and 16 of these were again positive, with 14 having the 
same bacteria isolated on both occasions; suggesting these bacteria were colonising the 
airways. The group with concurrent positive sputum cultures had a significantly longer 
duration of asthma and a greater number of exacerbations in the preceding year. 
 
d) Treatment 
Guidance on the treatment of asthma can be found in the BTS/SIGN asthma guidelines 
(535).  
 
The association between severe neutrophilic asthma and airway colonisation by potentially 
pathogenic bacteria (635) may suggest a mechanism for the reduction in asthma 
exacerbations and lower respiratory tract infections (LRTI) in a sub-group of patients with 
non-eosinophilic asthma treated with a prolonged course of azithromycin in the AZIZAST 
study (636). However, this finding is yet to be verified. The use of antibiotics in asthmatics 
with sputum production as a main symptom should probably be guided by the results of 
sputum culture if possible, although the limitations of identifying micro-organisms from 
sputum cultures as described above (Section 1.6.2.2) should be considered.  
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1.6.2.4 Immunodeficiency 
A small group of patients presenting with recurrent LRTI are shown to have 
immunodeficiencies, including IgG/IgA deficiency or Combined Variable Immunodeficiency 
(CVID). These patients may present with recurrent but discrete episodes of infection 
punctuated by periods of recovery, but over time are at risk of developing bronchiectasis 
(637). 
 
The natural history of the clinical, pathological and radiological features displayed by these 
patients is unclear. Previous studies have reported significant rates of bronchitis symptoms 
in patients with primary immunodeficiencies (638-640), but it is uncertain if these patients 
have symptoms secondary to established bronchiectasis or if they progress through a state 
of ‘pre-bronchiectasis’ with bacterial airway colonisation and persistent cough but no 
significant bronchiectasis on HRCT scan. 
 
1.6.2.5 IgA deficiency 
Diagnosis of IgA deficiency has been defined by international consensus as “an IgA level of 
0.07 g/L after the age of 4 years in the absence of IgG and IgM deficiency” (641). 
 
a) Epidemiology 
Selective IgA deficiency is the most common primary immunodeficiency with a prevalence in 
Caucasians of between 1/300 and 1/1200 (642).  
 
b) Clinical Presentation 
Although the majority of cases (estimated at around 85-90%) are asymptomatic, there are a 
significant number who develop clinical disease as listed in Table 3.3. This mostly consists of 
recurrent respiratory tract and gastrointestinal tract infections and autoimmune conditions 
such as coeliac disease (643). These complications are not unexpected given that IgA is the 
immunoglobulin found at the highest concentrations in secretions at mucosal surfaces, 
especially in the gut and respiratory tract (644). 
 
Respiratory tract infections are usually caused by bacteria including H. influenzae and 
Streptococcus pneumoniae. Some patients go on to develop bronchiectasis presumably 
secondary to recurrent infection causing airway damage and scarring (643, 645). 
 
 
Clinical Manifestation of IgA deficiency Details 
Asymptomatic 85-90% of patients may have no symptoms 
Recurrent sino-pulmonary infections Mostly bacterial e.g. H. influenzae and S. 
pneumoniae. May lead to bronchiectasis 
Gastrointestinal infections/disorders Infections include Giardiasis, other disorders 
linked with IgA deficiency include coeliac 
disease, lactose intolerance, malabsorption 
and ulcerative colitis 
Allergic disorders Increased frequency of asthma, atopy, food 
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and drug allergies reported 
Autoimmunity Including idiopathic thrombocytopaenic 
purpura (ITP), haemolytic anaemia, juvenile 
rheumatoid arthritis and systemic lupus 
erythematosus (SLE) 
Malignancy There may be an association between IgA 
deficiency and malignancies including 
lymphoid and GI malignancies 
Table 1.10: The clinical manifestations of IgA deficiency 
 
c) Treatment 
In general, IgA antibody replacement therapy is not indicated in patients with IgA deficiency, 
and such therapy may in fact be harmful (646). However a sub-group of patients with IgA 
deficiency and recurrent sino-pulmonary infections may benefit from extended courses of 
prophylactic antibiotics or sometimes intravenous gamma globulin (IVGG) therapy if they 
have other associated antibody deficiencies (643, 646). 
 
1.6.2.6 Combined Variable Immunodeficiency 
CVID is a disease defined by the defective production of immunoglobulins (647). Diagnosis 
of CVID can be made using internationally agreed diagnostic criteria, of which 1 of the 3 
parts required for diagnosis states there should be “hypogammaglobulinaemia with IgG 
levels two standard deviations below the mean” (647). 
 
a) Epidemiology 
The epidemiology of the condition is unclear but the prevalence is thought to be around 
1/30000 in Northern European populations (647, 648). 
 
b) Clinical Presentation 
Clinically the disease manifests with recurrent respiratory tract infections/pneumonias, 
progressing later in life to bronchiectasis (638, 649, 650). Patients with CVID may also 
experience repeated infections of other sites of the body including the skin, soft tissues, 
nervous system and gastrointestinal tract (638, 649). There is some evidence that 
asthmatics may be at greater risk of CVID than non-asthmatics, and this has been suggested 
as a potential reason for the increased risk of respiratory infection noted in asthmatic 
patients (651). 
 
Respiratory infections are usually caused by encapsulated bacteria, especially H. influenzae, 
S. pneumoniae and Staphylococcus spp. (638, 652), due to the inability of the immune 
system to produce IgG antibodies against these pathogens. Usually, the cumulative effect of 
these repeated infections leads to complications such as empyema, lung abscesses or, most 
commonly bronchiectasis (638, 650).  
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However, despite the prominent burden of symptoms this condition can cause the sufferer, 
there may often be delays in the diagnosis and treatment of the condition due to either a 
lack of awareness of its existence, or the misperception that the condition only presents in 
childhood, when in fact the average age of presentation is thought to be around 30 years 
(638, 639). 
 
c) Treatment 
The management of pulmonary complications of CVID usually consists of regular 
immunoglobulin replacement and suppressive antimicrobial treatment, although there are 
no RCT data to support these measures (653). Several other interventions to maintain or 
improve lung function in patients with CVID have also shown some efficacy including the 
maintenance of higher IgG trough levels, chest physiotherapy techniques including postural 
drainage, azithromycin and nebulised antibiotics for eradication of P. aeruginosa (653). 
 
1.6.2.7 Protracted Bacterial Bronchitis (PBB) 
The cohort of patients described in Section 1.6 have many similar features in common with 
the paediatric diagnosis of protracted bacterial bronchitis (PBB). 
 
a) Epidemiology 
PBB is a common diagnosis in children and is thought to account for up to 40% of cases of 
paediatric chronic cough (654). 
 
b) Clinical Presentation 
PBB has been clinically defined as the presence of an isolated chronic ‘wet’ cough, in the 
absence of an alternative cause, which resolves with a prolonged course of antibiotic 
treatment (655). Children with the condition do not usually respond to bronchodilator 
therapy, but as with the patients described in Section 1.6 are often misdiagnosed as having 
asthma. 
 
The condition is suspected to be a potential precursor to the development of bronchiectasis 
in adulthood (654) and some authors have suggested it should be renamed ‘pre-
bronchiectasis’ (656). In retrospective studies the majority of adult patients with idiopathic 
bronchiectasis give a history of persistent wet cough from childhood (563, 657). There are 
very few, if any, descriptions of PBB in adults, although one previous study identified 15 
adult subjects with chronic productive cough secondary to ‘unsuspected bacterial 
suppurative disease of the airways’ and grossly normal HRCT scans (658). 
 
c) Pathology 
The pathogenesis of PBB is as yet unclear, but the main finding on investigation of the 
condition is persistent infection of the airways with bacteria including H. influenzae, S. 
pneumoniae and M. catarrhalis and neutrophilic airway inflammation (659-661). It is 
thought that bacteria may colonise the airways from the upper respiratory tract following a 
period of impaired mucociliary clearance, as may occur following a viral respiratory tract 
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infection. Once present in sufficient numbers in the conducting airways, bacteria (especially 
non-typeable H. influenzae) may form biofilms as a means of defence against airway 
clearance mechanisms and antibiotics (662). 
d) Treatment 
Resolution of cough in PBB is typically seen only after a prolonged course of antibiotics 
(663). RCT evidence suggests treatment with at least 2 weeks of an appropriate agent, 
although in some cases a longer duration of treatment (4-6 weeks) may be required (664).  
 
1.6.2.8 Summary: Causes of chronic productive cough 
There are multiple causes for chronic productive cough with distinct pathologies and 
features of disease. Possible causes of productive cough in the cohort described in Section 
1.6 may include early stage bronchiectasis without radiological changes, “chronic bronchitis” 
(i.e. excessive mucus production) with or without other features of underlying airways 
disease in non-smokers, immunodeficiency or an adult version of protracted bacterial 
bronchitis. 
 
Initial observations suggest that the chronic productive cough in the described cohort 
responds well to a prolonged course of low dose azithromycin therapy. Hence the literature 
regarding mechanisms of action and previous use of macrolides in respiratory disease will 
now be discussed. 
 
1.6.3 Macrolides: mechanisms of action and use in respiratory disease 
1.6.3.1 Introduction 
Macrolides are a clinically important group of antibiotics characterised chemically by the 
presence of a macrocyclic lactone ring (665). They exert bacteriostatic effects on a broad 
range of organisms by interfering with bacterial protein synthesis through binding to 
ribosomal RNA (666). 
 
In addition to the well documented anti-microbial effects of macrolides, due to their good 
oral bioavailability, tissue penetration and broad spectrum activity, there is a growing 
recognition that macrolides also have immunomodulatory and anti-inflammatory properties 
(667-669). Although the mechanisms of these effects are not yet entirely clear, macrolides 
have proven efficacy in the treatment of a number of respiratory conditions and have been 
demonstrated to affect a number of pathophysiological processes that are likely to 
contribute to ongoing disease. 
 
In this chapter the likely mechanisms of action of macrolides will be outlined followed by 
the use of macrolides in airways disease to date. 
 
1.6.3.2 Mechanisms of action of macrolides in respiratory disease 
The proven effectiveness of macrolides in reducing morbidity in a variety of respiratory 
diseases has prompted a great deal of research investigating the mechanisms by which they 
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convey their anti-inflammatory and immunomodulatory effects. Some of the main 
mechanisms for these effects recognised to date will now be discussed. 
 
a) Anti-inflammatory effects 
On neutrophils: Macrolide therapy appears to reduce airway neutrophil accumulation 
probably through a reduction in the expression of pro-inflammatory cytokines such as IL-8 
(670-672). Macrolides have also been shown in a mouse model to reduce airway 
neutrophilia (673) with significant reductions in IL-1β, an inducer of neutrophil infiltration of 
the airways (674), and GM-CSF, which is a neutrophil survival factor (675).  
 
On cytokine production: As well as their effect on IL-8, which is a potent chemotactic factor 
for neutrophils, macrolides have also been demonstrated to down regulate a number of 
other pro-inflammatory mediators, many of which serve as chemoattractants, survival 
factors and adhesion molecules for neutrophils. These include TNFα, IL-5 and soluble 
vascular cell adhesion molecule (sVCAM)-1 (676, 677).  
 
On macrophages: Studies have demonstrated that macrolides are able to reduce by the pro-
inflammatory effects of macrophages by switching classically activated M1 macrophage 
phenotypes to alternatively activated M2 phenotypes (678). Whereas the MI “killer” 
phenotype, which is activated by bacterial lipopolysaccharide and interferon-γ produces 
pro-inflammatory cytokines such as IL-6 and IL-12, the M2 “repair” phenotype refers to 
macrophages involved in tissue remodelling and immunosuppressive responses, which 
release anti-inflammatory cytokines such as IL-10 (679).  
 
Azithromycin at ‘sub-bactericidal’ doses has also been shown to enhance clearance of dead 
(apoptotic) material from the airways through phagocytosis following inflammation 
(macrophage efferocytosis) in patients with COPD (680). Impaired efferocytosis and an 
impairment of the ability of alveolar macrophages to phagocytose bacteria has been noted 
in a variety of airways conditions including COPD (681) and non-eosinophilic asthma (682) 
and low dose macrolides may help in these conditions by restoring this function. 
 
b) Effects on airway epithelial cells / mucus production 
The bronchial epithelium plays a key role in host immunity, secreting cytokines and 
antimicrobial factors in response to infection and most importantly providing a mechanical 
barrier to pathogen infiltration (683). The integrity of this barrier is therefore paramount to 
prevent infection of the respiratory tract and a key component in maintaining this integrity 
are the ‘seals’ between intercellular spaces called tight junctions (684).   
 
Several studies have demonstrated how bacteria including P. aeruginosa (685, 686) and 
Vibrio cholerae (687) are capable of producing toxins and compounds that compromise tight 
junction function leading to reduced epithelial integrity and bacterial infiltration. 
Azithromycin appears to be protective against tight junction rearrangement in vitro, which 
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helps to maintain integrity of the respiratory epithelium leading to greater resistance 
against pseudomonal infection (688). 
 
Some of the chronic inflammatory conditions reviewed in Section 1.6.2 have the shared 
pathological characteristic of airway mucus hypersecretion leading to cough productive of 
sputum. This is due to inflammatory stimuli provoking Th2/Th17 mediated inflammation 
leading to increased transcription of mucin genes such as MUC5AC and mucus 
hypersecretion (366, 599, 624, 626). There is some evidence that bacteria including 
Chlamydophila pneumoniae are capable of inducing MUC5AC production in airway epithelial 
cells through the ERK-NF-κB pathway (689, 690). 
 
Macrolides have been demonstrated to inhibit hypersecretion of mucus from rat nasal 
epithelial cells (691) and this may be due to downregulation of MUC5AC transcription 
through reduction of NF-κB activation (689, 690). Azithromycin directly inhibits 
hypersecretion of mucus from airway epithelial cells by inhibiting TNFα induced 
MUC5AC secretion from airway and human nasal epithelial cells (692). 
 
c) Effects on Pathogens  
Most of the work assessing the effects of macrolides on bacteria has focussed on the 
organism P. aeruginosa, one of the most virulent respiratory pathogens which has 
developed a number of methods to evade antibiotic treatment. Although P. aeruginosa 
often possesses a natural resistance to the antibiotic effects of macrolides, several ‘non-
antibiotic’ mechanisms have been demonstrated through which macrolides may disrupt the 
colonisation and establishment of pseudomonal communities in the airways. 
 
The process of P. aeruginosa infection, colonisation and biofilm formation will now be 
outlined in brief, followed by a summary of the mechanisms through which macrolides may 
disrupt this process at various different stages. 
 
d) Pseudomonas infection and colonisation 
Following entry to the lung, pseudomonal infections establish as the organism, which is able 
to mobilise owing to its tail-like flagellae and hair-like fimbriae, adheres to the respiratory 
epithelium via adhesion molecules such as lectins (693). Once adhered, it releases toxins, 
causing tissue damage, loses its flagellae and fimbriae and begins to produce a 
polysaccharide which will eventually form the matrix of a protective structure known as a 
biofilm (693). During biofilm formation and establishment, organisms are able to 
communicate with each other to co-ordinate the expression of certain genes such as tissue-
damaging factors via a process known as quorum sensing (694). 
 
Macrolides can affect this process in the following ways: 
i) Mobility: Sub-inhibitory concentrations of macrolides including azithromycin seem to 
decrease motility of P. aeruginosa due to disruption of flagellae and fimbriae formation 
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(695, 696). This reduced mobility leads to an increased rate of phagocytosis by alveolar 
macrophages. 
 
ii) Bacterial Adherence: Macrolides have been demonstrated to have significant effects on 
the adherence of P. aeruginosa to airway epithelial cells, which is a crucial stage in the 
establishment of bacterial infection. Both an in vitro investigation of pseudomonal 
adherence to collagen before and after erythromycin (697) and a study of the adherence of 
a P. aeruginosa strain to the buccal mucosal cells of patients with CF before and after 
azithromycin treatment (698) showed decreased adherence of the organism following 
macrolide treatment.  
 
iii) Toxin release: The bacterial virulence of P. aeruginosa is determined partly by the 
bacterial toxins these micro-organisms release; these include the cytotoxic enzymes alkaline 
protease, elastase, exotoxin A and phospholipase C. Several macrolides including 
erythromycin and azithromycin suppress the release of these enzymes resulting in 
decreased bacterial virulence and tissue damage (699, 700). 
 
iv) Biofilm construction: The formation of biofilms by P. aeruginosa, as well as other 
organisms such as H. influenzae can be disrupted by macrolides (695, 701). In vitro studies 
suggest that this may be due to the inhibition of production of polysaccharides (702, 703). 
 
v) Quorum sensing: The effect of macrolides on quorum sensing is not yet clear, but it is 
thought that they may suppress transcription of quorum sensing genes resulting in reduced 
production of quorum sensing virulence factors (704, 705). 
 
1.6.3.3 Use of macrolides in respiratory disease 
a) Diffuse Panbronchiolitis  
One of the first and most notably successful uses of macrolides in respiratory disease was in 
the treatment of Diffuse Panbronchiolitis (DPB). DPB is a chronic idiopathic condition which 
almost exclusively affects East Asians characterised by neutrophilic inflammation of the 
respiratory tract. The disease may progress if untreated to destruction of lung parenchyma 
and early mortality (706, 707).   
 
From the late 1980s onwards courses of long term macrolide therapy were used to treat the 
condition with a resultant improvement in 5 year prognosis from around 63% in the 1970s 
to around 90% in the 1990s (708). The macrolide originally chosen for treatment of DPB was 
erythromycin, but similar benefits have been found with other macrolides including 
azithromycin and clarithromycin (709). 
 
Although there are a large number of studies reporting significant improvement of DPB with 
macrolide therapy, a recent Cochrane review (710) in the subject did not find 
comprehensive evidence to substantiate their use for this purpose owing to a lack of large 
RCTs. Only one of the studies assessed in the review was deemed to be of sufficient quality 
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to include, albeit with significant methodological limitations (711). However, despite these 
reservations and the small number of participants in the trial the results of this study were 
compelling. This was because all of the 12 patients randomised to receive low dose 
erythromycin treatment showed improvement on their post-treatment CT scans compared 
to none of the seven patients who received no treatment, 5 of whom actually showed 
progression of DPB on their second CT scan. 
 
b) Bronchiectasis 
Bronchiectasis is a condition that has historically been treated with long courses of 
antibiotics in order to improve the persistent symptoms of cough with production of sputum 
positive for bacteria. Clinical trials of long term antibiotics in patients with bronchiectasis 
were first conducted in the 1950s, with seemingly positive results. These included reduced 
sputum volume and reduced number of days off work in a group of bronchiectatic patients 
taking a year-long course of oxytetracycline compared to the placebo group (712). However, 
no formal statistical analysis on these data was ever performed. 
 
Since this initial study, many investigators have conducted clinical trials in patients with 
bronchiectasis to assess the effect of various antibiotics including oral amoxicillin (713) and 
nebulised tobramycin (714, 715), gentamicin (716) and ciprofloxacin (717). These studies 
produced mixed results, although in general seemed to demonstrate that long term non-
macrolide antibiotics decreased exacerbation frequency and reduced bacterial load in non-
CF bronchiectasis, with no effect on pulmonary function. 
 
Koh et al. (718) performed one of the first trials of macrolides in subjects with 
bronchiectasis in a double-blind placebo-controlled RCT of roxithromycin in 25 children with 
bronchiectasis. The primary outcome for the trial was AHR as measured by MCT, but it 
should be noted that one of the entry requirements for the study subjects was increased 
AHR at baseline. After 12 weeks of roxithromycin treatment (4 mg/kg twice daily), AHR was 
found to be significantly reduced in comparison with the placebo group and there was also 
an improvement in sputum features (sputum purulence and leucocyte scores). Despite the 
positive results of this study, the primary outcome of AHR was a strange endpoint to 
measure in subjects with bronchiectasis, as this is not one of the key pathological features 
of the disease. Also, due to the intentional selection of children with significant AHR prior to 
treatment, the generalisability of these results may be in question. 
 
Tsang et al. (719) conducted a small double-blind RCT of 8 weeks of low dose erythromycin 
(500 mg twice daily) vs placebo in 21 patients. The erythromycin group demonstrated a 
significantly improved FEV1, FVC and 24 h sputum volume compared to the placebo group. 
No significant difference was found following erythromycin in any of the multiple 
measurements taken from sputum including sputum pathogens, leucocyte count, IL-1α, IL-8, 
TNFα or leukotriene B4.   
 
Cymbala et al. (720) carried out a pilot study of 11 patients with bronchiectasis comparing 
exacerbation frequency of patients on their usual medications vs those taking additional 
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azithromycin. Despite the low number of patients in the study, azithromycin was found to 
significantly reduce the incidence of exacerbation and 24 h sputum volume, although there 
was no discernible change in lung function or peak flow recordings. 
 
Yalcin et al. (721) studied the effects of 3 months of low dose clarithromycin treatment (15 
mg/kg once daily) on inflammatory markers in bronchiectasis in a double-blind placebo-
controlled trial of 34 children. The inflammatory markers assessed were IL-8, TNFα, IL-10 
levels and cell profiles in BAL fluid as well as pulmonary function and amount of sputum 
production. Significantly reduced levels of IL-8, total cell count and neutrophil ratios in BAL 
fluid and daily sputum production were found in the clarithromycin group in comparison to 
the placebo group, although there was no difference in pulmonary function. 
 
Diego et al. (722) carried out an open label study of azithromycin treatment in patients with 
bronchiectasis (n=30) to determine its effect on markers of airway oxidative stress in 
exhaled breath condensate (EBC). The selected markers included FENO, 8-isoprostane, pH, 
nitrites and nitrates. Patients were allocated to treatment with azithromycin (250 mg three 
times weekly) for 3 months or to a control group who received no intervention. There was 
no significant difference in the markers of airway oxidative stress between the 2 groups at 
the end of the study, although some of the secondary outcomes such as sputum volume, 
number of exacerbations and St George’s respiratory questionnaire (SGRQ) symptom score 
were significantly improved in patients in the azithromycin group. 
 
The best evidence so far for the use of macrolides in bronchiectasis comes from three large 
scale clinical trials carried out in the last few years.  
 
The first of these by Wong et al. (723) was a multicentre double-blind RCT of 141 patients 
with bronchiectasis (confirmed by HRCT scan) who were assigned to receive 500 mg of 
azithromycin or placebo three times a week for 6 months. The co-primary endpoints of the 
study were exacerbation rate, FEV1 and SGRQ score. After the 6 month treatment period, a 
significantly lower rate of exacerbations occurred in the azithromycin group in comparison 
to the placebo group, although there was no significant difference between the two groups 
in FEV1 and symptom scores. Sputum microbiology at baseline and after treatment was also 
documented, and although bacterial resistance to macrolide was not tested routinely, two 
patients in the azithromycin group developed macrolide resistant S. pneumoniae following 
treatment. 
 
Altenburg et al. (724) also conducted a multicentre double blind RCT of azithromycin vs 
placebo. This trial comprised fewer participants (83) but assessed the effect of azithromycin 
(250 mg once daily) over a longer 12 month period, and the primary endpoint to the study 
was also exacerbation rate. Again, the study demonstrated a reduction in the number of 
exacerbations in the group treated with azithromycin compared to the placebo group. 
However, another significant finding was the increased bacterial macrolide resistance rate in 
the azithromycin group with 88% of cultured organisms from the treatment group 
demonstrating macrolide resistance compared to 26% of those from the control group. 
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Lastly, Serisier et al. (725) have evaluated the use of low dose erythromycin therapy over a 
12 month period in a double-blind placebo-controlled RCT in 117 patients with 
bronchiectasis. The primary outcome measure was exacerbation rate and secondary 
outcome measures included lung function and macrolide resistance rate of oropharyngeal 
bacteria. Erythromycin was found to significantly decrease exacerbation rate as well as 24 h 
sputum production with a borderline significant improvement in lung function compared to 
placebo. This study also provided evidence of increasing bacterial macrolide resistance as a 
result of long term macrolide therapy. The proportion of macrolide-resistant oropharyngeal 
streptococci isolated from patients in the azithromycin group (median change of 27.7%) was 
significantly increased in comparison to those from the placebo group (median change 
0.04%). 
 
c) COPD 
There is an abundance of trial data regarding the use of long term macrolide therapy in 
COPD and only a brief summary of the evidence to date is reported here. A number of 
studies conducted prior to 2001 on this subject are not reviewed owing to the significant 
heterogeneity in patient groups. For example, spirometric criteria were often not used to 
diagnose COPD, antibiotics were taken for short time periods and some of the studies were 
simply of poor quality. 
 
Suzuki et al. (726) conducted an unblinded RCT investigating the effect of erythromycin 
treatment (200-400 mg once daily) over a 12 month period in 109 patients with COPD. 
Outcome measures were the frequency of COPD exacerbations and the frequency of 
episodes of common cold. Patients in the erythromycin group experienced significantly 
fewer COPD exacerbations and episodes of the common cold than the placebo group and 
the rate of hospitalisation was reduced. However, the lack of blinding in this study is a 
potential source of bias in these results. 
 
Banerjee et al. (727) carried out a double-blind placebo-controlled RCT examining the effect 
of 3 months clarithromycin (500 mg once daily) on the health status, sputum bacterial load 
and exacerbation rate of 67 moderate to severe COPD patients. None of these measures 
were improved in comparison to those found in the placebo group. This trial had the 
shortest duration of treatment of those included here, and this may have influenced the 
results. 
 
Seemungal et al. (728) in another double-blind RCT, this time assessing 12 months of 
erythromycin (250 mg twice daily) in 109 patients with moderate COPD, found that there 
was a significant reduction in the exacerbation rate in the erythromycin group in 
comparison to the placebo group. Erythromycin had no effect however on FEV1, serum or 
sputum inflammatory markers or bacterial composition of sputum. A smaller RCT by He et 
al. (729) (n=36) also examining the role of erythromycin treatment (125 mg three times 
daily) over a 6 month period similarly found a lower exacerbation rate in the erythromycin 
group. Another finding from this trial was a decreased sputum neutrophil and neutrophil 
elastase count in the erythromycin group in comparison to the placebo group. 
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A further double-blind RCT by Mygind et al. (730) assessed the use of azithromycin in 575 
COPD patients using an intermittent or ‘pulsed’ dosing regimen over a 3 year time period. 
Azithromycin, at a dose of 500 mg per day, was given for 3 days every month over the 36 
month treatment period and its effect on exacerbation frequency and duration, hospital 
admission, quality of life, pulmonary function and mortality determined. The azithromycin 
group experienced significantly fewer total days of exacerbation and required significantly 
fewer antibiotics and systemic steroids than the placebo group, although there was no 
difference in terms of pulmonary function, quality of life or mortality. 
 
Finally, the most compelling evidence so far for the use of macrolides in COPD comes from a 
large scale clinical trial carried out in 2011 by Albert and co-investigators (615). This multi-
centre double-blind RCT assessed the use of azithromycin (250 mg daily) over a 12 month 
period. The trial included 1142 patients at risk of acute exacerbations of COPD, 570 of which 
received azithromycin whilst the other 572 received placebo in addition to standard care. 
The primary outcome for the study was time to first exacerbation which was significantly 
increased in the azithromycin group compared to the placebo group (226 days vs 174 days). 
Azithromycin also reduced the frequency of exacerbations and significantly improved 
quality of life scores, although there was no effect on hospitalisation or mortality. However, 
unwanted effects of azithromycin were also noted including an increased bacterial 
macrolide resistance rate and increased hearing loss in the azithromycin group. 
 
d) Asthma 
The first reported use of macrolides as an anti-inflammatory agent for use in the 
management of asthma was in the 1960s and was conducted using troleandomycin. This 
drug was investigated for some decades as an additional therapeutic agent for asthma 
owing to its apparent “steroid sparing” effect. Although early trials showed promising 
results (731), recognition of hepatic adverse effects (732) and a systematic review of 
available trial data showing no benefits in terms of steroid dose reduction or lung function 
(733) seem to have limited any potential further use of this agent. 
 
Several studies have investigated the potential of clarithromycin therapy in asthma, with 
mixed results. Gotfried et al. (734) conducted a double-blind RCT of clarithromycin versus 
placebo in 21 oral corticosteroid dependent asthmatics. Although the mean prednisolone 
requirement of the clarithromycin group decreased by 30%, they showed no improvement 
in lung function, asthma quality of life or symptom scores compared to those in the placebo 
group. 
 
Kostadima et al. (735) reported an improvement in AHR with the addition of short term 
clarithromycin treatment (250 mg twice daily or 250 mg three times daily) vs placebo to 
adult asthma patients on moderate doses of inhaled budesonide, although again there was 
no significant improvement of lung function. 
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Simpson et al. (670) studied 45 patients with severe refractory asthma in a double blind 
placebo-controlled RCT evaluating clarithromycin (500 mg twice a day for 8 weeks). The 
primary outcome measure for this study was sputum IL-8 concentration, as IL-8 is a potent 
chemotactic factor which attracts and activates neutrophils, the levels of which are elevated 
in non-eosinophilic asthma (NEA). After 8 weeks of clarithromycin therapy sputum IL-8 
levels, IL-8 gene expression and neutrophil activation (as measured by sputum neutrophil 
elastase levels) were significantly reduced in the clarithromycin group. Levels of these 
mediators were lower in the subgroup of patients with NEA, suggesting an anti-
inflammatory mechanism by which clarithromycin may have effect in this sub-group. The 
clarithromycin group also demonstrated a significant improvement in quality of life scores, 
and this effect was most profound in the NEA sub-group, although there was no significant 
improvement in presence of symptoms or asthma control score. 
 
A number of trials of macrolides in subjects with asthma have been conducted, since there 
is evidence implicating the presence in the airways of the atypical bacteria, such as 
Mycoplasma pneumoniae and C. pneumoniae, in the pathogenesis of asthma. The objective 
was to determine whether subjects with microbiological evidence of these bacteria in the 
airways formed a sub-group of asthmatics whose disease would respond to macrolides 
owing to their antibiotic properties. 
 
Kraft et al. (736) conducted a double-blind RCT of clarithromycin (500 mg twice daily for 6 
weeks) in 55 subjects with chronic stable asthma. Subjects were assessed pre and post 
treatment for the presence of M. and C. pneumoniae in their airways via PCR of BAL 
samples, in conjunction with standard microbiological culture. In all, 55% of patients were 
PCR positive for M. or C. pneumoniae (although interestingly all were culture negative), and 
only these positive subjects responded to clarithromycin with improvement in their lung 
function (as measured by FEV1).  
 
A similar larger double-blind RCT (n=92) by Sutherland et al. (737) which also assessed PCR 
positivity for M. or C. pneumoniae failed to replicate these results and found no 
improvement in lung function or asthma control in the clarithromycin group. Interestingly 
PCR negative patients showed an improvement in AHR which was not seen in PCR positive 
patients alone. 
 
Data from trials using roxithromycin in asthma are also inconclusive. Shoji et al. (738) failed 
to show any difference in lung function or AHR in a small RCT (n=14) of subjects with aspirin-
sensitive asthma receiving roxithromycin (150 mg twice daily), although the roxithromycin 
group showed some improvement in asthma symptom score. 
 
Black et al. (739) in a large multicentre RCT (n=232) of asthma patients with serological 
evidence of C. pneumoniae (Raised serum IgG or IgA titres against C. pneumoniae) receiving 
roxithromycin (150 mg twice daily for 6 weeks) found a significant improvement in evening 
PEFR readings post treatment. However, no improvement in morning PEFR values or asthma 
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symptom scores was found and at 6 months follow-up, the improvement in evening PEFR 
had returned to baseline. 
 
One of the largest studies of macrolides in subjects with asthma carried out to date was the 
‘Telithromycin in Acute Exacerbations of Asthma’ (TELICAST) study (740). The objective of 
this study was different to those discussed above, as it examined the effect of short term 
courses of telithromycin in patients with asthma exacerbations. However, owing to its large 
size (n=278) and findings it merits some further discussion here. The primary endpoints 
determined were asthma symptom scores and morning PEFR values. This study also 
attempted to ascertain subjects’ infection status with M. and C. pneumoniae by culture and 
PCR of sputum or nasopharyngeal samples in conjunction with serological evidence of M. or 
C. pneumoniae infection (i.e. raised serum IgG, IgM or IgA titres against M. and C. 
pneumoniae). In comparison to the placebo group, subjects in the telithromycin group 
reported a significant improvement in asthma symptom scores, although there was no 
difference in morning PEFR. Baseline FEV1 in the telithromycin group appeared significantly 
improved in comparison to the placebo group but this was a secondary outcome. No 
relationship was observed between M. or C. pneumoniae infection status and treatment 
response. 
 
Azithromycin has also been considered as an additional treatment in asthma. Strunk et al. 
(741) investigated its use as a steroid-sparing agent in children with moderate to severe 
asthma. The design of the study included a 6 week run-in period in which the budesonide 
dose needed to achieve stable asthma control was determined before randomisation to 
azithromycin or montelukast. Unfortunately this trial had to be stopped early due to lower 
than expected recruitment and the difficulty pre-randomisation of stabilising the child 
subjects’ asthma control. This was either due to non-adherence with treatment before 
randomisation or an improvement in asthma control under medical supervision suggesting 
non-adherence prior to trial entry and hence less severe disease than previously thought. A 
futility analysis of the subjects recruited suggested that azithromycin was unlikely to have a 
steroid-sparing effect. 
 
Hahn and colleagues (742) carried out a placebo-controlled RCT in stable asthma patients 
(n=45) evaluating the use of azithromycin (600 mg for 3 days, then a further 600 mg weekly 
for 5 weeks). C. pneumoniae serology was also assessed. Patients in the azithromycin group 
with high titres of IgA against C. pneumoniae reported some symptomatic improvement 
using an unvalidated symptom score, but there was no significant difference between 
azithromycin and placebo groups using the AQLQ (743). 
 
Hahn and the ‘Azithromycin Asthma Trial in Community Settings’ (AZMATICS) study group 
performed another RCT using azithromycin in adults with persistent asthma symptoms 
(744). There were three treatment arms in the study of patients randomised to azithromycin 
or placebo with a 3rd group of patients taking azithromycin on an open label basis. The 
group randomised to azithromycin showed no statistically significant improvement in 
asthma outcomes compared to placebo, although the study was underpowered to detect a 
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significant difference in its primary outcome (AQLQ scores). The open label group however, 
who had greater disease severity than subjects randomised to azithromycin which was 
usually treatment refractory, demonstrated improvements in asthma symptoms, asthma 
quality of life scores and control. This improvement appeared to persist after completion of 
azithromycin therapy. 
 
Finally, and perhaps most importantly, the most recent trial data for azithromycin use in 
asthma comes from the AZIZAST study by Brusselle et al. (636). This multicentre double-
blind RCT compared the efficacy of azithromycin vs placebo in prevention of asthma 
exacerbations in severe asthmatics (as an additional treatment to inhaled corticosteroids 
and LABA) over a 6 month period. Although there was no significant difference in the rate of 
exacerbation between the azithromycin and placebo groups, a predefined subgroup analysis 
stratifying patients by inflammatory phenotype determined a significant reduction in 
exacerbation rate in patients with a non-eosinophilic asthma subtype. 
 
1.6.3.4 Macrolides in Chronic Cough 
Two studies have assessed the use of macrolides in chronic cough. An RCT by Yousaf et al. 
(745) evaluated the effect of 12 weeks of low dose erythromycin therapy in 30 subjects with 
chronic cough. Chronic cough was defined as a cough lasting ≥8 weeks in a subject with 
normal spirometry, a PC20 >8 mg/mL, a normal sputum eosinophil count and HRCT scan 
whose symptoms had failed to improve despite trials of treatment for GORD and PNDS. 
There was no significant difference in the primary outcome measure of 24 h cough 
frequency (as assessed by a cough monitor) or any other measures except for sputum 
neutrophil count, which decreased significantly in the erythromycin group compared to the 
placebo group (mean difference 16.8%; 95% CI 1.6 to 32.1; p=0.03). 
 
Hodgson et al. (746) studied the effect of 12 weeks of low dose azithromycin in an RCT of 44 
subjects with chronic cough. Subjects had ongoing cough with normal spirometry and HRCT. 
All subjects underwent a MCT and sputum induction prior to entering the trial and 
underwent a treatment trial of 2 weeks of oral steroid treatment if they had a positive MCT 
or sputum eosinophils >3%. Subjects who did not have sputum eosinophils >3% or a positive 
MCT and those who failed to respond to oral steroids also received treatment trials for 
GORD or PNDS if symptomatic.  If their cough symptoms were refractory to these 
interventions they were entered into the study. There was a clinically important 
improvement in Leicester Cough Questionnaire (LCQ) score in the azithromycin group (mean 
change 2.4; 95% CI 0.5 to 4.2) but the difference between azithromycin and placebo groups 
was not significant. When the characteristics of the responders to azithromycin were 
assessed, a large significant improvement in LCQ score was noted in subjects with a 
concurrent diagnosis of asthma (mean change 6.19; 95% CI 4.06 to 8.32), implying 
azithromycin may be useful in the treatment of chronic cough associated with asthma.   
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1.6.3.5 Summary: Macrolides in Airways Disease 
Macrolide antibiotics are a clinically useful class of antibiotics, which are already used widely 
for their antibacterial properties. Evidence is accumulating of their useful anti-inflammatory 
and immunomodulatory effects which may explain their proven benefit in a growing 
number of chronic inflammatory respiratory conditions including DPB, COPD and 
bronchiectasis. Macrolides also appear to benefit subgroups of asthmatic patients with non-
eosinophilic asthma and chronic cough, for whom there are currently few treatment options 
available.  
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1.7 Microbiota in Asthma  
1.7.1 Introduction 
The human body is host to trillions of resident microbes, which outnumber our own cells 
and have a significant influence on many aspects of human physiology. Collectively, these 
micro-organisms make up what has been termed the human “microbiota”. Recent advances 
in DNA sequencing technology allowing fast and accurate assessment of these complex 
microbial communities have led to a rapidly growing interest in this area, with investigators 
attempting to discover the significance of the “microbiota” in states of health and disease.  
1.7.2 Microbiota in health 
The human microbiota is comprised of vast numbers of micro-organisms that colonise the 
skin and mucosal surfaces of the body. In the human gut alone there are estimated to be as 
many as 100 trillion microbes of over 1000 different species (771). Other body sites with 
distinctive microbial commensal populations include the skin (772, 773), oral cavity (774) 
and nasopharynx (775), urogenital tracts (776) and the lower respiratory tract (777). 
The term “microbiota” encompasses all of the micro-organisms including bacteria, viruses 
and fungi found in a specified location, be that the human body as a whole, or the mucosal 
surface of a particular organ. As yet few studies have attempted characterisation of the viral 
or fungal components of the microbiota owing to their relative scarcity in comparison to the 
bacterial element and also a relative lack of expertise in their detection and classification. 
Therefore further discussion of the microbiota will be based on current knowledge 
regarding the composition of bacterial communities at sites within the human body. 
The composition of the microbiota is usually described using well defined microbial 
ecological terms and an increasing number of statistical measures. Familiarity with some of 
the basic ecological and statistical terms used in this field is therefore essential to 
understand descriptions of the human microbiota to date and a brief glossary of these 
terms is provided in Table 1.11. 
 
Term Definition 
Microbiome The organisms, collective genomes of all 
these organisms and environmental 
conditions in a specified microbiota 
Metagenome The collection of genomes and genes in a 
specified microbiota 
Operational Taxonomic Unit (OTU) A cluster of DNA/RNA sequences that share 
more than a specified level of similarity 
(97%) which would be expected to 
correspond to a particular species 
Richness The number of different types of organisms 
present in a sample 
Abundance  The relative representation of an organism 
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in a sample 
(Relative species abundance = The number 
of organisms in one group/the total 
number of organism in all groups) 
Evenness The distribution of organisms across types  
Diversity A combination of richness and evenness to 
form a summary statistic measuring the 
variety present in a community 
Resilience The rate at which a community recovers to 
its native structure following a perturbation 
Resistance The ability of a community to resist change 
to its structure following an environmental 
challenge 
Table 1.11: A glossary of common microbial ecological terms used in 
discussion of the microbiota 
 
1.7.3 Gastrointestinal (GI) microbiota 
There are an estimated 1014 bacteria in the GI tract (778). Owing to these vast numbers of 
bacteria and their significant role in the development of the immune system, the majority of 
the current knowledge regarding the importance of the microbiota in health and disease 
comes from studies relating to the microbiota of the gut. As such, it is important to 
recognise some of the significant findings from this field and how they might influence and 
impact upon studies involving the airway microbiota. These include observations regarding 
the emergence of a bacterial community, the development of this community over time and 
the effect of perturbations on the community structure.  
Establishment of the human microbiota begins at birth with bacterial colonisation of the 
newborn gut occurring hours after delivery, with the mechanism of delivery immediately 
affecting the initial microbiota composition. Children born by vaginal delivery seem to 
develop a GI microbiota redolent of the vaginal flora of their mother, whereas children 
delivered by Caesarean section develop a gut microbiota consisting of organisms mostly 
found on the skin (779). Diversity of the infant GI microbiota gradually increases over time 
and is influenced by factors including type of feeding (breast vs formula milk feeding), infant 
hospitalisation and antibiotic use (780). 
As the interaction between the gut and the intestinal microbiota plays a critical role in the 
development of the immune system, it has been speculated that differences in the 
microbiota at this time of life may lead to disrupted immunotolerance of certain micro-
organisms and the development of allergic diseases including asthma in later life (781). 
This period of gradually increasing microbial diversity and “training” of the developing 
immune system lasts for around 3 years (782) after which the “core” members of the GI 
microbiota are established, and become less sensitive to perturbation, more closely 
resembling the adult gut microbiota (783). 
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Once established, the adult GI microbiota is thought to be fairly stable, demonstrating high 
levels of resilience to serious perturbations, including high dose antibiotic treatment and 
significant dietary changes (784, 785). However, following recurrent “high-impact” events 
such as repeated courses of high dose antibiotics the bacterial community may become 
permanently disordered (786), leading to the overgrowth of opportunistic strains of 
bacteria. This may lead to the overgrowth of opportunistic bacteria such as Clostridium 
difficile in the intestine following extended periods of antibiotic treatment, which 
aggressively colonises mucosal surfaces at the expense of typical commensal bacteria, and 
causes overt symptoms of colitis (787, 788). 
This disruption in the balance of a bacterial community leading to overgrowth of certain 
species which may in turn cause further disruption of other smaller, more beneficial 
members of that community is known as dysbiosis. Dysbiosis of the GI microbiota has been 
linked to a variety of diseases including inflammatory bowel disease (789), type 2 diabetes 
(790), bowel cancer (791) and obesity (792). 
1.7.4 Airway microbiota 
Although the GI tract microbiota is the largest and most complex in the body there is a 
growing recognition of the potentially significant influence of the composition and 
interactions of the microbiota at other mucosal surfaces, including that extant within the 
airways.  
Classically, except in advanced stages of airways disease such as bronchiectasis or cystic 
fibrosis, the lower respiratory tract was considered to be sterile.  The first study to 
demonstrate this was not the case by Hilty et al. (777) used non-culture bacterial DNA 
detection techniques on samples taken at bronchoscopy to elucidate that the airways of the 
lungs are not sterile even in healthy subjects and that there appears to be a microbiota 
unique to the lower airways. Subsequently it has been determined that the bacterial 
biomass of the lower airways in healthy subjects is comparatively low with studies 
demonstrating a BAL bacterial load of 103-4/ml (793, 794). It is unclear whether or not the 
airway microbiome in healthy subjects is resident and distinct, or whether it simply consists 
of a transient collection of organisms aspirated from the upper airways (795, 796).  
The Hilty study also demonstrated a significant difference in the bacterial communities 
present in the lungs of healthy subjects as compared to those detected in COPD patients 
and asthmatic patients treated with high dose inhaled steroids. A much higher frequency of 
the potentially pathogenic Haemophilus species, including the organism H. influenzae which 
is one of the most common pathogens isolated in respiratory tract infections, was detected 
in samples from the bronchi of asthmatic and COPD patients in comparison to control 
subjects, who were more likely to be colonised with multiple species of Prevotella. 
Following this finding by Hilty and colleagues the number of studies of the lung microbiota 
in different disease states has expanded rapidly. A summary of the results so far based on a 
full literature review of this area will now be presented, followed by a more in depth look at 
the studies to date that have assessed the significance of the microbiota composition in 
asthma. 
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1.7.5 Microbiota in Cystic Fibrosis (CF) 
Owing to the well-recognised role of colonising micro-organisms in morbidity and mortality 
in cystic fibrosis, many different investigators have studied the lung microbiota of CF 
patients in the hope of further understanding the dynamics of the CF lung bacterial 
community and its role in the clinical features and progression of the disease. A table 
detailing the full literature review can be found in Appendix I. The bacterial load in the CF 
lung is many orders of magnitude higher than that of the healthy lung at around 109/ml 
(797). Clearly, therefore, there is a significant difference in the airway microbiota between 
health and disease states but the processes that lead to this great disparity are not yet fully 
understood. It is likely that the physicochemical changes within the airways in individuals 
with CF as the disease progresses serve to create ecological niches that favourably support 
the growth of certain organisms (798). Such changes include the increasing amount and 
tenacity of respiratory secretions, airway wall inflammation and damage with subsequent 
development of bronchiectasis and potentially effects of treatments for the condition 
including antibiotics and steroids (799). However, the extent to which the microbiota 
composition is determined by such processes and to which the selected micro-organisms 
are then able to further alter the characteristics of their environment and actively cause 
disease progression is unclear. 
Some general concepts have emerged from studies of the CF microbiota to date which may 
help to guide further work relating to the airways microbiota. 
Firstly, as recognised previously in studies of the GI microbiota, the CF microbiota seems to 
be fairly stable and resilient to short term perturbation such as antibiotic treatment or 
disease exacerbation (800-803). Over the longer term i.e. ≥5 year periods, the community 
diversity of the CF microbiota in patients with progressive disease may decrease significantly 
but tends to remain relatively stable in patients with a mild lung disease phenotype (801, 
804). It has been suggested that antibiotic use is the primary cause of any decreasing 
diversity over time, rather than age or lung function (801).  
Secondly, also in common with previous GI microbiota studies, multiple investigators have 
found that the variability between the lung bacterial communities of different subjects 
(inter-subject variability) is greater than the variability between longitudinal samples from 
the same subject (intra-subject variability) (800, 801). This indicates that although subjects 
with the same disease process may have similarities in the composition of their lung 
microbiota, such that the bacterial communities in samples from these subjects could 
broadly be distinguished from those from healthy controls or subjects with other disease 
processes, each individual possesses their own unique microbiota.  
Several studies of the CF microbiota have demonstrated that decreased richness of the 
bacterial community of the CF lung is associated with decreased lung function (805-807). 
Zemanick et al. (808) found a significant negative correlation between bacterial diversity 
and relative abundance of Pseudomonas spp., which as expected, was found to be the most 
dominant organism in virtually all patients in CF microbiota studies to date. 
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Finally, several investigators have assessed the composition of the airway microbiota prior 
to and during disease exacerbations and also tried to determine how the microbiota is 
affected by antibiotic treatment. Generally these studies have showed decreased 
abundance of Pseudomonas spp. with antibiotic treatment but no change in the overall 
bacterial community composition (797, 800, 808). 
1.7.6 Microbiota in COPD 
Following the original description by Hilty et al. of the distinct bacterial microbiome of the 
COPD lung in comparison to that of healthy controls a number of further studies have 
attempted to characterise the bacterial COPD microbiota in greater detail. A table detailing 
the full literature review can be found in Appendix J. 
Erb-Downward et al. (809) compared the bacterial microbiota isolated in bronchial lavage 
(BAL) samples from healthy non-smoking controls (n=3), healthy smokers (n=7) and COPD 
patients (n=8) with that detected in lung tissue samples from patients with severe COPD 
(n=6) . They found that the diversity of the bacterial microbiota was similar in the non-
smoking and smoking controls groups to that of patients with mild COPD whereas the 
microbiota in moderate to severe COPD patients was much less diverse and was more 
commonly dominated by Pseudomonas spp. Despite these differences in diversity, the total 
bacterial load in each subject was not significantly different. Another interesting finding 
from this study was the heterogeneity of the bacterial communities between different 
anatomical sites in the same lung from patients with severe COPD. The authors suggested 
this may be due to either local differences in lung airway microarchitecture leading to the 
favourable development of certain bacteria or the anatomical heterogeneity in the 
development of the disease meaning areas with different amounts of inflammation and/or 
tissue damage may favour the growth of particular species. 
Huang et al. (614) attempted to characterise the bacterial composition of endotracheal 
aspirates from mechanically ventilated severe COPD patients using a bacterial 16S 
PhyloChip. Although this study included only 8 patients in total, two distinctly different 
bacterial populations were detected from the samples; a ‘more diverse’ and a ‘less diverse’ 
population. The ‘less diverse’ population identified in samples from 4 of the patients tended 
to contain more members of the Pseudomonadaceae group (containing Pseudomonas spp.) 
and these patients had been intubated for significantly longer than the others. The ‘more 
diverse’ population identified in samples from 3 of the patients intubated for a shorter 
duration demonstrated an increased abundance of the phylum Firmicutes. 
In order to negate the effect of contamination from the upper airways on estimates of the 
lung microbiota, Sze et al. (810) analysed the microbiota present in lung tissue samples from 
patients with severe COPD (n=8), CF (n=8), smokers (n=8) and non-smokers (n=8). This study 
confirmed there were significant differences in the bacterial microbiota found in the COPD 
lung compared to the lungs of healthy controls.  There was also a significant difference in 
the bacterial communities of the COPD and the CF lung, with a higher bacterial density and 
lower diversity of organisms in the CF subjects, although both of these groups had relatively 
high abundance of the Firmicutes phylum in comparison to controls.  Overall the lung tissue 
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samples had lower bacterial densities than those obtained by bronchial lavage or bronchial 
brushing.  
Pragman et al. (811) assessed the microbiota present in BAL samples from 22 patients with 
moderate to severe COPD and 10 healthy controls. This study again demonstrated a distinct 
bacterial community in the lungs of COPD patients compared to healthy controls, but was 
unable to discern any significant difference between COPD patients of different severity. 
There were consistent differences in microbiota composition between patients who used 
inhaled corticosteroids or bronchodilators and those who did not, although causality could 
not be determined due to the cross-sectional nature of the study. 
1.7.7 Microbiota in Asthma 
Bacteria have long been implicated in the pathogenesis of asthma (812) especially atypical 
organisms such as Mycoplasma spp. and C. pneumoniae (813). 
As discussed above Hilty et al. (777) detected a much higher frequency of Haemophilus spp. 
in samples from the bronchi of asthmatic and COPD patients than controls, whereas 
controls were more likely to be colonised with multiple species of Prevotella, which have 
previously been shown to directly inhibit the growth of a number of other bacteria.  
Huang et al. (814) also found differences in bacterial community composition in bronchial 
lavage samples from asthmatic patients compared to those from healthy control subjects. 
The diversity of the microbiota in asthmatic patients was found to be significantly higher 
than that of controls and a significant positive correlation between diversity and bronchial 
hyper-responsiveness was observed. In particular the relative abundance of certain bacterial 
taxa primarily belonging to the Proteobacteria phylum were highly correlated with AHR.  
A further study by Marri et al. (815) investigated the differences between the respiratory 
tract microbiota composition in the induced sputum of mild asthmatics (8 out of 10 of 
whom were not using inhaled corticosteroids) and non-asthmatic adults. This demonstrated 
that even subjects with mild asthma on minimal inhaled therapy exhibit a significantly 
different respiratory tract microbial composition to healthy subjects. Again, the microbiota 
of asthmatic patients were found to have a greater bacterial diversity than those of healthy 
subjects with increased levels of the Proteobacteria phylum. Healthy subjects tended to 
have higher relative abundances of Firmicutes and Actinobacteria, although these 
differences were not statistically significant. 
Recent data assessing the effect of azithromycin treatment on the lung microbiota of 
moderate and severe asthmatics revealed potentially pathogenic organisms, including 
Pseudomonas, Haemophilus and Staphylococcus species were amongst the most abundant 
bacteria detected in pre-treatment bronchoscopy samples. The abundance of each of these 
bacteria was reduced following azithromycin treatment (816). 
Goleva et al. (817) examined the potential contribution of the lung microbiota composition 
to the development of resistance to corticosteroid treatment in asthmatic subjects. Subjects 
were categorised as corticosteroid sensitive or corticosteroid resistant on the basis of their 
response to a treatment trial of oral prednisolone. Subjects were classified as corticosteroid 
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sensitive if their predicted FEV1% value increased by ≥15% or corticosteroid “resistant” if 
their predicted FEV1% improved <10%. BAL samples were obtained from 39 asthmatic 
subjects, 29 of whom were corticosteroid resistant and 10 of whom were corticosteroid 
sensitive, as well as from 12 healthy controls. The microbiota composition of the 
corticosteroid resistant and corticosteroid sensitive subjects did not differ at the phylum 
level. However, at the genus level 14 corticosteroid resistant patients displayed ‘expansions’ 
(i.e. sequences > 5% of the total 16S rRNA gene sequences) of bacteria not present in the 
corticosteroid sensitive group including the potential pathogen Haemophilus 
parainfluenzae. This organism was then demonstrated to inhibit the corticosteroid response 
of asthmatic airway macrophages in vitro. Other in vitro work also suggests H. influenzae 
may induce a steroid resistant inflammatory response by reducing histone deacetylase 
(HDAC) activity (818). 
 
Huang et al. (819) used a 16S rRNA Phylochip to characterise the microbiota in 40 patients 
with severe asthma, specifically to delineate any relationships between microbiota 
composition and disease features. The investigators found significant correlations between 
the presence in the microbiota of certain taxa and certain features of disease, including BMI, 
asthma control, sputum leukocyte values and bronchial biopsy eosinophil values. Poor 
asthma control (i.e. between visit differences in the Asthma Control Questionnaire) and 
increased sputum leucocyte values were associated with a high relative abundance of 
Proteobacteria, whereas high BMI was associated with high relative abundance of 
Bacteroidetes/Firmicutes. The presence of certain families of Proteobacteria was also 
positively associated with increased expression of Th17-related genes. In comparison to 
healthy controls or subjects with mild to moderate asthma, subjects with severe asthma had 
significantly higher levels of Actinobacteria. 
 
Green et al. (635) obtained sputum from 28 stable treatment resistant severe asthmatics 
and assessed the microbiota in these samples using T-RFLP profiling. Seventeen of the 28 
asthmatics were predominantly colonised by a potentially pathogenic bacterium (M. 
catarrhalis, Haemophilus spp. or Streptococcus spp.) and these subjects had significantly 
lower post-bronchodilator percent predicted FEV1 and higher sputum neutrophil differential 
cell counts. This suggests that colonisation of the airways by potentially pathogenic bacteria 
may lead to more severe airway obstruction and neutrophilic inflammation, both of which 
are features of a previously described phenotype of treatment resistant neutrophilic asthma 
(344). 
 
Further support for the association of potentially pathogenic bacteria in the airways with 
neutrophilic asthma comes from an investigation by Simpson et al. (820). In this study 
induced sputum samples from 30 subjects with stable asthma were taken and bacterial DNA 
extracted and profiled to allow comparison of microbiota composition between different 
asthma inflammatory subtypes. Microbiota analysis revealed reduced bacterial diversity and 
species richness in a group of 7 patients with neutrophilic asthma as compared to the 20 
patients with non-neutrophilic asthma. A significantly higher abundance of Proteobacteria 
were found in the sputum samples from subjects with neutrophilic asthma, the majority of 
which were consistent with Haemophilus spp., and these were particularly abundant in 4 of 
the 7 neutrophilic subjects. Other differences noted between subjects with neutrophilic and 
non-neutrophilic airway inflammation included a significantly lower abundance of 
137 
 
Actinobacteria and Firmicutes in those with neutrophilic asthma with a particular difference 
noted in the distribution of sequences corresponding to the Tropheryma genus (from the 
phylum Actinobacteria). Five of the 7 subjects in whom Tropheryma sequences were 
detected had eosinophilic inflammation.  
 
Zhang et al. (821) examined the microbiota content of sputum from 26 “severe” and 18 
“non-severe” asthmatics and 12 healthy controls using 16S rRNA gene sequencing.  Severe 
asthmatics were defined as those who required “either continuous or near-continuous oral 
corticosteroids, high-dose inhaled corticosteroids, or both” and non-severe asthmatics 
defined as those with no symptoms and minimal use of rescue medication using ≤2000 μg 
BDP. These study results suggested an increased abundance of Proteobacteria in the non-
severe asthma group in comparison to the severe asthma group and controls and increased 
Firmicutes abundance in the severe asthma group in comparison to the other two groups. 
1.7.8 Sampling the lung microbiota 
One of the key questions in the study of the lung microbiota is the appropriateness of 
different techniques for sampling lung organisms. A literature review of this topic is 
summarised in Appendix K. The initial studies in this area performed sampling by direct 
bronchoscopic methods (777, 814) in order to minimise potential contamination from the 
mouth and upper airways, although this technique is invasive and uncomfortable for 
subjects. Induced sputum using hypertonic saline is far less invasive and very well tolerated, 
making repeat sampling on large numbers of subjects possible. However, the upper 
respiratory tract (URT) has been shown to contain its own unique microbiota, and there are 
concerns that the microbial profile in sputum samples (whether spontaneous or induced) 
from the lower respiratory tract (LRT) may either be contaminated with URT organisms or 
that the LRT ‘microbiota’ as sampled by bronchoscopy merely represents bronchoscopic 
carryover of URT organisms. 
Charlson et al. (794) assessed the microbial populations present at different locations 
throughout the respiratory tract of healthy individuals including the oral cavity, oro and 
naso pharynx and the upper and lower airways. Measures to minimise contamination of 
samples from the airways were taken through the use of a two bronchoscope/protected 
brush technique. The study concluded that in healthy individuals a bacterial community is 
present in the lungs, but this is much less abundant than that of the URT. The composition 
of the bacterial communities from these two sites was very similar, suggesting that the 
bacteria present in the lungs of healthy individuals may arise through aspiration of these 
bacteria in the upper airways.  
A study by the same group comparing the bacterial content of oral wash vs BAL fluid for 6 
subjects with different lung diseases found no significant difference between these samples 
in 3 out of the 6 subjects, whereas the BAL samples from the other 3/6 subjects showed a 
number of sequences that were significantly more abundant in BAL compared to oral wash 
(822). This suggests that contamination of a bronchoscope with upper airway bacteria or 
repeated microaspirations does not fully explain the detection of bacterial communities in 
the lung. 
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Further evidence for the existence of a lung specific bacterial community comes from 
studies that analysed the microbial content of whole-lung tissue samples such as those by 
Sze et al. (810) and Erb-Downward et al. (809) as described above. These both concluded 
that there are detectable bacterial communities in the human lungs (in healthy subjects and 
subjects with COPD), although the total number of bacteria detected in the lungs is small 
compared to that of the airways as a whole. 
Despite the seeming inability to be able to exclude a degree of URT contamination from 
samples ostensibly from the LRT, the most abundant bacteria in the asthma microbiota do 
not seem to be prominent members of the typical microbiota found in saliva, the nostrils or 
the oropharynx (823, 824). This was supported by the results of Marri et al. (815) who used 
the induced sputum method to sample the lower airways.  
1.7.9 Sequencing the microbiota 
The current study will detail the microbiota of the lower airways using state-of-the-art 
massively parallel pyrosequencing (825) of bacterial 16S ribosomal RNA gene region 
amplicons (826).  This non-culture dependent technique provides an unprecedented level of 
detail regarding the bacterial community of the lower airways. Pyrosequencing is an 
increasingly recognised technique for studies of microbial communities due to its ability to 
rapidly and accurately sequence large numbers of bacterial species.  
Several previous investigations have confirmed the applicability of this technique in the 
sequencing of the bacterial microbiota in the gut (827) and the lung (809, 828), but it has 
only been employed once in studies of asthma patients to date (815). It is expected that 
utilising this method will allow a greater depth of sequencing than in similar previous 
investigations (777, 814). 
The steps involved in sequencing the microbiota from sample collection to data processing 
are summarised in Figure 1.9 (829). 
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Figure 1.9: Flow diagram demonstrating the necessary steps in 
studies of the microbiota from sample acquisition to data analysis  
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1.7.10 Summary and rationale for study 
Analysis of the human microbiota is a promising and rapidly expanding field. Studies to date 
of the lung microbiota have led to new insights into the pathogenesis and progression of 
lung disease. Generally, findings so far in most respiratory conditions indicate that reducing 
bacterial diversity and dysbiosis of the microbiota with dominance of certain pathogenic 
species correlate with worsening disease severity and outcomes. Studies of the bacterial 
microbiota in asthma have revealed differences in its composition to that of healthy 
controls, suggesting that an increased abundance of potentially pathogenic species such as 
Proteobacteria are associated with asthma, particularly the neutrophilic asthma subgroup, 
and with certain clinical measures.  
As yet, it has not been possible to establish whether the presence of these organisms is due 
to disease itself, or whether this may represent a treatment effect of high dose inhaled 
steroids. It is hypothesised that the use of high dose ICS could alter the microbiota in 
asthma, acting as a selective pressure that favours the establishment of colonising species of 
potentially pathogenic species such as H. influenzae (Fig 1.10). Possible mechanisms for such 
an effect could include (1) a local immunosuppressive effect of ICS allowing the overgrowth 
of pathogenic species (2) a selective inhibitory effect on the growth of certain organisms to 
the benefit of others (3) the utilisation of ICS by certain organisms capable of steroid 
degradation as a source of energy.  
 
Figure 1.10: Illustrating hypothesised changes in the microbiota with 
increasing ICS dose 
 
It is further speculated that the type of ICS used by an individual may have an effect on the 
composition of the airway microbiota in asthma. Evidence suggests that fluticasone use 
leads to an increased risk of pneumonia (632, 830) and non-tuberculous mycobacterial 
disease (831) in subjects with airways disease compared to budesonide. It is possible this 
increased risk may be due to a selective pressure caused by fluticasone that favours the 
overgrowth of potentially pathogenic species that is not observed with budesonide. 
The proposed study aims to investigate two important questions regarding the microbiota 
composition in patients with a diagnosis of asthma. The first main aim of the study is to 
compare the microbiota composition in sputum samples from subjects with mild (BTS Step 
2) and moderate/severe asthma (BTS Step 4). Although initial studies have suggested 
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subjects with different severities of asthma may have similar lower respiratory tract 
microbiota composition, there is no direct evidence to support this assertion. The second 
main aim is to compare microbiota composition between samples from subjects with 
asthma using the inhaled steroid fluticasone and those using budesonide.  
Other aims of the study include assessment of the reproducibility of the induced sputum 
method for assessing the lung microbiota, assessment of the longitudinal stability of the 
bacterial population and comparison of the bacterial load of two common respiratory 
pathogens (H. influenzae and S. pneumoniae) in the BTS Step 2 and 4 groups. Clinical 
measurements of different components of airways disease; airflow obstruction, AHR and 
airway inflammation will be performed to assess correlation between bacterial community 
composition and these metrics and also to enable subgroup/phenotype analysis based on 
these characteristics.  
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1.8 Hypothesis of Thesis and Aims 
1.8.1 Hypothesis 
Strategies based on the measurement of selected phenotypic and biological characteristics 
of airways disease can help to improve the understanding of their pathogenesis and 
targeting of treatment. 
 
1.8.2 Aims 
1.8.2.1 Aim for Study 1  
To establish whether there is a set of baseline characteristics which can reliably distinguish 
which patients will not benefit from ICS treatment. 
1.8.2.2 Aims for Study 2  
1) To describe the clinical, pathological and radiological features of a cohort of patients with 
unexplained chronic productive cough  
2) To determine the response of this cohort to a 12 week course of low dose azithromycin 
therapy and assess if any of the baseline characteristics measured could predict response to 
azithromycin. 
1.8.2.2 Aims for Study 3  
1) To compare the microbiota composition in sputum samples from subjects with mild (BTS 
Step 2) and moderate/severe asthma (BTS Step 4) 
2) To compare microbiota composition between samples from subjects with asthma using 
the inhaled steroid fluticasone and those using budesonide.  
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Chapter 2: The utility of exhaled nitric 
oxide in patients with suspected asthma 
2.1 Background 
2.1.1 Summary of background (Chapter 1.5) 
Despite the established clinical importance of identifying cases of airways disease and the 
wealth of studies evaluating a range of objective measures for their detection the prospect 
of an accurate diagnostic test for “asthma” is still elusive. Some tests clearly perform better 
in identifying characteristics of the classical asthma syndrome than others. However, 
uncertainties owing to the poor definition of “asthma” and heterogeneity of the condition in 
addition to the often transient nature of the symptoms may always make the attempt to 
define and identify features of disease according to one diagnostic label futile.  
However, with increasing availability of objective tests capable of identifying the 
pathophysiological processes underlying airways disease and a growing range of effective 
treatment agents targeting these processes the need for “diagnosing asthma” per se may 
ultimately be made redundant in favour of a “characteristic-targeted” treatment approach. 
The proposed study will attempt to investigate the value of objectively measured features 
of airways disease (with a particular emphasis on FENO) to predict ICS treatment response in 
a cohort of steroid naïve patients with symptoms of asthma. 
2.1.2 Rationale for study 
Using FENO levels to predict steroid response would appear to be a logical approach given 
that FENO is a biomarker of Th2 inflammation and there is good evidence that this type of 
inflammation is responsive to steroid treatment. This approach avoids the complexities 
inherent in attempting to use the technique to classify heterogeneous airways diseases 
according to diagnostic labels. 
The study by Smith et al. provides good evidence that this strategy may be useful, but the 
optimal cut-point derived by these authors to predict ICS response (>47 ppb) may risk 
missing subjects with measured FENO levels in the ‘indeterminate’ range of 25-50 ppb 
identified in the ATS FENO guidelines who would benefit from steroid treatment. It would be 
useful for clinical practice if a ‘minimum’ FENO cut-point below which steroid response is 
unlikely could be determined in order to guide the decision of whether or not to initiate 
steroid treatment in subjects with symptoms suggestive of airways disease. 
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2.2 Methods 
2.2.1 Purpose and Design 
2.2.1.1 Aim 
To establish whether there is a set of baseline characteristics which can reliably distinguish 
which patients will not benefit from ICS treatment. 
2.2.1.2 Hypothesis 
A minimum FENO cut-point can be determined which reliably excludes a clinical response to 
inhaled corticosteroids in a cohort of steroid naïve patients with symptoms suggestive of 
asthma. 
2.2.1.3 Study Design 
A single centre non-interventional study was designed. 
 
2.2.1.4 Ethical Approval 
This study was approved by the National Research Ethics Committee East Midlands – Derby 
1 (Ref 12/EM/0241) and Nottingham University Hospitals NHS Trust Research and 
Innovation department (Ref 11RM001).  
2.2.2 Study Population: 
2.2.2.1 Eligibility criteria 
Patients were recruited according to the following eligibility criteria: 
Inclusion criteria 
 Male or Female aged between 18 and 80 years old 
 Suspected asthma diagnosis and prescribed a new ICS 
 
Exclusion criteria 
 Subjects already using inhaled or oral corticosteroid 
 Pregnant females  
 Subjects with other significant respiratory diagnosis 
 
2.2.2.2 Study setting and participant recruitment 
This study was conducted at the Nottingham Respiratory Research Unit (Nottingham City 
Hospital UK). Subjects with respiratory symptoms suggestive of asthma who were deemed 
by general practitioner (GP) to require ICS treatment were prospectively identified. 
Interested subjects were provided with full written information about the study and given 
contact information for the study team. Upon contacting the study team they were invited 
to a screening visit to ensure they met the eligibility criteria specified above. 
2.2.3 Outcome measures 
2.2.3.1 Primary endpoint 
 The sensitivity and specificity of low levels of FENO at predicting a lack of clinical 
benefit from ICS after 4 weeks of treatment   
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2.2.3.2 Secondary endpoints 
 To determine the sensitivity and specificity of FENO for diagnosing asthma 
 To determine whether there are other baseline characteristics which if used alone or 
in combination can exclude a response to ICS. 
2.2.3.3 Sample size calculation 
As this was a pilot study a formal power calculation was not possible. An initial target of 100 
participants was set. 
2.2.4 Summary of study protocol 
2.2.4.1 Visit 1 
Subjects attended a baseline study visit (visit 1) as soon as possible after being prescribed an 
ICS by their GP but before the treatment was started. FENO, skin prick testing (SPT), 
spirometry, MCT, asthma control questionnaire (ACQ), asthma control test (ACT), full blood 
count (FBC) and sputum induction were performed, as outlined in Fig. 2.1. Subjects were 
also questioned about their presenting symptoms, i.e. the symptoms that led them to 
consult with their GP. 
2.2.4.2 Visit 1a 
Subjects prepared to make a second visit on the day after visit 1 underwent reversibility 
testing with 400 μg salbutamol via a spacer. 
Subjects were instructed to start their GP prescribed ICS treatment after visit 1 (or visit 1a if 
they also attended this) which was predominantly inhaled beclomethasone (100 μg per puff, 
2 puffs twice daily) via a metered dose inhaler. 
2.2.4.3 Visit 2 
Visit 2 occurred 4 weeks post initiation of ICS treatment. At this visit subjects were asked 
about treatment adherence and FENO, spirometry, MCT, ACQ, ACT and FBC were performed 
(Fig. 2.7). 
2.2.4.4 Visit 3 
Visit 3 was after 12 weeks of ICS treatment. At this visit subjects were again asked about 
treatment adherence and FENO, spirometry, MCT, ACQ, ACT and FBC were performed.  
 
 
Visit 1 (Baseline)
ACQ, ACT, SPT, FENO, 
FEV1, MCT, Blood, 
Sputum
+ Visit 1a (optional)
Reversibility
Visit 2                 
(1 month)
ACQ, ACT, FENO, 
FEV1, MCT, Blood
Visit 3                 
(3 months)
ACQ, ACT, FENO, 
FEV1, MCT, Blood
Figure 2.1: Demonstrating investigations performed at each study visit.    
ACQ = asthma control questionnaire, ACT = asthma control test, SPT = skin prick test, 
FENO = Fractional exhaled nitric oxide level, FEV1 = spirometry, MCT = methacholine 
challenge, Blood = full blood count (including blood eosinophil count), Sputum = 
differential sputum eosinophil count  
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2.2.5 Clinical Measurements 
2.2.5.1 Spirometry and Reversibility 
Spirometry was performed using a Vitalograph™ dry wedge bellows spirometer 
(Vitalograph™ model 2150, Buckinghamshire, England) and the FEV1 and FVC were 
calculated. The best of 3 technically acceptable manoeuvres were recorded where the 
values of the largest and the next largest FEV1 results were ≤150 mL and within 5% of each 
other as per ERS guidelines (537). Percentage predicted values were calculated using 
reference values from the ERS prediction equations (544). Bronchodilator reversibility was 
assessed 15 min after administration of 400 µg of salbutamol inhaled via a Volumatic® 
spacer as per ERS guidelines (537).  
Reversibility was defined as: 
(𝑃𝑜𝑠𝑡 𝑏𝑟𝑜𝑛𝑐ℎ𝑜𝑑𝑖𝑙𝑎𝑡𝑜𝑟 𝐹𝐸𝑉1 − 𝑃𝑟𝑒 𝑏𝑟𝑜𝑛𝑐ℎ𝑜𝑑𝑖𝑙𝑎𝑡𝑜𝑟 𝐹𝐸𝑉1)
𝑃𝑟𝑒 𝑏𝑟𝑜𝑛𝑐ℎ𝑜𝑑𝑖𝑙𝑎𝑡𝑜𝑟 𝐹𝐸𝑉1
× 100 
with a 12% increase considered significant as per ATS guidelines (217). 
2.2.5.2 Skin Prick Tests (SPTs) 
Atopy was assessed by SPTs to a panel of common aeroallergens which included 
Dermatophagoides pteronyssinus (house dust mite), tree and grass pollen, cat and dog fur 
and Aspergillus fumigatus with normal saline and histamine controls (Alk-Abello™, 
Berkshire, UK). A small drop of each solution was placed on the skin of the volar aspect of 
the lower forearm. Disposable sterile lancets (Alk-Abello™, Berkshire, UK) were used to 
puncture the epidermis under each drop in turn and the diameters of any resultant wheals 
were measured in two perpendicular directions after 15 min. A positive response to an 
allergen on the SPTs was recorded in the presence of a wheal >3 mm greater in its longest 
measured dimension than the negative (saline) control. Participants were requested not to 
take any antihistamine medications for a minimum of 48 h prior to the test. 
2.2.5.3 Sputum Induction 
Sputum induction was performed using a protocol based on that described previously by 
Pavord et al. (417) based on the method of Pin et al. (405) using an ultrasonic nebuliser to 
deliver hypertonic saline. Due to the potential for nebulised saline to cause 
bronchoconstriction, subjects were pre-treated with inhaled salbutamol, their FEV1 was 
closely monitored and the test was supervised by a clinical fellow at all times. Briefly, after 
pre-treatment with 400 µg of salbutamol inhaled via Volumatic® spacer (if subjects post-
bronchodilator FEV1 was ≥60% predicted), subjects were asked to inhale nebulized saline via 
a saline nebulizer (NE-U17, Omron Healthcare™, Milton Keynes, UK). Subjects inhaled 10 mL 
of 3% saline for 5 min, were asked to blow their nose and rinse their mouth with drinking 
water and were encouraged to cough to try and aid expectoration of a sputum samples. 
Assuming their FEV1 did not decrease by ≥20% from the baseline measurement they went 
on to inhale 10 mL of 4% saline for 5 min after which they again were asked to blow their 
nose and rinse their mouth with water before a second attempt to try and expectorate a 
sample. If there was no resultant decrease in FEV1 of ≥20% after the second attempt, the 
147 
 
process was repeated once more with 10 mL of 5% saline for 5 min followed by a third 
attempt to produce a sputum sample.  
2.2.5.4 Sputum Processing 
Once collected, sputum samples were stored in ice and processed at 40C within 2 hours of 
collection as described previously (417) but with some minor adaptions to produce 
supernatants free of dithiothreitol (DTT) for future work. Sputum plugs were isolated from 
saliva using curved forceps on the lid of a petri dish and then processed as summarised in 
Fig 2.2. 
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Figure 2.2: Protocol for sputum processing and cell count  
 
 
 
1) Sputum plugs selected 
2) Weigh and incubate with 8 volumes (ml) x sputum weight (g) of phosphate 
buffered saline (PBS) 
3) Add 150 volumes (µl) x sputum weight (g) of protein inhibitor complex (PIC) 
4) Vortex sample for 15 s and rock on ice for 10 min 
5) Centrifuge at 600g for 10 minutes at 4°C 
6) Four volumes of the supernatant are then removed into a fresh 15ml falcon 
labelled ‘PBS Supernatant’ and centrifuged at 1500g for 10 minutes at 4°C.  
7) Other four volumes supernatant split between four cryovials labelled ‘PBS 
Supernatant’ and store at -80°C. 
8) Four volumes of 0.2% DTT added to sputum sample, ensuring a final DTT 
concentration of 0.1%. 
9) Vortex sample for 15 s and rock on ice for 10 min 
10) Filter through 48 µm nylon gauze 
11) Reweigh sample and aspirate 10µl, mix well with 10µl Trypan blue. Flood a 
haemocytometer chamber with 10µl of the cell suspension/Trypan blue solution. 
12) Count cells: Live leukocytes, dead leukocytes and squamous cells, calculate: 
1. Total number of cells in sample 
2. Cell concentration 
3. Total number of cells per gram of sputum 
4. Volume required for a concentration of 5x105 cells/ml 
 
13) Centrifuge cell suspension at 600g for 10 minutes at 4°C. 
14) Split the resulting supernatant between four cryovials labelled ‘DTT 
Supernatant’ and store at -80°C. 
15) Re-suspend cell pellet in appropriate volume of d-PBS to give a concentration 
of 5x105 cells/ml. 
16) Centrifuge 75µl on one slide and 150µl on another in Shandon cytospin at 
450rpm for 6 min 
17) Air-dry slides, fix in methanol and stain with RappiDiff II. 
18) Differential cell count of 400 cells 
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2.2.5.5 Methacholine Challenge  
AHR testing was performed using methacholine as a provocative agent and the tidal 
breathing method to determine the concentration of methacholine causing a 20% fall in 
FEV1 (PC20). The protocol was based on that described previously (545) and recommended 
by the ATS guidelines (434). 
In brief, the subject’s baseline FEV1 was measured, followed by the inhalation of normal 
saline and then doubling concentrations of methacholine from 0.03 mg/mL to 16 mg/mL via 
a Wright’s® nebuliser (Roxon, Canada) with a flow rate of 0.13 mL/min driven by dry 
compressed air. Each nebulisation period lasted 2 min, during which time the subject was 
wearing a nose clip and instructed to breathe normally through the nebuliser (which 
contained a two-way valve). After each nebulisation period the FEV1 was measured after 30, 
90 and 180 s. If the FEV1 did not decrease 20% from the baseline measurement the 
procedure was repeated with the next highest concentration. The test ended if the FEV1 fell 
≥20% from baseline or if the highest methacholine concentration of 16 mg/mL had been 
administered. 
Exact values for methacholine PC20 FEV1 concentration were calculated by linear 
interpolation of the log dose response curve. 
2.2.5.6 Phlebotomy 
Samples for FBC were obtained using the 21 gauge BD Vacutainer® Safety-Lok™ blood 
collection set (BD, Plymouth, UK) into 4 mL EDTA tubes. Samples were processed in the 
Nottingham City Hospital biochemistry laboratory by automated cytometers. 
Two extra EDTA and two serum samples (taken into 5 mL BD Vacutainer serum tubes) were 
also taken. EDTA tubes were immediately placed in ice and taken to the laboratory where 
one of these tubes was centrifuged at 1000 g for 15 min at 40C, whilst the other was 
immediately frozen at -80 ̊C. The supernatant from the other EDTA tube was aspirated and 
frozen in 10 aliquots at -80 ̊C for future use. The 2 serum tubes were allowed to clot in an 
upright position at room temperature for 45 min and were then centrifuged at 1300 g for 10 
min at 25 ̊C. Supernatants were aspirated and frozen in 10 aliquots at -80 ̊C for future use. 
2.2.5.7 Exhaled Nitric Oxide 
Exhaled nitric oxide concentration was measured using an offline electrochemical analyser 
(NIOX MINO®; Aerocrine™, Tolna, Sweden). All subjects inhaled NO-free air (via an NO 
scrubber built into the device) to near total lung capacity and exhaled for 10 s at a flow rate 
of 50 mL/s to provide two approved FENO measurements. The NIOX MINO device provides 
visual feedback to ensure an exhalation pressure of between 12-18 cmH2O, with a built in 
flow controller ensuring a resultant flow rate of 50 mL/s. 
2.2.5.8 Juniper Asthma Control Questionnaire 
The ACQ is a validated questionnaire, designed after international consultation with 91 
‘expert’ asthma clinicians, which has been used to assess the adequacy of asthma control 
and any changes in asthma control over time (546). It contains five questions on the five 
symptoms judged to be the most important when assessing asthma control (night time 
symptoms, morning symptoms, limitation of daily activities, shortness of breath and 
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wheeze), one question regarding the dose of daily ‘rescue’ bronchodilator used and one 
question assessing the subjects FEV1 as a percentage of their predicted value. Subjects are 
asked to recall the severity of each of the 5 symptoms and their bronchodilator use in the 
last week and quantify these on a 7 point scale (0=no impairment, 6=maximum 
impairment). The FEV1 % predicted is recorded and also quantified on a 7 point scale. The 
questions all have equal weight so the ACQ is the mean score of the 7 questions ranging 
between 0 (totally controlled) and 6 (severely uncontrolled). The ACQ has been 
demonstrated to give very consistent scores in patients with stable asthma between clinic 
visits as well as being very sensitive in detecting changes in asthma control (546). The 
minimal clinically important difference (smallest change in outcome that a subject would 
see as important) for the ACQ is 0.5 (547). A copy of the ACQ is included in Appendix B. 
2.2.5.9 Asthma Control Test 
The ACT is another validated questionnaire to assess asthma control designed by a working 
group of 4 primary care clinicians and 7 asthma specialists from the USA (548).  It contains 
five questions concerning symptoms of/statements with respect to asthma control (effect of 
asthma on daily activities, number of episodes of shortness of breath, night time or morning 
symptoms, frequency of ‘reliever’ bronchodilator use and self-rated “asthma control”). 
Subjects are asked to recall the severity of each of these 5 symptoms over the last 4 week 
period and quantify these on a 5 point scale (1=maximum impairment, 5=no impairment). 
The ACT test score is calculated by simply adding the scores of all of the questions to 
produce a total ranging between 5 (severely uncontrolled and 25 (totally controlled). The 
ACT has a high level of internal consistency reliability (548) and has a minimal clinically 
important difference of 3 points (549). A copy of the ACT is included in Appendix C. 
2.2.6 Analysis 
After the final visit the results of the investigations at each visit were reviewed in order to 
answer two questions: 
1) Does the patient meet any of the internationally recognised criteria for a diagnosis of 
asthma? 
2) Has there been any significant response to ICS treatment? 
Diagnosis of asthma was based on the following criteria: 
 Reversibility of ≥12% and ≥200 mL of FEV1 from baseline 15 min after inhaled 
salbutamol (217, 550)  
 A positive test for AHR, defined as a provocative concentration of methacholine 
resulting in a 20% reduction in FEV1 (PC20) of ≤8 mg/mL (434) 
 
Response to ICS was based on a combination of 2 of any of the objective criteria or 1 
objective criterion and 1 subjective criterion from the following previously defined response 
criteria: 
Objective: 
 Improvement in FEV1 ≥12% with ICS (217)  
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 Improvement in PC20 ≥1 doubling dose shift (434) 
 FENO: Decrease of ≥20% for baseline values >50 ppb or decrease of ≥10 ppb for 
baseline values ≤50 ppb (502) 
 
Subjective: 
 ACQ score decrease ≥0.5 (551)  
 ACT score increase ≥3 points (549)  
 
Data was entered into Stata (Statacorp, Texas, USA) and a series of logical operators were 
used to classify subjects’ asthma diagnosis and ICS response status based on the criteria 
above. ROC analysis was carried out in Stata and GraphPad Prism (GraphPad Software, 
California, USA) to produce ROC curves, ROC AUC values and values for sensitivity, 
specificity, PPV and NPV at selected cut-points.  
Odds ratios, sensitivity, specificity, PPV and NPV of symptoms for asthma diagnosis and to 
predict ICS response were also calculated in Stata. Stepwise logistic regression was 
performed with symptoms that were significant predictors of asthma diagnosis, high FENO or 
ICS response (p<0.05) in univariate analysis included in a multiple logistic regression model. 
Any symptoms that were not significantly associated with asthma diagnosis, high FENO or ICS 
response but changed the odds ratio for any of these outcomes by 10% or more on addition 
to the analysis were retained in the final model.
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2.3 Results 
2.3.1 Recruitment 
One hundred and ten subjects were referred by their general practitioners between 
November 2012 and November 2014. Of these 15 decided not to participate, and 18 did not 
meet the inclusion criteria (10 were already taking ICS, 6 had a significant respiratory 
comorbidity and 2 displayed acute symptoms not suggestive of asthma). Accordingly a total 
of 77 subjects were enrolled into the study. 
2.3.2 Losses and exclusions 
At visit 1, three subjects were unable to perform the required investigations and were 
withdrawn from the study. Seven patients were lost to follow up before visit 2 (3 of these 
withdrew consent and 4 were unable to be contacted despite repeated attempts) and a 
further 7 patients were lost before visit 3 (2 of these withdrew consent and 5 were unable 
to be contacted despite repeated attempts). 
 
 
 
Assessed for eligibility (n=110) 
Included in study (n=77) 
Figure 2.3: Consort diagram demonstrating losses and 
exclusions from study 
Enrolment 
Follow-Up 
Excluded (n=33) 
   Not meeting inclusion criteria (n=18) 
   Declined to participate (n=15) 
   Other reasons (n=0) 
Visit 2                                                                            
Lost to follow up (n=7) 
 3 withdrew consent                                    
 4 unable to be contacted despite repeat attempts 
Analysed (n=67) 
 
-  
 
Visit 1                                                             
Discontinued intervention as unable to perform study 
procedures (n=3)  
Analysed (n=74) 
Visit 3                                                                            
Lost to follow up (n=7) 
 2 withdrew consent                                    
 5 unable to be contacted despite repeat attempts 
Analysed (n=60) 
 
-  
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2.3.3 Missing data 
AHR could not be measured in all study participants due to low FEV1 at baseline (n=4), 
subjects declining the test (n= 4) or an inability to perform the test consistently (n=1). 
Also, sputum induction was attempted on the first 40 subjects recruited to the study, but 
only 4 of these were able to produce an adequate sample for analysis, therefore this test 
was abandoned and the limited data obtained were not included in the final analysis. 
2.3.4 Baseline demographics 
The baseline demographics and clinical features of all of the 74 participants able to 
complete sufficient investigations to rule in or rule out a diagnosis of asthma are shown in 
Table 2.1. The age distribution of the cohort is shown in Table 2.2. Table 2.3 shows the 
demographic information and clinical features of the subjects diagnosed with asthma and 
those classified as not having asthma. 
There was a slight female preponderance and a large majority of the subjects were 
Caucasian. This was predominantly a young cohort with ~50% of patients below the age of 
25. Around 31% were smokers or ex-smokers although the median pack year history was 0 
(IQR 0.05 pack years, range 0-20 pack years). 
The demographics of the groups categorised as having asthma or not having asthma were 
broadly similar although the median age of the group with asthma tended to be slightly 
higher (borderline significance p=0.06) and the ethnic composition of the groups was 
significantly different (p=0.02). The difference in ethnic composition of the groups is largely 
explained by the observation by that 4/28 subjects with asthma were Black/Black British 
whilst none of the 46 non-asthma subjects were Black/Black British. 
The asthmatic group had on average a lower mean FEV1 (p=0.005), lower mean FEV1/FVC 
ratio (p=0.007), higher mean reversibility (p=0.0001) and higher median blood eosinophil 
count (p=0.004) and higher mean ACQ score (p=0.02) (i.e. symptoms less well controlled) 
(Table 2.7). However, some of these differences would be expected as FEV1 and reversibility 
are included in our definition of asthma. 
2.3.5 Primary outcome: ICS Response 
Response to ICS, as defined by the response criteria described in Section 2.3.6, was seen in 
27 out of 67 (40%) subjects after 4 weeks of ICS and 28/60 (47%) subjects after 12 weeks 
(Table 2.4).  
Eighteen of the 32 (56%) subjects with asthma showed a response to ICS after 4 weeks, with 
14 of these having sustained this response after 12 weeks. Eleven of the non-asthma 
subjects also demonstrated a response to ICS after 4 weeks, with 6 sustaining this response 
after 12 weeks. Figure 2.4 illustrates the response or non-response to ICS of subjects with 
asthma and subjects without asthma after 4 then 12 weeks of ICS treatment, and also lists 
the subjects lost to follow up in this time. 
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A ROC curve calculated for baseline FENO level as a predictor of ICS response after 4 weeks 
had an AUC of 0.89 (p<0.0001) (Fig 2.5).The optimal FENO cut-off point for predicting non-
response to ICS was <27 ppb (NPV 93%) and for predicting response was >33 ppb (PPV 92%).  
Exploratory analysis was conducted using different combinations of objective and subjective 
response variables as ICS response criteria after 4 weeks with baseline FENO level as a 
predictor of response. This produced ROC curves with AUCs between 0.7 (FEV1 or PC20 
response alone) and 0.91 (response in either FEV1 or FENO) as shown in Table 2.5.  
The accuracy of FENO level to predict steroid response after 12 weeks was consistent with 
response at 4 weeks (ROC AUC = 0.86 p<0.0001) although a few individuals who showed a 
response in objective measures after 4 weeks did not sustain this response at 12 weeks and 
vice versa (Fig 2.6).  
2.3.6 Secondary outcomes:  
2.3.6.1 FENO for asthma diagnosis 
The diagnosis of asthma, according to the international consensus criteria outlined in 
Section 2.2.6, was made in 28 out of 74 patients. Of these 28 patients 10 were diagnosed by 
reversibility criteria alone and 12 were diagnosed by PC20 alone, with 6 being positive on 
both investigations. 
A ROC curve was constructed to assess the utility of baseline FENO level as a diagnostic test 
for asthma (as diagnosed by reversibility and PC20) as shown in Figure 2.7. The AUC for the 
curve was 0.62 (p=0.09). 
2.3.6.2 Ability of other baseline characteristics to predict a response to ICS 
When baseline PC20 and FEV1 were used as predictors of response (as defined by different 
combinations of response variables) this produced ROC curves with AUCs between 0.02 and 
0.67, shown in Table 2.6. ROC AUC values of <0.5 are negative predictors of an outcome i.e. 
the lower the value of the predictor variable, the greater the probability of a response. 
Therefore PC20 would appear to be an excellent predictor of response when response is 
defined by PC20 alone (ROC AUC = 0.02); PC20 with subjective response criteria (ROC AUC = 
0.04) or ≤2 objective criteria (ROC AUC = 0.12). However, these results are misleading 
because ‘response’ using these response criteria is based solely (or largely) on a doubling 
dose increase in PC20. These ROC AUC figures therefore simply reflect that of the 58 subjects 
who had MCT performed at V1 and V2, all of the 13/58 subjects who ‘responded’ in terms of 
PC20 had a baseline PC20 of ≤8 mg/mL whereas 40/45 who did not ‘respond’ had a baseline 
PC20 of ≥16 mg/mL (the highest concentration of methacholine used in the test). These 
latter subjects were all classified (correctly or incorrectly) using these response criteria as 
‘non-responders’ as their PC20 could not improve due to a ‘ceiling’ effect, hence artificially 
increasing the AUC values.  
The odds ratios, sensitivity, specificity, PPV and NPV of symptoms to predict ICS response 
and diagnose asthma were also calculated and these are shown in Table 2.8.  
Cough was found to be a significant positive predictive factor for raised FENO (odds ratio 
(OR) 8.7; 95% CI 3.1-24.6; p<0.0001) and symptoms on activity were a negative predictor of 
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raised FENO (OR 0.3; 95% CI 0.1-0.8; p<0.02). The symptom of wheeze was found to be of 
borderline statistical significance as a positive predictor for raised FENO (OR 2.5; 95% CI 1-
6.5; p<0.06). None of the other symptoms altered the OR for cough by >10% on addition to 
a stepwise regression model, suggesting there are no significant associations between these 
symptoms. To predict raised FENO (>27 ppb) the symptom of cough performed best overall 
in terms of sensitivity, specificity, PPV and NPV.  
Cough was also a significant positive predictor of ICS response (OR 10.6; 95% CI 3.0-37.4; 
p<0.0001) with a particularly good sensitivity (0.85) and NPV (0.85) to predict ICS response 
according to the defined criteria used in the study. None of the other symptoms significantly 
predicted ICS response and did not alter the OR for cough by >10% on addition to a stepwise 
regression model. 
2.3.6.3 Ability of other baseline characteristics to diagnose asthma 
The diagnostic value of blood eosinophil count and skin prick test positivity for asthma were 
also assessed. Blood eosinophil count had a ROC AUC of 0.7 (p=0.005) for asthma diagnosis 
(Table 2.6) and a positive skin prick test (weal diameter >3mm in response to any of the 
allergens listed in Section 2.2.5.2) had a moderate sensitivity/NPV but low specificity/PPV 
for asthma diagnosis (Table 2.7) 
None of the recorded symptoms were significantly associated with a diagnosis of asthma 
although cough (OR 2.3; 95% CI 0.9-6.0; p<0.08) and wheeze (OR 2.3; 95% CI 0.9-5.8; 
p<0.09) reached borderline statistical significance. In terms of the predictive value of 
symptoms to diagnose asthma, symptoms on waking had the highest specificity and 
dyspnoea, wheeze and cough produced similar values of sensitivity, specificity, PPV and NPV 
between 0.5 and 0.7 (Table 2.9).  
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 Frequency Percentage   
Total number included for 
analysis 
74   
Mean age (range) 32.3 (18-73)   
Sex: male 33  45  
Ethnic group: 
Asian Or Asian British 
Black Or Black British 
Mixed Ethnicity 
White Or White British 
 
6 
4 
1 
63 
 
8.1      
5.4    
1.4       
85.1      
 
Smoking history:  
Current 
Ex-smokers 
Non smokers 
 
10  
13  
51  
 
13.5  
17.5   
68.9 
 
Positive family history of asthma  34  45.9  
History/symptoms of GORD 15  20.3  
History/symptoms of eczema  9  12.2  
History/symptoms of rhinitis  17  23.0  
History/symptoms of hay fever  31  41.9  
History of NSAID allergy  2  2.7  
Positive skin prick for ≥1 allergen 43 59.7  
 Mean Standard 
deviation 
Range 
FEV1 % predicted  93  15.7 56-141 
FEV1/FVC ratio %  79.8  9.5 52-94 
Reversibility (%) 7.0  9.7 -18-43 
Blood eosinophil count (x109/L)*   0.2*  0.2* 0-0.9 
Baseline ACQ score 1.67 0.89 0-4 
Baseline ACT score 16.6 4.3 7-25 
*Data presented are median and interquartile range as variable not normally distributed 
Table 2.1: Demographics of study population 
 
Age group Frequency Percentage 
<20 16 21.1        
20-25 21 27.6        
25-30 9 11.8       
30-40 8 10.5        
40-50 8 10.5        
50-60 8 10.5       
60+ 6 7.9      
Total 76 100 
Table 2.2: Age distribution of study population 
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 Asthmatics Non asthmatics  
 Frequency 
(%) 
(except a) 
Frequency (%) 
(except a) 
Significance 
(p=) 
Total number included for 
analysis 
28 46  
Median age (range) 29 (18-70)a 22 (18-73)a 0.06 
Sex: male 11 (39) 23 (50) 0.37 
Ethnic group: 
Asian Or Asian British 
Black Or Black British 
Mixed Ethnicity 
White Or White British 
 
1 (3.6) 
4 (14.3) 
1 (3.6) 
22 (78.6) 
 
5 (10.9) 
0 (0) 
0 (0) 
41 (89.1) 
 
 
 
 
0.01* 
Smoking history:  
Current 
Ex-smokers 
Non smokers 
 
5 (17.9) 
4 (14.3) 
19 (67.9) 
 
5 (10.9) 
9 (19.6) 
32 (69.6) 
 
 
 
0.62 
Positive family history of 
asthma  
13 (46.4) 21 (45.7) 0.95 
History/symptoms of GORD 5 (17.9) 9 (19.6) 0.86 
History/symptoms of eczema  4 (14.3) 6 (13.0) 1.0 
History/symptoms of rhinitis  9 (32.1) 8 (17.4) 0.14 
History/symptoms of hay fever  12 (42.9) 20 (43.5) 0.96 
History of NSAID allergy  1 (3.6) 1 (2.2) 1.0 
Positive skin prick for ≥1 
allergen 
17 (60.7) 26 (56.5) 0.86 
    
 Mean (SD) Mean (SD)  
FEV1 % predicted  86.7 (14.0) 96.9 (15.6) 0.005* 
FEV1/FVC ratio %  76 (10) 82.1 (8.4) 0.007* 
Reversibility (mL) 12.6 (11.7) 3.6 (6.3) 0.0001* 
Blood eosinophil count 
(x109/L)b  
0.35 (0.4) 0.2 (0.1) 0.004* 
Baseline ACQ score 1.96 (0.81) 1.42 (0.82) 0.02* 
Baseline ACT score 15.8 (4.4) 17.2 (4.2) 0.09 
bData presented are median and interquartile range as variable not normally distributed 
*Figures highlighted represent statistically significant differences between the two groups 
 
Table 2.3: Demographics and clinical characteristics of subjects with 
and without asthma 
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Responded between V1-
V2: 
Frequency 
FEV1 ↑≥12% 2 
PC20 ↑≥ 1 doubling dose 
shift 
5 
FENO  
↓20% if baseline >50 ppb or 
↓≥10 ppb if baseline ≤50 
ppb 
13 
FEV1+PC20 1 
FEV1+FENO 1 
PC20+FENO 5 
All 3 objective criteria 2 
Any objective criteria 29 
Using study defined 
criteria 
27 
  
Responded between V1-
V3: 
 
FEV1 ↑≥12% 2 
PC20 ↑≥ 1 doubling dose 
shift 
5 
FENO  
↓20% if baseline >50 ppb or 
↓≥10 ppb if baseline ≤50 
ppb 
12 
FEV1+PC20 1 
FEV1+FENO 1 
PC20+FENO 8 
All 3 objective criteria 1 
Any objective criteria 30 
Using study defined 
criteria 
28 
 
Table 2.4: Frequency of subjects responding to ICS treatment 
according to different criteria/combinations of criteria 
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Figure 2.4: Showing pathway of patients through the study  
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Figure 2.5: ROC curve analysis showing the sensitivity (%) and the 
100 – specificity (%) of FENO levels for predicting ICS response after 4 
weeks of ICS treatment 
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Baseline value Response Criteria ROC AUC Optimal cut-off  
FENO Study defined criteria 0.89 
(p<0.0001) 
For non-response: 
<27 ppb 
 Sensitivity 92% 
 Specificity 75% 
 NPV 93% 
 PPV 71% 
For response: 
>33 ppb 
 Sensitivity 85% 
 Specificity 95% 
 NPV 91% 
 PPV 92% 
FENO Any objective criteria 0.85  
FENO ≥2 objective criteria 0.84  
FENO Any subjective response 0.53  
FENO FEV1 alone 0.7  
FENO PC20 alone 0.7  
FENO FENO alone 0.89  
FENO FEV1 or PC20 0.7  
FENO FENO or PC20 0.86  
FENO FEV1 or FENO 0.91  
FENO FEV1 + subjective response 0.7  
FENO PC20 + subjective response 0.74  
FENO FENO+ subjective response 0.88  
Table 2.5: ROC AUCs for FENO to predict ICS response as defined by 
different combinations of response criteria 
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Table 2.6: ROC AUCs for baseline PC20 and FEV1 to predict ICS 
response as defined by different combinations of response criteria  
 
 Sensitivity 
(%) 
Specificity 
(%) 
PPV (%) NPV (%) 
Skin prick positive 
(weal >3mm) 
60.1 41.3 38.6 63.3 
Table 2.7: Sensitivity, specificity, PPV and NPV of skin prick 
positivity (to any allergen) to diagnose asthma 
 
 
Baseline value Response Criteria ROC AUC 
PC20 Study defined criteria 0.32 
PC20 Any objective criteria 0.32 
PC20 ≥2 objective criteria 0.12 
PC20 Any subjective response 0.44 
PC20 FEV1 alone 0.36 
PC20 PC20 alone 0.02 
PC20 FENO alone 0.46 
PC20 FEV1 or PC20 0.09 
PC20 FENO or PC20 0.30 
PC20 FEV1 or FENO 0.43 
PC20 FEV1 + subjective response 0.36 
PC20 PC20 + subjective response 0.04 
PC20 FENO+ subjective response 0.47 
FEV1 Study defined criteria 0.58 
(p=0.25) 
FEV1 Any objective criteria 0.43 
FEV1 ≥2 objective criteria 0.29 
FEV1 Any subjective response 0.39 
FEV1 FEV1 alone 0.29 
FEV1 PC20 alone 0.33 
FEV1 FENO alone 0.49 
FEV1 FEV1 or PC20 0.29 
FEV1 FENO or PC20 0.44 
FEV1 FEV1 or FENO 0.46 
FEV1 FEV1 + subjective response 0.28 
FEV1 PC20 + subjective response 0.31 
FEV1 FENO+ subjective response 0.49 
Blood eosinophils Our defined criteria 0.67 
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Figure 2.6: ROC curve analysis showing the sensitivity (%) and the 
100 – specificity (%) of FENO levels for predicting ICS response after 
12 weeks of ICS treatment 
 
 
Figure 2.7: ROC curve analysis showing the sensitivity (%) and the 
100 – specificity (%) of FENO levels for asthma diagnosis 
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a) For diagnosing asthma 
Symptom Sensitivity Specificity PPV NPV 
Nocturnal Sx 0.25 0.74 0.42 0.56 
Sx on waking 0.22 0.81 0.47 0.58 
Sx on activity 0.53 0.52 0.46 0.59 
Dyspnoea 0.69 0.5 0.51 0.65 
Wheeze 0.53 0.67 0.55 0.65 
Cough 0.66 0.55 0.53 0.68 
 
b)  For predicting ‘high FENO’ (>27 ppb) 
Symptom Sensitivity Specificity PPV NPV 
Nocturnal Sx 0.2 0.69 0.42 0.43 
Sx on waking 0.15 0.78 0.43 0.44 
Sx on activity 0.38 0.34 0.39 0.32 
Dyspnoea 0.55 0.4 0.51 0.44 
Wheeze 0.5 0.71 0.67 0.55 
Cough 0.75 0.74 0.77 0.72 
 
c)  For predicting ‘high FENO’ (>33 ppb) 
Symptom Sensitivity Specificity PPV NPV 
Nocturnal Sx 0.17 0.69 0.26 0.55 
Sx on waking 0.1 0.76 0.21 0.56 
Sx on activity 0.37 0.37 0.37 0.37 
Dyspnoea 0.53 0.4 0.37 0.56 
Wheeze 0.5 0.67 0.5 0.67 
Cough 0.73 0.62 0.56 0.78 
 
d)  For predicting response to ICS 
Symptom Sensitivity Specificity PPV NPV 
Nocturnal Sx 0.18 0.75 0.36 0.54 
Sx on waking 0.25 0.81 0.5 0.58 
Sx on activity 0.5 0.44 0.41 0.53 
Dyspnoea 0.53 0.44 0.43 0.55 
Wheeze 0.5 0.67 0.54 0.63 
Cough 0.85 0.64 0.65 0.85 
 
Table 2.8:  Sensitivity, specificity, positive (PPV) and negative (NPV) 
predictive values for each of the listed symptoms to a) diagnose 
asthma b) predict FENO >27 ppb c) predict FENO >33 ppb and d) 
predict response to ICS 
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Symptoms to predict asthma diagnosis 
 
Odds 
ratio 95% CI p >Z 
Nocturnal Sx 0.94 0.33 - 2.70 0.91 
Sx on waking 1.19 0.38-3.71 0.77 
Sx on activity 1.25 0.50-3.13 0.64 
Dyspnoea 2.2 0.81-5.75 0.11 
Wheeze 2.27 0.88-5.83 0.09 
Cough 2.31 0.89-5.97 0.08 
Increased SABA use 3.64 0.86-15.4 0.08 
   
 
Symptoms to predict high FENO (>27 ppb) 
 
Odds 
ratio 95% CI p >Z 
Nocturnal Sx 0.55 0.19-1.56 0.26 
Sx on waking 0.6 0.18-1.92 0.39 
Sx on activity 0.31* 0.12-0.81 0.02 
Dyspnoea 0.81 0.32-2.04 0.66 
Wheeze 2.5 0.96-6.53 0.06 
Cough 8.67* 3.1-24.6 <0.0001 
Increased SABA use 1.37 0.35-5.30 0.65 
  
  
Symptoms to predict ICS response 
 
Odds 
ratio 95% CI p >Z 
Nocturnal Sx 0.65 0.19-2.22 0.5 
Sx on waking 1.38 0.42-4.53 0.6 
Sx on activity 0.8 0.30-2.15 0.66 
Dyspnoea 0.92 0.34-2.49 0.87 
Wheeze 2 0.73-5.52 0.18 
Cough 10.62* 3.02-37.35 <0.0001 
Increased SABA use 0.74 0.16-3.42 0.7 
 
Table 2.9: Odds ratios of symptoms to predict asthma diagnosis, 
high FENO (>27 ppb) and ICS response. Significant values are 
indicated* 
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2.4 Discussion 
The results of this study indicate that measuring exhaled nitric oxide levels in patients 
presenting to primary care with symptoms suggestive of asthma is useful in predicting a 
response to ICS but not in diagnosing asthma. Another finding was that the symptom of 
cough in this patient cohort is associated with a significantly increased likelihood of 
response to ICS. 
2.4.1 FENO for predicting ICS response 
Our results suggest that FENO is a good predictor of ICS treatment response, with a high NPV 
and PPV for ICS non-response and response using cut-points of <27 and >33 ppb.  
 
This supports previous findings where FENO was reported to be a useful predictor of 
response to ICS treatment in steroid naïve patients with symptoms suggestive of asthma 
(540). Similarly Little et al. (541) demonstrated FENO to have good predictive accuracy for 
oral steroid response in a group of 37 subjects, although these subjects had chronic asthma 
and were already treated with ICS.  
The results obtained in the current study, do however, differ from those found previously 
(540) in terms of the optimal FENO cut-point to signify a likely ‘negative’ response to ICS. 
Smith et al. reported a FENO cut-point of 47 ppb to have a NPV for steroid response of 77-
94% depending on the steroid response endpoint chosen, whereas these data suggest a 
lower value than this of 27 ppb with a NPV of 93%. This may be due to the different criteria 
chosen to designate ICS response as Smith et al. did not include decreased FENO value as a 
response criterion and considered a significant improvement in PC20 to be two or more 
doubling doses. Although the response criteria selected by the earlier study (540) are 
probably more definitive measures of ICS response, the criteria here are likely to be more 
sensitive to the detection of a response, and hence less likely to miss potential responders 
to ICS treatment. A fall in FENO was included as a criterion here which is not used routinely 
but was frequently the only objective change in patients with a subjective improvement in 
cough. This test has the advantage of being easily performed in primary care. Also, it has 
previously been established that a reduction in Th2 inflammation is associated with a 
reduced risk of exacerbations (552, 553), bringing some validity to the inclusion of FENO as a 
response criterion. 
A selected cut-off of 33 ppb for ICS response found by this study is similar to the FENO value 
of 36 ppb previously determined to identify significant eosinophilic inflammation as defined 
by a sputum eosinophil count >3% (481).  
Using investigations to determine the nature of airway inflammation underlying a patient’s 
symptoms is attractive because it allows a prediction of response to treatment that labelling 
individuals with a diagnosis of ‘asthma’ or ‘COPD’ does not (159). Asthma has been shown 
to have eosinophilic and neutrophilic phenotypes (Sections 1.4.6 and 1.4.7) with a 
potentially good response to ICS being limited to the former (303).  Of the 32 patients 
diagnosed with asthma in the current study only 18 (56%) responded to ICS, a finding in 
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keeping with that of Martin et al. (554) who found that only 54% of 72 asthma patients who 
had ICS withheld for 4 weeks responded when ICS were re-introduced. Likewise there is a 
subpopulation of patients with COPD who have eosinophilic inflammation and respond well 
to ICS treatment (555) and patients with cough secondary to EB who also improve with ICS 
(87). Our findings suggest that FENO could be a useful test in primary and secondary care but 
as a tool to target corticosteroid-responsive patients rather than to make or exclude a 
diagnosis of asthma.  
2.4.2 FENO for asthma diagnosis 
The poor sensitivity and specificity of FENO in diagnosing asthma may be due to the 
heterogeneity of the condition with different inflammatory subtypes expressing high or low 
levels of Th2 inflammation (552). Subjects with neutrophilic asthma, who may comprise up 
to 30% of all asthmatics (260, 296), by definition have no active eosinophilic/Th2 airway 
inflammation and therefore are likely to have normal FENO levels. The finding that only 57% 
of subjects with confirmed asthma responded to ICS further highlights the limitations of this 
diagnostic label. 
Previous studies investigating the role of FENO for asthma diagnosis have produced mixed 
results, with widely varying values of sensitivity and specificity for a range of different 
defined optimal cut-points and a recent meta-analysis concluded the sensitivity and 
specificity of FENO was insufficient for accurate diagnosis (556). Some of this variation may 
be explained by differences in study methodology and FENO devices, which even using 
standardised flow rates may produce significantly different FENO readings (557). Measured 
FENO levels can be affected by a number of other factors including coexistent atopy (508) 
and respiratory tract infection (558) which increase FENO levels, whilst decreased FENO levels 
may be caused by smoking (558) and certain medications.  
Owing to the variety of factors that can affect FENO levels, and the significant crossover in 
values between healthy and asthmatic populations the proposed NICE guidelines have 
advocated an approach to using FENO to help ‘rule in’ or ‘rule out’ asthma diagnosis, with 
subjects with ‘intermediate’ FENO levels requiring further investigation (543) (Section 
2.2.4.5). However, the results of this study do not support this strategy. 
2.4.3 Symptoms for predicting asthma diagnosis and ICS response 
None of the symptoms assessed were significant independent predictors of objectively 
defined asthma. This is consistent with the results of the studies presented in Section 1.3.  A 
literature review conducted as part of the draft NICE guidelines for asthma diagnosis (539) 
also concluded that the sensitivities and specificities of individual symptoms for asthma 
diagnosis were moderate or low, and as such the diagnosis of asthma based on 
symptomatology could not be recommended. 
 
The symptom of cough was found to be an independent predictor of a FENO value >27 ppb, 
which was the optimal cut-off point derived for non-response to ICS in the first part of the 
study. The presence of cough made it ~9 times more likely that the subject would have a 
FENO value >27 ppb. It is not surprising then, given the results of the first part of the study, 
that cough was also a significant predictor of ICS response, with the presence of cough 
168 
 
signalling a 10 fold increase in likelihood of ICS response. Cough also had a high sensitivity 
and NPV for the prediction of ICS response but only moderate specificity and PPV. 
The ability of symptoms to predict ICS response has not previously been assessed so this is a 
novel finding. The most likely explanation for this result is that Th2 high inflammation is 
more likely to cause the symptom of cough than other typical symptoms of airways disease 
such as dyspnoea and wheeze. A cough, which is usually dry, is described as the 
characteristic symptom of EB (88). Therefore if the sole or main underlying 
pathophysiological feature of a subjects’ airway disease is Th2 high inflammation rather 
than other pathology such as AHR and airway obstruction, the most likely resultant clinical 
picture may be of a subject with a dry cough, rather than predominant dyspnoea or wheeze.  
The value of high FENO and the symptom of cough in predicting ICS response could both be 
used in future to improve targeting of ICS treatment to subjects who are more likely to 
respond.  
2.4.4 Study limitations 
This study had several limitations which need to be addressed.  
 
Firstly, criteria had to be selected on which to base a diagnosis of asthma whilst recognising 
there is no gold standard. The diagnostic criteria selected are standard criteria from 
international consensus guidelines and subject was classified as asthmatic if any one of the 
two chosen criteria were positive. Despite the lack of gold standard these objective tests 
were deemed to be the best on which to classify asthma diagnosis and limiting the criteria 
to positive MCT (considered the best ‘rule-in’ ‘rule-out’ test available) alone did not 
significantly alter the ROC AUC value for asthma diagnosis.   
Secondly there was no formal measure of ICS adherence during the study although patients 
were questioned about their ICS usage at each visit. Therefore failure to respond to ICS may 
have been due to lack of adherence rather than a true negative response to treatment. This 
may also explain why three asthmatic patients who responded to ICS at 4 weeks did not 
show a sustained response at week 12 (Fig. 2.6).  However, it is very unlikely that the degree 
of adherence with ICS would have varied markedly and consistently enough between those 
with higher and lower FENO baseline values to explain these findings, especially as patients 
were blinded to their FENO results. 
Thirdly, this was an open label trial of ICS which did not include a placebo arm meaning at 
least part of the ICS treatment response was likely to be a placebo effect. However, when 
examining an individual’s response to ICS a placebo treatment cannot be included unless a 
crossover study design is used. This was deemed unethical because it would have meant 
delaying patients’ treatment as prescribed by their GPs. Further, several different objective 
measures of airway function were measured before and after treatment and subjects were 
blinded to the results, limiting the likelihood of bias.  
Finally, the selected criteria for ICS response included a reduction in FENO levels which has 
not been used by others.  Although it seems reasonable to assume that a decrease in FENO 
will translate into a clinical benefit this is, as yet, unproven. As with the other selected ICS 
169 
 
response criteria, a reduction in FENO alone was not considered significant unless 
accompanied by an improvement in another objective or subjective criterion. The nine 
subjects who had a response to ICS limited to a reduction in FENO with symptomatic 
improvement all presented with cough as their predominant symptom and none of them 
met the diagnostic criteria for asthma. Including a response measure relating to the level of 
eosinophilic airway inflammation was deemed important as suppression of eosinophilic 
inflammation is the main mechanism by which ICS have a beneficial treatment effect (543). 
A direct and therefore superior method of measuring eosinophilic airway inflammation is 
sputum induction to determine sputum eosinophil count. This was also attempted in 40/74 
of our subjects but only 4 of these produced an adequate sample for analysis, making this 
an unsuitable investigation for use in this patient cohort.   
 
2.5 Conclusion 
In conclusion, in this group of patients presenting to primary care with symptoms suggestive 
of asthma, FENO is not a useful test for asthma diagnosis but is accurate at predicting ICS 
treatment response and non-response. The symptom of cough, which was predictive of 
raised FENO levels, also appears to be sensitive at predicting ICS response and could help to 
identify patients more likely to respond to ICS. We propose that FENO measurement in 
patients with symptoms suggestive of airways disease (shortness of breath, chest tightness 
and cough) could be used to identify patients in whom ICS response is highly unlikely. This 
would avoid unnecessary treatment with inhaled steroids and encourage further 
investigation of the cause of the symptoms and more effective treatment. This study has 
provided pilot data for the design of a multicentre placebo-controlled clinical trial to assess 
the value and safety of this approach.
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Chapter 3: Chronic Productive Cough and 
the use of Macrolides in Airways Disease 
3.1 Background 
3.1.1 Summary of background (Chapter 1.6) 
A cohort of adult patients presenting with chronic productive cough which improves with 
antibiotic treatment but quickly relapses has been described (1). A number of conditions 
that result in the symptom of chronic productive cough have been described but this cohort 
cannot be accurately described using any of these diagnostic labels, although  the clinical 
course of the disease and response to antibiotics seems similar to that of the paediatric 
condition ‘protracted bacterial bronchitis’ (PBB). Many subjects in this cohort have been 
given a diagnostic label of asthma and are being treated with inhaled corticosteroids. (1).  
A marked, and often sustained, improvement in symptoms has been observed in these 
patients following a 3 month course of low dose azithromycin. Azithromycin is a macrolide 
antibiotic which has demonstrated efficacy in the treatment of respiratory conditions 
including diffuse panbronchiolitis (DPB) (2), chronic obstructive pulmonary disease (COPD) 
(3) and bronchiectasis (4). In addition to antibiotic effects, azithromycin has demonstrated 
immunomodulatory and anti-inflammatory effects (5) which may be more pronounced in 
subjects with underlying neutrophilic airway inflammation (6).  
3.1.2 Rationale for study 
Although this cohort of patients seems to be recognised by clinicians in the respiratory clinic 
these patients are not described in the scientific literature. Hence the purpose of this study 
is to try and describe the clinical and pathological features of this condition and assess the 
response of these patients to an open label treatment trial of azithromycin. 
3.1.3 Hypothesis and Aims 
3.1.3.1 Hypothesis 
There is a cohort of patients with chronic productive cough whose underlying pathology 
cannot be described by existing labels and who respond to treatment with azithromycin. 
3.1.3.2 Aims 
1) To describe the clinical, pathological and radiological features of this cohort of patients  
2) To determine the response to a 12 week course of low dose azithromycin therapy and 
assess if any of the baseline characteristics measured could predict response to 
azithromycin. 
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3.2 Methods 
3.2.1 Purpose and Design 
3.2.1.1 Purpose 
1) The primary objectives of the study were to describe the clinical and pathological features 
of a cohort of patients who present with chronic productive cough (with no evidence of 
bronchiectasis, smoking-related chronic bronchitis or immunodeficiency) and determine if 
treatment of these patients with 12 weeks of low dose azithromycin is both effective and 
safe. 
2) The secondary objectives of the study were to determine the effect of 12 weeks 
azithromycin treatment on selected clinical measures and biomarkers and to describe the 
features of responders and non-responders to azithromycin  
 
3.2.1.2 Study Design 
This was a single centre open label clinical trial with an in-depth description of baseline 
clinicopathological features. 
 
3.2.1.3 Ethical Approval 
This study was approved by the National Research Ethics Committee Yorkshire & The 
Humber – Leeds West (Ref 13/YH/0245) and Nottingham University Hospitals NHS Trust 
Research and Innovation department (Ref 13RM015).  
 
3.2.2 Study Population: 
3.2.2.1 Eligibility criteria 
Patients were recruited according to the following eligibility criteria: 
 
Inclusion criteria 
 Age 18 or above 
 Male or female 
 Non-smokers for 10 years and <20 pack year equivalents in total 
 Persistent productive cough for >3 months in duration 
 Use of effective contraception: 
o Acceptable contraceptive methods include: established use of oral, injected 
or implanted hormonal methods; placement of an intrauterine device (IUD) 
or intrauterine system (IUS); condom or occlusive cap (diaphragm or 
cervical/vault caps) with spermicide; true abstinence (when this is in line 
with the preferred and usual lifestyle of the participant); or vasectomised 
partner 
 
Exclusion criteria 
 History of obvious inhaled irritant exposure 
 Evidence of primary or secondary immunodeficiency 
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 Clinically important bronchiectasis on HRCT scan 
 Prolonged QT interval on baseline or 1 month electrocardiogram (ECG) or significant 
cardiac pathology prior to commencing azithromycin 
 Pregnancy or intent to become pregnant during course of study 
 Contra-indication to bronchoscopy (as per BTS Guidelines (747)) 
 Abnormal liver function tests (LFTs) (greater than 2x upper limit of normal) 
 Hypersensitivity to azithromycin or any macrolide/ketolide antibiotic 
 
3.2.2.2 Study setting and participant recruitment 
This study was conducted at the Nottingham Respiratory Research Unit (Nottingham City 
Hospital UK). Subjects with symptoms of chronic productive cough without bronchiectasis, 
smoking-related chronic bronchitis or immunodeficiency were prospectively identified from 
outpatient respiratory clinics according to the eligibility criteria. 
 
Interested subjects were provided with full written information from their respiratory 
consultant regarding the study and given the contact information for the study team 
(Appendix D). Upon contacting the study team by telephone they were screened to ensure 
they met the inclusion and exclusion criteria. 
 
3.2.3 Outcome measures 
3.2.3.1 Primary endpoints 
 A description of the baseline clinicopathological features of the cohort including 
FEV1, FENO, LCQ score, sputum differential cell count, 24 hour sputum volume, HRCT 
scan features and histological analysis of bronchial biopsy samples 
 The effect of 12 weeks of azithromycin treatment on LCQ score  
 
3.2.3.2 Secondary endpoints 
 The effect of 12 weeks of azithromycin on sputum colour and 24 h sputum collection 
volume 
 The effect of 12 weeks of azithromycin on sputum cell counts and FENO level 
 The effect of 12 weeks of azithromycin on FEV1  
 The effect of 12 weeks of azithromycin treatment on sputum microbiology 
 The effect of 12 weeks of azithromycin treatment on the levels of IL-8, IL-1β, IL-17A 
and TNFα in pre and post treatment sputum supernatant 
 Comparison of the baseline clinical features of responders and non-responders to 
azithromycin 
 
3.2.3.3 Sample size calculation 
A power calculation was performed using a common standard deviation of 1.2 in LCQ score 
from a previous successful interventional study in patients with chronic cough, using LCQ 
score as a primary outcome (748). This determined that 30 patients would need to complete 
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the trial in order to give a 90% power at a 5% two-sided significance level to detect a drop in 
our primary outcome of the LCQ of at least 1.3 points, which is the minimum clinically 
important difference in LCQ (749). 
 
3.2.4 Summary of study protocol 
3.2.4.1 Visit 1 
All patients meeting the entrance criteria for the study were invited to attend the first study 
visit where eligibility was rechecked and written informed consent obtained prior to any 
study-related interventions. FENO, exhaled carbon monoxide (ECO), spirometry, LCQ, sputum 
induction, electrocardiogram (ECG), liver function tests (LFTs) and pregnancy tests (if 
applicable) were carried out as outlined in Fig. 3.1 below.  
 
The subject was asked to score the colour of their sputum according to a sputum colour 
chart. If an adequate sputum sample was produced by induction sputum colour was also 
visually assessed by the investigator and scored according to the sputum colour chart. 
 
Subjects were given a universal sample container and instructed to collect all of the sputum 
produced by coughing in the 24 h period prior to their next study visit. Any subjects who 
opted out of having a bronchoscopy were instructed to begin the course of azithromycin 
following completion of 24 h sputum collection. 
 
3.2.4.2 Visit 2 
Subjects then attended a bronchoscopy visit as soon as possible after Visit 1, unless they 
had specifically opted out of this procedure. Bronchial biopsies and washes were taken. The 
24 h sputum volume was also measured. Following bronchoscopy subjects were instructed 
to begin the course of azithromycin. 
 
3.2.4.3 Visit 3 
Visit 3 was a safety visit after 6 weeks of azithromycin treatment in which any adverse 
effects of the azithromycin were recorded. An ECG and LFTs were performed and use of 
medication was confirmed. Subjects were again given a universal sample container and 
instructed to collect all of the sputum produced by coughing in the 24 h period prior to their 
next study visit. 
 
3.2.4.4. Visit 4 
Visit 4 was the post-treatment visit (following 12 weeks of treatment) and use of medication 
was confirmed. Exhaled nitric oxide, spirometry and reversibility, LCQ and sputum induction 
were carried out (Fig. 3.1) and the 24 h sputum volume was also measured. Subjects were 
asked to score the colour of their sputum according to the sputum colour chart. If an 
adequate sputum sample was produced by induction this was visually assessed by the 
investigator and scored according to the sputum colour chart. If an adequate sputum 
sample was not produced an objective sputum colour score was determined from the 24 h 
sputum volume sample.  
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3.2.4.5 Visit 5 
Visit 5 was the follow up visit 4 weeks after stopping treatment. The LCQ was performed 
and subjects were asked to score the colour of their sputum according to the sputum colour 
chart. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Investigations performed at each study visit.  
Sputum MC+S = sputum microscopy, culture and sensitivity, ECG = electrocardiogram, 
LFTs = liver function tests, FENO = Fractional exhaled nitric oxide level, ECO = Exhaled 
carbon monoxide, FEV1 = spirometry, Reverse = reversibility, LCQ = Leicester cough 
questionnaire, Sputum % = Sputum differential cell count, Sputum colour = Sputum 
colour chart assessment, 24 h sputum vol = 24 hour sputum collection volume 
Visit 1 (Baseline) 
Routine NHS investigations: 
Sputum MC+S, ECG, LFTs 
Research investigations: 
FENO, ECO, FEV1, Reverse, LCQ, Sputum % 
Sputum colour (objective and subjective) 
24 h sputum vol, Pregnancy test 
Visit 2 (Bronchoscopy) 
Optional 
Endobronchial Biopsies 
Bronchial Wash 
Visit 3 (Safety visit) 
ECG, LFTs 
Visit 4 (Post - treatment) 
FENO, FEV1 , Reverse, LCQ, Sputum % 
Sputum colour (objective and subjective) 
24 h sputum vol 
Visit 5 (Follow up) 
LCQ, Sputum colour (subjective) 
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3.2.5 Clinical Measurements 
3.2.5.1 Leicester Cough Questionnaire 
The LCQ is a validated questionnaire designed to assess the health related quality of life in 
patients with chronic cough (750). A copy is included in Appendix E. 
 
It consists of 19 questions which are divided into 3 different domains: physical, 
psychological and social. Subjects are asked to provide a rated response to each question, all 
of which are designed to assess the impact of cough on the subject’s life over the preceding 
2 weeks. The total score ranges from 3 to 21, with a higher score corresponding to a better 
health related quality of life. 
 
The LCQ has been validated for use in subjects with a number of different conditions leading 
to cough. It has been demonstrated to have a good level of internal consistency and 
reliability (751) and the minimal clinically important difference (MCID) is 1.3 (749).  
 
3.2.5.2 24 hour sputum volume 
The 24 h sputum collection volume is frequently used as an outcome measure in 
interventional studies in patients with chronic productive cough secondary to bronchiectasis 
(752, 753).  
 
Subjects were asked to collect all sputum expectorated over a 24 h period in a universal 
sample container before visit 2 (bronchoscopy). Subjects who did not have bronchoscopy 
were asked to collect all sputum expectorated in a 24 h period at visit 1 and to return this to 
study staff prior to starting azithromycin treatment.  
 
24 h sputum volume was measured by transfer of sputum from the universal sample 
container via a pipette to a measuring cylinder with 0.1 mL graduations. Any obvious 
salivary portion of the sample was discarded before final measurement.  
 
3.2.5.3 Sputum Colour Chart 
Sputum colour was assessed using a commercially available sputum colour chart 
(BronkoTest®, Heredilab Inc., Salt Lake City, UT, USA). This is a 5 point colour chart based on 
a 9 point colour chart demonstrated by Stockley et al. to correlate well with ongoing airway 
inflammation (610, 754). Colours 1 and 2 on the chart are regarded as non-purulent and 
colours 3–5 as purulent. More recently, Simpson et al. (755) found a BronkoTest® score of 
≥3 to be a good predictor of ongoing neutrophilic bronchitis. 
 
Subjects were asked to subjectively score their sputum colour based on the chart and this 
was also assessed objectively by study staff.  
 
3.2.5.4 Exhaled Nitric Oxide 
FENO concentration was measured using the Bedfont NOBreath offline electrochemical 
analyser (Bedfont Scientific Ltd, Harrietsham, UK).  
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All subjects first inhaled ambient air to near total lung capacity and then exhaled for 16 s at 
a constant flow rate through a mouthpiece into the device to provide two approved FENO 
measurements. The NOBreath device provides visual feedback to ensure an exhalation 
pressure of between 10-20 cmH2O, regulated by the device to ensure a resultant flow rate 
of 50 mL/s. 
 
3.2.5.5 Electrocardiogram (ECG) 
12 lead ECGs were obtained according to American Heart Association (AHA) Guidelines 
(756). Patients were positioned in a semi-recumbent position at approximately 45 degrees 
to the horizontal. ECG electrodes were positioned in accordance with AHA guidelines (756) 
and 2 ECGs were recorded for each subject with the best quality of the two used for analysis 
of the QT interval. The QT interval was calculated as per AHA guidelines (757). 
 
3.2.5.6 Liver Function Tests (LFTs) 
Serum samples for LFTs were obtained using the 21 gauge BD Vacutainer® Safety-LokTM 
blood collection set (BD, Plymouth, UK) into 5 mL serum tubes. Samples were processed in 
the Nottingham City Hospital biochemistry laboratory by automated cytometers. 
 
3.2.5.7 Exhaled Carbon Monoxide 
Exhaled carbon monoxide (ECO) was measured using an electrochemical CO monitor (CO 
Monitor, Clement Clarke Intl., Essex UK). An ECO value of <10 ppm was used to confirm 
subjects non-smoking status. 
 
3.2.5.8 Spirometry and Reversibility 
Performed as described in Section 2.2.5.1. 
 
3.2.5.9 Sputum Induction 
Performed as described in Section 2.2.5.3. 
 
3.2.6 Bronchoscopy 
3.2.6.1 Bronchoscopic Technique 
Bronchoscopies were performed in the Nottingham City Hospital Endoscopy Centre by the 
clinical fellow with appropriate supervision by a named consultant and assisted by at least 
two endoscopy nurses. A clinical scientist was also present to aid with the initial sample 
capture in the appropriate storage media (see below). All bronchoscopies were conducted 
in accordance with BTS guidelines (747) and local research protocols. Subjects were nil by 
mouth for 4 h prior to the procedure and patients with a diagnosis of asthma had 
spirometry assessed prior to the procedure and premedication with 400 µg of salbutamol 
inhaled via Volumatic® spacer if necessary.  
 
An intravenous cannula was inserted and all procedures performed under light sedation 
with midazolam (2.5 – 5 mg as necessary) and alfentanyl (250-500 µg as necessary). 
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Subjects’ oxygen saturations were continuously monitored throughout the procedure by 
pulse oximeter and supplemental oxygen was delivered nasally. Local anaesthesia of the 
naso- and oro-pharynx and vocal cords to achieve suppression of gag and cough reflexes 
was achieved using 5-7.5 mL Instillagel® (CliniMed, Bucks, UK) nasally, 4-5 sprays (40-50 mg) 
of 10% lidocaine orally and 10 mL 4% followed by 10 mL 2% lidocaine to the vocal cords. 
Further 10 mL volumes of 2% lidocaine were also administered in the right and left main 
bronchi with further doses given as necessary. 
 
Following a brief systematic inspection of the subjects’ bronchial anatomy, bronchial washes 
were performed in the right upper lobe to provide a minimal wash volume of 20 mL. This 
was divided into four 5 mL volumes, with one volume being sent to the Nottingham City 
Hospital Microbiology laboratory for microscopy, culture and sensitivity and three 5 mL 
volumes being sent to the Nottingham Respiratory Research Unit (NRRU) laboratory for 
processing as described below. Between 4-8 bronchial biopsies were then taken from the 
right bronchus intermedius using 1.8 mm width alligator forceps (Radial Jaw®4, Boston 
Scientific, Costa Rica). At least two of these were placed in universal specimen pots 
containing 5 mL 4% formaldehyde in phosphate buffered saline (PBS) and transported at 
room temperature to the Nottingham City Hospital Histopathology department for 
specimen processing, paraffin embedding and staining. The remaining samples were 
transported to the NRRU laboratory for processing and cell culture. Finally, two bronchial 
brushings were taken at the sub-carina/right bronchus intermedius into a 3 mL Falcon tube 
containing bronchial epithelial cell growth medium with 1% penicillin-streptomycin-
fungizone (BEGM + 1% PSF) and also transported to the NRRU laboratory for cell culture. 
After the procedure subjects were monitored for a 30 min period and asthmatic subjects 
underwent spirometry again, if clinically indicated. 
 
3.2.6.2 Processing of Bronchial Wash samples 
The full protocol describing this process is included in the Appendix F. Briefly: 
 1 x 5 mL sample was sent for differential cell count.  This sample was centrifuged at 
600 g for 10 min at 40C. The resultant pellet was re-suspended at approximately 5 x 
105 cells/mL whilst the supernatant was divided into aliquots and frozen at -800C for 
future work including cytokine profiling. 75 µl of the re-suspended pellet was added 
to a cytospin funnel attached to a glass slide which was centrifuged and stained (See 
Section 2.3.5.4). A differential cell count was performed as in Section 2.3.5.4. 
 1 x 5 mL sample was centrifuged at 200 g for 5 min at 40C. The supernatant was 
transferred to a fresh tube and centrifuged at top speed (4147 g) for 15 min at 40C. 
The pellets from the first and second spins were labelled with the anonymised study 
subject number and stored at -800C for future analysis of bacterial DNA. 
 
3.2.6.3 Processing of Bronchial Biopsy samples 
Biopsies were removed from sample containers with blunt forceps and embedded using a 
standard paraffin wax embedding centre. The resultant embedded sample was cut with a 
microtome into 4-5 μm thick slices ensuring 4-8 biopsy slices per slide. All sections were 
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mounted on poly-L-lysine coated slides (Fisher Scientific UK Ltd.) and stained with 
haematoxylin and eosin (+/- alcian blue).  
 
3.2.6.4 Radiological review of HRCT scans 
The HRCT scans of study subjects were reviewed by a consultant radiologist blinded to 
subjects’ response to azithromycin. After an initial review to look for any commonly 
occurring radiological features a checklist detailing the presence and absence of certain 
features and allowing a semi-quantitative assessment of certain important features was 
developed (See Appendix G). Scans were then reviewed in detail by the same consultant 
radiologist and the checklist completed for each subject’s scan.  
 
3.2.6.5 Cytokine profiling of baseline sputum supernatant/bronchial wash samples 
The induced sputum and bronchial wash supernatant levels of IL-8, IL-1β, IL-17A and TNFα in 
all available samples from the study were quantified using a multiplex suspension 
immunoassay system (Bio-Plex, Bio-Rad, Hemel Hempstead, UK). Briefly, samples were 
added to microplate wells containing beads conjugated with capture antibodies specific to 
the cytokines listed above. Following binding of the capture antibodies to the target protein 
the plates were washed and then incubated with biotinylated detector antibodies. The 
plates were then washed a second time and a reporter streptavidin-phycoerythrin (SA-PE) 
conjugate added. Labelled beads were then passed through an array reader which 
quantified the fluorescence of bound SA-PE. Fluorescence values were compared to a 
standard curve, allowing quantification of the target cytokine levels.  
 
In order to optimise the assay a test run was performed using aliquots of selected samples 
to establish an expected range of values. The assay was then performed again in triplicate 
on all available samples with appropriate dilution of samples where necessary based on the 
results of the test run.  
 
 
3.2.7 Analysis 
3.2.7.1 Statistical software 
Microsoft Excel was used for data cleaning. Data were then imported into Stata v11.0 
(Statacorp, Texas, USA) and GraphPad Prism Version 6 (GraphPad Software, California, USA) 
for statistical analysis. The demographics and baseline clinical measures of the cohort were 
determined. 
 
3.2.7.2 Primary endpoints 
a) Histological review of bronchial biopsy samples 
Following completion of the study bronchial biopsy slides (Section 3.2.6.3) were reviewed by 
a consultant histopathologist under light microscopy with settings for histological colour 
images. This individual was blinded to subjects’ response to azithromycin and was 
specifically asked to determine; (1) if there were any histological features common to this 
cohort of patients and (2) if there were significant differences in the biopsies of responders 
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and non-responders to azithromycin. Following a primary review for any notable features, 
slides were again reviewed and the presence or absence of these features was recorded. 
 
b) Radiological review of HRCT scans 
The sensitivity, specificity, positive and negative predictive values of HRCT scan features to 
predict treatment response to azithromycin were calculated. 
 
c) Effect of azithromycin on LCQ score 
Median LCQ scores pre- and post- 12 weeks of azithromycin treatment were calculated and 
pre- and post-LCQ scores compared using the Wilcoxon signed-rank test as data were not 
normally distributed and could not be transformed to normality.  
 
3.2.7.3 Secondary endpoints 
a) Effect of azithromycin on other clinical measures and sputum supernatant cytokine levels 
The secondary endpoints of sputum volume and FENO were non-normally distributed and 
could not be transformed to normality. Hence median values were calculated for both 
variables pre- and post- azithromycin and the Wilcoxon signed-rank test was used to 
compare pre- and post-values. FEV1 was normally distributed and mean FEV1 values pre- 
and post- treatment were calculated with the paired T-test used to compare pre- and post-
treatment values. Frequency tables for objective and subjective sputum colour score pre- 
and post-treatment were constructed and the Wilcoxon signed-rank test used to compare 
pre- and post-treatment scores.  
 
The median concentration of the cytokines IL-8, IL-1β, IL-17A and TNF-α in pre and post 
treatment sputum samples and bronchial wash samples were compared using the Wilcoxon 
signed-rank test if they could not be transformed to normality. Pre and post treatment IL-1β 
levels were transformed to normality using a logarithmic transformation and pre and post 
geometric means were calculated and compared using a paired T-test. 
 
b) Sub-group assessment: Responders vs non-responders and asthma vs non-asthma 
Subjects were divided into two groups of “responders” or “non-responders”. Responders 
were defined as subjects whose LCQ score had increased by greater than the MCID of the 
LCQ of 1.3 points (749). The analyses for the primary and secondary endpoints stated above 
were repeated in these two groups in order to try and determine any differences between 
these groups. Subjects’ sputum inflammatory type was classified accordingly: 
 eosinophilic subjects had a sputum differential eosinophil count (from V1) or 
bronchial wash differential cell count of ≥3% 
 neutrophilic subjects had a sputum differential neutrophil count (from V1) or 
bronchial wash differential cell count of ≥61% 
 mixed granulocytic subjects had a sputum differential eosinophil count (from V1) or 
bronchial wash differential cell count of ≥3% and a sputum differential neutrophil 
count (from pre- or post-treatment visits) or bronchial wash differential cell count of 
≥61% 
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 paucigranulocytic subjects had a sputum differential eosinophil count (from V1) or 
bronchial wash differential cell count of <3% and a sputum differential neutrophil 
count (from pre- or post-treatment visits) or bronchial wash differential cell count of 
<61% 
 missing sample subjects did not have a differential cell count on any sputum or 
bronchial wash samples due to either poor toleration of sputum induction or failure 
to produce an adequate or viable sample and either declining or being unsuitable for 
the bronchoscopy procedure  
 
Subgroup analyses were also performed on subjects with and without asthma. 
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3.3 Results 
 
3.3.1 Recruitment 
Between January 2014 and January 2016 274 subjects presenting to one of eight different 
outpatient respiratory clinics were identified in screening with symptoms of chronic 
productive cough of unknown cause. Following further investigations, including standard 
workup for this symptom 120 subjects were identified as being in the cohort of interest for 
the study. Of these 120 subjects, 75 were unable to participate in the study for the reasons 
listed in Table 3.1 leaving 45 patients who were eligible and invited to participate in the 
study. Fifteen of these declined to participate, and 30 agreed and were recruited to the 
study. 
 
Reason Number  
Already taking or had previously taken long 
term azithromycin 
52 
Already taking other long term antibiotic 
treatment 
5 
Documented macrolide allergy 2 
Symptoms eventually improved/seasonal 7 
Deranged liver function tests 2 
Did not attend planned appointments 
following investigation 
6 
Declined CT scan 1 
Total 75 
 
Table 3.1: Reasons for non-eligibility for study in subjects identified 
with chronic productive cough of unknown cause 
 
3.3.2 Losses and exclusions 
One subject was withdrawn from the study following an adverse event (periorbital oedema) 
after taking the first dose of azithromycin. All of the other 29 participants completed the full 
12 weeks of azithromycin treatment and contributed data for the primary analysis. Thirteen 
subjects did not have a bronchoscopy at visit 2 as 2 were unsuitable for the procedure, 5 
had already had bronchoscopy procedures as part of their routine work-up and 6 declined 
bronchoscopy. Three participants did not attend the four week follow-up visit (V5). 
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Assessed for eligibility (n=120) 
Included in study (n=30) 
Enrolment 
Follow-Up 
Excluded (n=90) 
   Not meeting inclusion criteria (n=75) 
   Declined to participate (n=15) 
   Other reasons (n=0) 
Visit 2 (Bronchoscopy) 
 17 had procedure  
 2 unsuitable for procedure 
 5 already had procedure as part of standard 
clinical care 
 6 declined procedure  
 
Remaining in study (n=30) 
 
 
Visit 1                                                              
Remaining in study (n=30) 
Visit 3: Safety visit                                                                           
Lost to follow up (n=1) 
 1 withdrawn due to adverse event  
Remaining in study (n=29) 
 
-  
 Visit 4: Post treatment visit                                                                             
Remaining in study (n=29) 
 
Visit 5: Follow up visit   
Lost to follow up (n=3) 
 3 did not attend                                              
Remaining in study (n=26) 
 
Figure 3.2: Consort diagram demonstrating losses and 
exclusions from study 
AZITHROMYCIN STARTED 
AZITHROMYCIN STOPPED 
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3.3.3 Missing data  
As AZCC03 was withdrawn from the study following the first dose of azithromycin, only 
baseline (V1) data and data from the bronchoscopy visit (V2) were collected from this 
subject. 
  
Thirteen subjects were not suitable for or declined bronchoscopy meaning histological 
review of bronchial biopsy specimens and analysis of bronchial wash samples were not 
undertaken for these subjects. 
 
One of the 30 subjects had an HRCT scan performed in another hospital and although the 
report was available to check the eligibility of this subject for the study the images were not 
accessible for subsequent radiological review on completion of the study.  
 
Three subjects did not attend the final post-treatment visit (V5) and therefore V5 LCQ scores 
were not available for these subjects. 
 
In terms of sputum samples for differential cell count; 7 subjects produced pre-treatment 
samples that were uncountable and 1 subject was unable to tolerate sputum induction. Post 
treatment samples were missing for 13 subjects; 8 of whom did not produce adequate 
samples post treatment; 3 produced samples that were uncountable; 1 could not tolerate 
sputum induction and 1 sputum induction had to be stopped for safety reasons. Three 
values for V4 subjective sputum colour were missing as these subjects were no longer 
producing sputum. Eight values for V4 objective sputum colour were missing as subjects did 
not produce sputum samples. Eight values for V5 subjective sputum colour were missing as 
these subjects were no longer producing sputum.  
 
3.3.4 Primary outcomes 
3.3.4.1 Baseline features of cohort 
The baseline demographics and clinical features of the 30 participants in the study are 
shown in Table 3.2. The age distribution of the cohort is shown in Table 3.3. Overall there 
was a slight female preponderance and a large majority of the subjects were Caucasian. The 
age of the cohort ranged considerably from 25-77 years with a mean age of 57.3 years. Most 
of the cohort were overweight or obese with a median BMI of 29.9. Twelve subjects (40%) 
were ex-smokers (all of whom had not smoked for the preceding 10 years as stated in the 
inclusion criteria) and the mean pack year history was 6.8 pack years (SD 3.7 pack years, 
range 0.15-15 pack years). Seventeen of the 30 subjects had a diagnosis of asthma of whom 
all were taking ICS. 
 
Histopathological examination of bronchial biopsies obtained from 17 of the 30 subjects 
revealed changes of chronic airway inflammation in 15 out of 17 of the subjects (Figs 3.3-
3.6; Table 3.4). Inflammatory infiltrates were lymphocytic or plasmocytic in nature with no 
eosinophils seen and the severity of inflammation ranged from mild to severe. Basement 
membrane thickening was noted in 9/17 subjects but this did not correlate with asthma 
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status. Both subjects with no airway inflammation did not respond to azithromycin and the 
other 4 non-responders had changes consistent with mild airway inflammation only. In 
contrast the severity of airway inflammation in responders (n=10) varied from mild (n=5) to 
moderate (n=3) to severe (n=2), suggesting that the greater the burden of inflammatory 
changes, the more likely the response to azithromycin. The presence of moderate or severe 
airway inflammation had a reasonable sensitivity (0.7) and very high specificity (1.0) to 
predict response to azithromycin (Table 3.5). 
 
The three most frequently identified abnormalities in the HRCT scans of 29 of the study 
subjects were; 1) airway dilatation graded 0=none (n=8), 1=mild dilatation (n=16) and 
2=minor/borderline radiological bronchiectasis (n=5), 2) bronchial wall thickening graded 
0=none (n=16), 1=some (n=11) and 2=prominent (n=2) and 3) atelectasis graded 0=none 
(n=9), 1=< 3 areas (n=11), 2=>3 areas (n=8) and 3=large bands (n=1). Airway dilatation 
(grade 1 or 2) had a good sensitivity (0.86) to predict azithromycin treatment response, but 
only a moderate specificity (0.56) whilst bronchial wall thickening (grade 1 or 2) had a low 
sensitivity and specificity (Table 3.6).  Atelectasis had a reasonable sensitivity (0.62) for 
treatment response but no specificity. The other radiological features assessed (mosaic 
perfusion, lymphadenopathy, pleural thickening, patulous oesophagus, collapsible airways, 
endobronchial mucus, ground glass changes and tree in bud changes) were each present in 
only a few subjects and therefore sensitivity analysis was not performed (See Appendix H 
for data). 
 
3.3.4.2 Effect of 12 weeks azithromycin treatment on LCQ score 
Treatment with 12 weeks of azithromycin resulted in a significant overall improvement in 
the primary outcome measure of LCQ score (pre-treatment median 11.5 vs post-treatment 
median 17.8 p<0.00001) (Table 3.7). Twenty-two out of 29 subjects (76%) demonstrated a 
significant increase in LCQ score above the MCID of 1.3 points. 
 
This improvement was largely sustained at 4 weeks post-treatment, with a follow-up 
median LCQ score of 15.9 (p=0.0006) (Table 3.7). Seventeen out of 26 (65%) subjects still 
reported LCQ scores greater than the MCID above baseline. However, 4 subjects (15%) did 
report worsening of their symptoms following the end of the azithromycin treatment course 
with visit 5 LCQ scores that were within the MCID from baseline or lower than the baseline 
LCQ score. 
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 Frequency Percentage  
Total number included for analysis 30   
Mean age (range) 
57.3  
(25-77) 
  
Sex: male 13 43.3  
Ethnic group: 
Black Or Black British 
White Or White British 
 
1 
29 
 
3.3 
96.7 
 
Smoking history: 
Ex-smokers 
Non smokers 
 
12 
18 
 
40 
60 
 
Diagnosis of asthma 17 56.7  
On inhaled steroid treatment 17 56.7  
History/symptoms of GO reflux 6 20  
History/symptoms of PNDS 6 20  
 Mean 
Standard 
deviation 
Range 
ICS dose (BDP equivalent µg)* 800 1000 0-4000 
FEV1 % predicted 96.4 22.0 49-131 
FEV1/FVC ratio % 76 8.5 60-90 
 Median 
Interquartile 
range 
Range 
Baseline (V1) sputum % neutrophils 65.6 41.3 4.5-99.25 
Baseline (V1) median sputum % 
eosinophils 
0.68 1.5 0-58 
LCQ score 11.5 3.0 7.8-18.2 
FENO (ppb) 19 20.5 0.5-52.5 
Sputum volume (ml) 8.1 5.5 3-31.1 
*Figures shown are median and interquartile range 
Table 3.2: Demographics of all study subjects 
 
Age group Frequency Percentage 
20-30 2 6.7 
30-40 3 10 
40-50 4 13.3 
50-60 7 23.3 
60-70 9 30 
70-80 5 16.7 
Total 30 100 
Table 3.3: Age distribution of study population  
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Figure 3.3: Representative image of bronchial biopsy from study 
patient AZCC06 (non-responder) showing no inflammation 
(Hematoxylin and eosin (H&E) stain, original magnification x200)  
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Figure 3.4: Representative image of bronchial biopsy from study 
patient AZCC21 (non-responder) showing mild inflammation with a 
lymphocytic infiltrate (H&E stain, original magnification x200)  
 
188 
 
 
Figure 3.5: Representative image of bronchial biopsy from study 
patient AZCC10 (responder) showing moderate inflammation with a 
lymphocytic infiltrate (H&E stain, original magnification x200)  
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Figure 3.6: Representative image of bronchial biopsy from study 
patient AZCC03 showing severe inflammation with a lymphocytic 
infiltrate with prominent neutrophils  and slight thickening of the 
basement membrane (H&E stain, original magnification x200)  
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Table 3.4: Histological features of bronchial biopsy samples  
 
Table 3.5: Predictive values of moderate to severe airway 
inflammation on bronchial biopsy for azithromycin treatment 
response 
 
Table 3.6: Predictive value of HRCT abnormalities for azithromycin 
treatment response 
 
 
Study 
No Inflammation 
Inflammatory 
infiltrate 
Basement 
membrane 
thickening 
Other 
features Asthma Response 
AZCC01 Y Mild chronic  Lymphocytic + N Y Y 
AZCC03 Y Severe chronic 
Plasmocytic/ 
lymphocytic  + N N 
dropped 
out 
AZCC04 Y Severe chronic 
Plasmocytic 
/lymphocytic  Normal 
Squamous 
metaplasia N Y 
AZCC06 N NA + N Y N 
AZCC07 Y Mild chronic  Lymphocytic Normal 
Slightly 
oedematous Y Y 
AZCC10 Y Mod chronic Lymphocytic ++ N Y Y 
AZCC12 Y Mild chronic  Lymphocytic Normal N Y N 
AZCC14 Y Very Mild 
N ?artefact of 
biopsy Normal N Y Y 
AZCC15 Y Mild chronic  Lymphocytic Normal N Y Y 
AZCC16 Y Severe chronic Plasmocytic ++ N N Y 
AZCC18 Y Mild chronic  Lymphocytic + N Y N 
AZCC21 Y Mild chronic  Lymphocytic Normal N N N 
AZCC22 Y Mild chronic  Lymphocytic + N N N 
AZCC23 Y Mod chronic 
Plasmocytic/ 
lymphocytic  + N Y Y 
AZCC24 N NA + N Y N 
AZCC25 Y Mild chronic  N Normal N N Y 
AZCC26 Y Mod chronic Lymphocytic Normal N N Y 
Feature Sensitivity Specificity PPV NPV 
Moderate to severe 
airway inflammation 
0.7 1.0 1.0 0.67 
Feature Sensitivity Specificity PPV NPV 
Airway 
dilatation 
0.86 0.57 0.86 0.57 
Bronchial wall 
thickening 
0.33 0.14 0.54 0.07 
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Figures shown are Median (IQR) except FEV1† which is Mean (SD) 
 
Table 3.7: Changes in primary and secondary outcome measures for 
whole cohort (n=29) with azithromycin treatment 
 
 
 
 V1  
(n=) 
V4  
(n=) 
V1-V4 
difference (p=) 
V5  
(n=) 
V1-V5 
difference (p=) 
V4-V5 
difference 
(p=) 
Subjective sputum colour: 
1  
(non-purulent) 
4 4 0.44 5 0.76 0.33 
2 7 8 3 
3 13 11 9 
4 3 2 3 
5  
(purulent) 
3 4 1 
Objective sputum colour: 
1  
(non-purulent) 
6 9 0.003*  
 
  
2 6 7  
3 9 3  
4 5 2  
5  
(purulent) 
3 0  
Table 3.8: Changes in subjective and objective sputum colour for 
whole cohort (n=29) with azithromycin treatment 
 V1 V4 V1-V4 
difference 
Significance 
(p=) 
V5 V1-V5 
difference 
Significance 
(p=) 
LCQ 
score  
11.5 
(3) 
17.8 
(5.9) 
6.3 <0.00001* 15.9 
(8.3) 
4.4 0.0006* 
24 hour 
sputum 
volume 
(ml) 
7.9 
(5.5) 
2.1 
(7.2) 
-5.8 0.0001*    
FENO 
level 
(ppb) 
19 
(19.5) 
12.5 
(12) 
-6.5 0.14    
FEV1 (l) † 2.77 
(0.99) 
2.75 
(1.0) 
-0.02 0.78    
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3.3.5 Secondary Outcomes:  
3.3.5.1 Effect of treatment on other outcome measures 
Treatment with 12 weeks of azithromycin also resulted in significant improvements in the 
secondary outcome measures of 24 h sputum volume (pre-treatment median 7.9 mL vs 
post-treatment median 2.1 mL, p=0.0003) (Table 3.7) and objective sputum colour (p=0.003) 
post-treatment (Table 3.8).  
 
There were no statistically significant differences in FEV1, FENO or subjective sputum colour 
score (Tables 3.7 & 3.8). Ten subjects produced paired pre and post treatment sputum 
samples. There was a significant decrease in the sputum differential neutrophil count (pre-
treatment median 86.1% vs post-treatment median 69.4%, p=0.049) but no significant 
change in the sputum differential eosinophil count (Table 3.9). 
 
Adequate sputum samples for cytokine analysis were obtained from 28 subjects at visit 1 
and 15 of these subjects also produced adequate samples for analysis at visit 4. In these 15 
subjects there was no significant difference in the sputum concentration of IL-17, TNF-α or 
IL-8 after azithromycin treatment, although sputum IL-1β concentration decreased 
significantly (p=0.02) following azithromycin treatment (Table 3.10).  
 
Table 3.9: Changes in sputum differential neutrophil and eosinophil 
counts in subjects with pre and post treatment sputum samples 
(n=10) 
 
 
Cytokine Median 
concentration pre – 
treatment pg/ml (IQR) 
Median 
concentration post 
treatment pg/ml (IQR) 
Difference 
in median 
p value 
IL-17 15.2 (6.4) 11.8 (5.7) -3.4 0.82 
TNF-α 52.2 (38.7) 38.3 (18) -13.9 0.33 
IL-8 14146.1 (3904.3) 14324 (5326.3) 177.9 0.46 
IL-1β* 943.8 372.4 -571.4 0.02 
Table 3.10:   Sputum concentrations of measured cytokines pre and 
post azithromycin treatment (v1 n=28, v4 n=15) *Data presented for 
IL-1β are geometric means as variable logarithmically transformed 
to normality 
 V1 V4 V1-V4 difference Significance 
(p=) 
% Sputum differential 
neutrophil count (IQR)  
86.1 
(33.5) 
69.4 
(18.6) 
-16.7 0.049 
% Sputum differential 
eosinophil count (IQR)   
0.75  
(1.5) 
0.5 
(7) 
-0.25 0.64 
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3.3.5.2 Responders vs non-responders 
Table 3.11 shows the demographic information and clinical features of the subjects who 
responded to azithromycin and those who did not. The demographics of the group who 
responded to azithromycin (n=22) and those who did not respond (n=7) were compared. 
There were no significant differences in the composition of these groups in terms of age, 
gender, ethnicity, smoking status or diagnoses of asthma, PNDS or GORD. The majority of 
the responder group had underlying neutrophilic inflammation (63.6%) in sputum or BAL 
whereas most of the non-response group had underlying eosinophilic inflammation (71.4%). 
The responder group also had significantly higher FEV1 values and FEV1/FVC ratios than the 
non-responder group. 
 
When considered separately the difference between the pre and post treatment median 
LCQ score in the response group was 7 (p<0.0001) (Table 3.12). Significant improvements 
were also seen in median 24 h sputum volume (pre-treatment 6.9 mL vs post-treatment 2.0 
mL p<0.0001), subjective sputum colour between V1 and V5 (p=0.01) and objective sputum 
colour (p=0.001) (Tables 3.12 & 3.13). There was also a significant decrease in median FENO 
level (pre-treatment 18 ppb vs post-treatment 12 ppb p=0.009) (Table 3.12). There were no 
significant changes in any of these measures for the non-response group, except for the 
subjective sputum colour becoming more purulent between V1 and V5 (p=0.02) (Tables 3.14 
& 3.15). 
 
3.3.5.3 Sub-group analysis based on asthma diagnosis  
The demographics of the groups categorised as having a diagnosis of asthma or not having 
asthma were also compared (Table 3.16). There were no statistically significant differences 
in the composition of these groups and no significant differences in their average 
spirometric values.  
 
Seventeen subjects (57%) had a diagnosis of asthma. Twelve of these (71%) showed 
improvements in LCQ score above the MCID following 12 weeks of azithromycin treatment 
and the median LCQ score improved from 12 to 16.5 following treatment (p=0.008) (Table 
3.17). The median 24 h sputum volume also significantly decreased from 9.5 mL to 2.1 mL 
(p=0.005) and objective sputum colour improved significantly (p=0.02) (Tables 3.17 & 3.18). 
No significant changes were noted in FEV1, FENO or subjective sputum colour (Tables 3.17 & 
3.18). 
 
Of the 12 subjects without an asthma diagnosis, 10 (83%) had a significant improvement in 
LCQ score and the median LCQ score improved from 11.4 to 18.8 (p=0.002) (Table 3.19). The 
median 24 h sputum volume significantly decreased from 6.8 mL to 0 mL (p=0.02) and there 
were significant changes in subjective sputum colour between visits 1 and 5 (p=0.05), 
although not between visits 1 and 4 (Tables 3.19 & 3.20). Objective sputum colour also 
improved significantly between visits 1 and 4 (p=0.05) (Table 3.20). There were no 
significant changes in FEV1 or FENO (Table 3.19). 
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*Figures shown are median and IQR 
 
Table 3.11: Demographics of azithromycin responders vs non-
responders 
 
 
 
 
 
 
Responders Non 
responders 
 
 Frequency 
(%) 
(except a) 
Frequency (%) 
(except a) 
Significance 
(p=) 
Total number included for 
analysis 
22 7  
Mean age (range) 55.5 (25-77) 63.9 (55-70) 0.20 
Sex: male 7 (31.8) 5 (71.4) 0.09 
Ethnic group: 
Black Or Black British 
White Or White British 
 
1 (4.6) 
21 (95.4) 
 
0 (0) 
7 (100) 
 
 
1.0 
Smoking history:  
Ex-smokers 
Non smokers 
 
7 (31.8) 
15 (68.2) 
 
4 (57.1) 
3 (42.9) 
 
 
0.38 
Diagnosis of asthma  11 (50) 6 (85.7) 0.19 
On inhaled steroid treatment 11 (50) 6 (85.7) 0.19 
History/symptoms of GO 
reflux  
4 (18.2) 1 (14.3) 1.0 
History/symptoms of PNDS  4 (18.2) 2 (28.6) 0.61 
Sputum/bronch 
inflammatory type 
   
Neutrophilic (>61%) 14 (63.6) 1 (14.3)  
 
 
<0.001 
Eosinophilic (>3%) 0 (0) 5 (71.4) 
Paucigranulocytic 5 (22.7) 1 (14.3) 
Missing sample 3 (13.6) 0 (0) 
 Mean (SD) Mean (SD) Range 
ICS dose (BDP equivalent 
µg)* 
800 (800) 900 (800) 0.12 
FEV1 % predicted  103.6 (18.8) 73.6 (17.3) 0.0009 
FEV1/FVC ratio %  78.4 (7) 67.6 (8) 0.0019 
Baseline (V1) sputum % 
neutrophils 
73.2 (21.9) 46.8 (34.2) 0.06 
Baseline (V1) sputum % 
eosinophils 
0.5 (0.75) 13.7 (24.8) 0.03 
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Figures shown are Median (IQR) except FEV1† which is Mean (SD) 
 
Table 3.12: Changes in primary and secondary outcome measures for 
azithromycin responders (n=22) with azithromycin treatment  
 
 
 V1  
(n=) 
V4  
(n=) 
V1-V4 
difference (p=) 
V5  
(n=) 
V1-V5 
difference (p=) 
V4-V5 
difference (p=) 
Subjective sputum colour: 
1  
(non-purulent) 
1 4 0.09 5 0.01* 0.59 
2 6 6 2 
3 10 8 7 
4 3 1 0 
5  
(purulent) 
2 0 0 
Objective sputum colour: 
1  
(non-purulent) 
3 6 0.001*  
 
  
2 6 6  
3 5 2  
4 5 0  
5  
(purulent) 
3 0  
Table 3.13: Changes in subjective and objective sputum colour for 
azithromycin responders (n=22) with azithromycin treatment  
 
 
 
 V1 V4 V1-V4 
difference 
Significance 
(p=) 
V5 V1-V5 
difference 
Significance 
(p=) 
LCQ 
score  
11.5 
(2.9) 
18.5 
(3.2) 
7.0 <0.0001* 19.2 
(6.3) 
7.7 0.0003* 
24 hour 
sputum 
volume 
(ml) 
6.9 
(4.9) 
2.0 
(3.5) 
-4.9 <0.0001*    
FENO 
level 
(ppb) 
18 
(17) 
12 (9) -6 0.009*    
FEV1 (l) † 2.91 
(0.98) 
2.96 
(1.0) 
0.05 0.23    
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Figures shown are Median (IQR) except FEV1† which is Mean (SD) 
 
Table 3.14: Changes in primary and secondary outcome measures for 
azithromycin non-responders (n=7) with azithromycin treatment 
 
 
 
 V1  
(n=) 
V4  
(n=) 
V1-V4 
difference (p=) 
V5  
(n=) 
V1-V5 
difference (p=) 
V4-V5 
difference (p=) 
Subjective sputum colour: 
1  
(non-purulent) 
3 1 0.16 0 0.02 0.03 
2 1 2 1 
3 3 3 2 
4 0 1 3 
5  
(purulent) 
0 0 1 
Objective sputum colour: 
1  
(non-purulent) 
3 3 0.56  
 
  
2 0 1  
3 4 1  
4 0 2  
5  
(purulent) 
0 0  
Table 3.15: Changes in subjective and objective sputum colour for 
azithromycin non-responders (n=7) with azithromycin treatment 
 
 V1 V4 V1-V4 
difference 
Significance 
(p=) 
V5 V1-V5 
difference 
Significance 
(p=) 
LCQ 
score  
12.0 
(4.0) 
10.8 
(4.2) 
-1.2 0.5 11.1 
(2.7) 
-0.9 0.45 
24 hour 
sputum 
volume 
(ml) 
11.5 
(5.9) 
13.5 
(8.3) 
2 0.61    
FENO 
level 
(ppb) 
19 
(37.5) 
35.5 
(70) 
16.5 0.13    
FEV1 (l) † 2.31 
(0.94) 
2.09 
(0.93) 
0.23 0.23    
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Asthma Non asthma  
 Frequency 
(%) 
(except a) 
Frequency (%) 
(except a) 
Significance 
(p=) 
Total number included for 
analysis 
17 13  
Mean age (range) 55 (25-75) 59 (30-77) 0.45 
Sex: male 6 (35.3) 7 (53.9) 0.43 
Ethnic group: 
Black Or Black British 
White Or White British 
 
0 (0) 
17 (100) 
 
1 (7.7) 
12 (92.3) 
 
 
0.41 
Smoking history:  
Ex-smokers 
Non smokers 
 
5 (29.4) 
12 (70.6) 
 
7 (53.9) 
6 (46.1) 
 
 
0.26 
On inhaled steroid treatment 17 (100) 0 (0)  
History/symptoms of GO 
reflux  
2 (11.8) 4 (30.8) 0.62 
History/symptoms of PNDS  3 (17.7) 3 (23.1) 0.67 
Sputum/bronch 
inflammatory type 
   
Neutrophilic (>61%) 9 6  
 
 
0.11 
Eosinophilic (>3%) 5 0 
Paucigranulocytic 2 4 
Missing sample 1 2 
 Median (IQR) Median (IQR)  
ICS dose (BDP equivalent 
µg) 
800 (200) 0 (0)  
FEV1 % predicted  89 (36) 100.5 (24) 0.71 
FEV1/FVC ratio %*  76 (10.1) 76.1 (6.2) 0.86 
*Figures shown are mean and standard deviation 
 
Table 3.16: Demographics of sub-group with asthma diagnosis vs 
those without asthma diagnosis 
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Figures shown are Median (IQR) except FEV1† which is Mean (SD) 
 
Table 3.17: Changes in primary and secondary outcome measures for 
subjects with a diagnosis of asthma (n=17) with azithromycin 
treatment 
 
 
 V1  
(n=) 
V4  
(n=) 
V1-V4 
difference (p=) 
V5  
(n=) 
V1-V5 
difference (p=) 
V4-V5 
difference (p=) 
Subjective sputum colour: 
1  
(non-purulent) 
2 3 0.69 3 0.23 0.12 
2 5 5 0 
3 8 6 6 
4 2 2 3 
5  
(purulent) 
0 0 1 
Objective sputum colour: 
1  
(non-purulent) 
4 8 0.02  
 
  
2 2 3  
3 7 2  
4 2 2  
5  
(purulent) 
2 0  
Table 3.18: Changes in subjective and objective sputum colour for 
subjects with a diagnosis of asthma (n=17) with azithromycin 
treatment 
 V1 V4 V1-V4 
difference 
Significance 
(p=) 
V5 V1-V5 
difference 
Significance 
(p=) 
LCQ 
score  
12 
(3.8) 
16.5 
(4.8) 
4.5 0.008 13.6 
(5.7) 
1.6 0.09 
24 hour 
sputum 
volume 
(ml) 
9.5 
(7.0) 
3.5 
(8.3) 
6.0 0.002    
FENO 
level 
(ppb) 
19 
(17) 
12 
(11.5) 
7 0.36    
FEV1 (l) † 2.67 
(0.96) 
2.59 
(1.02) 
-0.08 0.37    
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Figures shown are Median (IQR) except FEV1† which is Mean (SD) 
 
Table 3.19: Changes in primary and secondary outcome measures for 
subjects without a diagnosis of asthma (n=12) with azithromycin 
treatment 
 
 
 V1  
(n=) 
V4  
(n=) 
V1-V4 
difference (p=) 
V5  
(n=) 
V1-V5 
difference (p=) 
V4-V5 
difference (p=) 
Subjective sputum colour: 
1  
(non-purulent) 
2 2 0.45 2 0.05 0.47 
2 2 3 3 
3 5 5 3 
4 1 0 0 
5  
(purulent) 
2 0 0 
Objective sputum colour: 
1  
(non-purulent) 
2 1 0.05  
 
  
2 4 4  
3 2 1  
4 3 0  
5  
(purulent) 
1 0  
Table 3.20: Changes in subjective and objective sputum colour for 
subjects without a diagnosis of asthma (n=12) with azithromycin 
treatment 
 V1 V4 V1-V4 
difference 
Significance 
(p=) 
V5 V1-V5 
difference 
Significance 
(p=) 
LCQ 
score  
11.4 
(2.2) 
18.8 
(3.0) 
7.4 0.002 19.7 
(4.9) 
8.3 0.005 
24 hour 
sputum 
volume 
(ml) 
6.8 
(4.3) 
1.05 
(5.25) 
-5.75 0.01    
FENO 
level 
(ppb) 
15.25 
(17.25
) 
13.5 
(11.25) 
-1.75 0.48    
FEV1 (l) † 2.90 
(1.06) 
2.98 
(1.07) 
0.08 0.28    
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3.4 Discussion 
 
The results of this study support previous observations that there is a cohort of patients 
with chronic productive cough of unknown cause whose symptoms frequently respond well 
to prolonged low dose azithromycin treatment (560). There was a marked improvement in 
the primary outcome of LCQ score, a subjective measure of cough-related quality of life, as 
well as significant improvements in the objective secondary outcome measures of 24 h 
sputum volume and sputum colour as assessed objectively. 
 
3.4.1 Primary Outcome: Description of cohort 
Although some further work needs to be done to carefully delineate the underlying 
pathophysiology in this cohort of subjects several key features of this previously 
undescribed phenotype of airways disease have been recognised. 
 
Firstly, although the overall number of subjects (n=30) recruited to the study in a 24 month 
period seems relatively few, which would suggest a low incidence of subjects with this 
phenotypic characteristic, the number of subjects screened who met the entrance criteria 
for this study was much higher. The majority of screen positive subjects could not be 
included in the study as they were already being treated with prolonged low-dose 
azithromycin, suggesting recognition of this patient group and the response of their 
symptoms to azithromycin may already be widespread amongst consultant respiratory 
physicians in the respiratory clinic. 
 
Secondly, the symptoms experienced by this cohort do not appear to be related to some of 
the most frequent recognised causes of chronic cough. Only 6 subjects (20%) had a 
diagnosis of GORD and/or were receiving treatment for the condition but none described 
active symptoms. Entirely eliminating clinically silent reflux as a cause of these symptoms 
would be very challenging, but the diagnosis of GORD alone as an explanation of these 
symptoms seems insufficient given the significant symptom burden displayed by most of 
these patients. Similarly, only 6 subjects (20%) had the clinical features or diagnosis of post 
nasal drip syndrome (PNDS), and none of these had responded symptomatically to a lengthy 
period of conventional treatment for this condition. Equally, these subjects’ symptoms are 
unlikely to be due to chronic bronchitis secondary to cigarette smoking or other noxious 
stimuli. None of the patients described in the study had smoked in the last 10 years, and all 
of them had total smoking pack year histories of less than 20 pack years. None of the study 
subjects had a significantly raised ECO on entering the study, which would be consistent 
with a non-smoking population.   
 
The relationship between asthma and this cohort of patients is harder to discern. The 
majority of patients (n=17, 56.7%) had an asthma diagnosis, but this was usually a historic 
diagnosis on the basis of symptoms with little or no supporting objective evidence. Ten 
(33%) patients had evidence of airways obstruction (9 of whom had diagnoses of asthma) 
and 4 of these (40%) had evidence of ongoing eosinophilic inflammation. These 4 patients 
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seemed to fit more suitably into a ‘classical’ eosinophilic asthma phenotype than the rest of 
the cohort, and their productive cough was likely secondary to ongoing airway eosinophilia 
and chronic mucus hypersecretion, which have previously been described as features of 
uncontrolled severe asthma (621).  
 
Unfortunately as the study did not include measures of reversibility or AHR further 
supporting or opposing objective evidence of asthma in this cohort was not available. A 
significant proportion of this cohort did not have an asthma diagnosis and it is clear that the 
prominent symptom in all of these subjects was cough, with very few describing other 
symptoms of airways disease such as significant dyspnoea, wheeze or episodes of asthma 
exacerbation. It is possible therefore that some of the cases in the described cohort may 
represent neutrophilic asthma. It is also possible that some of the subjects may have 
originally had eosinophilic asthma with suppressed eosinophilic inflammation due to ICS 
treatment and these subjects are now displaying neutrophilic inflammation as a result of 
other factors, for example, bacterial airway colonisation. However, this does not explain the 
significant proportion of subjects with no clinical features of asthma who were not taking 
ICS treatment and had ongoing neutrophilic inflammation. 
  
The two most frequent radiological features of disease noted in this cohort were airway 
dilatation and bronchial wall thickening. A small proportion of the cohort (n=5) exhibited a 
minor degree of bronchiectasis on detailed review of their HRCT scans but with a disparity 
between their low burden of disease and prominent symptoms. Airway dilatation was a 
sensitive but non-specific predictor of azithromycin treatment response. Bronchial wall 
thickening is a common radiological feature of airways disease especially recognised in 
subjects with neutrophilic asthma (758) but this was not sensitive or specific at predicting 
treatment response.  
 
The changes of airway dilatation, in combination with histological changes of chronic 
inflammation and cytokine profiling demonstrating high levels of Th1 and Th17 cytokines 
would all be compatible with a diagnosis of bronchiectasis. This cohort may represent 
subjects with “pre” - bronchiectasis, who have sustained an initial airway insult and have 
features of persisting neutrophilic inflammation and excessive airway secretions, but whose 
disease has not yet progressed to macroscopic airway destruction.  
 
3.4.2 Primary Outcome: Effect of 12 weeks azithromycin treatment on LCQ score 
LCQ improved significantly with azithromycin treatment in this group of patients. LCQ was 
selected as the primary outcome measure as this is a well validated quality of life measure 
relating to cough. The LCQ has been validated in separate distinct conditions such as 
bronchiectasis (759), but the symptoms in this cohort would seem to be sufficiently similar 
for this measure to retain validity. This measure was chosen as azithromycin has previously 
been demonstrated to improve symptom or quality of life scores in studies of subjects with 
neutrophilic asthma, COPD and bronchiectasis (615, 722, 760). The outcome of disease 
exacerbation rate, which has also been demonstrated to improve with azithromycin 
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treatment (723-725) was not suitable to use in this study as most subjects reported a 
constant level of symptomatology rather than ‘exacerbations’ of disease activity.  
 
3.4.3 Secondary Outcome: Effect of azithromycin on clinical measures/biomarkers 
Evidence of an objective response to azithromycin treatment was observed with a reduction 
in sputum amount and purulence. As expected, azithromycin treatment did not result in any 
improvement in lung function, a finding consistent with multiple previous RCTs 
demonstrating no significant change in lung function with azithromycin treatment (719, 723, 
725, 728, 730). There was also no significant change in FENO level. 
 
Ten subjects produced paired pre and post treatment sputum samples. There was a 
significant decrease in the sputum differential neutrophil count (pre-treatment median 
86.1% vs post-treatment median 69.4%, p=0.049) but no significant change in the sputum 
differential eosinophil count. This suggests azithromycin treatment may lead to 
symptomatic improvement by decreasing levels of neutrophilic inflammation. This finding is 
consistent with previous studies showing significant decreases in neutrophilic airway 
inflammation with azithromycin treatment (671, 672, 760).  
 
Levels of IL-8, IL-1β, IL-17A and TNFα were assessed in sputum and bronchial wash samples 
as increased levels of these cytokines have previously been noted in neutrophilic airways 
disease (674, 761). In comparison with previous investigations that utilised the same 
multiplex immunoassay system to quantify sputum cytokine levels in patients with asthma 
and COPD, the sputum concentrations of IL-8, IL-1β, IL-17 and TNFα were generally found to 
be much higher in our patients (762, 763). The sputum concentrations of IL-8 and TNFα 
were comparable to those detected in sputa from subjects with bronchiectasis using ELISA 
(764). IL-1β is a potent pro-inflammatory cytokine found at high levels in the sputum and 
lung tissue of COPD patients (765) and sputum in more severe phenotypes of bronchiectasis 
(766). Expression of IL-1β is induced by transcription factor NF-κB which is released by 
innate immune cells after exposure to alarmins (endogenous molecules released by tissue 
damage which cause activation of the immune system) (767) and high IL-1β levels have 
been demonstrated to induce pulmonary neutrophil airway inflammation and airway 
damage in mice (674). Sputum levels of IL-1β decreased significantly with azithromycin 
treatment which is consistent with findings from previous studies (673, 768) and may 
suggest a mechanism for decreased neutrophilic inflammation.  
 
3.4.4 Responders vs non-responders 
The improvement in LCQ was significant across the cohort as a whole, but separate 
consideration of azithromycin responders and non-responders revealed that none of the 
subjects with underlying eosinophilic airway inflammation (n=5) responded symptomatically 
to azithromycin. This is consistent with previous RCT data demonstrating no significant 
treatment response to azithromycin in subjects with asthma, a significant proportion of 
whom would be expected to have underlying eosinophilic airway inflammation (636, 742, 
744). However, one previous study (769) investigating clarithromycin treatment in asthmatic 
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subjects reported an improvement in symptoms, AHR and sputum eosinophilia after 8 
weeks of clarithromycin treatment, although the number of subjects was small (n=17).  
 
The response of subjects with neutrophilic airways inflammation to azithromycin is 
consistent with the clinical improvement seen in other cohorts of patients with proven 
sputum neutrophilia (760, 770) or likely neutrophilic predominant airway disease such as 
bronchiectasis and COPD (615, 723-725). When considered separately from the neutrophilic 
subgroup the improvement seen in the paucigranulocytic group is less marked, with a lesser 
degree of improvement in LCQ score and no improvement in any other variable. The reason 
for this improvement in LCQ score with azithromycin in the paucigranulocytic group is less 
clear. Potential mechanisms for this observed improvement include immunomodulatory or 
antibiotic effects of azithromycin as well as the possibility of a placebo response. 
 
Recognition of the heterogeneity and complexity of airways disease has led to proposals for 
a different system of classifying disease, based not on archetypal disease labels but on the 
recognition of phenotypic or biological markers of disease (so-called ‘treatable traits’) that 
enable targeted treatment (160). The results of this study, irrespective of the exact 
underlying airway pathology in this cohort, indicate that the symptom of chronic productive 
cough, especially when combined with evidence of ongoing neutrophilic airway 
inflammation, may represent a trait which could in future be used to target prolonged 
macrolide therapy.  
 
3.4.5 Study limitations 
The main limitations of this study include its relatively small size and the lack of a placebo 
group.  
 
A significant number of subjects who were eligible according to our criteria were already 
using low dose azithromycin (Figure 3.2) and hence were not suitable for the trial. As 
suggested above this means the prevalence of individuals with this phenotype is much 
higher than the study suggests. Although the final number completing the trial was small 
(n=29) the improvement in the primary outcome measure of LCQ was very highly significant 
owing to a large reported improvement in symptoms by the majority of participants.  
 
The true magnitude of this effect is difficult to discern firstly because of the subjective 
nature of the LCQ as an outcome in comparison to objective measures and secondly 
because of the potential of a placebo response in these subjects. However, placebo 
response alone in these subjects is less likely owing to the concurrent improvement noted in 
more objective measures such as 24 hr sputum collection volume and sputum colour (as 
assessed objectively) as well as the significant decreases in the sputum differential 
neutrophil count and sputum IL-1β concentrations.  
 
A placebo controlled arm was not included in the study as the underlying pathophysiology in 
these subjects was still obscure and may have been attributable to an existing disease label 
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that had already been demonstrated to be responsive to azithromycin treatment such as 
bronchiectasis or asthma. On conclusion of the study there is now further evidence to 
suggest these patients may represent a distinct phenotype, or at least exhibit features that 
are not adequately described by an existing disease label.  
 
3.4.6 Further work 
The findings of this study need confirmation via a placebo controlled trial of azithromycin in 
subjects selected using similar eligibility criteria. Further work that would help to establish 
the nature of disease in this cohort of patients would include a longitudinal cohort study of 
such patients to clarify the natural history of disease progression in these subjects. In view 
of the increasing evidence suggesting that disturbances in the airway microbiota (dysbiosis) 
may be associated with neutrophilic airway inflammation further studies assessing the 
airway microbiota of these subjects are also warranted. 
3.5 Conclusion 
This study describes a cohort of patients with chronic productive cough not adequately 
described by existing disease labels whose symptoms responded well to low dose 
azithromycin. Patients who demonstrated the most significant symptomatic response to 
azithromycin primarily had neutrophilic airway inflammation while those with 
paucigranulocytic airway inflammation also improved albeit less markedly. Good predictors 
of treatment response also included moderate to severe inflammatory changes on bronchial 
biopsy and airway dilatation on HRCT scan. Possible mechanisms of response to 
azithromycin include reduction in airway neutrophilia and IL-1β levels. Further studies, 
especially longitudinal studies of this cohort, are required to validate these initial findings 
and determine the prognosis and progression of disease in this patient group.  
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Chapter 4: Microbiota in Asthma 
4.1 Background 
4.1.1 Summary of background (Chapter 1.7) 
Analysis of the human microbiota is a promising and rapidly expanding field. Studies to date 
of the lung microbiota have led to new insights into the pathogenesis and progression of 
lung disease. Generally, findings so far in most respiratory conditions indicate that reducing 
bacterial diversity and dysbiosis of the microbiota with dominance of certain pathogenic 
species correlate with worsening disease severity and outcomes. Studies of the bacterial 
microbiota in asthma have revealed differences in its composition to that of healthy 
controls, suggesting that an increased abundance of potentially pathogenic species such as 
Proteobacteria are associated with asthma, particularly the neutrophilic asthma subgroup, 
and with certain clinical measures.  
 
4.1.2 Rationale for study  
It has not been possible to establish whether the presence of these organisms in the airways 
of asthmatic subjects is due to disease itself, or whether this may represent a treatment 
effect of high dose inhaled steroids. This study aims to examine, in unprecedented detail, 
the effects of ICS dose and type on the microbiota composition in subjects with asthma. 
 
4.1.3 Hypothesis and Aims 
4.1.3.1 Hypothesis 
It is hypothesised that the use of high dose ICS alters the microbiota in asthma, acting as a 
selective pressure that favours the establishment of colonising species of potentially 
pathogenic species such as H. influenzae (See Fig 1.10).  
It is further speculated that the type of ICS used by an individual may have an effect on the 
composition of the airway microbiota in asthma.  
4.1.3.2 Aims 
1) To compare the microbiota composition in sputum samples from subjects with mild (BTS 
Step 2) and moderate/severe asthma (BTS Step 4) 
2) To compare microbiota composition between samples from subjects with asthma using 
the inhaled steroid fluticasone and those using budesonide.  
Other aims of the study include assessment of the reproducibility of the induced sputum 
method for assessing the lung microbiota, assessment of the longitudinal stability of the 
bacterial population and comparison of the bacterial load of two common respiratory 
pathogens (H. influenzae and S. pneumoniae) in the BTS Step 2 and 4 groups.  
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4.2 Methods 
4.2.1 Purpose and Design 
4.2.1.1 Purpose 
1) To determine if there is any relationship between the diversity of the bacterial microbiota 
of the lung (as sampled by induced sputum) and clinical features of asthma and severity 
2) To determine if there is any difference in lung microbiota diversity between patients 
using inhaled fluticasone and those using inhaled budesonide  
3) To assess the reproducibility and stability of the composition of the microbiota in sputum 
samples induced at multiple time points. 
 
4.2.1.2 Study Design 
This was a single centre non-interventional study. 
 
4.2.1.3 Ethical Approval 
This study was approved by the National Research Ethics Committee East Midlands – Derby 
1 (Ref 14/EM/0091) and Nottingham University Hospitals NHS Trust Research and 
Innovation department (Ref 14RM006).  
 
4.2.2 Study Population 
4.2.2.1 Eligibility criteria 
Patients were recruited according to the following eligibility criteria: 
Inclusion criteria 
 Age 18 or above 
 Male or female 
 Diagnosis of asthma (previous physician diagnosis) 
 Non-smokers for 10 years and <10 pack year equivalents in total 
 BTS Step 2 patients must have been using inhaled steroids at a dose of BDP ≤400 
µg/day, FP ≤200 µg/day or BUD ≤400 µg/day for at least 1 year (535) 
 BTS Step 4 patients must have been using inhaled steroids at a dose of FP ≥500 
µg/day or BUD ≥800 µg/day for at least 1 year as a separate steroid or inhaled 
steroid/long acting beta agonist combination (535) 
Exclusion criteria 
 Respiratory infection or antibiotics within last month 
 Pregnancy or intent to become pregnant during course of study 
 Other respiratory diagnosis 
 Post bronchodilator FEV1 of <60% (417) 
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4.2.2.2 Study setting and participant recruitment 
This study was conducted at the Nottingham Respiratory Research Unit (Nottingham City 
Hospital UK). Subjects with asthma were identified from an existing research subject 
database (Ref 09/H0405/27) or prospectively identified from outpatient respiratory clinics 
according to the eligibility criteria. 
Interested subjects were provided with full written information regarding the study and 
given the contact information for the study team (Appendix L). Upon contacting the study 
team by telephone or e-mail they were screened to ensure they met the inclusion and 
exclusion criteria. 
 
4.2.3 Outcome measures 
4.2.3.1 Primary endpoint 
The difference in sputum microbiota diversity/composition and quantitation between the 
BTS Step 2 and BTS Step 4 groups 
4.2.3.2 Secondary endpoints 
The difference in sputum microbiota diversity/composition and quantitation between: 
 The BTS Step 4 group using inhaled fluticasone and the BTS Step 4 group using 
inhaled budesonide 
 Sputum samples taken at baseline and those taken at 24 hours to assess the 
repeatability of the sampling technique 
 Sputum samples taken at baseline and those taken at 14 days to assess the stability 
of the sampled microbiota 
Other planned analyses included: 
 Sputum microbiota diversity/composition and quantitation vs FEV1 
 Sputum microbiota diversity/composition and quantitation vs FENO level 
 Sputum microbiota diversity/composition and quantitation vs PC20 
 Sputum microbiota diversity/composition and quantitation vs LCQ score 
 Sputum microbiota diversity/composition and quantitation vs ACQ score 
 Sputum microbiota diversity/composition and quantitation vs ICS dose (BDP 
equivalent) 
 Abundance of known respiratory pathogens (H. influenzae and S. pneumoniae) in 
BTS Step 2 and BTS Step 4 BUD/FLU groups 
 
4.2.3.3 Sample size calculation 
As published data in this field is so limited, a formal power calculation to determine the 
necessary sample size was not possible. 
Based on the numbers of patients required in previous studies of the human microbiota to 
determine differences between subject groups we specified a target of 50 subjects divided 
into the following groups (Fig 4.1): 
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Figure 4.1: Demonstrating target patient recruitment numbers for 
each subgroup 
Where FP Rx = Fluticasone therapy 
And    BUD Rx = Budesonide therapy 
 
A sub-group of 20 patients who were available for visits 2 and 3 and successfully produced a 
sputum sample at visit 1 were invited to attend two further research visits. We attempted 
to select a sub-group of patients representative of the whole population, but the 
composition of this sub-group was largely determined by the subject availability for further 
visits. 
 
4.2.4 Summary of study protocol 
4.2.4.1 Visit 1 
All patients meeting the entrance criteria for the study were invited to attend the first study 
visit where eligibility was rechecked and written informed consent obtained prior to any 
study-related interventions. The tests performed at visit 1 are listed in Figure 4.2 below: 
4.2.4.2 Visits 2 and 3 
Patients who were able to attend the two optional follow up visits and who successfully 
produced a sputum sample at Visit 1 also attended Visit 2 (within 24 h of Visit 1) and Visit 3 
(within 2 weeks of Visit 1) for further sputum induction. 
 
 
  50 subjects 
20 BTS Step 2 30 BTS Step 4 
15 FP Rx 15 BUD Rx 
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4.2.5 Clinical Measurements 
4.2.5.1 Spirometry  
Performed as described in Section 2.2.5.1 (537). 
4.2.5.2 Methacholine challenge  
Performed as described in Section 2.2.5.5 (434). 
4.2.5.3 Exhaled Nitric Oxide 
Exhaled nitric oxide concentration was measured using an offline electrochemical analyser 
(Bedfont Scientific Ltd, Harrietsham, UK) as described in Section 3.2.5.4.  
4.2.5.4 Leicester Cough Questionnaire 
Performed as described in Section 3.2.5.1 (750). 
4.2.5.5 Juniper Asthma Control Questionnaire 
Performed as described in Section 2.2.5.8 (546). 
4.2.5.6 Sputum Induction 
Sputum induction was performed largely as described in Section 2.2.5.4 (405). However, 
slight alterations to this protocol were introduced to attempt to minimise oropharyngeal 
and environmental bacterial contamination of the samples.  
These alterations consisted of: 
1) Subjects were asked to rinse their mouths with 10 mL of 0.9% saline solution prior to 
nebulisation of saline to minimise oral contamination 
2) Samples were collected into sterile specimen containers rather than standard universal 
collection containers 
Visit 1
FENO, FEV1, BHR, 
ACQ, LCQ, 
Sputum (for 
1,2,3)
Visit 2
Sputum (for 
1,2,3)
Visit 3
Sputum (for 
1,2,3)
Figure 4.2: Demonstrating investigations performed at each study 
visit    
ACQ = asthma control questionnaire, LCQ=Leicester cough questionnaire,                                                                  
FENO = Fractional exhaled nitric oxide level, FEV1 = spirometry, BHR = methacholine 
challenge, Sputum = sputum samples taken for (1) microbiota analysis then (2) for 
differential sputum cell count if sufficient remaining then (3) for microscopy, 
culture and sensitivity count if sufficient remaining 
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4.2.6 Protocol for processing induced sputum samples 
All sputum samples were processed within 2 hours of induction. In summary, the steps 
according to the protocol were: 
1) Isolate a 50 mg sputum plug (saliva free). 
2) Add 4 x 0.1% DTT per mg sputum. 
3) Vortex for 30 s to allow thorough mixing. 
4) Transfer homogenate to a pre-labelled cryovial and store at -80oC for future transfer 
to King’s College London 
5) If there is remaining sputum send ≥50 µL Homogenised Sputum/DTT for 
Microbiology.  
6) If there is any remaining sample perform cell count and cytospin as per Sputum 
processing protocol (Section 2.2.5.4) 
7) If any remaining sample divide into 4 x Equal aliquots of Homogenised Sputum/DTT 
≤500 µL. (Extra equal aliquots can be used for large samples). 
Transfer of samples to King’s College London 
Samples were transported by courier in one batch on dry ice to King’s College London and 
were stored again at -80oC prior to DNA extraction. 
 
4.2.7 DNA extraction 
DNA extraction was conducted using the GenElute™ Bacterial Genomic DNA Kit (Sigma-
Aldrich Co. Ltd., Dorset, UK) according to specific instructions for Gram-positive bacteria, 
with the following modifications. Sputum samples (100 µL) were initially mixed with 
lysozyme (200 µL; 45 mg/mL, Sigma-Aldrich Co. Ltd., Dorset, UK) suspended in Gram-
Positive Lysis Solution (included in the kit), prior to incubation at 37 ⁰C for 30 min (832). Cell 
disruption was then achieved by insertion of tungsten carbide and glass beads (Qiagen, 
Crawley, UK), followed by agitation in a Fastprep-24 Instrument (MP Biomedicals Europe, 
Illkirch, France) at 6.5 m/s for 60 sec (833). Further steps remained unchanged, and the DNA 
was resuspended in 50 µL of Elution Solution (included in the kit). DNA concentrations were 
quantified using the Picodrop Microlitre Spectrophotometer (GRI, Braintree, UK). 
 
4.2.8 Quantitative PCR (qPCR) assays 
4.2.8.1 Total Bacterial Load (TBL) qPCR 
Total bacterial load was estimated by using the SYBR Green dye, using the primers EubF 5’-
TCCTACGGGAGGCAGCAGT-3’ and EubR 5’-GGACTACCAGGGTATCTA ATCCTGTT-3’ (Sigma-
Aldrich Co. Ltd., Dorset, UK) which amplified a 466-bp region between positions 331 to 797 
of the Escherichia coli 16S rRNA gene (834). The assay was performed as described in (835). 
All PCR reactions were carried out in a total volume of 20 μl containing primers at a 
concentration of 500 nM each, 1 μl of template and Rotor-Gene SYBR Green PCR Master 
Mix (Qiagen, Crawley, UK) at 1x final concentration. Quantitative PCR assay was performed 
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using Rotor-Gene Q real-time thermocycler (Qiagen, Crawley, UK) with a temperature 
profile of 95 °C for 5 min, followed by 50 cycles at 95 °C for 15 s and 58 °C for 50 s. Gain 
optimisation was set manually at 5.33 on the green channel (Cycling A. Green). Melt-curve 
analysis was then conducted between 58°C to 99°C with 1 °C steps, to detect non-specific 
amplifications. 
4.2.8.2 H. influenzae (HI) qPCR 
H. influenzae densities were estimated by a TaqMan assay, using the primers HelSF 5’-
CCGGGTGCGGTAGAATTTAATAA-3’, HelSR 5’-CTGATTTTTCAGTGCTGTCTTTGC-3’ (Eurofins 
Genomics, Ebersberg, Germany)  and probe HelSPr 5’-FAM-ACAGCCACAACGGTA 
AAGTGTTCTACG-TAMRA-3’ (Eurofins Genomics, Ebersberg, Germany) which amplify a 90-bp 
region between positions 518 to 608 of the H. influenzae hel gene (836). All PCR reactions 
were carried out in a total volume of 20 μl containing primers and probe at a concentration 
of 500:500:250 nM (HelSF: HelSR; HelSPr), 1 μl of template and LightCycler 480 Probes 
Master (Roche Diagnostics GmbH, Mannheim, Germany) at 1x final concentration. 
Quantitative PCR assays were carried out using the Rotor-Gene Q (Qiagen, Crawley, UK) 
with a temperature profile of 95 °C for 5 min, followed by 45 cycles at 95 °C for 15 s and 60 
°C for 60 s. Gain setting on the green channel was optimized manually to 4.00 for each run. 
4.2.8.3 S. pneumoniae (SPN) qPCR 
The assay was performed using a TaqMan based probe, lytA-CDCPr 5′-FAM-
TGCCGAAAACGCTTGATACAGGGAG- BHQ1-3′ (Eurofins Genomics, Ebersberg, Germany) and 
primers lytA-CDCF 5′-ACGCAATCTAGCAGATGAAGCA-3′, lytA-CDCR 5′-
TCGTGCGTTTTAATTCCAGCT-3′ (Eurofins Genomics, Ebersberg, Germany). A 53-bp region 
was amplified between positions 1840961 to 1841014 of the S. pneumoniae genome 
specifically targeting a region of the lytA gene (837). Primers and probe concentrations were 
optimised to produce an assay with a final 25 µL reaction volume as follows: Primers and 
probe at a concentration of 500:500:250 nM (lytA-CDCF: lytA-CDCR: lytA-CDCPr), 1 µL of 
template and LightCycler 480 Probes Master (Roche Diagnostics GmbH, Mannheim, 
Germany) at 1x final concentration. Quantification of DNA copies was performed using the 
Rotor-Gene Q (Qiagen, Crawley, UK) with a temperature profile of 95 °C for 5 min, followed 
by 45 cycles at 95 °C for 15 s and 60 °C for 60 s. Gain setting on the green channel was set 
manually to 4.00 for each run. 
4.2.9 16S rRNA gene sequencing  
The DNA samples were transported to Public Health England for 16S rRNA gene 
sequencing. The V3-V4 region of the 16S rRNA gene was amplified using a 16S Amplicon 
Forward primer (5’-TCG TCG GCA GCG TCA GAT GTG TAT AAG AGA CAG CCT ACG GGN GGC 
WGC AG-3’) and 16S Amplicon Reverse primer (5’-GTC TCG TGG GCT CGG AGA TGT GTA TAA 
GAG ACA GGA CTA CHV GGG TAT CTA ATC C-3’) (838). Library preparation was carried out 
according to the 16S Metagenomic sequencing library preparation manual (Illumina, USA). 
The size of the library was measured using the Agilent High Sensitivity DNA kit (Agilent, 
Germany) and quantified using ABI Viaa7 and KAPA Library Quantification Kit Illumina® 
platforms (KAPABiosystems). The sequencing was then performed on the MiSeq platform 
(Illumina, USA) using the MiSeq reagent kit V2 (500 cycles) according to the manufacturer’s 
instructions. 
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The raw sequence data obtained from the Illumina MiSeq sequencer were then filtered to 
remove any chimeric sequences from the input sequences, which could present at a low 
level due to premature amplicon termination during the library preparation step. The paired 
end reads were rarefied to 9311 reads followed by analysis based on Operational Taxonomic 
Unit (OTU) approach. This was determined using the QIIME version 1.9.1 pipeline to cluster 
the 16S rRNA gene sequences based on their similarity. Within these data, a total of 
5615037 sequencing reads were clustered into a final 167 OTUs, where OTUs less than 
0.01% relative abundance across all samples sets were discarded. One sample was removed 
from the whole OTU analysis due to low sequence reads (4693 reads).  
 
4.2.10 Analysis 
4.2.10.1 Demographic and clinical measurement data 
Data were exported from the electronic study database to Microsoft Excel for data cleaning. 
Data were then imported into Stata v11.0 (Statacorp, Texas, USA) for statistical analysis. The 
demographics and baseline clinical measures of the cohort were determined. qPCR data was 
analysed using SPSS version 21.0 (IBM Corp, 2012). The 16S rRNA gene sequencing data was 
analysed using the R statistical framework version 2.11 with version 2.0–7 of the R package 
“vegan”. 
4.2.10.2 qPCR and 16S rRNA gene sequencing data 
For qPCR data the mean bacterial load in colony forming units (cfu)/ml were calculated for 
each sample along with the mean loads of H. influenzae and S. pneumoniae. The mean 
overall bacterial loads and loads of H. influenzae and S. pneumoniae of the following groups 
were then compared using either an independent T test or Mann-Whitney U test depending 
on whether data were normally or non-normally distributed: 
1. BTS Step 2 vs BTS Step 4 
2. BTS Step 2 : BUD vs FLU 
3. BTS Step 2 : BUD vs BEC 
4. BTS Step 2 : FLU vs BEC 
5. BTS Step 4 : BUD vs FLU 
6. BUD : BTS 2 vs BTS 4 
7. FLU : BTS 2 vs BTS 4 
8. BUD vs FLU 
 
For the 16S rRNA gene sequencing data OTUs were calculated in cfu/ml by multiplying their 
percentage abundance by the bacterial load from 16S qPCR data. Version 2.0–7 of the R 
package “vegan” was used to generate richness, Shannon’s and Simpson’s diversity indices.  
Richness and Simpson’s indices were compared between the BTS 2 vs BTS 4 groups and the 
BTS 4 FLU vs BTS 4 BUD groups by analysis of variance (ANOVA). As Shannon’s index is not a 
scaled vector a Kruskal-Wallis rank sum test was used to compare between the BTS 2 vs BTS 
4 groups and BTS 4 FLU vs BTS 4 BUD groups.  
 
213 
 
For further analysis of similarity between the microbiota composition of the different 
severity and steroid types the analysis of similarity (ANOSIM) test was used. This is a non-
parametric multidimensional scaling (NMDS) technique that assesses for differences 
between graphical representations of community composition. 
 
Differences in OTU abundance between BTS 2 vs 4 and BTS 4 FLU vs BTS 4 BUD were 
assessed for using a Wilcoxon rank sum test.  
 
For comparison of baseline alpha-diversity indices (richness, Shannon’s and Simpson’s) and 
bacterial load with these measures after 24 hours and then 2 weeks later in the subgroup of 
subjects who had multiple samples taken (n=19) repeated measure ANOVA tests were used. 
In order to assess the test-retest reliability of the total bacterial load as determined by qPCR 
from these 19 subjects after 24 hours and then 2 weeks, the intraclass coefficient for this 
measure was calculated using a two-way mixed effects model. The intraclass coefficient 
measure reflects both the degree of correlation and agreement between measurements. 
 
Finally to investigate the correlation of alpha-diversity indices (richness, Shannon’s and 
Simpson’s) and microbiota composition (plotting NMDS axis 1) with clinical measurements 
(FEV1 % predicted, FENO, PC20, LCQ, ACQ or ICS dose) Spearman’s rank correlation 
coefficients were calculated. 
 
4.3 Results 
4.3.1 Recruitment 
One hundred and five subjects were identified on the research database who met the 
eligibility criteria for the study. They were all contacted between May 2014 and May 2015 
by post, e-mail or telephone regarding taking part in the study.  Of these 72 patients agreed 
to participate in the study. 
4.3.2 Losses and exclusions 
Whilst there were no losses or exclusions for this study per se, 18 participants were unable 
to produce an adequate sputum sample for analysis, and hence their demographic and 
clinical data will not be used in the final analysis (See Fig 4.3). 
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Assessed for eligibility (n=110) 
Figure 4.3: Consort diagram demonstrating losses and 
exclusions from study 
Enrolment 
Follow-Up 
Excluded (n=33) 
   Declined to participate (n=15) 
 
Visit 2                                                                             
Produced sample (n=20) 
 
 
 
Visit 1                                                            
Unable to produce sputum sample (n=16).  
Analysed (n=56) 
Agreed to follow-up visits (n=20) 
Visit 3                                                                             
Produced sample (n=20) 
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4.3.3 Missing data 
AHR was not measured in 3 subjects as two declined and one had symptoms of chest pain 
during the test. As stated above, 16 participants failed to produce sputum samples. MIA 048 
attended V1, V2 and V3 and provided sputum samples but a subsequent sputum culture 
was positive for S. pneumoniae. This subject was treated with antibiotics and their 
microbiota results were excluded from analyses. 
4.3.4 Baseline demographics 
The baseline demographics and clinical features of the 72 participants who took part in the 
study (Table 4.1) and the 56 participants who produced sputum samples that were used in 
the study (Table 4.2) are shown. Table 4.4 shows the participants who provided samples 
divided into those who were BTS Step 2 and BTS Step 4. 
In the overall cohort there was a slight female preponderance and a large majority of the 
subjects were Caucasian. The mean age of the cohort was 56, with a range of ages from 21-
80. Around 32% were ex-smokers who all had pack year histories of <10 pack years and had 
not smoked in the previous 10 years as per the inclusion criteria. The group were fairly well 
controlled symptomatically with an average ACQ score of 1.1 and LCQ score of 18.3. The 
median bacterial load was 9.6x106 cfu/mL.  
There were no statistically significant differences in the demographic composition or 
baseline clinical measures of the BTS Step 2 and BTS Step 4 groups (Table 4.3). Also, there 
were no statistically significant differences between the BTS Step 4 fluticasone and 
budesonide groups (Table 4.4).  
Twenty-four subjects produced sufficient sputum to also obtain sputum cell counts (Table 
4.5). The majority of these had ongoing neutrophilic inflammation (n= 14; 58%) with 6 
subjects (25%) displaying paucigranulocytic counts, 3 (12.5%) with mixed granulocytic 
counts and only 1 (4%) with isolated ongoing eosinophilic inflammation. 
4.3.5 Primary Outcomes:  
4.3.5.1 Sputum microbiota diversity/composition and quantitation between the BTS Step 2 
and BTS Step 4 groups 
No significant differences in sputum bacterial load were seen between the BTS 2 and 4 
groups (Tables 4.3 & 4.7, Figs 4.4 & 4.5, Appendix M). There were also no significant 
differences in the relative abundance of the respiratory pathogens H. influenzae or S. 
pneumoniae between the two groups (Tables 4.6 & 4.7). 
 
There was no significant difference in the alpha diversity measures of species richness 
(Table 4.8), Simpson’s (Table 4.9) and Shannon’s (Table 4.10) indices between BTS2 and BTS 
4. The groups also showed no significant difference in community composition when 
compared with ANOSIM (Fig 4.8, Table 4.11).  
 
On comparison of the abundance of individual OTUs in BTS Step 2 and 4 subjects, 39 OTUs 
were found to have significantly different abundances in the two groups (Table 4.16), with 
14 of these belonging to the phylum Firmicutes.  
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4.3.5.2 Sputum microbiota diversity/composition and quantitation between the BTS Step 4 
fluticasone and BTS Step 4 budesonide groups 
No significant differences in sputum bacterial load were seen between the BTS 4 fluticasone 
and BTS 4 budesonide groups (Table 4.6, Figs 4.6 & 4.7). There were also no significant 
differences in the relative abundance of the respiratory pathogens H. influenzae or S. 
pneumoniae between the two groups. H. influenzae was more abundant than S. 
pneumoniae in all groups (Table 4.7). 
 
There was no significant difference in the alpha diversity measures of species richness 
(Table 4.12), Simpson’s (Table 4.13) and Shannon’s (Table 4.14) indices between BTS 4 
fluticasone and BTS 4 budesonide groups. The groups also showed no significant difference 
in community composition when compared with ANOSIM (Table 4.15, Fig 4.9).  
 
The abundance of OTUs in BTS 4 fluticasone and BTS 4 budesonide patients was also 
compared. There were significant differences in the abundance of 13 OTUs between the 
groups (Table 4.17).  
 
4.3.6 Secondary Outcomes 
4.3.6.1 Sputum microbiota diversity/composition at baseline vs 24 h and 14 days 
There was no significant difference in sputum bacterial load or in alpha diversity measures 
(richness, Simpson’s or Shannon’s indices) in baseline samples and those taken at 24 h 
(n=20) or at 14 days (Table 4.22 and Table 4.23). This finding did not alter when these 20 
subjects were divided into BTS 2 (n=8) and BTS 4 (n=12) groups (Table 4.18, Figs 4.10-4.13).   
The test-retest reliability of the qPCR bacterial load measurements appeared to be poor 
with an intraclass coefficient value of 0.17 (Figures 4.13 & 4.14; Table 4.20). However, this 
result was not statistically significant which was likely owing to the relatively low number of 
subjects. 
4.3.6.2 Sputum microbiota diversity/composition at baseline vs clinical features/measures 
No significant correlation was found between alpha diversity measures (richness, Simpson’s 
or Shannon’s indices) or microbiota composition (plotting NMDS axis 1) with any of the 
clinical measurements (FEV1 % predicted, FENO, PC20, LCQ, ACQ or ICS dose) (Table 4.21). 
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Table 4.1: Demographics and clinical characteristics of all subjects 
recruited to study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Frequency Percentage  
Total number included for 
analysis 
72  
Mean age (range) 55.3 (21-80)  
Sex: male 34 47.2 
Ethnic group: 
Asian Or Asian British 
Black Or Black British 
White Or White British 
 
1 
3 
68 
 
1.4 
4.2 
94.4 
Smoking history:  
Ex-smokers 
Non smokers 
 
22 
50 
 
30.6 
69.4 
Current eczema 9 12.5 
Current hay fever 29 40.3 
ACQ score 
Median + IQR 
 
6 (6) 
 
LCQ score 
Median + IQR 
18.3 (3.0)  
FEV1 mean (SD) 92.3 (24.1)  
FEV1/FVC ratio 70.4 (10.9)  
FENO concentration (ppb) 
Geometric mean and 95% CI 
13.6  
(11.0 – 16.9) 
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Table 4.2: Demographics and clinical characteristics of all subjects 
who produced samples in the study 
 
 
 
 
 
 
 
 
 
 
 
 Frequency Percentage  
Total number included for 
analysis 
56  
Mean age (range) 56.0 (21-80)  
Sex: male 26 46.4 
Ethnic group: 
Asian Or Asian British 
Black Or Black British 
White Or White British 
 
1 
2 
53 
 
1.8 
3.6 
94.6 
Smoking history:  
Ex-smokers 
Non smokers 
 
18 
38 
 
32.1 
67.9 
Current eczema 7 12.5 
Current hay fever 23 41.1 
ACQ score 
Mean + SD 
1.10 (0.74)  
LCQ score 
Median + IQR 
18.28 (2.71)  
FEV1 mean (SD) 93.2 (24.6)  
FEV1/FVC ratio 70.3 (10.9)  
FENO concentration (ppb) 
Geometric mean and 95% CI 
14.5  
(11.3-18.5) 
 
Sputum bacterial load 
(cfu/mL) (Median + IQR) 
9.63x106 
(4.28x107) 
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 STEP 2 STEP 4  
 Frequency (%) Frequency (%) Significance 
(p=) 
Total number 
included for analysis 
22 34 (16 BUD / 18 
FLU) 
 
Mean age (range) 58.9 (14.4) (21-72) 54.1 (14.3) (25-80) 0.22 
Sex: male 12 (54.6) 14 (41.2) 0.33 
Ethnic group: 
Asian Or Asian 
British 
Black Or Black 
British 
White Or White 
British 
 
0 
0 
22 (100) 
 
1 (2.9) 
2 (5.9) 
31 (91.2) 
 
 
 
0.70 
Smoking history:  
Ex-smokers 
Non smokers 
 
7 (31.8) 
15 (68.2) 
 
11 (32.4) 
22 (67.7) 
 
 
0.97 
Current eczema 4 (18.2) 3 (8.8) 0.42 
Current hay fever 10 (45.5) 13 (38.2) 0.59 
ICS dose (BDP 
equivalent) (Median 
+ IQR) 
400 (200) 1000 (200)  
ACQ score 
Mean + SD 
0.9 (0.6) 1.2 (0.8) 0.12 
LCQ score 
Median + IQR 
19.0 (2.0) 17.8 (3.5) 0.08 
FEV1 mean (SD) 93.5 (28.0) 93.1 (22.5) 0.95 
FEV1/FVC ratio 68.8 (10.1) 71.2 (11.4) 0.43 
FENO concentration 
(ppb) 
Geometric mean and 
95% CI 
17.2 (12.8-23.1) 13.0 (9.0-18.6) 0.27* 
Sputum bacterial 
load (cfu/mL) 
(Median + IQR) 
1.35x107 (9.89x107) 8.86x106 (2.81x107) 0.27 
*T-test comparing log FENO 
Table 4.3: Demographics and clinical characteristics of BTS Step 2 
and BTS Step 4 groups that produced samples in the study 
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 STEP 4 BUD STEP 4 FLU  
 Frequency (%) Frequency (%) Significance 
(p=) 
Total number 
included for analysis 
16 18  
Mean age (range) 52.9 (25-80) 55.2 (39-71) 0.65 
Sex: male 7 (43.8) 7 (38.9) 0.77 
Ethnic group: 
Asian Or Asian 
British 
Black Or Black 
British 
White Or White 
British 
 
0 
2 (12.5) 
14 (87.5) 
 
1 (5.6) 
0 
15 (94.4) 
 
 
 
0.21 
Smoking history:  
Ex-smokers 
Non smokers 
 
8 (50.0) 
8 (50.0) 
 
3 (16.7) 
15 (83.3) 
 
 
1.0 
Current eczema 1 (6.3) 2 (11.1) 1.0 
Current hay fever 6 (37.5) 7 (38.9) 0.59 
ICS dose (BDP 
equivalent) (Median 
+ IQR) 
800 (0) 
*difficult due to 
common doses for 
each preparation –
“2 medians” for 
each 
1000 (100)  
ACQ score 
Mean + SD 
1.3 (0.9) 1.1 (0.8) 0.41 
LCQ score 
Median + IQR 
19.4 (2.3) 17.6 (6.2) 0.25 
FEV1 mean (SD) 86.5 (22.6) 98.9 (21.3) 0.11 
FEV1/FVC ratio 67.9 (10.6) 74.1 (11.6) 0.12 
FENO concentration 
(ppb) 
Geometric mean and 
95% CI 
16.0 (8.9-28.6) 10.8 (6.7-17.5) 0.28 
Sputum bacterial 
load (cfu/mL) 
(Median + IQR) 
1.08x107 (2.71x107) 8.23x106 (3.80x107) 0.59 
Table 4.4: Demographics and clinical characteristics of BTS Step 4 
budesonide and BTS Step 4 fluticasone groups that produced 
samples in the study 
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Sputum 
inflammatory type 
BTS Step 2 BTS Step 4 
BUD 
BTS Step 4 
FLU 
Totals 
Neutrophilic (>61%) 5 3 6 14 
Eosinophilic (>3%) 0 1 0 1 
Mixed granulocytic 
(N>61% and E>3%) 
1 1 1 3 
Paucigranulocytic 2 2 2 6 
Totals 8 7 8 24 
Table 4.5: Sputum inflammatory types of a subgroup of 24 subjects 
who produced sufficient sputum for cell counts 
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No. 
 
Group 1 
 
Group 2 
Group 1 
Mean total 
bacterial 
load 
(cfu/mL) 
Group 2 
Mean total 
bacterial 
load 
(cfu/mL) 
p-value 
 
Group 1  
Mean H. 
influenzae 
load 
(cfu/mL) 
Group 2  
Mean H. 
influenzae 
load 
(cfu/mL) 
 
p-value 
Group 1  
Mean S. 
pneumoniae 
load    
(cfu/mL) 
Group 2  
Mean S. 
pneumoniae 
load 
(cfu/mL) 
 
p-value 
1 
BTS 2 BTS 4 1.25E+08 
 
4.81E+07 0.272 6.35E+03 
 
1.31E+06 
 
0.705 8.57E+01 
 
7.83E+00 
 
1.00 
2 
BTS 2 / 
BUD 
BTS 2 / 
FLU 
4.26E+07 
 
1.64E+08 
 
0.973 5.35E+02 
 
8.04E+02 
 
0.152 4.64E+01 
 
2.67E+02 
 
1.00 
3 
BTS 2 / 
BUD 
BTS 2 / 
BEC 
4.26E+07 
 
1.62E+08 
 
0.493 5.35E+02 
 
1.32E+04 
 
0.583 4.64E+01 
 
2.28E+01 
 
0.340 
4 
BTS 2 / 
FLU 
BTS 2 / 
BEC 
1.64E+08 
 
1.62E+08 
 
0.563 8.04E+02 
 
1.32E+04 
 
0.407 2.67E+02 
 
2.28E+01 
 
0.535 
5 
BTS 4 / 
BUD 
BTS 4 / 
FLU 
2.73E+07 
 
6.77E+07 
 
0.589 1.79E+04 
 
2.52E+06 
 
0.650 7.13E+00 
 
8.50E+00 
 
0.743 
6 
BTS 2 / 
BUD 
BTS 4 / 
BUD 
4.26E+07 
 
2.73E+07 
 
0.919 5.35E+02 
 
1.79E+04 
 
0.630 4.64E+01 
 
7.13E+00 
 
0.488 
7 
BTS 2 / 
FLU 
BTS 4 / 
FLU 
1.64E+08 
 
6.77E+07 
 
0.784 8.04E+02 
 
2.52E+06 
 
0.218 2.67E+02 
 
8.50E+00 
 
0.957 
8 
BUD FLU 3.19E+07 
 
8.96E+07 
 
0.944 1.26E+04 
 
1.95E+06 
 
0.748 1.91E+01 
 
6.72E+01 
 
0.925 
9 
FLU BUD + 
BEC 
8.96E+07 
 
7.14E+07 
 
0.236 1.95E+06 
 
1.28E+04 
 
0.829 6.72E+01 
 
2.02E+01 
 
0.703 
 
Table 4.6: Comparisons of mean total bacterial load and abundance of H. influenzae and S. pneumoniae in 
groups as stated 
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No. Group Mean H. 
influenzae load 
(cfu/mL) 
Mean S. 
pneumoniae load 
(cfu/mL) 
p-value 
1 BTS 2 6.35E+03 8.57E+01 0.053 
2 BTS 4 1.31E+06 7.83E+00 0.001 
3 BUD 1.26E+04 1.91E+01 0.005 
4 FLU 1.95E+06 6.72E+01 0.028 
5 FLU/BTS 4 2.52E+06 8.50E+00 0.017 
Table 4.7: Demonstrating comparison of abundance of H. influenzae 
and S. pneumoniae in groups as stated.  
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Figure 4.4: Bacterial load (cfu/mL of sputum equivalent) in MIA patients
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Figure 4.5: Bacterial load (log cfu/mL of sputum equiv.) in BTS 2 and 
4 groups 
 
 
Figure 4.6: Bacterial load (log cfu/mL of sputum equiv.) based on 
patient’s inhaled steroid 
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Figure 4.7: Bacterial load (log cfu/mL of sputum equiv.) in BTS 2 and 
4 groups based on patient’s inhaled steroid  
  
 Sum Sq Df Mean Sq F value Pr (>F) 
Factor 
(severity) 
460.7 1 460.67 1.4972 0.2266 
Residuals 16000.1 52 307.70   
Table 4.8: ANOVA table for the effect of severity on bacterial 
richness 
 
 Sum Sq Df Mean Sq F value Pr (>F) 
Factor 
(severity) 
0.00002458 1 2.4578e-05 2.321 0.1337 
Residuals 0.00055065 52 1.0589e-05   
 Table 4.9: ANOVA table for effect of severity on Simpson’s index  
 
 Chi-square Df Pr (>Chi-Square) 
Factor 
(severity) 
1.291 1 0.2559 
Table 4.10: Kruskal-Wallis test for effect of severity on Shannon’s 
index 
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 R p 
BTS 2 vs BTS 4 -0.02035 0.676 
Number of permutations: 999 
Table 4.11: Results from ANOSIM between BTS 2 Group and BTS 4 
Group (Bray-Curtis dissimilarity) 
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Figure 4.8: Non-multidimensional scaling plot of the bacterial 
compositions of each samples, grouped by severity;  
Red = BTS Step 2, Blue = BTS Step 4. Both x and y axes are 
arbitrary scales. The distance between points in the figure 
represents the degree of similarity of the bacterial composition 
between samples. The closer the points are together, the more 
similar the bacterial composition. This figure demonstrates that 
the composition of the BTS Step 2 and 4  groups are similar as 
the clustering of points on the plot for both groups is similar. 
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Table 4.12: ANOVA table for the effect of steroid type on richness  
 
 Sum Sq Df Mean Sq F value Pr (>F) 
Factor 
(steroid) 
0.00000031 1 3.0530e-07 0.0204 0.8873 
Residuals 0.00046327 31 1.4944e-05   
Table 4.13: Steroid effect on Simpsons index 
 
 Chi-square Df Pr (>Chi-Square) 
Factor 
(steroid) 
0.0731 1 0.7868 
Table 4.14: Kruskal-Wallis test for effect of severity on Shannon’s 
index 
 
 R p 
BTS 4 Bud vs   
BTS 4 Flu 
0.008473 0.345 
Number of permutations: 999 
Table 4.15: Results from ANOSIM between BTS 2 Group and BTS 4 
Group (Bray-Curtis dissimilarity) 
 
 
 
 
 
 
 
 
 
 
 
 Sum Sq Df Mean Sq F value Pr (>F) 
Factor 
(steroid) 
6.1 1 6.1 0.016 0.9001 
Residuals 11796.8 31 380.54   
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Figure 4.9: NMDS of steroid effect on composition.  
Red = BUD, Blue = FLUTIC. Both x and y axes are arbitrary scales. This 
figure demonstrates that the composition of the BTS Step 4 Budesonide 
and Step 4 Fluticasone groups are similar as the clustering of points on 
the plot for both groups is similar 
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BTS2 BTS4 
OUT.ID p value 
Mean 
(cfu/mL) 
SD 
(cfu/mL) 
Mean 
(cfu/mL) 
SD 
(cfu/mL) 
Cerasicoccaceae 0.045 0 0 48136.46 242558.4 
Prevotella.tannerae 0.031 567421.5 2166916 37186.51 171202.7 
Weeksellaceae 0.002 57953.84 187283.1 4621.297 17242.01 
Acidocella.spp. 0.011 37739.59 122368.7 3285.693 7715.95 
Actinomyces.spp. 0.020 2402551 4704338 178311.9 681813.9 
Aggregatibacter.segnis 0.043 405902.9 996459.4 23549.74 62863.32 
Atopobium.spp. 0.006 614218.9 957477.6 81613.48 230382.3 
Bacillaceae1 0.047 22683.45 96642.81 261821.9 1010540 
Bacillaceae2 0.031 17273.54 73086.08 181728.9 571889.1 
Campylobacter.spp. 0.048 713264.1 1223965 225809.4 716058 
Capnocytophaga.spp. 0.005 408979.6 1067674 12787.48 35474.43 
Cardiobacterium.spp. 0.019 30024.16 89067.01 649.9432 1367.122 
Catonella.spp. 0.048 145950.7 325845 25571.6 84832.2 
Corynebacterium.durum 0.031 25080.47 65504.5 6904.183 26225.17 
Dialister.spp. 0.016 735403.8 2545526 138994.5 525555.5 
Dysgonomonas.spp. 0.008 572.3388 2577.694 53199.23 189629 
Enterobacteriaceae1 0.032 18.93667 86.77871 6524.605 23041.53 
Granulicatella.spp. 0.015 1227271 3155185 64060.74 140362.6 
Lautropia.spp. 0.039 740902.1 2328397 20944.79 104157.1 
Leptotrichia.spp. 0.003 10814168 28385555 2188100 7752618 
Megasphaera.spp. 0.009 382720.4 795826.2 57274.12 159554.3 
Microbacteriaceae1 0.012 896604.2 2419294 912765.1 4027665 
Moryella.spp. 0.001 801977.1 1531354 60022.51 187047.1 
Neisseriaceae 0.007 242214.6 532659.2 5252.301 9597.861 
Oribacterium.spp. 0.006 787499.9 1707436 160294.7 572340.5 
Parvimonas.spp. 0.005 502481.3 1465182 7597336 44172428 
Prevotella. 
melaninogenica 
0.016 10674788 20711212 1571315 4412534 
Prevotella.nigrescens 0.008 153201.7 310928.7 4767.503 9067.782 
Prevotella.pallens 0.029 737098.2 1449476 177312.4 646154.3 
Rothia.aeria 0.005 616580.9 1447615 19857.93 45271.42 
Rothia.dentocariosa 0.010 844303.4 1743688 63093.43 129531.7 
Rothia.mucilaginosa 0.021 14034074 34188166 609291.8 1428920 
Selenomonas.noxia 0.028 29108.5 82901.73 520.7932 964.6912 
Selenomonas.spp. 0.006 682271.2 1904229 310393.3 1462465 
Streptococcus.anginosus 0.002 95150.47 266841 11707.6 47283.08 
Streptococcus.spp. 0.002 25992589 55531721 1715461 2891616 
TM7 0.002 567835.6 1790638 14413.45 31237.25 
TM_7.Rs_045 0.035 137999.3 363084.4 1342.991 3414.309 
Veillonella.dispar 0.013 8799488 15574777 1091461 3438765 
Table 4.16: OTUs demonstrating significantly different abundance in 
BTS Step 2 and 4 groups 
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FLUTIC BUD 
OUT.ID p value 
Mean 
(cfu/mL) 
SD 
(cfu/mL) 
Mean 
(cfu/mL) 
SD 
(cfu/mL) 
Anaerobacillus.spp. 0.026 99984.27 420897.1 82621.61 194653.4 
Capnocytophaga.ochracea 0.038 10745.07 39826.14 1224.851 3779.901 
Dysgonomonas.spp. 0.035 53319.58 225535.9 53063.83 146497.4 
Exiguobacterium 0.026 312.1798 1324.467 4431.924 11758.82 
Fluviicola.spp. 0.043 13.83541 58.69869 1256.938 2695.984 
Haemophilus. 
parainfluenzae 0.047 963546.1 2920793 144552.9 309026.3 
Lactobacillus.reuteri 0.027 28511.36 91197.13 0 0 
Paracoccus.spp. 0.016 89993.13 380919.2 195139.2 570462.6 
Peptococcus.spp. 0.014 18608.36 75010.17 69.26747 277.0699 
Porphyromonas. 
endodontalis 0.009 64019.62 172897.6 6009.521 21444.89 
Rhodobaca.spp. 0.049 17989.71 75130.93 19048.09 42095.53 
Veillonellaceae2 0.048 11768.51 29602.59 5.81175 23.247 
Xanthomonadaceae1 0.019 71839.09 197731.9 5312.727 11613.61 
Table 4.17: Abundances of OTUs that change significantly in BTS 4 
patients treated with different steroids 
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 A) Mean total bacterial load (cfu/mL) 
Group Baseline After 24 
hours  
(V1 – V2) 
p value After 2 
weeks 
(V1 – V3) 
p value 
BTS 2 1.48E+08 1.45E+08 0.345 3.12E+08 0.679  
BTS 4 9.67E+07 9.35E+06 0.158 2.44E+07 0.651  
BUD / BTS 4 6.97E+06 4.18E+06 0.231 1.09E+07 0.334  
FLU / BTS 4 1.48E+08 1.23E+07 0.284 3.20E+07 0.349  
Combined groups 1.18E+08 6.63E+07 0.085 1.46E+08 0.545 
 
 B) H. influenzae load (cfu/mL) 
Group Baseline After 24 
hours  
(V1 – V2) 
p value After 2 
weeks 
(V1 – V3) 
p value 
BTS 2 3.16E+01 3.73E+00 0.416 8.83E+01 0.269 
BTS 4 1.55E+04 5.07E+02 0.269 1.78E+03 0.845 
BUD / BTS 4 2.70E+03 7.61E+02 0.761 1.59E+02 0.584 
FLU / BTS 4 2.27E+04 3.62E+02 0.072 2.70E+03 0.712 
Combined groups 8.96E+03 2.95E+02 0.153 1.07E+03 0.323 
 
 C) S. pneumoniae load (cfu/mL) 
Group Baseline After 24 
hours  
(V1 – V2) 
p value After 2 
weeks 
(V1 – V3) 
p value 
BTS 2 0.00E+00 4.75E+00 0.351 9.08E+00 0.351 
BTS 4 1.30E+01 3.76E+02 0.770 7.95E+00 0.384 
BUD / BTS 4 1.06E+00 0.00E+00 0.391 0.00E+00 0.391 
FLU / BTS 4 1.99E+01 5.91E+02 0.873 1.25E+01 0.497 
Combined groups 7.55E+00 2.20E+02 0.977 8.43E+00 0.755 
 
Table 4.18: Demonstrating A) Mean total bacterial load B) H. 
influenzae load and C) S. pneumoniae load in groups stated at 
baseline and after 24 hours and 2 weeks (total n=19). Comparisons 
between values made using repeated measure ANOVA tests. 
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 Richness Shannon’s Simpsons 
All subjects  0.131 0.113 0.106 
Table 4.19: Repeated measure ANOVA p-values for alpha-diversity 
measures for subjects that had repeat visits (n=19) after 24 hours 
and 2 weeks 
 
 
Figure 4.10: Bacterial load (log cfu/mL of sputum equiv.) in subjects 
(n=19) after 24 hours and 2 weeks.  
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Figure 4.11: Bacterial load (log cfu/mL of sputum equiv.) in subjects (n=19) based on inhaled steroid groups 
after 24 hours and 2 weeks. 
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Figure 4.12: Bacterial load (log cfu/mL of sputum equiv.) in BTS groups 2 and 4 (total n=19) after 24 hours and 
2 weeks. 
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Figure 4.13: Individual bacterial loads (cfu/mL) of BTS Step 2 subjects (total n=8) after 24 hours and 2 weeks 
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Figure 4.14: Individual bacterial loads (cfu/mL) of BTS Step 4 subjects (total n=12) after 24 hours and 2 weeks 
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 Intraclass coefficient 95% CI p value 
Total bacterial load 0.17 -0.74 – 0.65 0.3 
 
Table 4.20: Intraclass coefficient for repeated qPCR measures of 
total bacterial load from all subjects who made 3 visits (n=20 ) 
 
 
 
Measure Diversity p value Composition p value 
FEV1 
(%predicted) 
-0.122 0.3731 0.118 0.3891 
FENO -0.153 0.2648 -0.113 0.4124 
PC20 -0.051 0.7129 -0.149 0.282 
LCQ -0.218 0.1102 -0.241 0.0769 
ACQ 0.061 0.6568 -0.162 0.2363 
ICS dose -0.067 0.6253 0.208 0.1283 
 
Table 4.21: Spearman’s rank correlation coefficients of clinical 
measures with microbiota diversity (Shannon’s, Simpson’s and 
richness) and composition (composition measure based on non-
multidimensional scaling plot axis 1) 
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4.4 Discussion 
The results of this study indicate that there is no significant difference in bacterial 
community composition or total bacterial load of the airway microbiota between BTS Step 2 
and Step 4 asthma groups or the BTS Step 4 subgroups taking budesonide or fluticasone. 
However, significant differences in the abundance of many bacterial species (OTUs) 
between the groups were noted.  
4.4.1 Sputum microbiota diversity/composition and quantitation between the BTS 
Step 2 and BTS Step 4 groups 
The first point of interest from the study is the average sputum bacterial load of the cohort 
(~1x107 cfu/mL) which is in between that observed in healthy controls (~1x104 cfu/mL) and 
in individuals with CF (~1x109 cfu/mL). Even after accounting for oral/upper airway 
contamination and assuming that a significant number of these bacteria are viable this 
represents a substantial bacterial load which is likely to be biochemically and 
immunologically active and exert various effects upon the airways. It is possible that the 
increased bacterial load observed in this and other cohorts of subjects with airways disease 
could be used as a biomarker to distinguish patients with airways disease from those 
without although this requires further study. 
 
The lack of differences observed in the total bacterial load or the community composition of 
the microbiota between the BTS Step 2 and BTS Step 4 groups imply that the use of higher 
ICS doses in asthma does not lead to fundamental changes in the microbiota. The 
observation that several different species are found in higher abundance in subjects with 
less severe asthma is an interesting finding that requires further investigation.  
 
There are relatively few published studies in this area although two previous studies have 
compared the airway microbiota in asthmatic subjects with different severities of disease.  
 
Zhang et al. (821) compared the airway microbiota from of “severe” and “non-severe” 
asthmatics and found significant differences in bacterial community structure between the 
two groups. The severe group in this study consisted of subjects requiring “either 
continuous or near-continuous oral corticosteroids, high-dose inhaled corticosteroids, or 
both” whilst the non-severe asthmatics were defined as those with no symptoms and 
minimal use of rescue medication using ≤2000 μg BDP. It is clear from these definitions that 
the severe group from Zhang et al. had more severe asthma requiring higher steroid doses 
(equivalent to BTS Step 5) than the BTS Step 4 group from the present study.  In fact, the 
non-severe group from the Zhang et al. also had a higher average ICS dose than the BTS Step 
4 group of the present study (mean 1453 µg; SD 563 µg vs median 1000 µg; IQR 200 µg). A 
significantly increased abundance of Proteobacteria (including Haemophilus) and reduced 
numbers of Firmicutes were detected in the sputum of non-severe asthmatics when 
compared to severe asthmatics.  
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These findings would seem to be in contrast with those of the current study. However, the 
significant differences noted by Zhang et al were determined by comparing the relative 
abundance of bacteria grouped as phyla. The validity of comparing the relative abundances 
of whole phyla of bacteria is unclear due to the massive variation of organisms classified 
within the same phyla. Although such comparisons may allow the detection of a broad 
difference in microbiota community structure between two selected groups they are not 
biologically informative. This is because they allow no further assessment of the 
functionality of the organisms detected within these phyla and hence are unable to advance 
further understanding regarding the roles of particular species in the progression of disease. 
The current study did not make comparisons at phylum level for these reasons, instead 
comparing abundances at an OTU level, i.e. a much higher resolution level of sequencing, in 
order to try and identify specific species that could plausibly be linked to any observed 
differences between the two groups.   
 
Huang et al. (819) compared the microbial content of bronchial brushings from 30 “severe” 
and 41 “mild to moderate” asthmatic subjects. Severe asthmatics were defined as having a 
FEV1 of 40-80% predicted, an ACQ of >1.5 and a daily dose of ≥1000 µg beclomethasone. 
Subjects in the mild to moderate group with “sub-optimal” asthma control were defined by 
an ACQ >1.25 after 4 weeks of standardised treatment with 88 µg of fluticasone twice daily. 
These two groups were taking similar doses of ICS to the BTS Step 2 and 4 groups in the 
current study. However, both of these groups had sub-optimal asthma control whilst the 
groups in the present study had a lower ACQ score/better asthma control (BTS Step 2 0.9 
(0.6), BTS Step 4 1.2 (0.8)). The microbiota from the severe asthmatic group was found to be 
enriched in 53 genera compared to the mild to moderate subjects, the majority of which 
were Actinobacteria (with the remaining 5 all classifying to Gammaproteobacteria). Forty-
two genera were more abundant in the mild to moderate group with 19 of these belonging 
to the taxa Proteobacteria. These results contrast with those of the current study in which 
only 8 genera were enriched in the more severe (BTS 4) group and 31 were enriched in the 
less severe (BTS 2) group.  
 
At the species level there were significant differences in the abundance of a number of 
organisms between Step 2 and Step 4 groups. Upon review of the possible sources of these 
organisms they can be divided into several different groups (Table 4.22). 
 
 
Phylum OUT.ID BTS 2 BTS 4 
Environmental contaminants/uncertain significance 
Actinobacteria Microbacteriaceae1  ↑ 
Bacteroidetes Weeksellaceae ↑  
Frequent members of the oral microbiota (839) 
Actinobacteria Actinomyces.spp. (840) ↑  
Proteobacteria Aggregatibacter.segnis ↑  
Actinobacteria Atopobium.spp. ↑  
Bacteroidetes Capnocytophaga.spp. ↑  
Proteobacteria Cardiobacterium.spp. ↑  
Firmicutes Catonella.spp. ↑  
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Actinobacteria Corynebacterium.durum ↑  
Firmicutes Dialister.spp. ↑  
Firmicutes Granulicatella.spp. ↑  
Proteobacteria Lautropia.spp. ↑  
Fusobacteria Leptotrichia.spp. ↑  
Firmicutes Megasphaera.spp. ↑  
Firmicutes Oribacterium.spp. ↑  
Firmicutes Parvimonas.spp.  ↑ 
Actinobacteria Rothia.aeria ↑  
Actinobacteria Rothia.dentocariosa ↑  
Actinobacteria Rothia.mucilaginosa ↑  
Firmicutes Selenomonas.noxia ↑  
Firmicutes Selenomonas.spp. ↑  
Firmicutes Streptococcus.anginosus 
(841) ↑  
 TM7 (842) ↑  
 TM_7.Rs_045 (842) ↑  
Frequent members of the GI microbiota 
Proteobacteria Acidocella.spp. (843) ↑  
Firmicutes Bacillaceae1 (844)  ↑ 
Firmicutes Bacillaceae2 (844)   ↑ 
Proteobacteria Campylobacter.spp. (844) ↑  
Verrucomicrobia Cerasicoccaceae (845)  ↑ 
Bacteroidetes Dysgonomonas.spp.  ↑ 
Proteobacteria Enterobacteriaceae1  ↑ 
Firmicutes Moryella.spp. (846) ↑  
Organisms previously noted in lung microbiota 
Proteobacteria Neisseriaceae ↑  
Bacteroidetes Prevotella.melaninogenica ↑  
Bacteroidetes Prevotella.nigrescens ↑  
Bacteroidetes Prevotella.pallens ↑  
Bacteroidetes Prevotella.tannerae ↑  
Firmicutes Streptococcus.spp. ↑  
Firmicutes Veillonella.dispar ↑  
Table 4.22 The OTUs that demonstrate significantly different 
abundance between BTS 2 and 4 Groups grouped by most likely 
microbiota origin  
 
 
Broadly, the BTS 2 group were relatively enriched in a variety of organisms abundant in the 
oral microbiota and those previously noted in the lung microbiota whilst the BTS 4 group 
had a higher abundance of several organisms that are frequent members of the GI 
microbiota, although these differences are difficult to quantify.  
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Venkataraman et al. (796) have proposed that the lung microbiome in health is largely 
determined by a constant “neutral distribution” of microbes from the oral cavity via 
breathing and microaspiration, rather than the selective growth of bacteria within the 
airways. A model assuming this ‘neutral distribution’ of microbes from the upper airways in 
subjects with no lung disease found a strong overlap between OTUs detected in the oral 
cavity and those in the lung (goodness-of-fit/R2 of 0.86, where 1 is a perfect fit). By contrast, 
the poor fit of the model between OTUs in the upper airways and bacterial communities 
resident in diseased lungs suggest that the lung microbiota in disease states is shaped by 
processes of active selection. If such a model were to be correct, it may be that the critical 
determinant of lung microbiota composition “switches” at a certain point from dispersal of 
upper airway/oral microbes to establishment of a distinct and selective bacterial community 
during the progression of disease. The point at which this happens would necessarily 
depend on environmental selection pressures within the lung habitat including 
temperature, pH, oxygen tension, perfusion and the degree of inflammation and epithelial 
cell damage (799). The results of the current study would seem to provide some support for 
this model with the microbiota from the subjects with less severe disease (BTS Step 2) 
containing comparatively high abundances of species commonly isolated in the oral cavity 
which could be present in the lungs due to neutral distribution. The higher abundances of 
several organisms normally associated with the GI microbiota in BTS Step 4 subjects could 
represent the establishment of a distinct bacterial community that is either a cause or 
consequence of more severe disease.  
An increased abundance of Prevotella species was found in the BTS Step 2 group and 
reduced abundance of Prevotella species has previously been reported in subjects with 
severe asthma (821) and corticosteroid resistant asthma (817) in previous investigations. 
Hilty et al. (777) found controls were more likely than asthmatic subjects to be colonised 
with multiple species of Prevotella, which have previously been shown to directly inhibit the 
growth of a number of other bacteria. An increased abundance of Streptococcal species 
were identified in the BTS 2 group in comparison to the BTS 4 group which may be an 
interesting and unexpected finding given the obvious role of S. pneumoniae in respiratory 
disease. Unfortunately however the significance of this result is unclear as these 
Streptococcal OTUs lack the specificity to define distinct species. Cox et al. previously 
reported that 16S rRNA gene sequencing was unable to discriminate between S. 
pneumoniae and Streptococcus mitis, the latter being a normal commensal of the 
oropharynx (847). 
 
4.4.2 Sputum microbiota diversity/composition and quantitation between the BTS 
Step 4 Fluticasone and BTS Step 4 Budesonide groups 
No significant differences were found in the total bacterial load or the community 
composition of the microbiota between the BTS Step 4 Fluticasone (n=18) and BTS Step 4 
Budesonide (n=16) groups. This comparison was a specified outcome of the study as 
fluticasone use has been demonstrated to increase the relative risk of pneumonia in 
patients with COPD, with suggestions that this risk may also be increased in asthma and a 
possible cause of this could be alterations in the microbiota. No other studies have 
previously investigated this clinical question for comparative purposes.  
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Although there were no significant differences in the microbiota composition as a whole 
between these two groups, there were significant differences in the abundances of certain 
species. Upon review of the likely sources of these organisms several of them appear to be 
environmental contaminants or of uncertain significance (Anaerobacillus.spp., 
Exiguobacterium, Fluviicola.spp., Paracoccus.spp., Rhodobaca.spp., Xanthomonadaceae1), 
some are common members of the oral microbiota (Capnocytophaga.ochracea, 
Porphyromonas.endodontalis and Veillonellaceae2) and others of the GI microbiota 
(Dysgonomonas.spp., Lactobacillus.reuteri, Peptococcus.spp.).  
 
One potentially interesting difference between the two groups was the differing levels of H. 
parainfluenzae which was more abundant in Step 4 patients on fluticasone compared to 
those taking budesonide. This organism is a potential respiratory pathogen which has 
previously been noted to cause infection in subjects with chronic lung disease (848, 849). 
Goleva et al. (817) previously found an increased abundance of H. parainfluenzae in 
asthmatic subjects “resistant” to a treatment trial of oral prednisolone in comparison to 
those who were steroid “sensitive”. These authors also demonstrated an inhibitory effect of 
H. parainfluenzae on asthmatic airway macrophages in vitro. 
 
4.4.3 Sputum microbiota diversity/composition and quantitation between baseline 
and 24 h samples 
No significant differences were found in the total bacterial load or the community 
composition of the microbiota between baseline sputum samples and those taken at 24 
hours (n=20). This is in contrast to a previous study demonstrating significant differences in 
bacterial composition of sputa samples collected consecutively (850). However, this study 
was conducted using form of sequencing (T-RFLP) with a lower resolution in individuals with 
CF where a higher bacterial load and diversity would be expected and hence each individual 
sample may have been less representative of the overall microbiota. 
 
Another study assessing the day-to-day stability of the sputum microbiota from subjects 
with CF found no significant variability in the bacterial community structure or overall 
bacterial load during periods of clinical stability (851). 
 
4.4.4 Sputum microbiota diversity/composition and quantitation between baseline 
and 2 week samples 
No significant differences were found in the total bacterial load or the community 
composition of the microbiota between baseline sputum samples and those taken at 2 
weeks (n=20). 
 
This comparison was included in order to assess the longitudinal stability of the microbiota 
in stable asthma which has not previously been investigated. Longitudinal studies taking 
multiple sputum samples from individuals with CF over multiple time points have 
demonstrated an inherent stability in the microbiota even after short scale perturbations 
caused by exacerbations of disease or courses of antibiotics (800, 851-854).  
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4.4.5 Sputum microbiota diversity/composition and quantitation vs clinical measures 
No significant correlations were found between the total bacterial load or the community 
composition of the microbiota and the FEV1, sputum differential cell count, FENO level, PC20, 
LCQ score, ACQ score or inhaled steroid dose (BDP). 
 
Previous studies have found significant correlations between bacterial community structure 
and clinical measures in asthma. Huang et al. (814) found that the relative abundance of 
certain bacterial taxa primarily belonging to the Proteobacteria phylum were highly 
correlated with BHR. The cohort in the present study had an unusually low number of 
positive PC20 tests considering each had a physician diagnosis of asthma, the reasons for 
which are unclear. A standard protocol for the methacholine challenge was followed using 
appropriately calibrated equipment and subjects were asked to withhold their inhaled 
medication prior to the test as per the ATS guidelines on methacholine challenge testing 
(855). The fact that all subjects were clinically stable, had been using the same ICS dose for 
the past year and had not had any infections/asthma exacerbations in the last month would 
be expected to lessen the degree of AHR seen in these subjects, but this is unlikely to 
account for such a large number of negative tests. It is possible that some systemic error 
with the equipment or methacholine used for testing occurred, but this again seems unlikely 
given that the two staff who performed the test were experienced in performing the test 
and the methacholine used was replaced several times during the course of the study upon 
expiry.  
Huang et al. (819) found significant associations between poor asthma control (i.e. between 
visit differences in the Asthma Control Questionnaire) and increased sputum leucocyte 
values and a high relative abundance of Proteobacteria, whereas high BMI was associated 
with high relative abundance of Bacteroidetes/Firmicutes. However, no association between 
asthma control and microbiota diversity or composition were found in the present study. 
4.4.6 Study limitations 
The study results suggest there may be no true difference in the bacterial load or microbiota 
diversity between the groups compared. However, there are a number of possible 
confounding factors that could have influenced the lack of overall difference seen in the 
bacterial abundance and composition seen between the groups in this study. The first of 
these relates to a lack of specificity in selection of “asthmatic” patients. As described 
previously, asthma is a disease with a range of different endotypes/phenotypes. Previous 
investigations have found associations between certain disease characteristics and high 
relative abundance of certain organisms including subjects with severe neutrophilic asthma 
and abundant potentially pathogenic micro-organisms (635) and subjects with eosinophilia 
and high levels of Streptococcus (821). The subjects in this study were selected simply on 
the basis of a previous physician diagnosis of asthma but may contain several different 
endotypes/phenotypes with distinct differences in their microbiota. 
 
Another potential confounding factor in this study was the effect of age on the microbiota. 
This cohort was older than those examined in previous asthma microbiota studies with a 
mean age of 56 compared to a mean age in previous studies ranging between 26 and 48 
(777, 814, 815, 819, 821). Although the effect of age on the microbiota in asthmatic subjects 
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has not previously been investigated, studies from subjects with CF suggest that microbiota 
diversity decreases with age (856-858) potentially reducing any difference in microbiota 
composition between two groups of older subjects.  
 
A limitation inherent in all microbiota studies involving sputum is the contamination of 
sputum samples with upper respiratory tract and oral micro-organisms. Although it is likely 
that this contamination would be similar for most subjects some significant differences in 
the relative abundance of organisms commonly found in the oral cavity between BTS 2 and 
BTS 4 groups and BTS 4 fluticasone vs BTS 4 budesonide groups were noted. It is unclear if 
these differences are due to varying levels of oral contamination of sputum samples in 
subjects from different groups or if they represent changes in the lower respiratory tract 
microbiota. A degree of contamination is inevitable in studies of the respiratory microbiota 
as even in studies utilising bronchoscopy to collect samples directly with a protected 
specimen brush there may still be contamination of the bronchoscope when traversing the 
upper airways. Bronchoscopy studies in patients with asthma carry an inherent degree of 
risk and as such collecting sputum for microbiota analysis may represent the only suitable 
sampling method for studies involving significant numbers of subjects with asthma.  
 
Healthy controls were not included in the present study as it has already been quite well 
established that there are significant differences in the microbiota of those with asthma 
compared to those without.  However, the inclusion of controls might have been useful in 
determining likely environmental contaminants.  
 
Another limitation in this study is the lack of information regarding other micro-organisms. 
Whilst 16S rRNA gene sequencing allows detailed profiling of the bacterial content of a 
sample it does not enable identification of viruses and fungi. For a comprehensive 
understanding of the airways microbiota to form, the abundance and community 
composition of these other organisms needs to be quantified. 
 
4.4.7 Further Work 
Due to the relative paucity of knowledge in this area a number of questions are still to be 
answered. Ultimately to answer the question of whether ICS or other inhaled medications 
affect the microbiota a double blind RCT needs to be performed with microbiota sampling 
before and after an intervention. This could consist of either starting ICS in a steroid naïve 
cohort of asthmatic subjects or increasing ICS dose in a cohort of asthmatics already taking 
ICS. This design would minimise the problem of significant intra-subject baseline variability 
in microbiota composition that causes difficulty in the interpretation of cross-sectional 
studies.  
 
Another question that requires answering is the significance of high levels of potentially 
pathogenic bacteria detected using qPCR or 16S rRNA gene sequencing. Some of the 
subjects in the study had high levels of potential pathogens such as H. parainfluenzae 
detected but did not have active features of infection. This individuals could however be at 
risk of more severe features of disease such as more frequent exacerbations due to airway 
colonisation and further studies to investigate this possibility and the potential need for 
antibiotic treatment of these patients should be performed. 
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The findings of this study suggest that single sputum samples are well representative of the 
underlying microbiota and that the composition of the microbiota in asthma is largely stable 
over a short period when subjects are clinically stable. The stability of the microbiota in 
subjects with asthma over longer periods of time now needs to be established with 
longitudinal studies sampling the microbiota over a number of time points, ideally including 
periods of clinical stability and disease.  
 
Owing to the increasing awareness of different phenotypic/endotypic variants of asthma it 
will be necessary in future to specifically recruit subjects for microbiota studies that have 
already been phenotyped or incorporate into studies a planned post-hoc analysis of 
different sub groups or clusters of disease based on measured clinical or biochemical 
parameters. This is to avoid the potential error of failure of detection of significant 
differences in the microbiota between different sub-groups that may be specifically linked 
to certain features of disease. 
 
4.5 Conclusion 
In conclusion, there is no significant difference in the airway microbiota of BTS Step 2 and 
Step 4 asthma groups or BTS Step 4 subgroups taking budesonide or fluticasone in terms of 
overall bacterial load or microbiota diversity. However, certain species are more abundant 
in BTS 2 subjects and vice versa and these findings require further evaluation. The 
microbiota is likely to have an important role in the pathophysiology of airways disease, 
especially in severe disease.             
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Chapter 5: Conclusion 
Review of the existing literature in the field suggests airways diseases are heterogeneous 
phenomena which are currently categorised using ill-defined diagnostic labels that 
artificially separate patients with airways disease into ‘distinct’ groups. This categorisation is 
often based on symptoms and measurement of physiological markers such as airflow 
obstruction which lack specificity for the pathophysiological processes underlying these 
changes and hence are poor predictors of treatment response. This process has improved 
the recognition and outcomes of many patients that display the ‘classical’ features of these 
diagnostic labels, who probably represent frequently occurring phenotypes or ‘clusters’ of 
disease. However, the limitations of this approach for subjects elsewhere on the ‘spectrum’ 
of airways disease, who are often excluded from RCTs (859, 860), are becoming apparent. 
These limitations may account for the lack of further improvement in treatment outcomes 
of airways disease seen in Westernised nations over the last 10 years despite increasing 
expenditure. 
Evidence is accumulating that a number of different cellular and molecular pathways 
(‘endotypes’) underlie the clinical features (‘phenotype’) of airway disease expressed by an 
individual. These endotypes may combine and interact to produce an individual phenotype 
on the “spectrum” of airways disease (861), which may have the physical disease 
characteristics of any of the classically described conditions, either in isolation or 
combination. Therefore, rather than attempting to classify a subject as having a “disease” 
based on the measurement of certain physiological parameters and proceeding to treat 
them for that ‘disease’, outcomes may improve if treatment is specifically targeted at the 
underlying endotype(s) recognised in that individual. Studies demonstrating improved 
outcomes when treatment of airway disease is based on biomarkers appear to justify such 
an approach (299, 303). A new paradigm for the management of airways disease has been 
outlined based on the identification of characteristics (biomarkers or phenotypic 
characteristics) that are good predictors of treatment response (‘treatable traits’) in airways 
disease (160). 
The studies presented in this thesis provide further evidence of the potential benefits of 
such an approach. 
The first study “The utility of exhaled nitric oxide in patients with suspected asthma” 
demonstrated that the measurement of a biomarker of Th2 inflammation (FENO) has the 
potential to allow stratification of a cohort of patients presenting with “asthma-like” 
symptoms into those who are likely to benefit from ICS treatment and those who are not. 
Such an approach might avoid the problems associated with the current system of 
‘treatment trials’ of ICS which are complicated by issues of ‘regression to the mean’ of 
symptoms whilst using ICS and retrospective, often incorrect, diagnoses of “asthma”. This 
approach is currently being tested in a placebo controlled RCT which aims to determine 
whether a low level of exhaled nitric oxide can identify patients who will not benefit from 
inhaled steroid treatment. If this proves to be the case an algorithm that targets treatment 
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based on FENO level could potentially reduce the substantial costs associated with 
unnecessary ICS prescription, adverse effect exposure and incorrect diagnoses of asthma. 
Similar points regarding the identification of treatable characteristics in subjects with 
airways disease also emerge from the second study “An open label trial of azithromycin in 
chronic productive cough”. This cohort of patients with the symptom of chronic productive 
cough of ill-defined cause demonstrated a significant symptomatic improvement to 
azithromycin. These subjects are not easily categorised by any of the existing diagnostic 
labels for airways disease and many had experienced delayed recognition, consultation for 
and treatment of their symptoms, despite in some cases having had symptoms for years. 
The study suggests that using a biomarker (sputum neutrophil count) and/or biopsy 
evidence of inflammation may allow even more effective targeting of azithromycin than the 
CPC symptom alone, although the findings are limited by the lack of a placebo control and 
the small size of the study. Neutrophilic inflammation in airways disease appears to be a 
‘treatable trait’ which has been demonstrated to respond to macrolide therapy across 
groups of subjects with different disease labels. Further work in this area should 
concentrate on attempting to elucidate the pathological basis for this condition. The first 
step in doing this will be investigation of the bacterial content of the airways of these 
patients using the microbiota profiling techniques outlined in Chapter 4. Changes in 
microbiota composition have been noted in bronchiectasis and if this condition is indeed a 
precursor to bronchiectasis early changes to the microbiota such as increased abundance of 
potentially pathogenic organisms may be observed. Samples were taken and stored from 
this study and some initial microbiota analysis on these will be performed. Ultimately now 
this cohort has been identified and described further longitudinal studies need to be 
performed in patients from this cohort to determine the natural history of this condition. 
Such studies should aim to clarify whether these subjects will inexorably progress to 
develop radiological bronchiectasis and if treatment i.e. an RCT of azithromycin can delay or 
even potentially stop such progression.  
Both of these studies suggest that stratifying subjects with certain symptoms using 
biomarkers can allow accurate predictions of treatment response to be made. New studies 
investigating the potential of such an approach are currently underway.   
The third study “Microbiota in Asthma” aimed to characterise the airway bacterial 
microbiota in groups of subjects with diagnoses of asthma using specified dose ranges and 
types of inhaled steroids. The airway microbiota is a poorly described pathological 
component of airways disease, and this study aimed to describe in detail the bacterial 
communities extant within the airways of these different groups to determine whether 
inhaled steroid dose or type affected airway community composition. Broadly no 
differences in the abundance or community structure of bacteria in the airways were found 
between the BTS Step 2 and 4 treatment groups or the BTS Step 4 subgroups taking 
budesonide or fluticasone. This suggests that varying inhaled steroid dose or type does not 
fundamentally alter the airway microbiota, although significant differences in the 
abundance of certain bacterial species between the groups were noted. As the roles of 
particular bacterial species in the microbiota are further elucidated the importance of these 
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findings may become clearer. With the need to further characterise airways disease and 
recognise biomarkers for targeting treatment further studies of the airway microbiota, 
especially those based on answering clinically relevant questions, are required. Further work 
in this area should include the investigation of whether overall bacterial load or relative 
abundance of potentially pathogenic organisms such as H. influenzae or P. aeruginosa could 
serve as an early “biomarker” for airways disease that could be used to guide treatment. A 
future clinical interventional study should be planned in which ICS are introduced to steroid 
naïve subjects with longitudinal microbiota sampling over a prolonged time course. This 
study design would be the best way of answering the question of whether or not ICS affect 
the microbiota as it would allow comparison of intra subject comparison of bacterial airway 
composition pre and post ICS thus eliminating the considerable difficulties caused by 
significant inter subject microbiota variability. Systematic examination of whether 
microbiota composition varies between different airways disease phenotypes and 
interventional studies examining the effects of other therapeutic agents such as 
azithromycin on the microbiota should also be performed. 
In summary, the studies presented in this thesis provide support for the consideration of 
airways disease as a spectrum of disease with a number of underlying pathophysiological 
components, the recognition of which can be used to selectively target treatment 
potentially resulting in improved patient outcomes. As the biochemical and eventually 
fundamental genetic abnormalities that predispose to airways disease are further 
elucidated it is hoped that the continuing use of such an approach will ultimately abolish the 
need for existing archetypal disease labels and eventually lead to a new era of precision 
medicine in which specific treatments can be accurately targeted to an individual subject. 
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APPENDIX A:  
PATIENT INFORMATION SHEET  
(Version 2.0, 06/09/2012) 
 
Title: Reducing Costs in Asthma Management – A Pilot Study  
Chief Investigator: Dr Tim Harrison  
 
Introduction 
You are being invited to take part in a research study. Before you decide, it is important for 
you to understand why this research study is being conducted and what it will involve. 
Please take the time to read the following information carefully and discuss it with others if 
you wish. Please feel free to ask us if there is anything that is not clear or if you require any 
further information. You may keep this information for future reference.  
Purpose of the Study 
Your GP has recommended treatment with an inhaled steroid for suspected asthma. 
Although asthma is very common and you have symptoms which could be caused by 
asthma, we now know that a large number of patients treated for asthma have no firm 
evidence that they either have asthma or need inhaled steroid treatment. This is mainly 
because we have no really good tests to confirm if somebody does or does not have 
asthma.  
 
Researchers at the Respiratory Research Unit at Nottingham City Hospital wish to establish 
whether there are baseline tests which can reliably identify patients who will not benefit from 
inhaled corticosteroid treatment. If successful this will prevent patients taking a treatment, 
sometimes for many years, which they do not really require. 
 
Why have I been chosen? 
You have been chosen because you have been prescribed an inhaled steroid for suspected 
asthma.  
Do I have to take part? 
It is entirely up to you whether or not you decide to take part. If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent form (you will 
be given a copy of this as well). If you decide to take part you are still free to withdraw at any 
time and without giving a reason. A decision to withdraw, or a decision not to take part, will 
not affect the standard of care you already receive or your legal rights.  
What will happen to me if I take part? 
If after reading the information sheet, you would like to take part in this study, please get in 
touch with a member of the study research team (their contact details are on the bottom 
page of this information sheet) and we will arrange an appointment for you at Nottingham 
City Hospital to discuss the study further and if agreeable we will ask you to sign a consent 
form.  
In addition to any tests your GP has already arranged, we would like to perform some 
additional tests and then review your response to your inhaled steroid at various time points. 
This will allow us to determine whether there are better ways of deciding who does or does 
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not need this treatment and will help your GP determine whether you need to continue taking 
your inhaled steroid. 
Visit 1 (Respiratory Research Unit, Nottingham City Hospital) 
This visit will ideally take place before you start taking your new inhaled steroid; and your GP 
will advise you whether this will or will not be possible. During this visit (approximately 2 
hours), you will be asked about your past medical history and the following procedures will 
be carried out: 
 
 Respiratory Questionnaires: You will be asked to fill out 2 short questionnaires 
(Juniper Asthma Control Questionnaire & Asthma Control Test) about your asthma 
symptoms and how it affects your daily life. 
 Spirometry Test: This simple blowing test is used to measure your lung function (the 
size of your lungs and how quickly you can empty them). You will be asked to 
breathe in and then blow out very fast into a mouth piece.  
 Blood Sample: We would like to take a small amount of blood (20mls or the 
equivalent of 4 teaspoons) from your arm for further analysis. 
 Bronchial Challenge: This test is performed to measure how irritable your airways 
are. You will be asked to breathe in very small quantities of a drug (Methacholine) 
that is designed to make you wheezy. After each dose we will measure your lung 
function as described previously and we will stop when your blowing test falls by 20% 
or earlier if you feel unwell. 
 Exhaled Nitric Oxide: This simple test measures the amount of inflammation in the 
breathing tubes by measuring the concentration of exhaled nitric oxide. It involves 
breathing into a tube connected to an analyser for a few seconds at various flow 
rates.  
 Allergy Skin Prick Test: This test is performed to determine whether you have a 
specific allergy to something and involves pricking your skin through a solution 
containing an allergen. This is a standard test, which measures your reaction to 6 
allergens; cat, dog, house dust mite, aspergillum, tree pollen & grass pollen. 
 Sputum Induction: We would like to take a sputum/phlegm sample to be analysed 
in our laboratories, to look for inflammatory cells and chemicals that may be 
responsible for causing your chest problem. If you cannot produce a sample 
spontaneously, we would like to ‘induce sputum’. This procedure involves inhaling 
mildly salty water for 5 minutes to produce a sputum sample. 
 
Visit 1a (Optional Visit, 24 hours after Visit 1) 
 
If after Visit 1, we believe you may have airflow obstruction, we would like you to attend for 
an optional visit, up to 24 hours after Visit 1, which will provide further information about your 
airways. However; please be aware that this visit isn’t an essential part of the study should 
this be inconvenient.  
 
During this visit (approximately 30 minutes), we will perform a spirometry test as before, but 
will also repeat this test again after you have taken a drug called salbutamol to look for an 
improvement in your lung function; this is called reversibility testing.  
 
Please be aware that if you are already taking salbutamol, you must stop taking this 
medication up to 6 hours before this test is conducted. However, your study doctor will 
advise you in more detail about this.  
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Visit 2 (Follow-Up – 1 month) 
We will ask you to attend for a follow-up visit at Nottingham City Hospital, 1 month after your 
initial visit, and whilst you are taking your prescribed inhaled steroid. The following tests will 
be repeated:- 
 Respiratory Questionnaires  
 Spirometry  
 Exhaled Nitric Oxide 
 Bronchial Challenge 
 Sputum Induction  
 Blood Sample 
 
Visit 3 (Final Visit – 3 months) 
We will ask you to attend for a final follow-up visit at Nottingham City Hospital, 3 months 
after your initial visit, and after you have finished taking your inhaled steroid where the 
following tests will be repeated:- 
 Respiratory Questionnaires 
 Spirometry  
 Exhaled Nitric Oxide Measurements 
 Bronchial Challenge 
 Sputum Induction  
 Blood Sample 
 
At this visit we will also be able to provide you and your GP with an in-depth review of your 
response to the inhaled steroid you will have been taking for 3 months, allowing your GP to 
make a clear decision on whether or not they feel you should continue with this treatment. 
What do I have to do? 
You should continue to carry on with your normal daily activities and take your usual 
medication. We also ask that you attend the scheduled study visits (although there is some 
flexibility in terms of the days and times when these occur) and complete the study 
paperwork.  
What are the possible benefits of taking part? 
It is hoped that the results of this study will lead to a greater understanding of asthma and 
which patients will and will not benefit from inhaled corticosteroid treatment. By taking part in 
this study you and your doctor will also have very detailed information about whether or not 
you have benefitted from the inhaled steroid you were prescribed and therefore whether or 
not it should be continued.  
 
What are the possible disadvantages/risks of taking part? 
As with all tests/procedures some people experience side effects, some of which are 
detailed below:- 
Sputum Induction: Occasionally the inhalation of salt solution in order to produce a sputum 
sample can make you wheezy. However, we will monitor you closely, and if necessary, this 
can quickly be reversed by using a Salbutomol inhaler (Ventolin) which will be present 
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throughout this procedure. Please be aware that this test will be performed by an 
experienced research nurse/officer. 
Bronchial Challenge: This is a simple and safe test widely used in the assessment of 
asthma. Nevertheless you may experience chest tightness, wheeze and a cough; however 
these symptoms are usually mild and only last for a few minutes. They are easily reversed 
by inhaling a drug for treating asthma (salbutamol).   
Allergy Skin Prick Test: This is a very safe test but can commonly cause itching around the 
site where the allergen has been introduced into the skin. The itching will last for about an 
hour, and can be reduced by taking an antihistamine if necessary.   
Blood Tests: Occasionally, some people feel faint during a blood test. If this occurs, please 
tell the person doing the test, as you should immediately lie down to prevent fainting. 
Sometimes after donating blood, a bruise develops where the needle was inserted.  
If you experience any unwanted side effects during the study you should inform a member of 
the research team. 
 
What will happen if I don’t want to carry on with the study? 
You are free to withdraw from this study at any time and without giving a reason. A decision 
to withdraw, will not affect the standard of care you already receive. However, please be 
aware, that should you wish to withdraw, the information collected so far cannot be erased 
and may still be used in the final project analysis. Any stored tissue samples that can still be 
identified as yours will be destroyed if you wish. 
Will my taking part in the study be kept confidential? 
We will follow ethical and legal practice and all information about you will be handled in 
confidence. 
If you join the study, some parts of your medical records and the data collected for the study 
will be looked at by authorised persons from the University of Nottingham who are 
organising the research. They may also be looked at by authorised people to check that the 
study is being carried out correctly. All will have a duty of confidentiality to you as a research 
participant and we will do our best to meet this duty.  
All information which is collected about you during the course of the research will be kept 
strictly confidential, stored in a secure and locked office, and on a password protected 
database.  Any information about you which leaves the hospital will have your name and 
address removed (anonymised) and a unique code will be used so that you cannot be 
recognised from it.   
Your personal data (address, telephone number) will be kept for up to 12 months after the 
end of the study so that we are able to contact you about the findings of the study. All other 
data (research data) will be kept securely for 7 years.  After this time your data will be 
disposed of securely.  During this time all precautions will be taken by all those involved to 
maintain your confidentiality, only members of the research team will have access to your 
personal data.  
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Information on the storage and use of tissue samples for research 
Any tissue sample you donate will be stored in a secure research facility at the University of 
Nottingham (Respiratory Research Unit, Clinical Sciences Building, Nottingham City 
Hospital), for as long as is required for the purposes of this study. The study researchers 
wish to measure the small particles (molecules/cells) found in your blood and 
sputum/phlegm in order to better understand asthma.  
Your sample will have your code which is unique to yourself, a barcode and date of study. 
By using these numbers, we can trace which sample belongs to you. The analysis of 
samples will take place within the Respiratory Research Unit at Nottingham City Hospital. 
Please note; your sample will not be sold for profit or used in any animal research.  
With your permission we would like to retain any remaining tissue/blood in a link-anonymised 
form for future laboratory research into respiratory disease (as yet unspecified). If you agree, 
the remaining tissue/blood will be stored on University premises under our Human Tissue 
Authority License. Finally, we often work together with scientists at other universities, as well 
as with commercial companies, and this often involves sharing research samples with them. 
With your consent we may wish to send some of your sample to third parties; including EU 
and Non-EU countries and commercial companies. Please be aware that your personal 
details would be removed in order that you cannot be identified by these third parties. If you 
agree to this, please indicate on the consent form as this is optional. 
 
Will any genetic tests be carried out?  
No 
Will travel expenses be reimbursed?  
Participants will not be paid an inconvenience allowance to participate in the study. 
However, we will cover the cost of travelling to the hospital (maximum £20 allowance per 
visit). 
Involvement of the General Practitioner/Family Doctor (GP) 
With your permission we will write to your GP to notify them that you are going to take part in 
this study and provide him/her with an in-depth review of your response to the inhaled 
steroid you will have been taking for 3 months; allowing your GP to make a clear decision on 
whether or not they feel you should continue with this treatment. 
Who is organising and funding this study? 
The research has been organised by the University of Nottingham and funded by the 
National Institute for Health Research (NIHR). Please be aware that the research team 
involved in this study are not being paid for including you in this study. 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given a 
favourable ethical opinion for conduct in the NHS by the Derby 1 Research Ethics 
Committee and will be subject to the Data Protection Act.   
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What will happen to the results of this study? 
We intend to publish the results of this study in a medical respiratory journal. A summary of 
these results will also be made available on the Nottingham Respiratory Research Unit’s 
website (www.nrbru.org.uk). Furthermore, a copy of any published material regarding the 
study will be made freely available to you. Please be aware that you will not be identified in 
any publications – all data used in the publications will be anonymous. 
 
What if there is a problem? 
If you wish to complain or have any concerns about the way in which you have been treated, 
please get in touch with the research team (see below), who will do their best to answer any 
problems you might have. In addition, the normal NHS complaints procedures are also 
available to you (e.g. Patient Advice and Liaison Service – PALS); please telephone  
0115 92449924 ext 65412 for Nottingham University Hospitals NHS Trust. 
 
In the event that something does go wrong and you are harmed during the research study 
there are no special compensation arrangements.  If you are harmed and this is due to 
someone’s negligence then you may have grounds for a legal action for compensation but 
you may have to pay your legal costs. 
 
Contact for Further Information 
If after reading this information sheet, you would like to take part in this study, please get in 
touch with a member of the research team (see contact details below, or please complete 
the reply slip and return it to us in the pre-paid envelope) and we will arrange an 
appointment for you at Nottingham City Hospital to discuss the study further.  
 
Dr Tim Harrison 
 
Respiratory Research Unit 
Clinical Sciences Building 
Nottingham City Hospital 
Nottingham 
NG5 1PB 
Tel: 0115 8231317 
E-Mail: tim.harrison@nottingham.ac.uk 
 
Or  
 
Emma Wilson (researcher)  
 
Respiratory Research Unit 
Clinical Sciences Building 
Nottingham City Hospital 
Nottingham 
NG5 1PB 
Tel: 0115 8231935 
E-Mail: emma.wilson@nottingham.ac.uk 
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Appendix B: Juniper Asthma Control Questionnaire (ACQ)  
 
Please complete questions 1-6. Circle the number of the response that best describes 
how you have been during the past week.  
 
1. On average, during the past week, how often were you woken by your asthma during 
the night?  
 
0 Never  
1 Hardly ever  
2 A few minutes  
3 Several times  
4 Many times  
5 A great many times  
6 Unable to sleep because of asthma 
2. On average, during the past week, how bad were your asthma symptoms when you 
woke up in the morning?  
 
0 No symptoms  
1 Very mild symptoms  
2 Mild symptoms  
3 Moderate symptoms  
4 Quite severe symptoms  
5 Severe symptoms  
6 Very severe symptoms  
 
3. In general, during the past week, how limited were you in your activities because of 
your asthma?  
 
0 Not limited at all  
1 Very slightly limited  
2 Slightly limited  
3 Moderately limited  
4 Very limited  
5 Extremely limited  
6 Totally limited  
 
4. In general, during the past week, how much shortness of breath did you experience 
because of your asthma?  
 
0 None  
1 A very little  
2 A little  
3 A moderate amount  
4 Quite a lot  
5 A great deal  
6 A very great deal 
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5. In general, during the past week, how much of the time did you wheeze?  
 
0 Not at all  
1 Hardly any of the time  
2 A little of the time  
3 A moderate amount of the time  
4 A lot of the time  
5 Most of the time  
6 All the time  
 
6. On average, during the past week, how many puffs of short-acting bronchodilator (e.g. 
Ventolin) have you used each day?  
 
0 None  
1 1±2 puffs most days  
2 3±4 puffs most days  
3 5±8 puffs most days  
4 9±12 puffs most days  
5 13±16 puffs most days  
6 More than 16 puffs most days  
 
To be completed by a member of the clinic staff:  
 
7. FEV1 pre-bronchodilator: ..................................  
FEV1 predicted: ................................................  
FEV1 % predicted: ............................................  
(Record actual values on the dotted lines and score the FEV1 % predicted in the next 
column) 
0 >95% predicted 
1 95-90%  
2 89-80%  
3 79-70%  
4 69-60%  
5 59-50%  
6 <50% predicted 
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Appendix C: Asthma Control Test 
1) During the past 4 weeks, how often did your asthma prevent you from getting as 
much done at work, school or home? 
1 All of the time  
2 Most of the time  
3 Some of the time  
4 A little of the time  
5 None of the time  
 
2) During the past 4 weeks, how often have you had shortness of breath? 
 
1 More than once a day  
2 Once a day  
3 3-6 times a week  
4 1-2 times a week  
5 Not at all 
 
3) During the past 4 weeks, how often did your asthma symptoms (wheezing, coughing, 
chest tightness, shortness of breath) wake you up at night or earlier than usual in the 
morning?  
 
1 4 or more times a week  
2 2-3 nights a week 
3 Once a week  
4 Once or twice  
5 Not at all 
 
4) During the past 4 weeks, how often have you used your reliever inhaler (usually 
blue)? 
 
1 3 or more times a day  
2 1-2 times a day  
3 2-3 times a week  
4 Once a week or less  
5 Not at all  
 
5) How would you rate your asthma control during the past 4 weeks? 
1 Not controlled 
2 Poorly controlled 
3 Somewhat controlled  
4 Well controlled  
5 Completely controlled 
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APPENDIX D:  
Participant Information Sheet 
Final version 1.0 
 
Title of Study: An open label trial of azithromycin in chronic 
productive cough 
Name of Researcher(s): Dr Tim Harrison, Dr Matthew Martin, Dr Dominick 
Shaw, Dr Helen Roberts 
 
We would like to invite you to take part in our research study. Before you 
decide we would like you to understand why the research is being done 
and what it would involve for you. One of our team will go through the 
information sheet with you and answer any questions you have. Talk to 
others about the study if you wish. Ask us if there is anything that is not 
clear. 
 
 
What is the purpose of the study? 
 
We have noticed a group of patients presenting with a longstanding wet 
cough which has often been treated as asthma. The cough is productive 
of phlegm which frequently contains bacteria, and it does not get better 
with standard antibiotic treatment. 
 
A very similar cough is seen in people who smoke, have exposure to 
airbourne dusts or chemicals or have a condition known as bronchiectasis 
in which there is scarring of the airways in the lung leading to coughing 
up lots of phlegm. In our research study these problems have already 
been ruled out. 
 
We have found that prolonged treatment of people with longstanding wet 
cough with an antibiotic called azithromycin is very effective at improving 
the cough. However, using azithromycin in this way has not yet been 
studied in detail to work out how effective it is. 
 
Our research will try to work out what the cause for your cough is and if it 
is actually caused by a new condition which does not yet have a name. 
We will also try to determine how effective azithromycin is at improving 
the cough. 
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Why have I been invited? 
 
You are being invited to take part because you have a longstanding wet 
cough of unknown cause. We are inviting 50 participants like you to take 
part. 
 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part.  If you do decide to 
take part you will be given this information sheet to keep and be asked to 
sign a consent form. If you decide to take part you are still free to 
withdraw at any time and without giving a reason. This would not affect 
your legal rights. 
 
What will happen to me if I take part? 
 
Investigations 
 
Participants in this study will first have a series of additional investigations 
aimed at trying to discover the cause of their wet cough. These include:  
 Sputum microbiology and differential cell counts: Taking a 
sputum sample to look for inflammatory cells, bacteria and 
chemicals that may be responsible for causing your chest problem. 
We will take a further sputum sample with your agreement for 
storage and future analysis by a research team. This future analysis 
may involve looking for other inflammatory cells, chemicals or for 
DNA of any bacteria that may be present in the sputum.  
 Exhaled nitric oxide measurement: Measuring the amount of 
exhaled nitric oxide in your breath to measure the amount of 
inflammation in the breathing tubes of your lungs. 
 Exhaled carbon monoxide measurement: Measuring the 
amount of carbon monoxide in your breath to assess any exposure 
you may have had to cigarette smoke. 
 Leicester Cough Questionnaire: Completing a questionnaire 
assessing how your cough affects your life. 
 Blood samples: Blood samples will be taken at a certain point to 
ensure the azithromycin treatment does not affect your liver, which 
is one of its recognised side effects. 
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All of these investigations will take place in our research clinic at the 
Nottingham City Hospital. Further information on these investigations can 
be found on our website: 
(http://www.nrru.org/NRRU_Patient_Information.html). If you do not 
have access to the internet, printed information leaflets describing these 
tests in further detail are available upon contacting the Nottingham 
Respiratory Research Unit on the telephone number given below. 
 
Bronchoscopy 
 
We also intend to perform a procedure called a bronchoscopy on each of 
the participants in the study. Bronchoscopy is a routine diagnostic 
examination which allows us to directly examine the large air passages in 
the lung and retrieve cells from the lining of the airways.  Bronchoscopy is 
a safe procedure and carries little risk. 
 
The test takes about 15 minutes but you will need to be at the hospital for 
about half a day. It involves the following: 
   
You will be asked not to eat or drink anything for at least 6 hours prior to 
the bronchoscopy.  You can take your medication including inhalers as 
normal.  
 
You will be given oxygen to breathe throughout the procedure and the 
amount of oxygen in your blood will be measured throughout the test 
with a monitor around a finger (oximeter).  A small drip (cannula) will be 
placed in a vein in your arm and we will monitor your heart rate, and 
measure your blood pressure.  
 
A local (topical) anaesthetic called lignocaine, or an alternative, is then 
sprayed on to the back of the mouth and into the nose.  This anaesthetic 
numbs the nerves so that the bronchoscope can be easily inserted into 
the wind passage without discomfort.  Lignocaine is the same as the local 
anaesthetic used by dentists (you should let us know if you are allergic to 
any local anaesthetic agents).  Midazolam, or an alternative sedative, 
injected through the drip, is also given at this point to make you more 
relaxed and drowsy.  You may be given an injection of alfentanyl or 
fentanyl which are medicines which will also calm you and will prevent 
you from coughing too much. 
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The bronchoscope, which is a thin flexible instrument, is then passed 
usually through the nose and down the back of the throat.  If it is not 
easy to pass the bronchoscope through the nose, it will be passed through 
the mouth instead. More local anaesthetic is then placed on the vocal 
cords and the bronchoscope passed through the voice box and into the 
lungs. The following samples will be collected: 
 
1) Wash – a small amount of fluid is injected and sucked out. In all, we 
do this four times in succession.  
2) Biopsies – Small tissue samples (maximum of 10) will be taken 
from the airway wall.  
  
The samples obtained will be used to evaluate the structure of the airway, 
the types of inflammatory cells found in the airway wall and to measure 
the presence of proteins which could be involved in inflammation. With 
your consent some of the samples will be stored for future analysis which 
may include detecting the DNA of any micro-organisms present in the 
lung.  
 
After your examination, the lining of your mouth and throat will remain 
numb just in the same way as your mouth would after a dental 
procedure.  You will experience a sore-throat and a cough. These 
discomforts will wear off within the next 2 hours or so.  You should not 
eat or drink for at least 2 - 3 hours.  This precaution is necessary to keep 
food or liquids from accidentally entering the windpipe or lungs.  
 
As you will be given midazolam you will not be able to drive or operate a 
machine for 24 hours after administration. 
 
If clinically relevant information is obtained at the time of the 
bronchoscopy this will be shared with you and the relevant doctors 
involved with your care. The samples obtained will be anonymised and 
the results will not be put in your medical records 
 
Following bronchoscopy, we will invite you to start part 2 of the study, 
which involves treatment with the azithromycin antibiotic for a period of 
12 weeks. 
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Azithromycin (Other names: Zithromax) 
In this study, one tablet of azithromycin (dose 250mg) must be taken by 
mouth 3 times per week, on Monday, Wednesday and Friday. 
 
Timing of study 
Overall, participation in this study will require five visits to the 
Nottingham City Hospital over a period of 17-18 weeks, which is 
summarised here: 
 
PART 1 OF STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinic appointment visit 
 
You will be identified potential candidate for the study in a respiratory clinic appointment by 
one of the study team or one of our colleagues. You should have already had a number of 
investigations for your cough that have not fully explained the cause. You will be asked if you 
would like to take part in the study and any questions you may have will be answered. You will 
be asked to give written informed consent in order to take part in 
the study. 
 
Duration: 10-15 minutes 
Hospital visit 1 
 
Face to face visit with our research team in the hospital. This visit will take place in the 
Nottingham City Respiratory Research Unit. You will be seen by a doctor who will ask some 
questions relating to your condition to make sure you are eligible for the study. If so, we will 
measure the exhaled gases (nitric oxide and carbon monoxide) in your breath (explained 
above) and take some sputum samples with your permission for future analysis. We will 
perform a set of breathing tests (spirometry), and ask you to collect the sputum you produce 
over a day in a container, also making a note of the colour of this sputum.  
 
You will be asked to complete a questionnaire assessing how your cough affects your life. 
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PART 2 OF STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bronchoscopy visit (week 2) 
 
You will attend the endoscopy unit in the hospital for a bronchoscopy (as described above).  
We will ask you to start taking the azithromycin after your bronchoscopy. 
Duration: 4 hours 
Hospital visit 3 (after 12 weeks of treatment) 
 
Face to face visit with our research team at the Nottingham City Respiratory Research Unit. 
You will be seen by a doctor who will repeat the investigations you had in visit 2, including the 
questionnaire, spirometry, sputum collection and colour, blood tests and ECG to assess the 
effects of the treatment. 
 
Duration: 1 – 1.5 hours 
Hospital visit 2 (4 weeks after starting treatment) 
 
Face to face visit with our research team at the Nottingham City Respiratory Research Unit. 
We will ask you some questions to see if you have experienced any problems with treatment 
and repeat some blood tests. 
 
Duration: 0.5 hours 
Finally, we will also take some blood tests and perform a simple electronic tracing of your 
heart activity (ECG) to ensure azithromycin will be safe for you to take. 
 
After these investigations we will provide you with the full 3 month course of azithromycin, to 
begin taking following bronchoscopy. 
 
Duration: 1.5 -2 hours 
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Expenses and payments 
 
Participants will be paid an inconvenience allowance to participate in the 
study of up to £150 including time and travel expenses. 
 
 
What are the possible disadvantages and risks of taking part?  
 
Investigations 
Providing sputum and blood samples and having the levels of carbon 
monoxide and nitric oxide in your breath measured do not pose any risks 
and are usually well tolerated.  
 
Bronchoscopy 
Bronchoscopy with lung biopsy is usually a very safe procedure but there 
are some very small risks associated with this.  
 
The medication for the bronchoscopy may make you feel lightheaded or 
dizzy. The initial medication, or placement of an IV drip, may cause local 
pain, bleeding and swelling. There is a very small risk (less than 1 in 100) 
of infection at the IV site. 
 
Likely side effects of the bronchoscopy and the related lavage and biopsy 
(occurring in 25 out of 100 procedures) include discomfort (coughing and 
occasionally gagging) and nosebleed (if the bronchoscope was passed 
through your nose). You may cough up small flecks of blood for 24 hours 
after the procedure. 
 
Hospital visit 4 (follow up visit) 
 
Face to face visit with our research team at the Nottingham City Respiratory Research Unit. 
You will be seen by a doctor who will assess your symptoms after treatment. We will again ask 
you to complete a questionnaire assessing how your cough affects your life. 
 
We will also take some final samples of your sputum including, with your permission, samples 
for future analysis. 
 
Duration: 0.5 – 1 hours 
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More serious complications from the bronchoscopy, lavage, and biopsy 
include major bleeding, collapse of the lung, vocal cord and windpipe 
spasms, pneumonia or bronchitis and irregular heartbeats. These have 
been reported but are extremely rare (occurring in less than 1 out of 
1000 procedures). One death has been reported after research 
bronchoscopy in the USA, but not in the UK. Many thousands of research 
bronchoscopies have been performed, so the risk of death is extremely 
remote. 
 
Azithromycin 
Azithromycin is a very safe medication which is commonly used to treat 
infection, and is often used over long courses of 3 months or longer. As 
with all medicines, it has side effects. Common side effects include 
stomach upsets and diarrhoea (which may occur in around 1 in 10 
people) and headaches and dizziness, tiredness or skin rashes (which 
may occur in around 1 in 100 people), but these are usually temporary 
and not serious. In rare cases azithromycin may cause more serious side 
effects relating to the heart or liver (less than 1 in 10,000) which will be 
carefully monitored for as part of the study. If you are allergic to any 
medications including antibiotics please let us know. 
 
It is important to note that in this study, azithromycin is being used “off 
licence” which means that the manufacturers of this drug do not currently 
have enough information to recommend or not recommend using the 
drug in this way. However, the drug has been licensed for use in very 
similar conditions as it has proven to be of benefit, and is already used off 
licence in our respiratory unit for people with your symptoms. 
 
 
What are the possible benefits of taking part? 
 
You may benefit from the 3 months of azithromycin treatment although 
we cannot promise that this study/trial will cure your cough. The 
information we get from this study may help explain what is causing it 
and help us treat patients in the future.  
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What happens when the research study stops? 
 
You will be referred back to your usual respiratory physician or GP and 
have further follow up if necessary in the normal respiratory clinic. 
 
 
What if there is a problem? 
 
If you have a concern about any aspect of this study, you should ask to 
speak to the researchers who will do their best to answer your questions.  
The researchers contact details are given at the end of this information 
sheet. If you remain unhappy and wish to discuss the matter further, you 
can do this by getting in touch with the Nottingham Hospitals Patient 
Advice and Liaison Service (PALS) in person, by telephone or e-mail who 
can try and resolve the situation. Details are provided below. If you still 
wish to make a formal complaint you can do this through the NHS formal 
complaints procedure (further details of which can be provided by the 
PALS service). 
 
Nottingham City Campus PALS service 
By person: PALS is on the South Corridor at Junction S6. Opening times 
9:30 – 4:30 pm Monday - Friday 
Tel: 0800 052 1195 (free from a landline) or 0115 969 1169 ext 59671 
E-mail: pals@nuh.nhs.uk 
Post: NUH NHS Trust, c/o PALS, Freepost, NEA 14614, Nottingham NG7 
1BR 
 
 
Will my taking part in the study be kept confidential? 
 
We will follow ethical and legal practice and all information about you will 
be handled in confidence. 
 
If you join the study, some parts of your medical records and the data 
collected for the study will be looked at by authorised persons from the 
University of Nottingham who are organising the research. They may also 
be looked at by authorised people to check that the study is being carried 
out correctly. All will have a duty of confidentiality to you as a research 
participant and we will do our best to meet this duty.  
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All information which is collected about you during the course of the 
research will be kept strictly confidential, stored in a secure and locked 
office, and on a password protected database.  Any information about you 
which leaves the hospital will have your name and address removed 
(anonymised) and a unique code will be used so that you cannot be 
recognised from it.   
 
Your personal data (address, telephone number) will be kept for 12 
months after the end of the study so that we are able to contact you 
about the findings of the study and possible follow-up studies (unless you 
advise us that you do not wish to be contacted).  All other data (research 
data) will be kept securely for 7 years.  After this time your data will be 
disposed of securely.  During this time all precautions will be taken by all 
those involved to maintain your confidentiality, only members of the 
research team will have access to your personal data. 
 
 
What will happen if I don’t want to carry on with the study?  
 
Your participation is voluntary and you are free to withdraw at any time, 
without giving any reason, and without your legal rights being affected. If 
you withdraw then the information collected so far cannot be erased and 
this information may still be used in the project analysis. 
 
 
Involvement of the General Practitioner/Family doctor (GP)  
 
We will inform your GP about your participation in the trial and send 
him/her a copy of this information sheet. 
 
 
What will happen to any samples I give? 
 
We would also like to seek your consent so that any remaining samples 
may be stored and used in possible future research – this is optional 
(please indicate you agree to this on the consent form). The samples will 
be stored with a code unique to you and securely at the University of 
Nottingham under the University’s Human Tissue Research Licence (no 
12265). 
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Some of these future studies may be carried out by researchers other 
than current team of Dr Harrison including researchers working for 
commercial companies. Any samples or data used will be anonymised, 
and you will not be identified in any way. If you do not agree to this any 
remaining samples will be disposed of in accordance with the Human 
Tissue Authority’s codes of practice. 
 
 
Will any genetic tests be done? 
 
No tests will be performed on any of your samples to determine any of 
your genetic information. In future studies, tests may be performed to 
detect the DNA of any micro-organisms (including bacteria) that may be 
present in the samples 
 
 
What will happen to the results of the research study 
 
We will publish the results of the trial in a high-profile respiratory 
medicine journal, present the results at various scientific conferences, and 
this work will form part of a thesis for a higher degree. You will not be 
identified in any report/publication. We will send you a newsletter with a 
summary of the results. 
 
 
Who is organising and funding the research? 
 
This research is being organised by the University of Nottingham and is 
being funded by the Nottingham Respiratory Medicine Department. 
 
 
Who has reviewed the study? 
 
All research in the NHS is looked at by independent group of people, 
called a Research Ethics Committee, to protect your interests. This study 
has been reviewed and given favourable opinion by Yorkshire & The 
Humber – Leeds West Research Ethics Committee. 
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Further information and contact details 
 
Further information can be obtained from our website: 
http://www.nrru.org/ 
 
Or by telephoning us on:  
 
Matthew Martin 
(Study Doctor) 
Tel: 0115 8231935 
 
Denise Barber                        OR           Tina Wilkinson 
(NRRU Secretary)                                  (CTU Receptionist)  
Tel: 0115 86231317                            Tel: 0115 8404844               
Fax: 0115 8231946                             Fax:0115 84026217 
 
Alternatively, you can write to us at the following address: 
 
Nottingham Respiratory Research Unit         
Room B28 
Clinical Sciences Building 
Nottingham City Hospital 
Hucknall Road 
Nottingham 
NG5 1PB 
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Appendix E: Leicester Cough Questionnaire 
 
This questionnaire is designed to assess the impact of cough on various aspects 
of your life.  Read each question carefully and answer by CIRCLING the response 
that best applies to you. Please answer ALL questions, as honestly as you can.  
 
1. In the last 2 weeks, have you had chest or stomach pains as a result of your 
cough? 
1 
All of 
the time 
2       
Most of 
the time 
3            
A good 
bit of the 
time 
4     
Some of 
the time 
5            
A little of 
the time 
6    
Hardly 
any of 
the time 
7      
None of 
the time 
    
 
2. In the last 2 weeks, have you been bothered by sputum (phlegm) production 
when you cough? 
1 
Every 
time 
2         
Most 
times    
3            
Several 
times 
4     
Some 
times 
5            
Occasionally 
6         
Rarely 
7      
Never 
 
     
3. In the last 2 weeks, have you been tired because of your cough? 
1 
All of 
the time 
2       
Most of 
the time 
3            
A good 
bit of the 
time 
4     
Some of 
the time 
5            
A little of 
the time 
6    
Hardly 
any of 
the time 
7      
None of 
the time 
    
 
4. In the last 2 weeks, have you felt in control of your cough? 
1 
None of 
the time  
 
2      
Hardly 
any of 
the time  
3            
A little of 
the time         
4     
Some of 
the time 
5            
A good 
bit of the 
time  
6       
Most of 
the time  
7          
All of 
the time    
    
 
5. How often during the last 2 weeks have you felt embarrassed by your 
coughing? 
1 
All of 
the time 
2       
Most of 
the time 
3            
A good 
bit of the 
time 
4     
Some of 
the time 
5            
A little of 
the time 
6    
Hardly 
any of 
the time 
7      
None of 
the time 
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6. In the last 2 weeks, my cough has made me feel anxious 
1 
All of 
the time 
2       
Most of 
the time 
3            
A good 
bit of the 
time 
4     
Some of 
the time 
5            
A little of 
the time 
6    
Hardly 
any of 
the time 
7      
None of 
the time 
    
 
7. In the last 2 weeks, my cough has interfered with my job, or other daily tasks 
1 
All of 
the time 
2       
Most of 
the time 
3            
A good 
bit of the 
time 
4     
Some of 
the time 
5            
A little of 
the time 
6    
Hardly 
any of 
the time 
7      
None of 
the time 
    
 
8. In the last 2 weeks, I felt that my cough interfered with the overall enjoyment 
of my life 
1 
All of 
the time 
2       
Most of 
the time 
3            
A good 
bit of the 
time 
4     
Some of 
the time 
5            
A little of 
the time 
6    
Hardly 
any of 
the time 
7      
None of 
the time 
    
 
9. In the last 2 weeks, exposure to paints or fumes has made me cough 
1 
All of 
the time 
2       
Most of 
the time 
3            
A good 
bit of the 
time 
4     
Some of 
the time 
5            
A little of 
the time 
6    
Hardly 
any of 
the time 
7      
None of 
the time 
    
 
10. In the last 2 weeks, has your cough disturbed your sleep? 
 
1 
All of 
the time 
2       
Most of 
the time 
3            
A good 
bit of the 
time 
4     
Some of 
the time 
5            
A little of 
the time 
6    
Hardly 
any of 
the time 
7      
None of 
the time 
    
 
11. In the last 2 weeks, how many times have you had coughing bouts? 
1 
All  
the time 
(continuously) 
2       
Most 
times 
during 
the day 
3            
Several 
times 
during 
the day 
4     
Some 
times 
during 
the day 
5            
Occasionally 
throughout 
the day 
6    
Rarely 
7      
None  
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12. In the last 2 weeks, my cough has made me feel frustrated 
1 
All of 
the time 
2       
Most of 
the time 
3            
A good 
bit of the 
time 
4     
Some of 
the time 
5            
A little of 
the time 
6    
Hardly 
any of 
the time 
7      
None of 
the time 
    
    
13. In the last 2 weeks, my cough has made me feel fed up 
1 
All of 
the time 
2       
Most of 
the time 
3            
A good 
bit of the 
time 
4     
Some of 
the time 
5            
A little of 
the time 
6    
Hardly 
any of 
the time 
7      
None of 
the time 
    
 
14. In the last 2 weeks, have you suffered from a hoarse voice as a result of 
your cough? 
1 
All of 
the time 
2       
Most of 
the time 
3            
A good 
bit of the 
time 
4     
Some of 
the time 
5            
A little of 
the time 
6    
Hardly 
any of 
the time 
7      
None of 
the time 
    
 
15. In the last 2 weeks, have you had a lot of energy? 
 
1 
None of 
the time  
 
2      
Hardly 
any of 
the time  
3            
A little of 
the time         
4     
Some of 
the time 
5            
A good 
bit of the 
time  
6       
Most of 
the time  
7          
All of 
the time    
    
 
16. In the last 2 weeks, have you worried that your cough may indicate a 
serious illness? 
1 
All of 
the time 
2       
Most of 
the time 
3            
A good 
bit of the 
time 
4     
Some of 
the time 
5            
A little of 
the time 
6    
Hardly 
any of 
the time 
7      
None of 
the time 
    
    
 
17. In the last 2 weeks, have you been concerned that other people think 
something is wrong with you, because of your cough? 
1 
All of 
the time 
2       
Most of 
the time 
3            
A good 
bit of the 
time 
4     
Some of 
the time 
5            
A little of 
the time 
6    
Hardly 
any of 
the time 
7      
None of 
the time 
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18. In the last 2 weeks, my cough has interrupted conversation or telephone 
calls 
1 
All of 
the time 
2       
Most of 
the time 
3            
A good 
bit of the 
time 
4     
Some of 
the time 
5            
A little of 
the time 
6    
Hardly 
any of 
the time 
7      
None of 
the time 
    
 
19. In the last 2 weeks, I feel that my cough has annoyed my partner, family or 
friends 
1 
Every 
time I 
cough 
 
2       
Most 
times 
when I 
cough  
3            
Several 
times 
when I 
cough         
4     
Some 
times 
when I 
cough 
5            
Occasionally 
when I 
cough  
6       
Rarely  
7          
Never    
 
 
 
 
LCQ score:     
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Appendix F: AZCC Bronchoscopy Sample Collection  
Order of collecting samples*: 
*Order can be changed if patient not tolerating procedure/frequently coughing as washing 
first may stimulate increased cough. However, this order is preferable to minimise 
contamination of wash samples with blood* 
 
[1] RUL bronchial wash (15ml total – split into 3) – collected into universal sample 
containers 
 
 
[2] 4-8 bronchial biopsies from R bronchus intermedius: 
 
 
OPTIONAL – depending on specific patient consent and tolerance of 
procedure 
[3] 2 bronchial brushings of sub-carina/right bronchus intermedius 
 
 
 1 x 5ml sample labelled with patient details/NHS no and sent to microbiology 
labelled ‘CLINICAL TRIAL 13RM015’ 
 2 x 5ml samples labelled with patient study number only and sent to CSB lab 
 
 
 2-4 into formalin containing histopathology sample container (Labelled with patient 
details/NHS no) and sent to histopathology labelled ‘Azithromycin in Chronic Cough 
Study FAO Dr Soomro’ 
 
 2-4 into universal sample containers containing PBS (labelled with patient study 
number only) sent to CSB lab 
 into 1x 3ml Falcon tube containing BEGM + 1%PSF (labelled with patient study number 
only) sent to CSB lab 
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AZCC Bronchoscopy Sample Processing 
 
Bronchial Washes (x2) 
1x 5ml sample for cell count/viability/supernatant frozen for cytokine analysis 
 Centrifuge for 10 min at 400g  
o Pellet – For cell count/differential 
o Supernatant – divide into aliquots and freeze at -700C (for later cytokine 
analysis) 
 
1x 5ml sample for storage for microbiota work 
 Centrifuge at 1000 rpm for 5 mins  
 Supernatant transferred to a fresh tube and centrifuged at top speed (4180xg) for 15 
mins.  
 Pellet from the first spin labelled “pellet 1” along with the donor information/date 
 Second pellet labelled as “pellet 2” again with donor information 
 Supernatant stored (backup for cytokine analysis) 
Both cell pellets are stored at -800C for bacterial PCR at a later date 
 
Bronchial Biopsies (x4) 
2 sent to histopathology (FAO Dr Soomro) 
Processed, paraffin blocks made 
Initial report made. Samples saved for later reporting once responders/non responders 
identified 
2 for Biobank 
 
Bronchial Brushes (x2) 
For Biobank 
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Appendix G: Radiology  Scoring  Sheet  for  CTs   
 
Atelectasis 0 
None 
1 
<3 areas 
<3cm bands 
2 
>3 areas 
3 
Large 
bands 
 
 
Characteristic   Areas affected 
Lymphadenopathy 
 
Yes No  
Pleural thickening 
 
Yes No  
Patulous oesophagus 
 
Yes No  
Collapsible airways 
 
Yes No  
Endobronchial mucus 
retention 
Yes No  
Ground glass change 
 
Yes No  
Tree in bud changes Yes 
 
No  
AP diameter  
 
 
Other changes/ 
Relevant clinical info 
 
 
 
 
 
Obesity 0 
Underweight 
1 
Expected  
2 
Overweight 
3 
Obese 
Characteristic    Areas affected 
Bronchial wall 
thickening 
0 
None 
1 
Some  
2 
Prominent 
 
Airway 
dilatation 
0 
None 
1 
Minor 
dilatation 
2 
Minor 
bronchiectasis 
 
Mosaic 
perfusion 
0 
None 
1 
Some  
2 
Prominent 
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Study No Bronchial wall thickening BWT Areas affected Airway Dilatation AD Areas affected
AZCC01 0 0
AZCC02 0 0
AZCC03 1 3,4 1 3,4
AZCC04 0 1 4
AZCC05 1 perihilar 2 3,4
AZCC06 0 1 2,3
AZCC07 0 1 3,4
AZCC08 1 perihilar 1 4
AZCC09 0 0
AZCC10 0 2 3,4
AZCC11 2 2,3,4 2 3,4
AZCC12 1 perihilar 1 2,3,4
AZCC13 1 perihilar 1 4
AZCC14 0 1 2
AZCC15 0 1 2,3,4
AZCC16 0 1 4
AZCC17 0 2 3,4
AZCC18 2 perihilar 0 0
AZCC19 0 0
AZCC20 1 2,3 1 2,3
AZCC21 0 1 4
AZCC22
AZCC23 0 1 2
AZCC24 1 perihilar 1 3
AZCC25 1 3 2 3,4
AZCC26 0 1 4
AZCC27 0 0
AZCC28 1 perihilar 0
AZCC29 1 perihilar 0
AZCC30 1 3,4 1 3,4
APPENDIX H: AZITHROMYCIN STUDY CT FEATURES DATA
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Study No Atelectasis Atel Areas affected Mosaic Perfusion MP Areas affected Lymphadenopathy
AZCC01 0 0 0
AZCC02 1 2 0 0
AZCC03 0 0 0
AZCC04 0 0 0
AZCC05 2 4 1 0
AZCC06 2 4 0 0
AZCC07 0 0 0
AZCC08 2 0 0
AZCC09 1 4 0 0
AZCC10 1 4 0 0
AZCC11 2 3,4 1 0
AZCC12 2 4 1 0
AZCC13 2 4 1 0
AZCC14 0 0 0
AZCC15 0 0 0
AZCC16 1 4 0 0
AZCC17 2 3,4 0 0
AZCC18 1 3 0 0
AZCC19 1 4 0 0
AZCC20 1 3,4 1 0
AZCC21 3 4 0 1
AZCC22
AZCC23 1 4 1 0
AZCC24 2 3,4 1 1
AZCC25 1 4 1 0
AZCC26 0 0 0 0
AZCC27 0 0 0
AZCC28 1 2 0 0
AZCC29 0 0 1
AZCC30 1 4 1 2,3 0
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Study No Pleural changes Patulous oesophagus Collapsible airways Endobronchial mucus 
AZCC01 0 0 0 0
AZCC02 0 0 0 0
AZCC03 0 0 0 0
AZCC04 0 0 0 0
AZCC05 0 1 0 0
AZCC06 0 1 0 0
AZCC07 0 0 0 0
AZCC08 0 0 0 0
AZCC09 0 0 0 0
AZCC10 0 0 0 1
AZCC11 0 0 1 1
AZCC12 0 0 0 1
AZCC13 0 0 0 1
AZCC14 0 0 0 0
AZCC15 0 0 0 0
AZCC16 0 0 0 0
AZCC17 1 0 0 0
AZCC18 0 0 0 0
AZCC19 0 0 0 0
AZCC20 0 0 0 0
AZCC21 1 1 0 1
AZCC22
AZCC23 0 0 0 0
AZCC24 0 0 0 0
AZCC25 0 0 0 0
AZCC26 0 0 0 0
AZCC27 0 0 1 0
AZCC28 0 0 0 0
AZCC29 0 0 0 0
AZCC30 0 0 0 0
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Study No Ground glass change Tree in bud AP Diameter Obesity Other changes
AZCC01 0 0 1 Poor quality scan
AZCC02 1 0 1 Ground glass changes (4)
AZCC03 0 0 2
AZCC04 1 0 1 Ground glass changes patchy, small
AZCC05 0 1 3  breathing artefact on scan
AZCC06 0 0 29.8/16.0 1
AZCC07 0 0 3 Poor quality breath-hold
AZCC08 0 0 1 Longstanding elevated R hemidiaphragm 
AZCC09 0 0 1 Enlarged thyroid. Pulmonary nodule RLL
AZCC10 0 0 24.3/9.1 1 Poor quality breath-hold
AZCC11 0 0 21.6/14.0 2 Slight collapse of trachea
AZCC12 1 0 30.6/16.4 1  ground glass change peribronchial 
AZCC13 0 1 21.2/13.4 1 patchy tree in bud 
AZCC14 0 0 24.4/11.3 1 thymic density ant mediastinum
AZCC15 0 0 2
AZCC16 0 0 23.1/11.5 2 movement artefact
AZCC17 0 0 1 few small areas pleural thickening (3)
AZCC18 0 0 23.5/21.1 3
AZCC19 0 0 28.0/20.0 3 motion artefact
AZCC20 1 0 2 ground glass change lingula
AZCC21 1 0 2 hilar +mediastinal LN
AZCC22
AZCC23 0 0 2 poor breath hold
AZCC24 0 1 2 mediastinal LN >12mm
AZCC25 0 0 2
AZCC26 0 0 1
AZCC27 0 0 2 L+R main bronchi narrowed
AZCC28 0 0 1 thyroid enlargement
AZCC29 0 0 1 small volume mediastinal LN
AZCC30 0 0 1
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Appendix I: Microbiota in CF Literature Review 
YEAR NAME NO OF PTS SAMPLING 
TYPE 
SEQUENCING 
METHOD  
DESCRIPTION/RESULTS 
2008 Bittar et 
al. 
16 children 
9 adults 
Spontaneously 
expectorated 
sputum (SES) 
Sanger 
sequencing 
1) One of the first studies to compare standard microbiological culture 
and DNA sequencing for bacterial detection. 
2) ~58% of isolated bacteria were detected only after cloning and 
sequencing. The pathogenic species were only detected after 
amplification and cloning (7 cases). 
3) New or emerging bacteria not or rarely reported in CF patients 
were detected including Dolosigranulum pigrum, Dialister 
pneumosintes, and Inquilinus limosus. 
2010 Cox et al. 51 patients 
19 children 
32 adults 
SES (from 
adults) 
Deep throat 
swab (from 
paediatric 
patients) 
Phylochip 1) Older CF patients with worse pulmonary function have a less 
diverse lung microbiota consisting of a ‘core’ of phylogenetically 
related colonising pathogenic species in comparison to younger 
patients.  
2) Using longitudinal samples collected from a subset of patients the 
initially diverse bacterial community observed in younger patients 
becomes less rich and diverse over time. 
2011 Tunney et 
al. 
23 patients, before 
and after IV ABx 
treatment for CF 
exacerbation 
SES T-RFLP 
qPCR 
1) One of the first studies examining the respiratory microbiota in CF 
patients before and after antibiotic treatment of CF exacerbations. 
2) Demonstrated significant inter-patient variability in microbiota 
composition but little intra-patient variability (i.e. stability) in 
composition of the bacterial community despite treatment with IV 
antibiotics. 
3) There was a decrease in bacterial abundance following treatment, 
and this effect was more evident for aerobes including 
Pseudomonas spp. than for anaerobes. This may well be because 
antibiotic treatment was targeted at Pseudomonas spp. 
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2011 Van der 
Gast et al. 
14 adult CF patients SES Sanger 
sequencing 
1) Study attempted to partition bacterial community into core and 
satellite taxa. 
2) The ‘Core’ taxa consisted of 15 taxa from 7 genera including 
Pseudomonas (1 taxon), Streptococcus (2), Neisseria (2), Catonella 
(1), Porphyromonas (1), Prevotella (5) and Veillonella. 
Pseudomonas was by far the most dominant organism. 
3) The ‘Satellite’ taxa consisted of 67 bacterial taxa from 33 genera. 
4) The CFTR genotype and antibiotic treatment were significantly 
correlated with the composition of all taxa and the core group 
members. 
5) A significant correlation was found between FEV1 and taxa richness 
(number of different taxa), with a significant positive linear 
relationship between these two variables. 
2011 Sibley et 
al. 
   1) Comparison of DNA based sequencing of microbiota with standard 
culture techniques. 
2) Standard culture detected a fraction (65.1%) of the organisms in 
sputum detected using T-RFLP. However, by using extended culture 
techniques to enhance the growth of organisms which are not 
classic CF pathogens (particularly anaerobes) this proportion was 
increased to 84%. 
3) Organisms detectable with 103 and 104 16S rRNA gene sequences 
recovered by culture in 100% and 86.8% of instances respectively.  
2012 Zhao et al. 6 adult male CF 
patients (3 stable 
disease, 3 
‘progressive’ disease). 
Multiple samples over 
8-9 year period 
totalling 126 
SES Pyrosequencing 1) Demonstrated significant decrease in bacterial community 
diversity (measured by Shannon index) over time in patients with 
typically progressive lung disease but remained relatively stable in 
patients with a mild lung disease phenotype. 
2) Antibiotic treatment was associated with pronounced shifts in 
community structure, but communities showed both short and 
long term resilience after antibiotic perturbation. 
3) Antibiotic use, rather than patient age or lung function, was the 
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primary driver of decreasing diversity. Inter-patient variability in 
community structure exceeded intra-patient variability in serial 
samples. 
4) Despite decreasing community diversity in patients with 
progressive disease, total bacterial density remained relatively 
stable over time.  
2012 Stressman 
et al. 
14 adult patients, 
samples collected 
every month for 12 
months 
SES T-RFLP 1) Subjects’ bacterial communities were found to be stable over the 
course of a year, changing little during this time despite 
intervening respiratory exacerbation periods. 
2) Some changes were observed during antibiotic treatment but 
these did not persist and returned to approximate pre-treatment 
structures within a month. 
3) Concluded that in the CF lung, community richness is inversely 
correlated with lung disease severity. 
4) P. aeruginosa was associated with lower community richness and 
lower lung function. 
2012 Delhaes et 
al. 
4 adult CF patients, 2 
samples each 
SES Pyrosequencing 
(16S rDNA and 
ITS2 locus for 
fungi) 
1) First study in CF patients to sequence both bacterial and fungal 
lung communities. 
2) Discovered diverse and complex bacterial and fungal communities, 
in which more than 60% of the species or genera were not 
detected by standard cultures.  
3) The diversity and species richness of fungal and bacterial 
communities was significantly lower in patients with decreased 
lung function and poor clinical status. 
2012 Fodor et 
al. 
23 adult CF patients. 
Samples collected 
before and after 
antibiotic treatment 
for exacerbation. 
SES 
Mouthwash 
samples 
Pyrosequencing 1) Antibiotic treatment was associated with a small decrease in 
species richness but minimal change in overall microbial 
community structure. 
2) Microbial community composition was highly similar in patients 
during an exacerbation and when clinically stable, suggesting that 
exacerbations may represent intrapulmonary spread of infection 
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Total of 26 matched 
pairs. 
rather than a change in microbial community composition. 
3) Mouthwash samples, obtained from a subset of patients, showed a 
nearly identical distribution of taxa to expectorated sputum, 
indicating that aspiration may contribute to colonization of the 
lower airways.  
4) Strong correlation between low species richness and poor lung 
function. 
2012 Goddard 
et al. 
10 CF subjects 
undergoing lung 
transplantation – 
lung, sputum and 
throat samples taken 
 
5 non-transplant 
subjects with 
FEV1<30% predicted 
provided throat and 
sputum samples. 
  
3 non-transplant 
subjects provided 
multiple day sputum 
samples while 
clinically stable. 
Lung samples, 
SES and throat 
samples 
Pyrosequencing 1) The microbiota of lung explants from patients with advanced CF 
was found to be almost entirely comprised of typical CF pathogens 
(~98%) with Pseudomonas spp. by far the most dominant.  
2) Throat and sputum samples obtained from the same patients 
immediately before surgery gave different results. 
3) The throat specimens were highly discordant with lung samples, 
containing a wide range of non-typical organisms not found in the 
lung explants.  
4) The sputum samples identified the dominant lung pathogen. 
However, in ∼1/2 of the cases, sputum contained diverse mixtures 
of non-typical organisms (comprising ∼25% of microbiota) that 
were either not found or were at very low abundance in the lungs 
of subjects.  
5) Sputum specimens showed day-to-day variation in the abundance 
of non-typical organisms in the absence of clinical changes.  
6) These findings suggest that oropharyngeal contamination may 
confound DNA based measurements on upper airway samples. 
2013 Zemanick 
et al. 
21 CF subjects 
37 sputum samples 
collected 
SES samples Pyrosequencing 1) Comparison of microbial content of sputum taken during early 
treatment (days 0-3) and late treatment (>7 days) of pulmonary 
exacerbation, with concurrent measurement of inflammatory 
markers.  
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2) At early treatment, lower diversity was associated with high 
relative abundance of Pseudomonas spp. (r =-0.67, p<0.001), 
decreased FEV1% predicted (r = 0.49, p = 0.03) and increased CRP  
(r =-0.58, p = 0.01).  
3) Obligate and facultative anaerobes were associated with less 
inflammation and higher FEV1.  
4) P. aeruginosa abundance decreased with treatment (by qPCR), 
while anaerobic genera showed a variable response.  
5) Change in the relative abundance of Prevotella was associated with 
more variability in FEV1 response to treatment than changes in 
Pseudomonas or Staphylococcus abundance. 
2013 Carmody 
et al. 
28 patients 
68 paired 
baseline/exacerbation 
sputa 
SES Pyrosequencing 1) There was no significant difference in bacterial community 
diversity and bacterial density between baseline and exacerbation 
samples.  
2) However, in a subset of patients considerable changes in 
community structures were observed. In these patients, the initial 
level of community diversity and dominant taxa were found to 
significantly predict the magnitude of community structure 
changes at exacerbation. 
3) The diversity of Pseudomonas dominant communities increased at 
exacerbation compared with communities with other or no 
dominant species.  
4) The relative abundance of Gemella increased in 24 (83%) of the 29 
exacerbation samples and this was the genus found to have the 
best discriminatory value between baseline and exacerbation 
samples. 
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Appendix J: Microbiota in COPD Literature Review 
YEAR NAME NO OF PTS SAMPLING 
TYPE 
SEQUENCING 
METHOD  
DESCRIPTION/RESULTS 
2011 Erb-
Downward 
et al. 
3 ‘healthy 
controls’ 
7 ‘healthy 
smokers’ 
4 COPD 
6 explanted 
lungs from 
severe COPD 
BAL 
 
 
 
 
Dissected 
lung 
explants 
Pyrosequencing 1) Subjects had distinct pulmonary microbiome – significantly different from 
oral cavity/nasopharynx 
2) Propose “core” lung microbiome including Pseudomonas, Streptococcus, 
Prevotella, Fusobacterium, Haemophilus, Veillonella, and Porphyromonas 
species 
3) No significant quantitative differences in bacterial numbers between groups 
4) Diversity of microbiome lower in moderate/severe COPD than other groups 
and most commonly dominated by Pseudomonas spp. 
5) Demonstrated significant heterogeneity in bacterial community between 
microanatomic sites in severe COPD lung 
2010 Huang et al. 8 mechanically 
ventilated 
COPD patients 
with ‘COPD 
exacerbation’ 
Endotrache
al aspirates 
Phylochip Suggested ‘core’ pulmonary bacterial community of 75 taxa detected in all 
patients including pathogenic species 
2012 Sze et al. 8 ‘healthy’ 
non-smokers 
8 ‘healthy’ 
smokers 
8 severe COPD 
(GOLD 4) 
8 CF 
Lung tissue 
sections 
T-RFLP 
Pyrosequencing 
1) Lower bacterial densities from lung tissue samples than BAL/PBB samples 
2) No difference in total bacterial number or diversity between non-smokers, 
smokers and COPD 
3) CF lung much higher bacterial density and lower diversity 
4) COPD –increased abundance of Firmicutes phylum 
5) T-RFLP/sequencing demonstrated 3 distinct bacterial community 
compositions: Non-smoker/smoker, COPD and CF 
2012 Pragman et 14 Moderate BAL Pyrosequencing 1) Main phyla in all samples were Actinobacteria, Firmicutes, and 
Proteobacteria 
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al. COPD 
8 Severe COPD 
4 smokers 
6 non-smokers 
2) Moderate and severe COPD samples showed significantly higher diversity 
than control samples but not significantly different to each other (when 
corrected for age) 
3) A few COPD patients by contrast had very low diversity scores 
4) Patients using ICS or inhaled bronchodilators found to have consistent 
differences in microbiota composition compared to those who did not using 
‘principal co-ordinate analysis’  
2012 Cabrera-
Rubio et al. 
6 Moderate 
COPD (3 
surgically 
treated for 
lung ca and 1 
for breast Ca) 
Sputum, 
bronchial 
aspirate, 
BAL and 
bronchial 
mucosa 
from each 
patient 
Pyrosequencing 1) Upper respiratory samples, sputum and bronchial aspirate, showed low 
diversity and the frequent recovery of phyla that are part of the 
oropharyngeal ﬂora of the healthy subject, such as Firmicutes and 
Bacteroidetes 
2) Lower bronchial tree samples (BAL and bronchial biopsy specimens) showed 
a more diverse microbiome with a close community proﬁle in both samples, 
a minor representation of oropharyngeal ﬂora, and the recovery of genera 
that included potentially pathogenic micro-organisms 
2013 Zakharkina 
et al. 
9 Severe COPD 
(GOLD 3-4) 
9 ‘Healthy’ 
controls 
BAL T-RFLP 
Sanger 
sequencing 
1) Suggested ‘core’ microbiome in the lower respiratory tract comprising of 
Prevotella, Sphingomonas, Pseudomonas, Acinetobacter, Fusobacterium, 
Megasphaera, Veillonella, Staphylococcus, and Streptococcus species 
2) No difference in diversity between COPD/’healthy’ subjects 
3) Two COPD patients were identified with significantly lower diversity 
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Appendix K: Methodology/Sample Collection of Lung Microbiota Literature Review 
YEAR NAME NO OF PTS SAMPLING 
TYPE 
SEQUENCING 
METHOD  
DESCRIPTION/RESULTS 
2006 Rogers et al. 19 adult CF 
patients 
SES 
Oral wash 
T-RFLP profiling 1) Comparison of T-RFLP profiles of sputum and oral wash to 
determine degree of any possible contamination.  
2) T-RFLP profiles significantly different in paired SES and oral wash 
samples. 
3) Suggests that sputum expectorated from the lungs of CF patients 
is not contaminated to a significant degree by bacteria present in 
the oral cavity. 
2010 Rogers et al. 10 adult CF 
patients. SES 
and induced 
sputum (IS) 
samples 
collected on 
days 1,3 and 7 
SES 
IS 
T-RFLP profiling 1) Found no significant difference in the bacterial composition of 
SES and IS samples, regardless of the period for which induction 
was performed. 
2) Showed that analysis of multiple samples is required in order to 
obtain a comprehensive view of the bacteria present in the 
lower CF airways. 
3) Only after analysis of multiple (≥5) samples did the number of 
new species detected from each further sample decrease. 
4) Estimate that one SES sample only contains about 60% of all of 
the species identified in total from 5 samples. 
2011 Charlson et 
al. 
6 healthy 
subjects 
Oral wash 
Oropharyngeal 
swabs 
Nasopharyngeal 
swabs  
Serial BAL 
Lower airway 
protected brush 
Pyrosequencing  
16S qPCR  
1) Compared samples taken from the URT (oral wash and 
oropharyngeal swabs) with those taken from the lung (BAL and 
protected airway brushings). 
2) Found no significant difference between bacterial communities 
in lung and upper airway – but bacteria in lung much less 
abundant (biomass 2 to 4 logs lower). 
3) Some lung specific sequences isolated but these were rare. 
4) Also noted low level contamination (with ‘environmental’ 
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organisms) of lavage saline and pre-bronchoscopy channel 
specimens. 
5) Nasopharyngeal samples showed distinctly different bacterial 
community, with the detection of many species associated with 
the skin microbiota, including Staphylococcaceae and 
Propionbibacteriaceae. NP samples also contained some 
organisms usually found in the oral cavity e.g. Streptococcaceae 
and Prevotellaceae. 
2012 Charlson et 
al. 
6 subjects: 
3 lung 
transplant 
recipients 
1 subject with 
sarcoidosis 
1 subject with 
adenocarcinoma 
1 subject with 
bronchiolitis 
obliterans 
organizing 
pneumonia 
(BOOP)  
Matched oral 
wash and BAL 
samples 
Pyrosequencing 
 
1) Compared BAL and oral wash samples in ‘healthy subjects’. 
2) Found no significant difference in bacterial communities in lung 
and oral cavity for 3/6 subjects. 
3) BAL samples from the other 3/6 subjects showed a number of 
sequences that were significantly more abundant in BAL 
compared to OW, suggesting that contamination of a 
bronchoscope with upper airway bacteria or repeated micro-
aspirations may not fully explain the detection of bacterial 
communities in the lung. 
4) Concluded that oral wash appears to be a reasonable sampling 
method (in conjunction with bronchoscopic sampling) to use to 
exclude URT contamination of lower airway samples obtained by 
bronchoscopy. 
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APPENDIX L:  
Participant Information Sheet 
Version 2.0 
 
Title of Study: Microbiota in Asthma 
Name of Researcher(s): Dr Tim Harrison, Dr Matthew Martin, Dr Dominick 
Shaw 
 
We would like to invite you to take part in our research study. Before you 
decide we need you to understand why the research is being done and 
what it will involve. One of our team will go through the information sheet 
with you and answer any questions you have. Talk to others about the 
study if you wish. Ask us if there is anything that is not clear. 
 
 
What is the purpose of the study? 
 
Previous research has shown that there are differences in the 
communities of bacteria found in the airways of asthmatic patients 
compared to those found in the airways of healthy people. 
 
It is not yet clear if these bacterial communities are similar in all patients 
with asthma or if they are different in people with more severe asthma, or 
those taking different treatment for their asthma.  
 
This is important to know as any differences in the bacteria present 
between groups may help to explain why people with asthma do not all 
have the same symptoms or severity of disease. 
 
This research aims to determine if there are any differences in the 
number and type of bacteria found in the airways of asthmatic patients 
(1) with different severities of asthma and (2) who use different types of 
inhaled steroid treatment for asthma. We will do this by detecting the 
DNA of bacteria present in phlegm (sputum) samples, as well as taking 
routine measurements of different features of asthma (explained further 
below) to see if the bacteria are different in people with different types of 
disease. 
 
As it is not yet known if the bacteria in the airways change over time, we 
will be taking more than one sample from some patients to see if the 
bacteria change over time 
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Why have I been invited? 
 
You are being invited to take part because you have asthma, are taking 
an inhaled steroid. In order to take part you must not have had any chest 
infections or antibiotics within the last month. We are inviting 50 
participants like you to take part. 
 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part.  If you do decide to 
take part you will be given this information sheet to keep and be asked to 
sign a consent form. If you decide to take part you are still free to 
withdraw at any time and without giving a reason. This would not affect 
your clinical care or legal rights. 
 
 
What will happen to me if I take part? 
 
Investigations 
 
Participants in this study will have a series of investigations to measure 
certain features of asthma. These include:  
 Sputum microbiology and differential cell counts: This 
procedure will involve giving you salty water to breathe in to help 
loosen any mucus in your lungs so you can cough it up. We will try 
and detect the DNA of any bacteria that may be present in the 
sputum. We will also look for any inflammatory cells that may be 
present due to your asthma. If possible we will take a further 
sputum sample with your agreement for storage and future analysis 
by a research team. This future analysis may involve looking for 
other inflammatory cells, chemicals or for further analysis of 
bacterial DNA or proteins.  
 Spirometry test: This is a simple blowing test that is used to 
measure your lung function (the size of your lungs and how quickly 
you can empty them). You will be asked to breathe in and then blow 
out very fast into a mouthpiece. 
 Bronchial challenge: This test is performed to measure how 
irritable your airways are. You will be asked to breathe in small 
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quantities of a drug called Methacholine which may cause slight 
narrowing of your airways. After each dose we will measure your 
lung function as described previously and we will stop when your 
blowing test falls by 20% or earlier if you feel unwell. 
 Exhaled nitric oxide measurement: Measuring the amount of 
exhaled nitric oxide in your breath to measure the amount of 
inflammation in the breathing tubes of your lungs. 
 Leicester Cough Questionnaire: Completing a questionnaire 
assessing how your cough affects your life. 
 Asthma Control Questionnaire: Completing a questionnaire 
assessing how your asthma affects your life 
 
All of these investigations will take place in our research clinic at the 
Nottingham City Hospital. Further information on these investigations can 
be found on our website: (http://www.nrru.org/patients.html). If you do 
not have access to the internet, printed information leaflets describing 
these tests in further detail are available upon contacting the Nottingham 
Respiratory Research Unit on the telephone number given below. 
 
 
Timing of study 
Overall, participation in this study will usually require 1 visit only to the 
Nottingham City Hospital, although we will ask some patients to come 
back for 3 visits over a period of 2 weeks, which is summarised here: 
 
PART 1 OF STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Telephone screening/Clinic appointment visit 
 
You will be identified as a potential candidate for the study in a respiratory clinic appointment 
by one of the study team or from the Respiratory Research Unit Database. You will be asked if 
you would like to take part in the study and any questions you may have will be answered. You 
will be asked to give written informed consent in order to take part in 
the study. 
 
Duration: 10-15 minutes 
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Expenses and payments 
 
Participants will be reimbursed for any travel expenses. 
 
 
 
 
 
 
Hospital visit 1 
 
Face to face visit with our research team in the hospital. This visit will take place in the 
Nottingham City Respiratory Research Unit. You will be seen by a doctor who will ask some 
questions relating to your condition to make sure you are eligible for the study. If so, we will 
perform a set of breathing tests (spirometry) and ask you to complete questionnaires 
assessing how asthma affects your life. We will then measure an exhaled gas (nitric oxide) in 
your breath (explained above) and perform a test to determine 
how irritable your airways are (methacholine challenge) which is also explained above. 
 
Sputum samples will then be taken for analysis including extra samples for storage and future 
analysis with your permission. In order to obtain these sputum samples you will be given salty 
water to breathe in, which will help to loosen any mucus in your lungs so you can cough it up 
(induced sputum). 
 
Duration: 2 hours 
 
At this point we may ask you to attend an optional further 2 appointments described below, 
which will be your decision. 
 
 
 
 
Hospital visit 3 (2 weeks after visit 1) 
 
Face to face visit with our research team at the Nottingham City Respiratory Research Unit. 
This will tak  place 2 weeks after Visit 1 and will consist of taking 1 further induced sputum 
sample only. 
 
Duration: 15-20 minutes 
Hospital visit 2 (within 24 hours of first appointment) 
 
Face to face visit with our research team at the Nottingham City Respiratory Research Unit. 
This will take place the day after Visit 1 and will consist of taking 1 further induced sputum 
sample only 
 
Duration: 15-20 minutes 
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What are the possible disadvantages and risks of taking part?  
 
Investigations 
Exhaled Nitric Oxide: Having the levels of nitric oxide in your breath 
measured does not pose any risks and is well tolerated.  
 
Sputum Induction: Occasionally, the inhalation of salt solution in order 
to produce a sputum sample can make you wheezy. However, we will give 
you salbutamol (Ventolin) before the test and monitor you closely 
throughout, giving more salbutamol if necessary during the procedure.  
 
Bronchial Challenge: This is a simple and safe test widely used in the 
assessment of asthma. You may experience chest tightness, wheeze or a 
cough during the course of the test, but these symptoms are usually mild 
and are quickly reversed by using a salbutamol inhaler (Ventolin). 
 
 
What are the possible benefits of taking part? 
 
It is hoped that the results of this study will help us to understand any 
possible role that the bacteria in the airways have in causing the 
symptoms of asthma. This may help us to develop better treatment 
strategies for asthma in the future.  
 
 
What happens when the research study stops? 
 
You will be referred back to your usual respiratory physician or GP and 
have further follow up if necessary in the normal respiratory clinic. If any 
of your phlegm samples show evidence of infection, we will contact your 
GP with advice regarding the need for antibiotic treatment. 
 
 
What if there is a problem? 
 
If you have a concern about any aspect of this study, you should ask to 
speak to the researchers who will do their best to answer your questions.  
The researchers contact details are given at the end of this information 
sheet. If you remain unhappy and wish to discuss the matter further, you 
can do this by getting in touch with the Nottingham Hospitals Patient 
Advice and Liaison Service (PALS) in person, by telephone or e-mail who 
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can try and resolve the situation. Details are provided below. If you still 
wish to make a formal complaint you can do this through the NHS formal 
complaints procedure (further details of which can be provided by the 
PALS service). 
 
Nottingham City Campus PALS service 
By person: PALS is on the South Corridor at Junction S6. Opening times 
9:30 – 4:30 pm Monday - Friday 
Tel: 0800 052 1195 (free from a landline) or 0115 969 1169 ext 59671 
E-mail: pals@nuh.nhs.uk 
Post: NUH NHS Trust, c/o PALS, Freepost, NEA 14614, Nottingham NG7 
1BR 
 
 
Will my taking part in the study be kept confidential? 
 
We will follow ethical and legal practice and all information about you will 
be handled in confidence. 
 
If you join the study, some parts of your medical records and the data 
collected for the study will be looked at by authorised persons from the 
University of Nottingham who are organising the research. They may also 
be looked at by authorised people to check that the study is being carried 
out correctly. All will have a duty of confidentiality to you as a research 
participant and we will do our best to meet this duty.  
 
All information which is collected about you during the course of the 
research will be kept strictly confidential, stored in a secure and locked 
office, and on a password protected database.  Any information about you 
which leaves the hospital will have your name and address removed 
(anonymised) and a unique code will be used so that you cannot be 
recognised from it.   
 
Your personal data (address, telephone number) will be kept for 12 
months after the end of the study so that we are able to contact you 
about the findings of the study and possible follow-up studies (unless you 
advise us that you do not wish to be contacted).  All other data (research 
data) will be kept securely for 7 years.  After this time your data will be 
disposed of securely.  During this time all precautions will be taken by all 
those involved to maintain your confidentiality, only members of the 
research team will have access to your personal data. 
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What will happen if I don’t want to carry on with the study?  
 
Your participation is voluntary and you are free to withdraw at any time, 
without giving any reason, and without your legal rights being affected. If 
you withdraw then the information collected so far cannot be erased and 
this information may still be used in the project analysis. 
 
 
Involvement of the General Practitioner/Family doctor (GP)  
 
We will write to your GP about your involvement in this study and if your 
phlegm samples show evidence of infection, we will contact your GP with 
advice regarding the need for antibiotic treatment. 
 
 
What will happen to any samples I give? 
 
The sputum samples will be sent to a research team at King’s College in 
London for processing and will then be sent on to another facility abroad 
for detection of any bacterial DNA. All of these samples will have your 
name and address removed (anonymised) and a unique code will be used 
so that you cannot be recognised from it.   
 
We would also like to seek your consent so that any remaining samples 
may be stored and used in possible future research – this is optional 
(please indicate you agree to this on the consent form). The samples will 
be stored with a code unique to you and securely at the University of 
Nottingham under the University’s Human Tissue Research Licence (no 
12265). 
 
Some of these future studies may be carried out by researchers other 
than current team of Dr Harrison including researchers working for 
commercial companies. Any samples or data used will be anonymised, 
and you will not be identified in any way. If you do not agree to this any 
remaining samples will be disposed of in accordance with the Human 
Tissue Authority’s codes of practice. 
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Will any genetic tests be done? 
 
No tests will be performed on any of your samples to determine any of 
your genetic information. Tests will be performed to detect the DNA of 
any micro-organisms (including bacteria) that may be present in the 
samples. 
 
 
What will happen to the results of the research study 
 
We will publish the results of the trial in a respiratory medicine journal, 
present the results at various scientific conferences, and this work will 
form part of a thesis for a higher degree. You will not be identified in any 
report/publication. We will send you a newsletter with a summary of the 
results. 
 
 
Who is organising and funding the research? 
 
This research is being organised by the University of Nottingham and is 
being funded by Astra Zeneca (UK) 
 
 
Who has reviewed the study? 
 
All research in the NHS is looked at by independent group of people, 
called a Research Ethics Committee, to protect your interests. This study 
has been reviewed and given favourable opinion by East Midlands (Derby) 
Research Ethics Committee. 
 
 
Further information and contact details 
 
Further information can be obtained from our website: 
http://www.nrru.org/ 
 
Or by telephoning us on:  
 
Matthew Martin 
(Study Doctor) 
Tel: 0115 8231935 
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Denise Barber                        OR           Tina Wilkinson 
(NRRU Secretary)                                  (CTU Receptionist)  
Tel: 0115 86231317                            Tel: 0115 8404844               
Fax: 0115 8231946                             Fax:0115 84026217 
 
Alternatively, you can write to us at the following address: 
 
Nottingham Respiratory Research Unit         
Room B28 
Clinical Sciences Building 
Nottingham City Hospital 
Hucknall Road 
Nottingham 
NG5 1PB 
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APPENDIX M: Bacterial loads of individual MIA subjects (CFU/mL 
of sputum equiv.) 
 
  
NO. 
 
PATIENT 
BTS 
STEP 
2/4 
 
STEROID 
 
VISIT 
 
TOTAL 
BACTERIA 
 
H. influenzae 
 
S. 
pneumoniae 
1 MIA001 2 BEC 1 8.95E+06 2.12E+01 0.00E+00 
2 MIA001 2 BEC 2 9.94E+05 1.00E+01 0.00E+00 
3 MIA001 2 BEC 3 2.80E+05 0.00E+00 0.00E+00 
4 MIA002 4 FLUTIC 1 7.65E+06 1.62E+04 0.00E+00 
5 MIA003 2 BUD 1 8.47E+06 3.29E+03 0.00E+00 
6 MIA005 2 BEC 1 3.47E+08 2.26E+02 0.00E+00 
7 MIA005 2 BEC 2 6.68E+05 0.00E+00 0.00E+00 
8 MIA005 2 BEC 3 1.25E+07 4.37E+01 0.00E+00 
9 MIA007 2 BEC 1 5.61E+08 1.31E+05 0.00E+00 
10 MIA009 2 BEC 1 5.18E+07 0.00E+00 0.00E+00 
11 MIA009 2 BEC 2 1.80E+08 0.00E+00 0.00E+00 
12 MIA009 2 BEC 3 1.70E+08 0.00E+00 0.00E+00 
13 MIA010 2 FLUTIC 1 4.69E+07 4.02E+03 0.00E+00 
14 MIA013 4 FLUTIC 1 5.10E+07 1.12E+01 0.00E+00 
15 MIA014 4 FLUTIC 1 8.86E+06 0.00E+00 0.00E+00 
16 MIA015 4 BUD 1 1.28E+07 1.19E+02 0.00E+00 
17 MIA017 4 FLUTIC 1 8.68E+06 0.00E+00 0.00E+00 
18 MIA019 4 BUD 1 3.24E+06 0.00E+00 0.00E+00 
19 MIA020 4 BUD 1 1.45E+07 0.00E+00 0.00E+00 
20 MIA020 4 BUD 2 3.16E+06 0.00E+00 0.00E+00 
21 MIA020 4 BUD 3 1.08E+07 3.25E+01 0.00E+00 
22 MIA022 4 BUD 1 1.93E+06 0.00E+00 0.00E+00 
23 MIA022 4 BUD 2 7.88E+05 3.75E+01 0.00E+00 
24 MIA022 4 BUD 3 1.56E+07 2.16E+01 0.00E+00 
25 MIA024 2 BUD 1 2.98E+05 1.08E+02 0.00E+00 
26 MIA025 4 FLUTIC 1 1.09E+08 0.00E+00 0.00E+00 
27 MIA025 4 FLUTIC 2 2.60E+06 0.00E+00 0.00E+00 
28 MIA025 4 FLUTIC 3 1.32E+08 0.00E+00 0.00E+00 
29 MIA026 2 BUD 1 1.06E+08 6.47E+00 0.00E+00 
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30 MIA027 2 BEC 1 2.62E+07 2.96E+02 0.00E+00 
31 MIA029 2 BUD 1 1.53E+07 5.73E+00 0.00E+00 
32 MIA029 2 BUD 2 6.49E+07 1.98E+01 3.80E+01 
33 MIA029 2 BUD 3 3.01E+07 2.99E+02 7.26E+01 
34 MIA031 4 FLUTIC 1 1.01E+08 0.00E+00 8.14E+01 
35 MIA031 4 FLUTIC 2 2.77E+07 0.00E+00 0.00E+00 
36 MIA031 4 FLUTIC 3 1.79E+07 0.00E+00 0.00E+00 
37 MIA032 4 BUD 1 4.76E+07 0.00E+00 0.00E+00 
38 MIA034 4 BUD 1 9.23E+07 2.02E+02 0.00E+00 
39 MIA035 2 BEC 1 6.01E+08 0.00E+00 0.00E+00 
40 MIA035 2 BEC 2 7.29E+07 0.00E+00 0.00E+00 
41 MIA035 2 BEC 3 9.40E+05 0.00E+00 0.00E+00 
42 MIA036 2 BEC 1 3.47E+06 0.00E+00 0.00E+00 
43 MIA036 2 BEC 2 2.19E+06 0.00E+00 0.00E+00 
44 MIA036 2 BEC 3 1.63E+09 3.01E+02 0.00E+00 
45 MIA037 2 BUD 1 1.48E+07 1.59E+01 2.86E+02 
46 MIA038 2 FLUTIC 1 7.62E+08 0.00E+00 0.00E+00 
47 MIA039 2 FLUTIC 1 7.17E+06 0.00E+00 0.00E+00 
48 MIA040 2 BUD 1 9.97E+06 3.19E+02 3.88E+01 
49 MIA041 4 FLUTIC 1 8.23E+06 3.94E+07 0.00E+00 
50 MIA042 2 BEC 1 1.21E+07 0.00E+00 0.00E+00 
51 MIA042 2 BEC 2 4.37E+06 0.00E+00 0.00E+00 
52 MIA042 2 BEC 3 4.38E+06 5.90E+01 0.00E+00 
53 MIA043 4 BUD 1 1.07E+07 0.00E+00 0.00E+00 
54 MIA044 4 FLUTIC 1 2.39E+06 3.50E+00 0.00E+00 
55 MIA044 4 FLUTIC 2 5.35E+06 0.00E+00 0.00E+00 
56 MIA044 4 FLUTIC 3 8.17E+05 0.00E+00 0.00E+00 
57 MIA045 2 BUD 1 1.43E+08 0.00E+00 0.00E+00 
58 MIA045 2 BUD 2 8.30E+08 0.00E+00 0.00E+00 
59 MIA045 2 BUD 3 6.51E+08 3.77E+00 0.00E+00 
60 MIA046 4 BUD 1 3.29E+07 0.00E+00 0.00E+00 
61 MIA049 4 BUD 1 3.76E+06 1.10E+02 4.24E+00 
62 MIA049 4 BUD 2 3.34E+06 4.66E+01 0.00E+00 
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63 MIA049 4 BUD 3 4.05E+06 1.99E+02 0.00E+00 
64 MIA050 4 BUD 1 1.08E+07 0.00E+00 0.00E+00 
65 MIA051 4 FLUTIC 1 1.52E+06 0.00E+00 0.00E+00 
66 MIA052 4 BUD 1 1.50E+08 2.30E+04 0.00E+00 
67 MIA053 4 FLUTIC 1 7.75E+08 0.00E+00 5.14E+01 
68 MIA053 4 FLUTIC 2 6.18E+06 0.00E+00 0.00E+00 
69 MIA053 4 FLUTIC 3 1.65E+07 4.68E+01 0.00E+00 
70 MIA054 4 FLUTIC 1 2.34E+06 1.62E+02 0.00E+00 
71 MIA054 4 FLUTIC 2 1.79E+06 4.67E+01 4.14E+03 
72 MIA054 4 FLUTIC 3 1.23E+06 1.15E+01 8.75E+01 
73 MIA055 2 FLUTIC 1 3.55E+05 0.00E+00 1.33E+03 
74 MIA056 2 FLUTIC 1 4.00E+06 0.00E+00 0.00E+00 
75 MIA057 4 FLUTIC 1 1.99E+06 1.59E+05 0.00E+00 
76 MIA057 4 FLUTIC 2 1.89E+07 2.48E+03 0.00E+00 
77 MIA057 4 FLUTIC 3 1.92E+07 1.88E+04 0.00E+00 
78 MIA058 4 FLUTIC 1 4.37E+07 5.81E+01 6.40E+00 
79 MIA058 4 FLUTIC 2 2.36E+07 6.63E+00 0.00E+00 
80 MIA058 4 FLUTIC 3 3.66E+07 5.86E+01 0.00E+00 
81 MIA059 2 BEC 1 9.10E+06 4.10E+02 2.28E+02 
82 MIA061 4 FLUTIC 1 8.98E+06 3.25E+06 0.00E+00 
83 MIA062 4 FLUTIC 1 5.66E+06 3.92E+04 5.27E+00 
84 MIA063 4 FLUTIC 1 7.88E+06 0.00E+00 0.00E+00 
85 MIA064 4 FLUTIC 1 5.86E+06 5.77E+00 0.00E+00 
86 MIA065 4 BUD 1 4.85E+06 1.24E+01 0.00E+00 
87 MIA066 4 BUD 1 2.99E+07 0.00E+00 0.00E+00 
88 MIA067 4 BUD 1 7.69E+06 1.07E+04 0.00E+00 
89 MIA067 4 BUD 2 9.44E+06 2.96E+03 0.00E+00 
90 MIA067 4 BUD 3 1.32E+07 3.83E+02 0.00E+00 
91 MIA068 4 BUD 1 3.78E+06 2.52E+05 8.53E+01 
92 MIA069 4 BUD 1 9.63E+06 3.59E+02 2.45E+01 
93 MIA070 2 BEC 1 7.31E+05 0.00E+00 0.00E+00 
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